Gene;Omim;Synonym;OMIM_ID;Inheritance;Chromosom_arm
A2M ;Alpha-2-macroglobulin deficiency, 614036 (1);A2M , A2MD;103950;AD;12p13.31
A4GALT;NOR polyagglutination syndrome, 111400 (3);A4GALT, P1PK;607922;-;22q13.2
AA1;Alopecia areata 1 (2);AA1;104000;Mu;18p11.3-p11.2
AA2;Alopecia areata 2 (2);AA2;610753;-;16q11-q22
AAA1;Aortic aneurysm, familial abdominal 1 (2);AAA1, AAA;100070;AD;19q13
AAA2;Aortic aneurysm, familial abdominal 2 (2);AAA2;609782;-;4q31
AAA4;Aortic aneurysm, familial abdominal, 4 (2);AAA4;614375;-;12q13.3
AAAS;Achalasia-addisonianism-alacrimia syndrome, 231550 (3);AAAS, AAA;605378;AR;12q13.13
AAGAB;Keratoderma, palmoplantar, punctate type IA, 148600 (3);AAGAB, p34, PPKP1A, PPKP1, KPPP1;614888;AD;15q23
AARS;Charcot-Marie-Tooth disease, axonal, type 2N, 613287 (3),Epileptic encephalopathy, early infantile, 29, 616339 (3);AARS, CMT2N, EIEE29;601065;AD, AR;16q22.1
AARS2;Combined oxidative phosphorylation deficiency 8, 614096 (3),Leukoencephalopathy, progressive, with ovarian failure, 615889 (3);AARS2, KIAA1270, MTALARS, COXPD8, LKENP;612035;AR ;6p21.1
AASS;Hyperlysinemia, 238700 (3),Saccharopinuria, 268700 (1);AASS;605113;AR ;7q31.32
AAT1;Aortic aneurysm, familial thoracic 1 (2);AAT1, FAA1;607086;-;11q23.3-q24
AAT2;Aortic aneurysm, familial thoracic 2 (2);AAT2, FAA2;607087;-;5q13-q14
ABAT;GABA-transaminase deficiency, 613163 (3);ABAT, GABAT;137150;AR;16p13.2
ABCA1;HDL deficiency, type 2, 604091 (3),Tangier disease, 205400 (3);ABCA1, ABC1, HDLDT1, TGD;600046;AR, AD;9q31.1
ABCA12;Ichthyosis, autosomal recessive 4B (harlequin), 242500 (3),Ichthyosis, congenital, autosomal recessive 4A, 601277 (3);ABCA12, ARCI4A, ARCI4B, ICR2B, LI2;607800;AR ;2q35
ABCA3;Surfactant metabolism dysfunction, pulmonary, 3, 610921 (3);ABCA3, ABC3, SMDP3;601615;AR;16p13.3
ABCA4;Cone-rod dystrophy 3, 604116 (3),Fundus flavimaculatus, 248200 (3),Retinal dystrophy, early-onset severe, 248200 (3),Retinitis pigmentosa 19, 601718 (3),Stargardt disease 1, 248200 (3);ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2;601691;AR, AD;1p22.1
ABCB11;Cholestasis, benign recurrent intrahepatic, 2, 605479 (3),Cholestasis, progressive familial intrahepatic 2, 601847 (3);ABCB11, BSEP, SPGP, PFIC2, BRIC2;603201;AR;2q31.1
ABCB4;Cholestasis, intrahepatic, of pregnancy, 3, 614972 (3),Cholestasis, progressive familial intrahepatic 3, 602347 (3),Gallbladder disease 1, 600803 (3);ABCB4, PGY3, MDR3, ICP3;171060;AD, AR;7q21.12
ABCB6;Dyschromatosis universalis hereditaria 3, 615402 (3),Microphthalmia, isolated, with coloboma 7, 614497 (3),Pseudohyperkalemia, familial, 2, due to red cell leak, 609153 (3);ABCB6, MTABC3, MCOPCB7, LAN, DUH3, PSHK2;605452;AD;2q35
ABCB7;Anemia, sideroblastic, with ataxia, 301310 (3);ABCB7, ABC7, ASAT;300135;XLR;Xq13.3
ABCC2;Dubin-Johnson syndrome, 237500 (3);ABCC2, CMOAT;601107;AR;10q24.2
ABCC6;Arterial calcification, generalized, of infancy, 2, 614473 (3),Pseudoxanthoma elasticum, 264800 (3),Pseudoxanthoma elasticum, forme fruste, 177850 (3);ABCC6, ARA, ABC34, MLP1, PXE, GACI2;603234;AR, AD;16p13.11
ABCC8;Diabetes mellitus, noninsulin-dependent, 125853 (3),Diabetes mellitus, permanent neonatal, 606176 (3),Diabetes mellitus, transient neonatal 2, 610374 (3),Hyperinsulinemic hypoglycemia, familial, 1, 256450 (3),Hypoglycemia of infancy, leucine-sensitive, 240800 (3);ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2;600509;AD, AR;11p15.1
ABCC9;Atrial fibrillation, familial, 12, 614050 (3),Cardiomyopathy, dilated, 1O, 608569 (3),Hypertrichotic osteochondrodysplasia, 239850 (3);ABCC9, SUR2, CMD1O, ATFB12, CANTU;601439;AD;12p12.1
ABCD1;Adrenoleukodystrophy, 300100 (3),Adrenomyeloneuropathy, adult, 300100 (3);ABCD1, ALD, AMN;300371;XLR;Xq28
ABCD3;?Bile acid synthesis defect, congenital, 5, 616278 (3);ABCD3, PXMP1, PMP70, CBAS5;170995;AR;1p21.3
ABCD4;Methylmalonic aciduria and homocystinuria, cblJ type, 614857 (3);ABCD4, PXMP1L, P79R, PMP69, MAHCJ;603214;AR;14q24.3
ABCG5;Sitosterolemia, 210250 (3);ABCG5;605459;AR;2p21
ABCG8;Sitosterolemia, 210250 (3);ABCG8, GBD4;605460;AR;2p21
ABHD12;Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 (3);ABHD12, PHARC;613599;AR;20p11.21
ABHD5;Chanarin-Dorfman syndrome, 275630 (3);ABHD5, CGI58, IECN2, NCIE2;604780;AR;3p21.33
ABL1;Leukemia, Philadelphia chromosome-positive, resistant to imatinib (3);ABL1;189980;-;9q34.12
ABL2;Leukemia, acute myeloid, with eosinophilia (1);ABL2, ABLL, ARG;164690;-;1q25.2
ACACA;Acetyl-CoA carboxylase deficiency, 613933 (1);ACACA, ACAC, ACC1, ACACAD;200350;AR;17q12
ACAD8;Isobutyryl-CoA dehydrogenase deficiency, 611283 (3);ACAD8;604773;-;11q25
ACAD9;Mitochondrial complex I deficiency due to ACAD9 deficiency, 611126 (3);ACAD9;611103;AR;3q21.3
ACADM;Acyl-CoA dehydrogenase, medium chain, deficiency of, 201450 (3);ACADM, MCAD;607008;AR;1p31.1
ACADS;Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470 (3);ACADS, SCAD;606885;AR;12q24.31
ACADSB;2-methylbutyrylglycinuria, 610006 (3);ACADSB, SBCAD;600301;AR;10q26.13
ACADVL;VLCAD deficiency, 201475 (3);ACADVL, VLCAD;609575;AR;17p13.1
ACAN;Osteochondritis dissecans, short stature, and early-onset osteoarthritis, 165800 (3),Spondyloepimetaphyseal dysplasia, aggrecan type, 612813 (3),Spondyloepiphyseal dysplasia, Kimberley type, 608361 (3);ACAN, AGC1, CSPG1, MSK16, SEDK;155760;AD;15q26.1
ACAT1;Alpha-methylacetoacetic aciduria, 203750 (3);ACAT1;607809;AR;11q22.3
ACAT2;?ACAT2 deficiency, 614055 (1);ACAT2;100678;IC;6q25.3
ACD;?Dyskeratosis congenita, autosomal dominant 6, 616553 (3),?Dyskeratosis congenita, autosomal recessive 7, 616553 (3);ACD, PTOP, PIP1, TINT1;609377;AD, AR;16q22.1
ACE;Renal tubular dysgenesis, 267430 (3);ACE, DCP1, ACE1, MVCD3, ICH;106180;AR;17q23.3
ACF;Cayler cardiofacial syndrome (2);ACF;125520;AD;22q11
ACO2;?Optic atrophy 9, 616289 (3),Infantile cerebellar-retinal degeneration, 614559 (3);ACO2, ICRD, OPA9;100850;AR;22q13.2
ACOX1;Peroxisomal acyl-CoA oxidase deficiency, 264470 (3);ACOX1, ACOX, SCOX;609751;AR;17q25.1
ACP;Cerebral palsy, ataxic, autosomal recessive (2);ACP;605388;AR;9p12-q12
ACP2;?Lysosomal acid phosphatase deficiency, 200950 (1);ACP2;171650;AR;11p11.2
ACP33;Mast syndrome, 248900 (3);ACP33, MAST, SPG21;608181;AR;15q22.31
ACP5;Spondyloenchondrodysplasia with immune dysregulation, 607944 (3);ACP5, SPENCDI;171640;AR;19p13.2
ACR;?Male infertility due to acrosin deficiency (2);ACR;102480;-;22q13.33
ACRPS;Acropectoral syndrome (2);ACRPS;605967;AD;7q36
ACRPV;Acropectorovertebral dysplasia (2);ACRPV;102510;AD;2q36
ACSF3;Combined malonic and methylmalonic aciduria, 614265 (3);ACSF3;614245;-;16q24.3
ACSL4;Mental retardation, X-linked 63, 300387 (3);ACSL4, FACL4, ACS4, MRX63;300157;-;Xq23
ACSL6;Myelodysplastic syndrome (3),Myelogenous leukemia, acute (3);ACSL6, FACL6, ACS2;604443;-;5q31.1
ACTA1;?Myopathy, scapulohumeroperoneal, 616852 (3),Myopathy, actin, congenital, with cores, 161800 (3),Myopathy, actin, congenital, with excess of thin myofilaments, 161800 (3),Myopathy, congenital, with fiber-type disproportion 1, 255310 (3),Nemaline myopathy 3, autosomal dominant or recessive, 161800 (3);ACTA1, ASMA, NEM3, CFTD1, SHPM;102610;AD, AR;1q42.13
ACTA2;Aortic aneurysm, familial thoracic 6, 611788 (3),Moyamoya disease 5, 614042 (3),Multisystemic smooth muscle dysfunction syndrome, 613834 (3);ACTA2, ACTSA, AAT6, MYMY5;102620;AD;10q23.31
ACTB;?Dystonia, juvenile-onset, 607371 (3),Baraitser-Winter syndrome 1, 243310 (3);ACTB, BRWS1;102630;AD;7p22.1
ACTC1;Atrial septal defect 5, 612794 (3),Cardiomyopathy, dilated, 1R, 613424 (3),Cardiomyopathy, hypertrophic, 11, 612098 (3),Left ventricular noncompaction 4, 613424 (3);ACTC1, CMD1R, CMH11, ASD5, LVNC4;102540;AD;15q14
ACTG1;Baraitser-Winter syndrome 2, 614583 (3),Deafness, autosomal dominant 20/26, 604717 (3);ACTG1, DFNA20, DFNA26, BRWS2;102560;AD;17q25.3
ACTG2;Visceral myopathy, 155310 (3);ACTG2, ACTA3, VSCM;102545;AD;2p13.1
ACTN1;Bleeding disorder, platelet-type, 15, 615193 (3);ACTN1, BDPLT15;102575;AD;14q24.1
ACTN2;Cardiomyopathy, dilated, 1AA, with or without LVNC, 612158 (3),Cardiomyopathy, hypertrophic, 23, with or without LVNC, 612158 (3);ACTN2, CMD1AA, CMH23;102573;AD;1q43
ACTN4;Glomerulosclerosis, focal segmental, 1, 603278 (3);ACTN4, FSGS1, FSGS;604638;AD;19q13.2
ACVR1;Fibrodysplasia ossificans progressiva, 135100 (3);ACVR1, ACVRLK2, ALK2, FOP;102576;AD;2q24.1
ACVR1B;Pancreatic cancer, somatic (3);ACVR1B, ACVRLK4, ALK4;601300;-;12q13.13
ACVR2B;Heterotaxy, visceral, 4, autosomal, 613751 (3);ACVR2B, ACTRIIB, HTX4;602730;-;3p22.2
ACVRL1;Telangiectasia, hereditary hemorrhagic, type 2, 600376 (3);ACVRL1, ACVRLK1, ALK1, HHT2;601284;AD;12q13.13
ACY1;Aminoacylase 1 deficiency, 609924 (3);ACY1, ACY1D;104620;AR;3p21.2
AD10;Alzheimer disease-10, 104300 (2);AD10;609636;AD;7q36
AD11;Alzheimer disease-11 (2);AD11;609790;-;9p22.1
AD17;Alzheimer disease 17 (2);AD17;615080;-;6p21.2
AD5;Alzheimer disease-5, 104300 (2);AD5;602096;AD;12p11.23-q13.12
AD6;Alzheimer disease 6, 104300 (2);AD6;605526;-;10q24
AD7;Alzheimer disease-7 (2);AD7;606187;-;10p13
AD8;Alzheimer disease 8, 104300 (2);AD8;607116;-;20p
ADA;Adenosine deaminase deficiency, partial, 102700 (3),Severe combined immunodeficiency due to ADA deficiency, 102700 (3);ADA;608958;AR, Smo;20q13.12
ADAM10;Reticulate acropigmentation of Kitamura, 615537 (3);ADAM10, MADM, RAK, AD18;602192;AD;15q21.3
ADAM17;?Inflammatory skin and bowel disease, neonatal, 1, 614328 (3);ADAM17, TACE, NISBD1;603639;AR;2p25.1
ADAM9;Cone-rod dystrophy 9, 612775 (3);ADAM9, MDC9, MCMP, CORD9;602713;-;8p11.22
ADAMTS10;Weill-Marchesani syndrome 1, recessive, 277600 (3);ADAMTS10, WMS1;608990;AR;19p13.2
ADAMTS13;Thrombotic thrombocytopenic purpura, familial, 274150 (3);ADAMTS13, VWFCP, TTP;604134;AR;9q34.2
ADAMTS17;Weill-Marchesani-like syndrome, 613195 (3);ADAMTS17;607511;AR;15q26.3
ADAMTS18;Microcornea, myopic chorioretinal atrophy, and telecanthus, 615458 (3);ADAMTS18, MMCAT;607512;AR;16q23.1
ADAMTS2;Ehlers-Danlos syndrome, type VIIC, 225410 (3);ADAMTS2, NPI;604539;AR;5q35.3
ADAMTSL2;Geleophysic dysplasia 1, 231050 (3);ADAMTSL2, KIAA0605, GPHYSD1;612277;AR;9q34.2
ADAMTSL4;Ectopia lentis et pupillae, 225200 (3),Ectopia lentis, isolated, autosomal recessive, 225100 (3);ADAMTSL4, TSRC1, ECTOL2;610113;AR;1q21.2
ADAR;Aicardi-Goutieres syndrome 6, 615010 (3),Dyschromatosis symmetrica hereditaria, 127400 (3);ADAR, DRADA, DSH, DSRAD, IFI4, G1P1, AGS6;146920;AR, AD;1q21.3
ADAT3;Mental retardation, autosomal recessive 36, 615286 (3);ADAT3, TAD3, MRT36;615302;AR;19p13.3
ADCK3;Coenzyme Q10 deficiency, primary, 4, 612016 (3);ADCK3, COQ8, CABC1, SCAR9, ARCA2, COQ10D4;606980;AR;1q42.13
ADCK4;Nephrotic syndrome, type 9, 615573 (3);ADCK4, NPHS9;615567;AR;19q13.2
ADCY1;?Deafness, autosomal recessive 44, 610154 (3);ADCY1, DFNB44;103072;AR;7p12.3
ADCY5;Dyskinesia, familial, with facial myokymia, 606703 (3);ADCY5, FDFM;600293;AD;3q21.1
ADCY6;?Lethal congenital contracture syndrome 8, 616287 (3);ADCY6, LCCS8;600294;AR;12q13.12
ADD3;Cerebral palsy, spastic quadriplegic, 3, 617008 (3);ADD3, ADDL, CPSQ3;601568;AR;10q25.1-q25.2
ADFN;Albinism-deafness syndrome (2);ADFN, ALDS;300700;XL;Xq24-q26
ADGRE2;Vibratory urticaria, 125630 (3);ADGRE2, EMR2, VBU;606100;AD;19p13.12
ADGRV1;?Febrile seizures, familial, 4, 604352 (3),Usher syndrome, type 2C, 605472 (3),Usher syndrome, type 2C, GPR98/PDZD7 digenic, 605472 (3);ADGRV1, GPR98, MASS1, VLGR1, KIAA0686, FEB4, USH2C;602851;AD; DD; AR; DD,AR;5q14.3
ADIPOQ;Adiponectin deficiency, 612556 (3);ADIPOQ, APM1, GBP28, ADIPQTL1;605441;-;3q27.3
ADK;Hypermethioninemia due to adenosine kinase deficiency, 614300 (3);ADK;102750;AR;10q22.2
ADNP;Helsmoortel-van der Aa syndrome, 615873 (3);ADNP, ADNP1, KIAA0784, HVDAS, MRD28;611386;AD;20q13.13
ADRA2B;Epilepsy, myoclonic, familial adult, 2, 607876 (3);ADRA2B, ADRA2L1, FAME2;104260;AD;2q11.2
ADRB2;Beta-2-adrenoreceptor agonist, reduced response to (3);ADRB2;109690;-;5q32
ADSL;Adenylosuccinase deficiency, 103050 (3);ADSL;608222;AR;22q13.1
ADSL1;Myopathy, distal, 5, 617030 (3);ADSL1, MPD5;612498;AR;14q32.33
AF10;Leukemia, acute myeloid, 601626 (3);AF10;602409;AD;10p12.31
AFA1;Alopecia, androgenetic, 1 (2);AFA1, MPB;109200;AD;3q26
AFF2;Mental retardation, X-linked, FRAXE type, 309548 (3);AFF2, FMR2, FRAXE, MRX2;300806;XLR;Xq28
AFF4;CHOPS syndrome, 616368 (3);AFF4, AF5Q31, CHOPS;604417;AD;5q31.1
AFG3L2;Ataxia, spastic, 5, autosomal recessive, 614487 (3),Spinocerebellar ataxia 28, 610246 (3);AFG3L2, SCA28, SPAX5;604581;AR, AD;18p11.21
AFP;Alpha-fetoprotein deficiency, 615969 (3);AFP, HPAFP, AFPD;104150;AR;4q13.3
AGA;Aspartylglucosaminuria, 208400 (3);AGA;613228;AR;4q34.3
AGA2;Alopecia, androgenetic, 2 (2);AGA2;300710;-;Xq11-q12
AGA3;Alopecia, androgenetic, 3 (2);AGA3;612421;-;20p11.22
AGBL1;Corneal dystrophy, Fuchs endothelial, 8, 615523 (3);AGBL1, CCP4, FECD8;615496;AD;15q25.3
AGBL5;Retinitis pigmentosa 75, 617023 (3);AGBL5, CCP5, RP75;615900;AR;2p23.3
AGK;Cataract 38, autosomal recessive, 614691 (3),Sengers syndrome, 212350 (3);AGK, MULK, MTDPS10, CATC5, CTRCT38;610345;AR;7q34
AGL;Glycogen storage disease IIIa, 232400 (3),Glycogen storage disease IIIb, 232400 (3);AGL, GDE;610860;AR;1p21.2
AGMX2;Agammaglobulinemia, X-linked 2 (2);AGMX2, XLA2, IMD6;300310;XL;Xp22
AGPAT2;Lipodystrophy, congenital generalized, type 1, 608594 (3);AGPAT2, LPAAB, BSCL, BSCL1;603100;AR;9q34.3
AGPS;Rhizomelic chondrodysplasia punctata, type 3, 600121 (3);AGPS, ADHAPS, RCDP3;603051;AR;2q31.2
AGRN;Myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects, 615120 (3);AGRN, CMS8;103320;AR;1p36.33
AGSPX;Angio serpiginosum (2);AGSPX;300652;XLD;Xp11.3-q12
AGT;Renal tubular dysgenesis, 267430 (3);AGT, SERPINA8;106150;AR, Mu;1q42.2
AGTR1;Renal tubular dysgenesis, 267430 (3);AGTR1, AGTR1A, AT2R1;106165;AR, Mu;3q24
AGXT;Hyperoxaluria, primary, type 1, 259900 (3);AGXT, SPAT;604285;AR;2q37.3
AHCY;Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase, 613752 (3);AHCY, SAHH;180960;AR;20q11.22
AHDC1;Xia-Gibbs syndrome, 615829 (3);AHDC1, MRD25;615790;AD;1p36.1-p35.3
AHI1;Joubert syndrome-3, 608629 (3);AHI1;608894;AR;6q23.3
AI1E2;?Amelogenesis imperfecta, type IE, X-linked 2 (2);AI1E2, AIH3;301201;XL;Xq22-q28
AIC;Aicardi syndrome (2);AIC;304050;XLD;Xp22
AICDA;Immunodeficiency with hyper-IgM, type 2, 605258 (3);AICDA, AID, HIGM2;605257;AR;12p13.31
AIFM1;Combined oxidative phosphorylation deficiency 6, 300816 (3),Cowchock syndrome, 310490 (3),Deafness, X-linked 5, 300614 (3);AIFM1, PDCD8, AIF, COXPD6, COWCK, CMTX4, DFNX5;300169;XLR;Xq26.1
AIMP1;Leukodystrophy, hypomyelinating, 3, 260600 (3);AIMP1, SCYE1, EMAP2, EMAPII, HLD3;603605;AR;4q24
AIP;Pituitary adenoma, ACTH-secreting, 219090 (3),Pituitary adenoma, growth hormone-secreting, 102200 (3),Pituitary adenoma, prolactin-secreting, 600634 (3);AIP, XAP2, ARA9;605555;AR; AD, Smu;11q13.2
AIPL1;Cone-rod dystrophy, 604393 (3),Leber congenital amaurosis 4, 604393 (3),Retinitis pigmentosa, juvenile, 604393 (3);AIPL1, LCA4;604392;AR;17p13.2
AIR;Acute insulin response (2);AIR;601676;-;1p31
AIRE;Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia, 240300 (3);AIRE, APECED, APS1;607358;AD, AR;21q22.3
AK1;Hemolytic anemia due to adenylate kinase deficiency, 612631 (3);AK1;103000;AR;9q34.11
AK2;Reticular dysgenesis, 267500 (3);AK2;103020;AR;1p35.1
AKAP9;?Long QT syndrome-11, 611820 (3);AKAP9, YOTIAO, AKAP450;604001;-;7q21.2
AKR1C2;46XY sex reversal 8, 614279 (3),Obesity, hyperphagia, and developmental delay (3);AKR1C2, DDH2, DD2, HAKRD, SRXY8;600450;AR;10p15.1
AKR1D1;Bile acid synthesis defect, congenital, 2, 235555 (3);AKR1D1, SRD5B1, CBAS2;604741;AR;7q33
AKT1;Breast cancer, somatic, 114480 (3),Colorectal cancer, somatic, 114500 (3),Cowden syndrome 6, 615109 (3),Ovarian cancer, somatic, 167000 (3),Proteus syndrome, somatic, 176920 (3);AKT1, CWS6;164730;AD;14q32.33
AKT2;Diabetes mellitus, type II, 125853 (3),Hypoinsulinemic hypoglycemia with hemihypertrophy, 240900 (3);AKT2, HIHGHH;164731;AD;19q13.2
AKT3;Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, 615937 (3);AKT3, PKBG, MPPH2;611223;AD;1q43-q44
ALAD;Porphyria, acute hepatic, 612740 (3);ALAD, ALADH, PBGS;125270;AR;9q32
ALAS2;Anemia, sideroblastic, 1, 300751 (3),Protoporphyria, erythropoietic, X-linked, 300752 (3);ALAS2, ANH1, ASB, XLEPP, XLSA, ANH1, SIDBA1;301300;XLR, XLD;Xp11.21
ALB;Analbuminemia, 616000 (3);ALB, ANALBA, FDAH;103600;-;4q13.3
ALDH18A1;Cutis laxa, autosomal dominant 3, 616603 (3),Cutis laxa, autosomal recessive, type IIIA, 219150 (3),Spastic paraplegia 9A, autosomal dominant, 601162 (3),Spastic paraplegia 9B, autosomal recessive, 616586 (3);ALDH18A1, PYCS, GSAS, ARCL3A, SPG9A, SPG9B, ADCL3;138250;AD; IC, ARD; AD; AR;10q24.1
ALDH1A3;Microphthalmia, isolated 8, 615113 (3);ALDH1A3, ALDH6, MCOP8;600463;AR;15q26.3
ALDH2;Alcohol sensitivity, acute, 610251 (3);ALDH2;100650;-;12q24.12
ALDH3A2;Sjogren-Larsson syndrome, 270200 (3);ALDH3A2, ALDH10, SLS, FALDH;609523;AR;17p11.2
ALDH4A1;Hyperprolinemia, type II, 239510 (3);ALDH4A1, ALDH4, P5CDH;606811;AR;1p36.13
ALDH5A1;Succinic semialdehyde dehydrogenase deficiency, 271980 (3);ALDH5A1, SSADH;610045;AR;6p22.3
ALDH6A1;Methylmalonate semialdehyde dehydrogenase deficiency, 614105 (3);ALDH6A1, MMSDH;603178;AR;14q24.3
ALDH7A1;Epilepsy, pyridoxine-dependent, 266100 (3);ALDH7A1, ATQ1, EPD, PDE;107323;AR;5q23.2
ALDOA;Glycogen storage disease XII, 611881 (3);ALDOA, GSD12;103850;AR;16p11.2
ALDOB;Fructose intolerance, 229600 (3);ALDOB;612724;AR;9q31.1
ALG1;Congenital disorder of glycosylation, type Ik, 608540 (3);ALG1, HMAT1, HMT1, CDG1K;605907;AR;16p13.3
ALG11;Congenital disorder of glycosylation, type Ip, 613661 (3);ALG11, KIAA1266, CDG1P;613666;AR;13q14.3
ALG12;Congenital disorder of glycosylation, type Ig, 607143 (3);ALG12, CDG1G;607144;-;22q13.33
ALG13;Epileptic encephalopathy, early infantile, 36, 300884 (3);ALG13, GLT28D1, CDG1S, EIEE36;300776;XLR;Xq23
ALG14;?Myasthenic syndrome, congenital, 15, without tubular aggregates, 616227 (3);ALG14, CMS15;612866;-;1p21.3
ALG2;?Congenital disorder of glycosylation, type Ii, 607906 (3),Myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 (3);ALG2, CDGII, CMSTA3, CMS14;607905;AR;9q22.33
ALG3;Congenital disorder of glycosylation, type Id, 601110 (3);ALG3, NOT56L, CDGS4, CDG1D;608750;AR;3q27.1
ALG6;Congenital disorder of glycosylation, type Ic, 603147 (3);ALG6, CDG1C;604566;AR;1p31.3
ALG8;Congenital disorder of glycosylation, type Ih, 608104 (3);ALG8, CDG1H;608103;NOTHING;11q14.1
ALG9;Congenital disorder of glycosylation, type Il, 608776 (3),Gillessen-Kaesbach-Nishimura syndrome, 263210 (3);ALG9, DIBD1, CDG1L, GIKANIS;606941;AR;11q23.1
ALMS1;Alstrom syndrome, 203800 (3);ALMS1, ALSS, KIAA0328;606844;AR;2p13.1
ALOX12B;Ichthyosis, congenital, autosomal recessive 2, 242100 (3);ALOX12B, ARCI2;603741;AR;17p13.1
ALOXE3;Ichthyosis, congenital, autosomal recessive 3, 606545 (3);ALOXE3, ARCI3;607206;AR;17p13.1
ALPL;Hypophosphatasia, adult, 146300 (3),Hypophosphatasia, childhood, 241510 (3),Hypophosphatasia, infantile, 241500 (3),Odontohypophosphatasia, 146300 (3);ALPL, HOPS, TNSALP;171760;AD, AR; AR; AR; AD, AR;1p36.12
ALS2;Amyotrophic lateral sclerosis 2, juvenile, 205100 (3),Primary lateral sclerosis, juvenile, 606353 (3),Spastic paralysis, infantile onset ascending, 607225 (3);ALS2, ALSJ, PLSJ, IAHSP;606352;AR;2q33.1
ALS3;Amyotrophic lateral sclerosis 3 (2);ALS3;606640;AD;18q21
ALS7;Amyotrophic lateral sclerosis 7 (2);ALS7;608031;-;20p13
ALX1;?Frontonasal dysplasia 3, 613456 (3);ALX1, CART1, FND3;601527;-;12q21.31
ALX3;Frontonasal dysplasia 1, 136760 (3);ALX3, FND1;606014;AR;1p13.3
ALX4;Frontonasal dysplasia 2, 613451 (3),Parietal foramina 2, 609597 (3);ALX4, PFM2, FPP, FND2, CRS5;605420;AR, AD;11p11.2
AMACR;Alpha-methylacyl-CoA racemase deficiency, 614307 (3),Bile acid synthesis defect, congenital, 4, 214950 (3);AMACR, CBAS4, AMACRD;604489;AR, AR;5p13.2
AMBN;Amelogenesis imperfecta, type IF, 616270 (3);AMBN, AI1F;601259;AR;4q13.3
AMCN;Arthrogryposis multiplex congenita, neurogenic (2);AMCN, AMCN1;208100;AR;5q35
AMELX;Amelogenesis imperfecta, type 1E, 301200 (3);AMELX, AMG, AIH1, AMGX, AI1E;300391;XLD;Xp22.2
AMER1;Osteopathia striata with cranial sclerosis, 300373 (3);AMER1, FAM123B, WTX, OSCS;300647;XLD;Xq11.2
AMH;Persistent Mullerian duct syndrome, type I, 261550 (3);AMH, MIF;600957;AR;19p13.3
AMHR2;Persistent Mullerian duct syndrome, type II, 261550 (3);AMHR2, AMHR;600956;AR;12q13.13
AMMEC;Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis (4);AMMEC, DELXq22.3, CXDELq22.3;300194;-;Xq22.3
AMN;Megaloblastic anemia-1, Norwegian type, 261100 (3);AMN;605799;AR;14q32.32
AMPD1;Myopathy due to myoadenylate deaminase deficiency, 615511 (3);AMPD1, MMDD;102770;AR;1p13.2
AMPD2;?Spastic paraplegia 63, 615686 (3),Pontocerebellar hypoplasia, type 9, 615809 (3);AMPD2, SPG63, PCH9;102771;AR;1p13.3
AMT;Glycine encephalopathy, 605899 (3);AMT, NKH, GCE;238310;AR;3p21.31
ANBC;Aneurysmal bone cysts (2);ANBC;606179;-;16q22
ANC;?Anal canal carcinoma (2);ANC;105580;AD;11q22-qter
ANG;Amyotrophic lateral sclerosis 9, 611895 (3);ANG, RNASE5, ALS9;105850;-;14q11.2
ANGPTL3;Hypobetalipoproteinemia, familial, 2, 605019 (3);ANGPTL3, ANGPT5, FHBL2;604774;AR;1p31.3
ANGPTL4;Plasma triglyceride level QTL, low, 615881 (3);ANGPTL4, PGAR, HFARP, FIAF, TGQTL;605910;AD;19p13.2
ANIB1;Aneurysm, intracranial berry, 1 (2);ANIB1;105800;AD;7q11.2
ANIB11;Aneurysm, intracranial berry, 11 (2);ANIB11;614252;-;8p22
ANIB2;Aneurysm, intracranial berry, 2 (2);ANIB2;608542;-;19q13
ANIB3;Aneurysm, intracranial berry, 3 (2);ANIB3;609122;AD;1p36.13-p34.3
ANIB4;Aneurysm, intracranial berry, 4 (2);ANIB4;610213;-;5p15.2-p14.3
ANIB5;Aneurysm, intracranial berry, 5 (2);ANIB5;300870;-;Xp22
ANIB7;Aneurysm, intracranial berry, 7 (2);ANIB7;612161;-;11q24-q25
ANIB8;Aneurysm, intracranial berry, 8 (2);ANIB8;612162;-;14q23
ANIC;Anosmia, isolated congenital (2);ANIC;107200;AD;18p11.23-q12.2
ANK1;Spherocytosis, type 1, 182900 (3);ANK1, SPH1;612641;AD;8p11.21
ANK2;Cardiac arrhythmia, ankyrin-B-related, 600919 (3),Long QT syndrome 4, 600919 (3);ANK2, LQT4;106410;AD;4q25-q26
ANK3;?Mental retardation, autosomal recessive, 37, 615493 (3);ANK3, MRT37;600465;AR;10q21.2
ANKH;Chondrocalcinosis 2, 118600 (3),Craniometaphyseal dysplasia, 123000 (3);ANKH, HANK, ANK, CMDJ, CCAL2, CPPDD;605145;AD;5p15.2
ANKK1;Dopamine receptor D2, reduced brain density of (3);ANKK1;608774;-;11q23.2
ANKLE2;?Microcephaly 16, primary, autosomal recessive, 616681 (3);ANKLE2, LEM4, KIAA0692, MCPH16;616062;AR;12q24.33
ANKRD11;KBG syndrome, 148050 (3);ANKRD11, ANCO1, KBGS;611192;AD;16q24.3
ANKRD26;Thrombocytopenia 2, 188000 (3);ANKRD26, KIAA1074, THC2;610855;AD;10p12.1
ANKS6;Nephronophthisis 16, 615382 (3);ANKS6, PKDR1, NPHP16;615370;AR;9q22.33
ANLN;Focal segmental glomerulosclerosis 8, 616032 (3);ANLN, FSFS8;616027;AD;7p14.2
ANMA;Anisomastia (2);ANMA;605746;-;16q13-q21
ANO10;Spinocerebellar ataxia, autosomal recessive 10, 613728 (3);ANO10, TMEM16K, SCAR10;613726;AR;3p22.1-p21.3
ANO3;Dystonia 24, 615034 (3);ANO3, TMEM16C, C11orf25, DYT24;610110;AD;11p14.3-p14.2
ANO5;Gnathodiaphyseal dysplasia, 166260 (3),Miyoshi muscular dystrophy 3, 613319 (3),Muscular dystrophy, limb-girdle, type 2L, 611307 (3);ANO5, TMEM16E, GDD1, LGMD2L;608662;AD, AR;11p14.3
ANO6;Scott syndrome, 262890 (3);ANO6, TMEM16F, SCTS, BDPLT7;608663;AR;12q12
ANTXR1;GAPO syndrome, 230740 (3);ANTXR1, TEM8, ATR, GAPO;606410;AR, AD;2p13.3
ANTXR2;Hyaline fibromatosis syndrome, 228600 (3);ANTXR2, CMG2, HFS;608041;AR;4q21.21
AOCH;Acromegaloid features, overgrowth, cleft palate, and hernia (2);AOCH;606049;-;Chr.11
AOMS1;Abdominal obesity-metabolic syndrome 1 (2);AOMS1, SYNX;605552;-;3q27
AOMS2;Abdominal obesity-metabolic syndrome (2);AOMS2;605572;-;17p12
AP1S1;MEDNIK syndrome, 609313 (3);AP1S1, CLAPS1, AP19, MEDNIK;603531;AR;7q22.1
AP1S2;Mental retardation, X-linked syndromic 5, 304340 (3);AP1S2, MRX59, MRXSF, MRXS21, MRXS5, PGS;300629;XLR;Xp22.2
AP2S1;Hypocalciuric hypercalcemia, familial, type III, 600740 (3);AP2S1, CLAPS2, AP17, HHC3;602242;AD;19q13.32
AP3B1;Hermansky-Pudlak syndrome 2, 608233 (3);AP3B1, ADTB3A, HPS2;603401;AR;5q14.1
AP4B1;Spastic paraplegia 47, autosomal recessive, 614066 (3);AP4B1, SPG47, CPSQ5;607245;AR;1p13.2
AP4E1;Spastic paraplegia 51, autosomal recessive, 613744 (3),Stuttering, familial persistent, 1, 184450 (3);AP4E1, SPG51, CPSQ4, STUT1;607244;AR, AD;15q21.2
AP4M1;Spastic paraplegia 50, autosomal recessive, 612936 (3);AP4M1, SPG50, CPSQ3;602296;AR;7q22.1
AP4S1;Spastic paraplegia 52, autosomal recessive, 614067 (3);AP4S1, CPSQ6, SPG52;607243;AR;14q12
AP5Z1;Spastic paraplegia 48, autosomal recessive, 613647 (3);AP5Z1, KIAA0415, SPG48;613653;AR;7p22.1
APC;Adenoma, periampullary, somatic (3),Adenomatous polyposis coli, 175100 (3),Brain tumor-polyposis syndrome 2, 175100 (3),Colorectal cancer, somatic, 114500 (3),Desmoid disease, hereditary, 135290 (3),Gardner syndrome, 175100 (3),Gastric cancer, somatic, 613659 (3),Hepatoblastoma, somatic, 114550 (3);APC, GS, FPC, BTPS2;611731;AD;5q22.2
APCDD1;Hypotrichosis 1, 605389 (3);APCDD1, HHS, HYPT1, HTS;607479;-;18p11.22
APMR1;Alopecia-mental retardation syndrome 1 (2);APMR1;203650;AR;3q26.3-q27.3
APMR2;Alopecia-mental retardation syndrome 2 (2);APMR2;610422;AR;3q26.2-q26.31
APMR3;Alopecia-mental retardation syndrome 3 (2);APMR3;613930;AR;18q11.2-q12.2
APOA1;Amyloidosis, 3 or more types, 105200 (3),ApoA-I and apoC-III deficiency, combined (3),Corneal clouding, autosomal recessive (3),Hypoalphalipoproteinemia, 604091 (3);APOA1;107680;AD;11q23.3
APOA2;Apolipoprotein A-II deficiency (3);APOA2;107670;-;1q23.3
APOA5;Hyperchylomicronemia, late-onset, 144650 (3);APOA5;606368;AD;11q23.3
APOB;Hypercholesterolemia, due to ligand-defective apo B, 144010 (3),Hypobetalipoproteinemia, 615558 (3);APOB, FLDB, LDLCQ4;107730;AD, AR;2p24.1
APOC2;Hyperlipoproteinemia, type Ib, 207750 (3);APOC2;608083;AR;19q13.32
APOC3;Apolipoprotein C-III deficiency, 614028 (3);APOC3, HALP2;107720;-;11q23.3
APOE;Alzheimer disease-2, 104310 (3),Hyperlipoproteinemia, type III (3),Lipoprotein glomerulopathy, 611771 (3),Sea-blue histiocyte disease, 269600 (3);APOE, AD2, LPG, LDLCQ5;107741;AD, AR;19q13.32
APOPT1;Mitochondrial complex IV deficiency, 220110 (3);APOPT1, APOP;616003;Mi, AR;14q32.33
APP;Alzheimer disease 1, familial, 104300 (3),Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants, 605714 (3);APP, AAA, CVAP, AD1;104760;AD;21q21.3
APRT;Adenine phosphoribosyltransferase deficiency, 614723 (3);APRT, APRTD;102600;AR;16q24.3
APTX;Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3);APTX, AOA, AOA1;606350;AR;9p21.1
AQP2;Diabetes insipidus, nephrogenic, 125800 (3);AQP2;107777;AD, AR;12q13.12
AQP5;Palmoplantar keratoderma, Bothnian type, 600231 (3);AQP5, PPKB;600442;AD;12q13.12
AR;Androgen insensitivity, 300068 (3),Androgen insensitivity, partial, with or without breast cancer, 312300 (3),Hypospadias 1, X-linked, 300633 (3),Spinal and bulbar muscular atrophy of Kennedy, 313200 (3);AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1;313700;XLD, AD;Xq12
ARCI7;Ichthyosis, congenital, autosomal recessive 7 (2);ARCI7;615022;AR;12p11.2-q13.1
ARFGEF2;Periventricular heterotopia with microcephaly, 608097 (3);ARFGEF2, BIG2, PVNH2;605371;AR;20q13.13
ARG1;Argininemia, 207800 (3);ARG1;608313;AR;6q23.2
ARHGAP26;Leukemia, juvenile myelomonocytic, somatic, 607785 (3);ARHGAP26, GRAF;605370;-;5q31.3
ARHGAP31;Adams-Oliver syndrome 1, 100300 (3);ARHGAP31, CDGAP, KIAA1204, AOS1;610911;AD;3q13.32-q13.33
ARHGDIA;Nephrotic syndrome, type 8, 615244 (3);ARHGDIA, GDIA1, NPHS8;601925;AR;17q25.3
ARHGEF10;?Slowed nerve conduction velocity, AD, 608236 (3);ARHGEF10, KIAA0294, SNCV;608136;AD;8p23.3
ARHGEF6;Mental retardation, X-linked 46, 300436 (3);ARHGEF6, MRX46, COOL2;300267;XLR;Xq26.3
ARHGEF9;Epileptic encephalopathy, early infantile, 8, 300607 (3);ARHGEF9, PEM2, KIAA0424, EIEE8;300429;XLR;Xq11.1
ARID1A;Coffin-Siris syndrome 2, 614607 (3);ARID1A, C1orf4, B120, SMARCF1, MRD14, CSS2;603024;AD;1p36.11
ARID1B;Coffin-Siris syndrome 1, 135900 (3);ARID1B, BAF250B, KIAA1235, MRD12, CSS1;614556;AD;6q25.3
ARL13B;Joubert syndrome 8, 612291 (3);ARL13B, ARL2L1, JBTS8;608922;-;3q11.1-q11.2
ARL2BP;Retinitis pigmentosa with or without situs inversus, 615434 (3);ARL2BP, BART;615407;AR;16q13
ARL6;?Retinitis pigmentosa 55, 613575 (3),Bardet-Biedl syndrome 3, 600151 (3);ARL6, BBS3, RP55;608845;AR, DR, AR;3q11.2
ARL6IP1;?Spastic paraplegia 61, autosomal recessive, 615685 (3);ARL6IP1, KIAA0069, SPG61;607669;AR;16p12.3
ARMC4;Ciliary dyskinesia, primary, 23, 615451 (3);ARMC4, CILD23;615408;AR;10p12.1
ARMC5;ACTH-independent macronodular adrenal hyperplasia 2, 615954 (3);ARMC5, AIMAH2;615549;SMu,AD;16p11.2
ARMD10;Macular degeneration, age-related, 10 (2);ARMD10;611488;-;9q32-q33
ARNT2;?Webb-Dattani syndrome, 615926 (3);ARNT2, WEDAS;606036;AR;15q25.1
ARSA;Metachromatic leukodystrophy, 250100 (3);ARSA;607574;AR;22q13.33
ARSB;Mucopolysaccharidosis type VI (Maroteaux-Lamy), 253200 (3);ARSB, MPS6;611542;AR;5q14.1
ARSE;Chondrodysplasia punctata, X-linked recessive, 302950 (3);ARSE, CDPX1, CDPXR;300180;XLR;Xp22.33
ARV1;Epileptic encephalopathy, early infantile, 38, 617020 (3);ARV1, EIEE38;611647;AR;1q42.2
ARVD3;Arrhythmogenic right ventricular dysplasia 3 (2);ARVD3;602086;AD;14q12-q22
ARVD4;Arrhythmogenic right ventricular dysplasia 4 (2);ARVD4;602087;AD;2q32.1-q32.3
ARVD6;Arrhythmogenic right ventricular dysplasia 6 (2);ARVD6;604401;-;10p14-p12
ARX;Epileptic encephalopathy, early infantile, 1, 308350 (3),Hydranencephaly with abnormal genitalia, 300215 (3),Lissencephaly, X-linked 2, 300215 (3),Mental retardation, X-linked 29 and others, 300419 (3),Partington syndrome, 309510 (3),Proud syndrome, 300004 (3);ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32;300382;XLR, XL;Xp21.3
ASAH1;Farber lipogranulomatosis, 228000 (3),Spinal muscular atrophy with progressive myoclonic epilepsy, 159950 (3);ASAH1, AC, SMAPME;613468;AR;8p22
ASB10;Glaucoma 1, open angle, F, 603383 (3);ASB10, GLC1F;615054;-;7q36.1
ASCC1;?Spinal muscular atrophy with congenital bone fractures 2, 616867 (3),Barrett esophagus/esophageal adenocarcinoma, 614266 (3);ASCC1, p50, SMABF2;614215;AR;10q22.1
ASCL1;Central hypoventilation syndrome, congenital, 209880 (3),Haddad syndrome, 209880 (3);ASCL1, ASH1;100790;AD;12q23.2
ASD1;Atrial septal defect 1 (2);ASD1;108800;AD;5p
ASL;Argininosuccinic aciduria, 207900 (3);ASL;608310;AR;7q11.21
ASNS;Asparagine synthetase deficiency, 615574 (3);ASNS, ASNSD;108370;AR;7q21.3
ASPA;Canavan disease, 271900 (3);ASPA;608034;AR;17p13.2
ASPH;Traboulsi syndrome, 601552 (3);ASPH, HAAH, FDLAB;600582;AR;8q12.3
ASPM;Microcephaly 5, primary, autosomal recessive, 608716 (3);ASPM, MCPH5;605481;AR;1q31.3
ASPSCR1;Alveolar soft-part sarcoma, 606243 (3);ASPSCR1, RCC17, ASPL, ASPS;606236;-;17q25.3
ASS1;Citrullinemia, 215700 (3);ASS1, ASS;603470;AR;9q34.11
ASXL1;Bohring-Opitz syndrome, 605039 (3),Myelodysplastic syndrome, somatic, 614286 (3);ASXL1, KIAA0978, BOPS, MDS;612990;AD;20q11.21
ASXL3;Bainbridge-Ropers syndrome, 615485 (3);ASXL3, KIAA1713, BRPS;615115;-;18q12.1
ATCAY;Ataxia, cerebellar, Cayman type, 601238 (3);ATCAY, CLAC, KIAA1872;608179;AR;19p13.3
ATF6;Achromatopsia 7, 616517 (3);ATF6, ACHM7;605537;AR;1q23.3
ATFB1;Atrial fibrillation, familial, 1 (2);ATFB1;608583;AD;10q22-q24
ATFB2;Atrial fibrillation, familial, 2 (2);ATFB2;608988;-;6q14-q16
ATFB8;Atrial fibrillation, familial, 8 (2);ATFB8;613055;-;16q22
ATIC;AICA-ribosiduria due to ATIC deficiency, 608688 (3);ATIC, PURH, AICAR;601731;AR;2q35
ATL1;Neuropathy, hereditary sensory, type ID, 613708 (3),Spastic paraplegia 3A, autosomal dominant, 182600 (3);ATL1, SPG3A, HSN1D;606439;AD;14q22.1
ATL3;Neuropathy, hereditary sensory, type IF, 615632 (3);ATL3, HSN1F;609369;AD;11q13.1
ATM;Ataxia-telangiectasia, 208900 (3),Lymphoma, B-cell non-Hodgkin, somatic (3),Lymphoma, mantle cell, somatic (3),T-cell prolymphocytic leukemia, somatic (3);ATM, ATA, AT1;607585;AR, AD;11q22.3
ATN1;Dentatorubro-pallidoluysian atrophy, 125370 (3);ATN1, DRPLA, HRS, NOD;607462;AD;12p13.31
ATOH7;Persistent hyperplastic primary vitreous, autosomal recessive, 221900 (3);ATOH7, PHPVAR, NCRNA;609875;AR;10q21.3
ATP13A2;?Ceroid lipofuscinosis, neuronal, 12, 606693 (3),Kufor-Rakeb syndrome, 606693 (3);ATP13A2, PARK9, KRPPD, CLN12;610513;AR;1p36.13
ATP1A2;Alternating hemiplegia of childhood, 104290 (3),Migraine, familial basilar, 602481 (3),Migraine, familial hemiplegic, 2, 602481 (3);ATP1A2, FHM2, MHP2;182340;AD;1q23.2
ATP1A3;Alternating hemiplegia of childhood 2, 614820 (3),CAPOS syndrome, 601338 (3),Dystonia-12, 128235 (3);ATP1A3, DYT12, RDP, AHC2, CAPOS;182350;AD;19q13.2
ATP2A1;Brody myopathy, 601003 (3);ATP2A1, SERCA1;108730;AR;16p11.2
ATP2A2;Acrokeratosis verruciformis, 101900 (3),Darier disease, 124200 (3);ATP2A2, ATP2B, DAR;108740;AD;12q24.11
ATP2B3;?Spinocerebellar ataxia, X-linked 1, 302500 (3);ATP2B3, PMCA3, SCAX1;300014;XLR;Xq28
ATP2C1;Hailey-Hailey disease, 169600 (3);ATP2C1, BCPM, HHD;604384;AD;3q22.1
ATP5A1;?Combined oxidative phosphorylation deficiency 22, 616045 (3),?Mitochondrial complex (ATP synthase) deficiency, nuclear type 4, 615228 (3);ATP5A1, ATPM, ATP5A, ORM, MC5DN4, COXPD22;164360;AR,AR;18q21.1
ATP5E;?Mitochondrial complex V (ATP synthase) deficiency, nuclear type 3, 614053 (3);ATP5E, MC5DN3;606153;-;20q13.32
ATP6AP1;Immunodeficiency 47, 300972 (3);ATP6AP1, ATP6IP1, ATP6S1, VATPS1;300197;XLR;Xq28
ATP6AP2;?Mental retardation, X-linked, syndromic, Hedera type, 300423 (3),?Parkinsonism with spasticity, X-linked, 300911 (3);ATP6AP2, ATP6M8-9, XMRE, MRXSH, XPDS;300556;XLR,AR;Xp11.4
ATP6B1;Renal tubular acidosis with deafness, 267300 (3);ATP6B1, VPP3;192132;AR;2p13.3
ATP6B1B2;Deafness, congenital, with onychodystrophy, autosomal dominant, 124480 (3),Zimmermann-Laband syndrome 2, 616455 (3);ATP6B1B2, ATP6B2, VPP3, DOOD, ZLS2;606939;AD;8p21.3
ATP6V0A2;Cutis laxa, autosomal recessive, type IIA, 219200 (3),Wrinkly skin syndrome, 278250 (3);ATP6V0A2, WSS, ARCL2A;611716;AR;12q24.31
ATP6V0A4;Renal tubular acidosis, distal, autosomal recessive, 602722 (3);ATP6V0A4, ATP6N1B, VPP2, RTA1C, RTADR;605239;-;7q34
ATP7A;Menkes disease, 309400 (3),Occipital horn syndrome, 304150 (3),Spinal muscular atrophy, distal, X-linked 3, 300489 (3);ATP7A, MNK, MK, OHS, SMAX3;300011;XLR;Xq21.1
ATP7B;Wilson disease, 277900 (3);ATP7B, WND;606882;AR;13q14.3
ATP8A2;?Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 4, 615268 (3);ATP8A2, ATPIB, CAMRQ4;605870;AR;13q12.13
ATP8B1;Cholestasis, benign recurrent intrahepatic, 243300 (3),Cholestasis, intrahepatic, of pregnancy, 1, 147480 (3),Cholestasis, progressive familial intrahepatic 1, 211600 (3);ATP8B1, FIC1, BRIC, PFIC1, ICP1;602397;AR, AD;18q21.31
ATPAF2;Mitochondrial complex V (ATP synthase) deficiency, nuclear type 1, 604273 (3);ATPAF2, ATP12, MC5DN1;608918;AR;17p11.2
ATPLS;?Antiphospholipid syndrome, familial (2);ATPLS;107320;AD;6p21.3
ATR;?Cutaneous telangiectasia and cancer syndrome, familial, 614564 (3),Seckel syndrome 1, 210600 (3);ATR, FRP1, SCKL1, FCTCS;601215;AD, AR;3q23
ATRX;Alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3),Alpha-thalassemia/mental retardation syndrome, 301040 (3),Mental retardation-hypotonic facies syndrome, X-linked, 309580 (3);ATRX, XH2, XNP, SHS, SFM1, MRXHF1;300032;XLD, XLR;Xq21.1
ATXN1;Spinocerebellar ataxia 1, 164400 (3);ATXN1, ATX1, SCA1;601556;AD;6p22.3
ATXN10;Spinocerebellar ataxia 10, 603516 (3);ATXN10, SCA10;611150;AD;22q13.31
ATXN2;Spinocerebellar ataxia 2, 183090 (3);ATXN2, ATX2, SCA2, ASL13;601517;AD; IC, Mu;12q24.12
ATXN3;Machado-Joseph disease, 109150 (3);ATXN3, MJD, SCA3;607047;AD;14q32.12
ATXN7;Spinocerebellar ataxia 7, 164500 (3);ATXN7, SCA7, OPCA3;607640;AD;3p14.1
ATXN8;Spinocerebellar ataxia 8, 608768 (3);ATXN8;613289;AD;13q21
ATXN8OS;Spinocerebellar ataxia 8, 608768 (3);ATXN8OS, SCA8, KLHL1AS;603680;AD;13q21.33
AUH;3-methylglutaconic aciduria, type I, 250950 (3);AUH;600529;AR;9q22.31
AURKC;Spermatogenic failure 5, 243060 (3);AURKC, STK13, AIE2, SPGF5;603495;AR;19q13.43
AVP;Diabetes insipidus, neurohypophyseal, 125700 (3);AVP, AVRP, VP;192340;AD;20p13
AVPR2;Diabetes insipidus, nephrogenic, 304800 (3),Nephrogenic syndrome of inappropriate antidiuresis, 300539 (3);AVPR2, DIR, DI1, ADHR;300538;XLR;Xq28
AXIN1;?Caudal duplication anomaly, 607864 (3),Hepatocellular carcinoma, somatic, 114550 (3);AXIN1, AXIN;603816;-;16p13.3
AXIN2;Colorectal cancer, somatic, 114500 (3),Oligodontia-colorectal cancer syndrome, 608615 (3);AXIN2, ODCRCS;604025;AD;17q24.1
B2M;?Amyloidosis, familial visceral, 105200 (3),Immunodeficiency 43, 241600 (3);B2M, IMD43;109700;AD, AR;15q21.1
B3GALNT2;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11, 615181 (3);B3GALNT2, MGC39558, MDDGA11;610194;AR;1q42.3
B3GALT6;Ehlers-Danlos syndrome, progeroid type, 2, 615349 (3),Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640 (3);B3GALT6, SEMDJL1, EDSP2;615291;AR;1p36.33
B3GAT3;Multiple joint dislocations, short stature, craniofacial dysmorphism, with or without congenital heart defects, 245600 (3);B3GAT3, GLCATI, JDSCD;606374;AR;11q12.3
B3GLCT;Peters-plus syndrome, 261540 (3);B3GLCT, B3GALTL, B3GTL;610308;AR;13q12.3
B3GNT1;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13, 615287 (3);B3GNT1, IGNT, IGAT, MDDGA13;605517;AR;11q13.2
B4GALNT1;Spastic paraplegia 26, autosomal recessive, 609195 (3);B4GALNT1, GALGT, GALNACT, SPG26;601873;AR;12q13.3
B4GALT1;Congenital disorder of glycosylation, type IId, 607091 (3);B4GALT1, GGTB2, GT1, GTB, CDG2D;137060;AR;9p21.1
B4GALT7;Ehlers-Danlos syndrome with short stature and limb anomalies, 130070 (3);B4GALT7, XGALT1, XGPT1, EDSSLA;604327;AR;5q35.3
B9D1;?Meckel syndrome 9, 614209 (3);B9D1, MKSR1, MKS9;614144;AR;17p11.2
B9D2;Meckel syndrome 10, 614175 (3);B9D2, MKS10;611951;AR;19q13.2
BAAT;Hypercholanemia, familial, 607748 (3);BAAT;602938;-;9q31.1
BAG3;Cardiomyopathy, dilated, 1HH, 613881 (3),Myopathy, myofibrillar, 6, 612954 (3);BAG3, MFM6;603883;AD;10q26.11
BANF1;Nestor-Guillermo progeria syndrome, 614008 (3);BANF1, BAF, NGPS;603811;AR;11q13.1
BAP1;Tumor predisposition syndrome, 614327 (3);BAP1, TPDS;603089;AD;3p21.1
BAX;Colorectal cancer, somatic, 114500 (3),T-cell acute lymphoblastic leukemia, somatic, 613065 (3);BAX;600040;-;19q13.33
BBIP1;?Bardet-Biedl syndrome 18, 615995 (3);BBIP1, NCRNA00081, BBIP10, BBS18;613605;AR;10q25.2
BBS1;Bardet-Biedl syndrome 1, 209900 (3);BBS1;209901;DR, AR;11q13.2
BBS10;Bardet-Biedl syndrome 10, 615987 (3);BBS10, C12orf58, FLJ23560;610148;AR;12q21.2
BBS12;Bardet-Biedl syndrome 12, 615989 (3);BBS12, FLJ35630, C4orf24;610683;AR;4q27
BBS2;Bardet-Biedl syndrome 2, 615981 (3),Retinitis pigmentosa 74, 616562 (3);BBS2, RP74;606151;AR;16q13
BBS4;Bardet-Biedl syndrome 4, 615982 (3);BBS4;600374;AR;15q24.1
BBS5;Bardet-Biedl syndrome 5, 615983 (3);BBS5;603650;AR;2q31.1
BBS7;Bardet-Biedl syndrome 7, 615984 (3);BBS7;607590;AR;4q27
BCAP31;Deafness, dystonia, and cerebral hypomyelination, 300475 (3);BCAP31, BAP31, DXS1357E, DDCH;300398;XLR;Xq28
BCAT1;?Hyperleucinemia-isoleucinemia or hypervalinemia (1);BCAT1, BCT1;113520;-;12p12.1
BCAT2;?Hypervalinemia or hyperleucine-isoleucinemia (1);BCAT2, BCT2;113530;-;19q13.33
BCHE;Apnea, postanesthetic (3);BCHE, CHE1;177400;-;3q26.1
BCKDHA;Maple syrup urine disease, type Ia, 248600 (3);BCKDHA, MSUD1;608348;AR;19q13.2
BCKDHB;Maple syrup urine disease, type Ib, 248600 (3);BCKDHB, E1B;248611;AR;6q14.1
BCKDK;Branched-chain ketoacid dehydrogenase kinase deficiency, 614923 (3);BCKDK, BDK, BCKDKD;614901;-;16p11.2
BCL10;?Immunodeficiency 37, 616098 (3),Lymphoma, MALT, somatic, 137245 (3);BCL10, IMD37;603517;AR;1p22.3
BCL2;Leukemia/lymphoma, B-cell, 2 (3);BCL2;151430;-;18q21.33
BCL3;Leukemia/lymphoma, B-cell, 3 (2);BCL3;109560;-;19q13.32
BCL6;Lymphoma, B-cell (2);BCL6;109565;-;3q27.3
BCL7A;B-cell non-Hodgkin lymphoma, high-grade (3);BCL7A, BCL7;601406;-;12q24.31
BCMO1;Hypercarotenemia and vitamin A deficiency, autosomal dominant, 115300 (3);BCMO1, BCDO, BCO1;605748;AD;16q23.2
BCOR;Microphthalmia, syndromic 2, 300166 (3);BCOR, KIAA1575, MCOPS2, MAA2, ANOP2;300485;XLD;Xp11.4
BCPR;Breast cancer (1);BCPR;113721;-;17p13.3
BCR;Leukemia, acute lymphocytic, somatic, 613065 (3),Leukemia, chronic myeloid, somatic, 608232 (3);BCR, CML, PHL, ALL;151410;-;22q11.23
BCS1L;Bjornstad syndrome, 262000 (3),GRACILE syndrome, 603358 (3),Leigh syndrome, 256000 (3),Mitochondrial complex III deficiency, nuclear type 1, 124000 (3);BCS1L, FLNMS, GRACILE, BJS, PTD, MC3DN1;603647;AR; Mi, AR; AR;2q35
BDA1B;Brachydactyly, type A1, B (2);BDA1B;607004;AD;5p13.3-p13.2
BDET;Bleeding disorder, east Texas type (2);BDET;605913;-;1q23
BDMR;Chromosome 2q37 deletion syndrome (4);BDMR, C2DELq37, DEL2q37;600430;AD;2q37
BDNF;Central hypoventilation syndrome, congenital, 209880 (3);BDNF, BULN2, ANON2;113505;AD, Mu;11p14.1
BEAN;Spinocerebellar ataxia 31, 117210 (3);BEAN, SCA31;612051;AD;16q21
BED;Bornholm eye disease (2);BED;300843;XLR;Xq28
BEST1;Bestrophinopathy, autosomal recessive, 611809 (3),Macular dystrophy, vitelliform, 2, 153700 (3),Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma, 193220 (3),Retinitis pigmentosa, concentric, 613194 (3),Retinitis pigmentosa-50, 613194 (3),Vitreoretinochoroidopathy, 193220 (3);BEST1, VMD2, ARB, RP50;607854;AD;11q12.3
BFIS1;Seizures, benign familial infantile, 1 (2);BFIS1, BFIC1;601764;AD;19q
BFIS4;Seizures, benign familial infantile, 4 (2);BFIS4, BFIC4;612627;-;1p36.12-p35.1
BFSP1;Cataract 33, 611391 (3);BFSP1, CP115, CTRCT33;603307;-;20p12.1
BFSP2;Cataract 12, multiple types, 611597 (3);BFSP2, CP49, CP47, CTRCT12;603212;AD;3q22.1
BHLHA9;Syndactyly, mesoaxial synostotic, with phalangeal reduction, 609432 (3);BHLHA9, BHLHF42, MSSD;615416;AR;17p13.3
BICD2;Spinal muscular atrophy, lower extremity-predominant, 2, AD, 615290 (3);BICD2, KIAA0699, SMALED2;609797;AD;9q22.31
BIN1;Myopathy, centronuclear, autosomal recessive, 255200 (3);BIN1, AMPHL;601248;AR;2q14.3
BLK;Maturity-onset diabetes of the young, type 11, 613375 (3);BLK, MODY11;191305;AD;8p23.1
BLNK;Agammaglobulinemia 4, 613502 (3);BLNK, SLP65, AGM4;604515;AR;10q24.1
BLOC1S3;Hermansky-Pudlak syndrome 8, 614077 (3);BLOC1S3, BLOS3, HPS8;609762;-;19q13.32
BLOC1S6;Hermansky-pudlak syndrome 9, 614171 (3);BLOC1S6, BLOS6, PLDN, PA, HPS9;604310;AR;15q21.1
BLVRA;Hyperbiliverdinemia, 614156 (3);BLVRA;109750;AD, AR;7p13
BMIQ16;Chromosome 16p11.2 deletion syndrome, 220kb (4);BMIQ16, DEL16p.11.2, C16DELp11.2;613444;-;16p11.2
BMP1;Osteogenesis imperfecta, type XIII, 614856 (3);BMP1, OI13;112264;AR;8p21.3
BMP15;Ovarian dysgenesis 2, 300510 (3),Premature ovarian failure 4, 300510 (3);BMP15, GDF9B, ODG2, POF4;300247;-;Xp11.22
BMP2;Brachydactyly, type A2, 112600 (3);BMP2, BMP2A, BDA2;112261;AD, AR;20p12.3
BMP4;Microphthalmia, syndromic 6, 607932 (3),Orofacial cleft 11, 600625 (3);BMP4, BMP2B1, BMP2B, MCOPS6, OFC11;112262;AD;14q22.2
BMPER;Diaphanospondylodysostosis, 608022 (3);BMPER, CV2;608699;AR;7p14.3
BMPR1A;Juvenile polyposis syndrome, infantile form, 174900 (3),Polyposis syndrome, hereditary mixed, 2, 610069 (3),Polyposis, juvenile intestinal, 174900 (3);BMPR1A, ACVRLK3, ALK3;601299;AD;10q23.2
BMPR1B;Acromesomelic dysplasia, Demirhan type, 609441 (3),Brachydactyly, type A1, D, 616849 (3),Brachydactyly, type A2, 112600 (3);BMPR1B, ALK6, AMDD, BDA2, BDA1D;603248;AR, AD;4q22.3
BMPR2;Pulmonary hypertension, familial primary, 1, with or without HHT, 178600 (3),Pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 (3),Pulmonary venoocclusive disease 1, 265450 (3);BMPR2, PPH1, POVD1;600799;AD;2q33.1-q33.2
BMS1;?Aplasia cutis congenita, nonsyndromic, 107600 (3);BMS1, BMS1L, KIAA0187, ACC;611448;AD, AR;10q11.21
BOLA3;Multiple mitochondrial dysfunctions syndrome 2 with hyperglycinemia, 614299 (3);BOLA3, MMDS2;613183;AR;2p13.1
BOS2;Branchiootic syndrome 2 (2);BOS2;120502;AD;1q31
BPGM;Erythrocytosis due to bisphosphoglycerate mutase deficiency, 222800 (3);BPGM;613896;AR;7q33
BPP;Polymicrogyria, bilateral perisylvian (2);BPP, PMGX, CBPS;300388;XLD;Xq27.2-q28
BPPV;Vestibulopathy, familial (2);BPPV;193007;AD;6q
BRAF;Adenocarcinoma of lung, somatic, 211980 (3),Cardiofaciocutaneous syndrome, 115150 (3),Colorectal cancer, somatic (3),LEOPARD syndrome 3, 613707 (3),Melanoma, malignant, somatic (3),Nonsmall cell lung cancer, somatic (3),Noonan syndrome 7, 613706 (3);BRAF, NS7;164757;AD;7q34
BRAT1;Rigidity and multifocal seizure syndrome, lethal neonatal, 614498 (3);BRAT1, BAAT1, C7orf27, RMFSL;614506;AR;7p22.3
BRCA2;Fanconi anemia, complementation group D1, 605724 (3),Wilms tumor, 194070 (3);BRCA2, FANCD1, BROVCA2, GLM3, PNCA2;600185;AR, AD, Smu;13q13.1
BRCA3;?Breast cancer, type 3 (2);BRCA3, BRCAX;605365;-;13q21
BRCATA;Breast cancer, 11:22 translocation associated (1);BRCATA;600048;-;11q23
BRF1;Cerebellofaciodental syndrome, 616202 (3);BRF1, TAF3C, GTF3B, TF3B90, CFDS;604902;AR;14q32.33
BRIP1;Breast cancer, early-onset, 114480 (3),Fanconi anemia, complementation group J, 609054 (3);BRIP1, BACH1, FANCJ;605882;AD;17q23.2
BRP44L;Mitochondrial pyruvate carrier deficiency, 614741 (3);BRP44L, MPC1, MPYCD;614738;AR;6q27
BRV2;Vertigo, benign recurrent, 2 (2);BRV2;613106;-;22q12
BRWD3;Mental retardation, X-linked 93, 300659 (3);BRWD3, MRX93;300553;XLR;Xq21.1
BSCL2;Encephalopathy, progressive, with or without lipodystrophy, 615924 (3),Lipodystrophy, congenital generalized, type 2, 269700 (3),Neuropathy, distal hereditary motor, type VA, 600794 (3),Silver spastic paraplegia syndrome, 270685 (3);BSCL2, SPG17, HMN5, PELD;606158;AR, AD;11q12.3
BSND;Bartter syndrome, type 4a, 602522 (3),Sensorineural deafness with mild renal dysfunction, 602522 (3);BSND;606412;AR;1p32.3
BTD;Biotinidase deficiency, 253260 (3);BTD;609019;AR;3p25.1
BTK;Agammaglobulinemia and isolated hormone deficiency, 307200 (3),Agammaglobulinemia, X-linked 1, 300755 (3);BTK, AGMX1, IMD1, XLA, AT;300300;XLR;Xq22.1
BUB1;Colorectal cancer with chromosomal instability, somatic (3);BUB1;602452;-;2q13
BUB1B;Colorectal cancer, somatic, 114500 (3),Mosaic variegated aneuploidy syndrome 1, 257300 (3);BUB1B, BUBR1, MVA1;602860;AR, AD;15q15.1
BVES;?Muscular dystrophy, limb-girdle, type 2X, 616812 (3);BVES, HBVES, POPDC1, LGMD2X;604577;AR;6q21
BZX;Bazex syndrome (2);BZX;301845;XLD;Xq24-q27
C10orf11;Albinism, oculocutaneous, type VII, 615179 (3);C10orf11, OCA7;614537;AR;10q22.2-q22.3
C10orf2;Mitochondrial DNA depletion syndrome 7 (hepatocerebral type), 271245 (3),Perrault syndrome 5, 616138 (3),Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3, 609286 (3);C10orf2, TWINKLE, PEOA3, IOSCA, MTDPS7, PRLTS5;606075;AR, AD;10q24.31
C11orf73;Leukodystrophy, hypomyelinating, 13, 616881 (3);C11orf73, HIKESHI, HLD13;614908;AR;11q14.2
C12orf57;Temtamy syndrome, 218340 (3);C12orf57, C10, TEMTYS;615140;AR;12p13.31
C12orf65;Combined oxidative phosphorylation deficiency 7, 613559 (3),Spastic paraplegia 55, autosomal recessive, 615035 (3);C12orf65, COXPD7, SPG55;613541;AR;12q24.31
C15orf41;Dyserythropoietic anemia, congenital, type Ib, 615631 (3);C15orf41;615626;AR;15q14
C16DELq22;Chromosome 16q22 deletion syndrome (4);C16DELq22, DEL16q22;614541;IC;16q22
C16orf57;Poikiloderma with neutropenia, 604173 (3);C16orf57, PN;613276;AR;16q21
C19orf12;?Spastic paraplegia 43, autosomal recessive, 615043 (3),Neurodegeneration with brain iron accumulation 4, 614298 (3);C19orf12, NBIA4, SPG43;614297;AR;19q12
C19orf61;Heart and brain malformation syndrome, 616920 (3);C19orf61, SMG9, HBMS;613176;AR;19q13.31
C1GALT1C1;Tn polyagglutination syndrome, somatic, 300622 (3);C1GALT1C1, COSMC, C1GALT2, TNPS;300611;-;Xq24
C1NH;Angioedema, hereditary, types I and II, 106100 (3),Complement component 4, partial deficiency of, 120790 (3);C1NH, HAE1, HAE2, SERPING1;606860;AD;11q12.1
C1QA;C1q deficiency, 613652 (3);C1QA;120550;AR;1p36.12
C1QB;C1q deficiency, 613652 (3);C1QB;120570;AR;1p36.12
C1QC;C1q deficiency, 613652 (3);C1QC, C1QG;120575;AR;1p36.12
C1QTNF5;Retinal degeneration, late-onset, autosomal dominant, 605670 (3);C1QTNF5, CTRP5, LORD;608752;AD;11q23.3
C1R;C1r/C1s deficiency, combined, 216950 (1);C1R;613785;AR;12p13.31
C1S;C1s deficiency, 613783 (3);C1S;120580;-;12p13.31
C2;C2 deficiency, 217000 (3);C2, ARMD14;613927;AR;6p21.33
C21ORF59;Ciliary dyskinesia, primary, 26, 615500 (3);C21ORF59, CILD26;615494;AR;21q22.11
C2CD3;?Orofaciodigital syndrome XIV, 615948 (3);C2CD3, OFD14;615944;AR;11q13.4
C2orf25;Homocystinuria, cblD type, variant 1, 277410 (3),Methylmalonic aciduria and homocystinuria, cblD type, 277410 (3),Methylmalonic aciduria, cblD type, variant 2, 277410 (3);C2orf25, MMADHC;611935;AR;2q23.2
C2orf71;Retinitis pigmentosa 54, 613428 (3);C2orf71;613425;-;2p23.2
C3;C3 deficiency, 613779 (3);C3, ARMD9, AHUS5;120700;AR;19p13.3
C4A;C4a deficiency, 614380 (3);C4A, C4S, C4AD;120810;AR;6p21.33
C4B;C4B deficiency, 614379 (3);C4B, C4F, C4BD;120820;-;6p21.33
C4orf26;Amelogenesis imperfecta, type IIA4, 614832 (3);C4orf26, AI2A4;614829;AR;4q21.1
C5;C5 deficiency, 609536 (3);C5, C5D, ECLZB;120900;-;9q33.2
C5orf42;Joubert syndrome 17, 614615 (3),Orofaciodigital syndrome VI, 277170 (3);C5orf42, JBTS17, OFD6;614571;AR;5p13.2
C6;C6 deficiency, 612446 (3),Combined C6/C7 deficiency (3);C6;217050;AR;5p13.1
C7;C7 deficiency, 610102 (3);C7;217070;-;5p13.1
C7orf10;Glutaric aciduria III, 231690 (3);C7orf10, GA3;609187;AR;7p14.1
C7orf22;Cerebral cavernous malformations-2, 603284 (3);C7orf22, CCM2, MGC4067;607929;AD;7p13
C8A;C8 deficiency, type I, 613790 (3);C8A;120950;AR;1p32.2
C8B;C8 deficiency, type II, 613789 (3);C8B;120960;AR;1p32.2
C8orf37;Cone-rod dystrophy 16, 614500 (3),Retinitis pigmentosa 64, 614500 (3);C8orf37, CORD16, RP64;614477;AR;8q22.1
C9;C9 deficiency, 613825 (3);C9, C9D, ARMD15;120940;-;5p13.1
C9orf72;Frontotemporal dementia and/or amyotrophic lateral sclerosis 1, 105550 (3);C9orf72, FTDALS1, FTDALS, ALSFTD;614260;AD;9p21.2
CA12;Hyperchlorhidrosis, isolated, 143860 (3);CA12;603263;AR;15q22.2
CA2;Osteopetrosis, autosomal recessive 3, with renal tubular acidosis, 259730 (3);CA2;611492;AR;8q21.2
CA4;Retinitis pigmentosa 17, 600852 (3);CA4, RP17;114760;AD;17q23.1
CA5A;Hyperammonemia due to carbonic anhydrase VA deficiency, 615751 (3);CA5A, CA5AD;114761;AR;16q24.2
CA8;Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3, 613227 (3);CA8, CALS, CARP, CAMRQ3;114815;AR;8q12.1
CABP2;Deafness, autosomal recessive 93, 614899 (3);CABP2, DFNB93;607314;AR;11q13.2
CABP4;Cone-rod synaptic disorder, congenital nonprogressive, 610427 (3);CABP4, CRSD, CSNB2B;608965;AR;11q13.2
CACD1;Choroidal dystrophy, central areolar 1 (2);CACD1;215500;AR;17p
CACNA1A;Episodic ataxia, type 2, 108500 (3),Migraine, familial hemiplegic, 1, 141500 (3),Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3),Spinocerebellar ataxia 6, 183086 (3);CACNA1A, CACNL1A4, SCA6;601011;AD;19p13.13
CACNA1B;?Dystonia 23, 614860 (3);CACNA1B, CACNL1A5, DYT23;601012;AD;9q34.3
CACNA1C;Brugada syndrome 3, 611875 (3),Timothy syndrome, 601005 (3);CACNA1C, CACNL1A1, CCHL1A1, TS;114205;AD;12p13.33
CACNA1D;Primary aldosteronism, seizures, and neurologic abnormalities, 615474 (3),Sinoatrial node dysfunction and deafness, 614896 (3);CACNA1D, CACNL1A2, CCHL1A2, SANDD, PASNA;114206;AD, AR;3p21.1
CACNA1F;Aland Island eye disease, 300600 (3),Cone-rod dystrophy, X-linked, 3, 300476 (3),Night blindness, congenital stationary (incomplete), 2A, X-linked, 300071 (3);CACNA1F, CSNB2, CORDX3, CSNB2A, AIED, OA2;300110;XL, XLR;Xp11.23
CACNA1G;Spinocerebellar ataxia 42, 616795 (3);CACNA1G, SCA42;604065;AD;17q21.33
CACNA1H;Hyperaldosteronism, familial, type IV, 617027 (3);CACNA1H, EIG6, ECA6, HALD4;607904;AD;16p13.3
CACNA1S;Hypokalemic periodic paralysis, type 1, 170400 (3);CACNA1S, CACNL1A3, CCHL1A3, TTPP1, HOKPP1;114208;AD, IC;1q32.1
CACNA2D4;Retinal cone dystrophy 4, 610478 (3);CACNA2D4, RCD4;608171;-;12p13.33
CACNB2;Brugada syndrome 4, 611876 (3);CACNB2;600003;-;10p12.33-p12.31
CACNB4;Episodic ataxia, type 5, 613855 (3);CACNB4, EJM6, EA5, EIG9;601949;AD;2q23.3
CACNG2;Mental retardation, autosomal dominant 10, 614256 (3);CACNG2, MRD10;602911;-;22q12.3
CAD;?Congenital disorder of glycosylation, type Iz, 616457 (3);CAD, CDG1Z;114010;AR;2p23.3
CALM1;Long QT syndrome 14, 616247 (3),Ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 (3);CALM1, PHKD, CPVT4, LQT14;114180;AD;14q32.11
CALM2;Long QT syndrome 15, 616249 (3);CALM2, LQT15;114182;AD;2p21
CALR;Myelofibrosis, somatic, 254450 (3),Thrombocythemia, somatic, 187950 (3);CALR, SSA;109091;-;19p13.13
CALR3;?Cardiomyopathy, hypertrophic, 19, 613875 (3);CALR3, CRT2, CMH19;611414;AD;19p13.11
CAMPD1;Camptodactyly 1 (2);CAMPD1;114200;AD;3q11.2-q13.12
CAMTA1;Cerebellar ataxia, nonprogressive, with mental retardation, 614756 (3);CAMTA1, KIAA0833, CANPMR;611501;AD;1p36.31-p36.23
CANDF1;Candidiasis, familial, 1, autosomal dominant (2);CANDF1, CMCT;114580;AD;2p22.3-p21
CANDF3;Candidiasis, familial, 3 (2);CANDF3, CANDN1, FCNC;607644;AD;11p13-q12
CANT1;Desbuquois dysplasia 1, 251450 (3);CANT1, SCAN1, DBQD1;613165;AR;17q25.3
CAPN1;Spastic paraplegia 76, autosomal recessive, 616907 (3);CAPN1, SPG76;114220;AR;11q13.1
CAPN3;Muscular dystrophy, limb-girdle, type 2A, 253600 (3);CAPN3, CANP3;114240;AR;15q15.1
CAPN5;Vitreoretinopathy, neovascular inflammatory, 193235 (3);CAPN5, HTRA3, VRNI;602537;AD;11q13.5
CARD11;B-cell expansion with NFKB and T-cell anergy, 616452 (3),Immunodeficiency 11, 615206 (3);CARD11, CARMA1, BIMP3, PPBL, BENTA, IMD11;607210;AD, AR;7p22.2
CARD14;Pityriasis rubra pilaris, 173200 (3),Psoriasis 2, 602723 (3);CARD14, CARMA2, BIMP2, PSORS2, PSS1, PRP;607211;AD;17q25.3
CARD9;Candidiasis, familial, 2, autosomal recessive, 212050 (3);CARD9, CANDF2;607212;AR;9q34.3
CARS2;Combined oxidative phosphorylation deficiency 27, 616672 (3);CARS2, COXPD27;612800;AR;13q34
CASC5;Microcephaly 4, primary, autosomal recessive, 604321 (3);CASC5, AF15Q14, KIAA1570, D40, MCPH4;609173;AR;15q15.1
CASK;FG syndrome 4, 300422 (3),Mental retardation and microcephaly with pontine and cerebellar hypoplasia, 300749 (3),Mental retardation, with or without nystagmus, 300422 (3);CASK, MICPCH, FGS4, CMG, MRXSNA;300172;XLD;Xp11.4
CASP10;Autoimmune lymphoproliferative syndrome, type II, 603909 (3),Gastric cancer, somatic, 613659 (3),Lymphoma, non-Hodgkin, somatic, 605027 (3);CASP10, MCH4, ALPS2;601762;AD;2q33.1
CASP8;?Autoimmune lymphoproliferative syndrome, type IIB, 607271 (3),Hepatocellular carcinoma, somatic, 114550 (3);CASP8, MCH5, ALPS2B;601763;AR, AD;2q33.1
CASQ1;Myopathy, vacuolar, with CASQ1 aggregates, 616231 (3);CASQ1, VMCQA;114250;AD;1q23.2
CASQ2;Ventricular tachycardia, catecholaminergic polymorphic, 2, 611938 (3);CASQ2;114251;AR;1p13.1
CASR;Hypercalciuric hypercalcemia (3),Hyperparathyroidism, neonatal, 239200 (3),Hypocalcemia, autosomal dominant, 601198 (3),Hypocalcemia, autosomal dominant, with Bartter syndrome, 601198 (3),Hypocalciuric hypercalcemia, type I, 145980 (3);CASR, HHC1, PCAR1, FIH, EIG8, HYPOC1;601199;AR, AD;3q13.3-q21.1
CAST;Peeling skin with leukonychia, acral punctate keratoses, cheilitis, and knuckle pads, 616295 (3);CAST, PLACK;114090;AR;5q15
CAT;Acatalasemia, 614097 (3);CAT;115500;-;11p13
CATSPER1;Spermatogenic failure 7, 612997 (3);CATSPER1, CATSPER, SPGF7;606389;AR;11q13.1
CAV1;?Lipodystrophy, congenital generalized, type 3, 612526 (3),?Partial lipodystrophy, congenital cataracts, and neurodegeneration syndrome, 606721 (3),Pulmonary hypertension, primary, 3, 615343 (3);CAV1, BSCL3, CGL3, PPH3, LCCNS;601047;AD;7q31.2
CAV3;Cardiomyopathy, familial hypertrophic, 192600 (3),Creatine phosphokinase, elevated serum, 123320 (3),Long QT syndrome 9, 611818 (3),Muscular dystrophy, limb-girdle, type IC, 607801 (3),Myopathy, distal, Tateyama type, 614321 (3),Rippling muscle disease, 606072 (3);CAV3, LGMD1C, LQT9;601253;AD, AR;3p25.3
CBFB;Myeloid leukemia, acute, M4/M4Eo subtype, somatic, 601626 (1);CBFB, PEBP2B;121360;-;16q22.1
CBG;Corticosteroid-binding globulin deficiency, 611489 (3);CBG, SERPINA6;122500;AD, AR;14q32.13
CBL;?Juvenile myelomonocytic leukemia, 607785 (3),Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563 (3);CBL, CBL2, NSLL;165360;AD, Smu;11q23.3
CBS;Homocystinuria, B6-responsive and nonresponsive types, 236200 (3),Thrombosis, hyperhomocysteinemic, 236200 (3);CBS;613381;AR;21q22.3
CBX2;?46XY sex reversal 5, 613080 (3);CBX2, M33, SRXY5;602770;AR;17q25.3
CC2D1A;Mental retardation, autosomal recessive 3, 608443 (3);CC2D1A, MRT3;610055;AR;19p13.12
CC2D2A;COACH syndrome, 216360 (3),Joubert syndrome 9, 612285 (3),Meckel syndrome 6, 612284 (3);CC2D2A, KIAA1345, MKS6;612013;AR;4p15.32
CCAL1;Chondrocalcinosis with early-onset osteoarthritis (2);CCAL1;600668;AD;8q
CCBE1;Hennekam lymphangiectasia-lymphedema syndrome 1, 235510 (3);CCBE1, KIAA1983, HKLLS1;612753;AR;18q21.32
CCCSX;Cerebral-cerebellar-coloboma syndrome, X-linked (2);CCCSX;300864;XLR;Chr.X
CCDC103;Ciliary dyskinesia, primary, 17, 614679 (3);CCDC103, SMH, PR46B, CILD17;614677;AR;17q21.31
CCDC11;Heterotaxy, visceral, 6, autosomal recessive, 614779 (3);CCDC11, HTX6;614759;AR;18q21.1
CCDC111;Myopia 22, autosomal dominant, 615420 (3);CCDC111, MYP22;615421;AD;4q35.1
CCDC114;Ciliary dyskinesia, primary, 20, 615067 (3);CCDC114, CILD20;615038;AR;19q13.33
CCDC115;Congenital disorder of glycosylation, type IIo, 616828 (3);CCDC115, CCP1, CDG2O;613734;AR;2q21.1
CCDC151;Ciliary dyskinesia, primary, 30, 616037 (3);CCDC151, CILD30;615956;AR;19p13.2
CCDC174;Hypotonia, infantile, with psychomotor retardation, 616816 (3);CCDC174, HSPC212, IHPM;616735;AR;3p25.1
CCDC22;Ritscher-Schinzel syndrome 2, 300963 (3);CCDC22, RTSC2;300859;XLR;Xp11.23
CCDC39;Ciliary dyskinesia, primary, 14, 613807 (3);CCDC39;613798;-;3q26.33
CCDC40;Ciliary dyskinesia, primary, 15, 613808 (3);CCDC40, KIAA1640;613799;-;17q25.3
CCDC50;?Deafness, autosomal dominant 44, 607453 (3);CCDC50, C3orf6, DFNA44;611051;AD;3q28
CCDC65;Ciliary dyskinesia, primary, 27, 615504 (3);CCDC65, CILD27;611088;AR;12q13.12
CCDC78;Myopathy, centronuclear, 4, 614807 (3);CCDC78, C16orf25, CNM4;614666;AD;16p13.3
CCDC8;3-M syndrome 3, 614205 (3);CCDC8, 3M3;614145;AR;19q13.32
CCDC88C;?Spinocerebellar ataxia 40, 616053 (3),Hydrocephalus, nonsyndromic, autosomal recessive, 236600 (3);CCDC88C, HKRP2, DAPLE, KIAA1509, HYC, SCA40;611204;AD, AR;14q32.11-q32.12
CCM1;Cavernous malformations of CNS and retina, 116860 (3),Cerebral cavernous malformations-1, 116860 (3),Hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations, 116860 (3);CCM1, CAM, KRIT1;604214;AD;7q21.2
CCND2;Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3, 615938 (3);CCND2, MPPH3;123833;AD;12p13.32
CCNO;Ciliary dyskinesia, primary, 29, 615872 (3);CCNO, UNG2, CILD29;607752;AR;5q11.2
CCT5;Neuropathy, hereditary sensory, with spastic paraplegia, 256840 (3);CCT5, KIAA0098, CCTE;610150;AR;5p15.2
CD151;Nephropathy with pretibial epidermolysis bullosa and deafness, 609057 (3);CD151, PETA3, SFA1, MER2;602243;-;11p15.5
CD164;?Deafness, autosomal dominant 66, 616969 (3);CD164, DFNA66;603356;AD;6q21
CD19;Immunodeficiency, common variable, 3, 613493 (3);CD19, CVID3;107265;AR;16p11.2
CD207;?[Birbeck granule deficiency], 613393 (3);CD207, LANGERIN, CLEC4K;604862;-;2p13.3
CD247;?Immunodeficiency 25, 610163 (3);CD247, CD3Z, TCRZ, IMD25;186780;AR;1q24.2
CD2AP;Glomerulosclerosis, focal segmental, 3, 607832 (3);CD2AP, CMS;604241;-;6p12.3
CD320;Methylmalonic aciduria due to transcobalamin receptor defect, 613646 (3);CD320, 8D6, 8D6A, TCBLR;606475;-;19p13.2
CD36;Platelet glycoprotein IV deficiency, 608404 (3);CD36, CHDS7, BDPLT10;173510;AR;7q21.11
CD3D;Immunodeficiency 19, 615617 (3);CD3D, T3D, IMD19;186790;AR;11q23.3
CD3E;Immunodeficiency 18, 615615 (3),Immunodeficiency 18, SCID variant, 615615 (3);CD3E, IMD18;186830;AR;11q23.3
CD3G;Immunodeficiency 17, CD3 gamma deficient, 615607 (3);CD3G, IMD17;186740;AR;11q23.3
CD4;OKT4 epitope deficiency, 613949 (3);CD4;186940;-;12p13.31
CD40;Immunodeficiency with hyper-IgM, type 3, 606843 (3);CD40, TNFRSF5;109535;AR;20q13.12
CD59;Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy, 612300 (3);CD59, MIC11;107271;AR;11p13
CD79A;Agammaglobulinemia 3, 613501 (3);CD79A, IGA;112205;AR;19q13.2
CD79B;Agammaglobulinemia 6, 612692 (3);CD79B, IGB, B29, AGM6;147245;AR;17q23.3
CD81;Immunodeficiency, common variable, 6, 613496 (3);CD81, TAPA1, CVID6;186845;AR;11p15.5
CD8A;CD8 deficiency, familial, 608957 (3);CD8A;186910;AR;2p11.2
CD96;C syndrome, 211750 (3);CD96, TACTILE;606037;AR;3q13.1-q13.2
CDAGS;CDAGS syndrome (2);CDAGS;603116;AR;22q12-q13
CDAN1;Dyserythropoietic anemia, congenital, type Ia, 224120 (3);CDAN1, CDA1, CDAN1A;607465;AR;15q15.2
CDAN3;Dyserythropoietic anemia, congenital, type III (2);CDAN3, CDA3;105600;AD;15q21
CDC14A;Deafness, autosomal recessive 105, 616958 (3);CDC14A, DFNB105;603504;AR;1p21.2
CDC42;Takenouchi-Kosaki syndrome, 616737 (3);CDC42, TKS;116952;-;1p36.12
CDC6;Meier-Gorlin syndrome 5, 613805 (3);CDC6, CDC18L;602627;AR;17q21.2
CDCA7;Immunodeficiency-centromeric instability-facial anomalies syndrome 3, 616910 (3);CDCA7, JPO1, ICF3;609937;-;2q31.1
CDH1;Endometrial carcinoma, somatic, 608089 (3),Gastric cancer, familial diffuse, with or without cleft lip and/or palate, 137215 (3),Ovarian carcinoma, somatic, 167000 (3);CDH1, UVO, LCAM, ECAD;192090;AD;16q22.1
CDH15;Mental retardation, autosomal dominant 3, 612580 (3);CDH15, CDH14, CDH3, MRD3;114019;-;16q24.3
CDH23;Deafness, autosomal recessive 12, 601386 (3),Usher syndrome, type 1D, 601067 (3),Usher syndrome, type 1D/F digenic, 601067 (3);CDH23, USH1D;605516;AR; DR, AR;10q22.1
CDH3;Ectodermal dysplasia, ectrodactyly, and macular dystrophy, 225280 (3),Hypotrichosis, congenital, with juvenile macular dystrophy, 601553 (3);CDH3, CDHP, PCAD, HJMD;114021;AR;16q22.1
CDHR1;Cone-rod dystrophy 15, 613660 (3),Retinitis pigmentosa 65, 613660 (3);CDHR1, PCDH21, PRCAD, CORD15, RP65;609502;AR;10q23.1
CDK5;?Lissencephaly 7 with cerebellar hypoplasia, 616342 (3);CDK5, LIS7;123831;AR;7q36.1
CDK5RAP2;Microcephaly 3, primary, autosomal recessive, 604804 (3);CDK5RAP2, KIAA1633, MCPH3;608201;AR;9q33.2
CDK6;?Microcephaly 12, primary, autosomal recessive, 616080 (3);CDK6, PLSTIRE, MCPH12;603368;AR;7q21.2
CDKL5;Epileptic encephalopathy, early infantile, 2, 300672 (3);CDKL5, STK9, ISSX, EIEE2;300203;XLD;Xp22.13
CDKN1B;Multiple endocrine neoplasia, type IV, 610755 (3);CDKN1B, KIP1, CDKN4, MEN4;600778;AD;12p13.1
CDKN1C;Beckwith-Wiedemann syndrome, 130650 (3),IMAGE syndrome, 614732 (3);CDKN1C, KIP2, BWS, IMAGE;600856;AD;11p15.4
CDKN2A;Melanoma and neural system tumor syndrome, 155755 (3),Orolaryngeal cancer, multiple, (3),Pancreatic cancer/melanoma syndrome, 606719 (3);CDKN2A, MTS1, P16, MLM, CMM2;600160;AD;9p21.3
CDON;Holoprosencephaly 11, 614226 (3);CDON, CDO, HPE11;608707;AD, IC;11q24.2
CDSN;Hypotrichosis 2, 146520 (3),Peeling skin syndrome 1, 270300 (3);CDSN, HTSS1, HYPT2, PSS1;602593;AD, AR;6p21.33
CDT1;Meier-Gorlin syndrome 4, 613804 (3);CDT1;605525;AR;16q24.3
CEACAM16;Deafness, autosomal dominant 4B, 614614 (3);CEACAM16, CEAL2, DFNA4B;614591;AD;19q13.31-q13.32
CEBPA;?Leukemia, acute myeloid, 601626 (3),Leukemia, acute myeloid, somatic, 601626 (3);CEBPA, CEBP;116897;AD;19q13.11
CEBPE;Specific granule deficiency, 245480 (3);CEBPE, CRP1;600749;AR;14q11.2
CECR;Cat eye syndrome (4);CECR, CES;115470;AD;22q11
CECR1;?Sneddon syndrome, 182410 (3),Polyarteritis nodosa, childhood-onset, 615688 (3);CECR1, PAN, SNEDS;607575;AR;22q11.1
CEL;Maturity-onset diabetes of the young, type VIII, 609812 (3);CEL, BSSL, CELL, MODY8;114840;AD;9q34.13
CENPE;?Microcephaly 13, primary, autosomal recessive, 616051 (3);CENPE, MCPH13;117143;AR;4q24
CENPF;Stromme syndrome, 243605 (3);CENPF, CILD31, STROMS;600236;AR;1q41
CENPJ;?Seckel syndrome 4, 613676 (3),Microcephaly 6, primary, autosomal recessive, 608393 (3);CENPJ, CPAP, MCPH6, SCKL4;609279;AR;13q12.12-q12.13
CEP104;Joubert syndrome 25, 616781 (3);CEP104, GLYBP, KIAA0562, JBTS25;616690;AR;1p36.32
CEP120;Short-rib thoracic dysplasia 13 with or without polydactyly, 616300 (3);CEP120, CCDC100, SRTD13;613446;AR;5q23.2
CEP135;?Microcephaly 8, primary, autosomal recessive, 614673 (3);CEP135, KIAA0635, MCPH8;611423;AR;4q12
CEP152;Microcephaly 9, primary, autosomal recessive, 614852 (3),Seckel syndrome 5, 613823 (3);CEP152, KIAA0912, MCPH9, SCKL5;613529;AR;15q21.1
CEP164;Nephronophthisis 15, 614845 (3);CEP164, KIAA1052;614848;AR;11q23.3
CEP19;Morbid obesity and spermatogenic failure, 615703 (3);CEP19, C3orf34, MOSPGF;615586;AR;3q29
CEP290;?Bardet-Biedl syndrome 14, 615991 (3),Joubert syndrome 5, 610188 (3),Leber congenital amaurosis 10, 611755 (3),Meckel syndrome 4, 611134 (3),Senior-Loken syndrome 6, 610189 (3);CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14;610142;AR;12q21.32
CEP41;Joubert syndrome 15, 614464 (3);CEP41, TSGA14, JBTS15;610523;AR;7q32.2
CEP57;Mosaic variegated aneuploidy syndrome 2, 614114 (3);CEP57, PIG8, TSP57, KIAA0092, MVA2;607951;AR;11q21
CEP63;?Seckel syndrome 6, 614728 (3);CEP63, SCKL6;614724;AR;3q22.2
CEP83;Nephronophthisis 18, 615862 (3);CEP83, CCDC41, NPHP18;615847;AR;12q22
CERKL;Retinitis pigmentosa 26, 608380 (3);CERKL, RP26;608381;-;2q31.3
CERS1;?Epilepsy, progressive myoclonic, 8, 616230 (3);CERS1, LASS1, UOG1, EPM8;606919;AR;19p13.11
CERS3;Ichthyosis, congenital, autosomal recessive 9, 615023 (3);CERS3, LASS3, ARCI9;615276;AR;15q26.3
CES1;Carboxylesterase 1 deficiency (3);CES1, SES1;114835;-;16q12.2
CETP;Hyperalphalipoproteinemia, 143470 (3);CETP, HDLCQ10;118470;AD;16q13
CFB;?Complement factor B deficiency, 615561 (3);CFB, BF, GBG, AHUS4, ARMD14, CFBD;138470;-;6p21.33
CFC1;Heterotaxy, visceral, 2, autosomal, 605376 (3);CFC1, CRYPTIC, HTX2;605194;AD;2q21.1
CFD;Complement factor D deficiency, 613912 (3);CFD, ADN;134350;AR;19p13.3
CFEOM3C;Fibrosis of extraocular muscles, congenital, 3C (2);CFEOM3C, FEOM4;609384;AD;13q12.11
CFH;Basal laminar drusen, 126700 (3),Complement factor H deficiency, 609814 (3);CFH, HF1, HUS, ARMD4, AHUS1;134370;AD, AR;1q31.3
CFHR5;Nephropathy due to CFHR5 deficiency, 614809 (3);CFHR5, CFHL5, FHR5, CFHR5D;608593;AD;1q31.3
CFI;Complement factor I deficiency, 610984 (3);CFI, FI, AHUS3, ARMD13;217030;AR, AD;4q25
CFL2;Nemaline myopathy 7, autosomal recessive, 610687 (3);CFL2, NEM7;601443;AR;14q13.1
CFSS;?Craniofacioskeletal syndrome (2);CFSS;300712;XLD, XLR;Xq26-q27
CFTDX;Myopathy, congenital, with fiber-type disproportion, X-linked (2);CFTDX;300580;XLD ;Xq13.1-q22.1
CFTR;Congenital bilateral absence of vas deferens, 277180 (3),Cystic fibrosis, 219700 (3),Sweat chloride elevation without CF (3);CFTR, ABCC7, CF, MRP7;602421;AR, AD;7q31.2
CHAMP1;Mental retardation, autosomal dominant 40, 616579 (3);CHAMP1, ZNF828, C13orf8, KIAA1802, MRD40;616327;AD;13q34
CHAT;Myasthenic syndrome, congenital, 6, presynaptic, 254210 (3);CHAT, CMS6;118490;AR;10q11.23
CHCHD10;?Myopathy, isolated mitochondrial, autosomal dominant, 616209 (3),Frontotemporal dementia and/or amyotrophic lateral sclerosis 2, 615911 (3),Spinal muscular atrophy, Jokela type, 615048 (3);CHCHD10, FTDALS2, SMAJ, IMMD;615903;AD;22q11.23
CHCHD2;Parkinson disease 22, autosomal dominant, 616710 (3);CHCHD2, PARK22;616244;-;7p11.2
CHD2;Epileptic encephalopathy, childhood-onset, 615369 (3);CHD2, EEOC;602119;AD;15q26.1
CHD7;CHARGE syndrome, 214800 (3),Hypogonadotropic hypogonadism 5 with or without anosmia, 612370 (3);CHD7, HH5;608892;AD;8q12.2
CHDT3;Congenital heart defects, multiple types, 3 (2);CHDT3;614954;AD;9q31.1
CHEK2;Li-Fraumeni syndrome, 609265 (3),Osteosarcoma, somatic, 259500 (3);CHEK2, RAD53, CHK2, CDS1, LFS2;604373;AD;22q12.1
CHKB;Muscular dystrophy, congenital, megaconial type, 602541 (3);CHKB, CHKL, CKEKB, EKB, MDCMC;612395;AR;22q13.33
CHM;Choroideremia, 303100 (3);CHM, TCD;300390;XLD;Xq21.2
CHMP1A;Pontocerebellar hypoplasia, type 8, 614961 (3);CHMP1A, PCOLN3, PRSM1, PCH8;164010;AR;16q24.3
CHMP2B;Amyotrophic lateral sclerosis 17, 614696 (3),Dementia, familial, nonspecific, 600795 (3);CHMP2B, DMT1, VPS2B, ALS17;609512;AD;3p11.2
CHMP4B;Cataract 31, multiple types, 605387 (3);CHMP4B, SNF7, CTPP3, CTRCT31;610897;-;20q11.22
CHN1;Duane retraction syndrome 2, 604356 (3);CHN1, CHN, ARHGAP2, RHOGAP2, DURS2;118423;-;2q31.1
CHNG3;Hypothyroidism, congenital, nongoitrous, 3 (2);CHNG3, RTSH;609893;-;15q25.3-q26.1
CHRDL1;Megalocornea 1, X-linked 309300 (3);CHRDL1, VOPT, MGC1;300350;XLD;Xq23
CHRM3;?Prune belly syndrome, 100100 (3);CHRM3, PBS, EGBRS;118494;AR;1q43
CHRNA1;Multiple pterygium syndrome, lethal type, 253290 (3),Myasthenic syndrome, congenital, 1A, slow-channel, 601462 (3),Myasthenic syndrome, congenital, 1B, fast-channel, 608930 (3);CHRNA1, ACHRD, CMS1B, CMS1A;100690;AR, AD;2q31.1
CHRNA2;Epilepsy, nocturnal frontal lobe, type 4, 610353 (3);CHRNA2;118502;AD;8p21.2
CHRNA4;Epilepsy, nocturnal frontal lobe, 1, 600513 (3);CHRNA4, ENFL1;118504;AD;20q13.33
CHRNA7;Schizophrenia, neurophysiologic defect in (2);CHRNA7;118511;-;15q13.3
CHRNB1;?Myasthenic syndrome, congenital, 2C, associated with acetylcholine receptor deficiency, 616314 (3),Myasthenic syndrome, congenital, 2A, slow-channel, 616313 (3);CHRNB1, ACHRB, SCCMS, CMS2A, CMS2C;100710;AR, AD;17p13.1
CHRNB2;Epilepsy, nocturnal frontal lobe, 3, 605375 (3);CHRNB2, EFNL3;118507;-;1q21.3
CHRND;?Myasthenic syndrome, congenital, 3A, slow-channel, 616321 (3),?Myasthenic syndrome, congenital, 3C, associated with acetylcholine receptor deficiency, 616323 (3),Multiple pterygium syndrome, lethal type, 253290 (3),Myasthenic syndrome, congenital, 3B, fast-channel, 616322 (3);CHRND, ACHRD, SCCMS, CMS3A, CMS3B, CMS3C;100720;AD, AR;2q37.1
CHRNE;Myasthenic syndrome, congenital, 4A, slow-channel, 605809 (3),Myasthenic syndrome, congenital, 4B, fast-channel, 616324 (3),Myasthenic syndrome, congenital, 4C, associated with acetylcholine receptor deficiency, 608931 (3);CHRNE, SCCMS, CMS4A, CMS4B, CMS4C;100725;AD, AR;17p13.2
CHRNG;Escobar syndrome, 265000 (3),Multiple pterygium syndrome, lethal type, 253290 (3);CHRNG, ACHRG;100730;AR;2q37.1
CHST14;Ehlers-Danlos syndrome, musculocontractural type 1, 601776 (3);CHST14, D4ST1, ATCS, EDSMC1;608429;AR;15q15.1
CHST3;Spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 (3);CHST3, C6ST, C6ST1, HSD;603799;AR;10q22.1
CHST6;Macular corneal dystrophy, 217800 (3);CHST6, MCDC1;605294;AR;16q23.1
CHST8;?Peeling skin syndrome 3, 616265 (3);CHST8, GALNAC4ST1, PSS3;610190;AR;19q13.11
CHSY1;Temtamy preaxial brachydactyly syndrome, 605282 (3);CHSY1, KIAA0990, TPBS;608183;AR;15q26.3
CHUK;Cocoon syndrome, 613630 (3);CHUK, IKBKA, NFKBIKA, IKKA, IKK1;600664;-;10q24.31
CHX10;Microphthalmia with coloboma 3, 610092 (3),Microphthalmia, isolated 2, 610093 (3);CHX10, HOX10, MCOP2, MCOPCB3;142993;-;14q24.3
CIB2;Deafness, autosomal recessive 48, 609439 (3),Usher syndrome, type IJ, 614869 (3);CIB2, KIP2;605564;AR;15q25.1
CIDEC;?Lipodystrophy, familial partial, type 5, 615238 (3);CIDEC, FSP27, CIDE3, FPLD5;612120;AR;3p25.3
CILD4;Ciliary dyskinesia, primary, 4 (2);CILD4;608646;-;15q13.1-q15.1
CILD8;Ciliary dyskinesia, primary, 8 (2);CILD8;612274;-;15q24-q25
CIMT;Carotid intimal medial thickness (2);CIMT;608447;-;12q24
CIRH1A;Cirrhosis, North American Indian childhood type, 604901 (3);CIRH1A, NAIC, TEX292, KIAA1988;607456;-;16q22.1
CISD2;Wolfram syndrome 2, 604928 (3);CISD2, WFS2, ZCD2, ERIS;611507;AR;4q24
CITED2;Atrial septal defect 8, 614433 (3),Ventricular septal defect 2, 614431 (3);CITED2, MRG1, P35SRJ, VSD2, ASD8;602937;AD;6q24.1
CKAP2L;Filippi syndrome, 272440 (3);CKAP2L, RADMIS;616174;AR;2q14.1
CLCF1;Cold-induced sweating syndrome 2, 610313 (3);CLCF1, BSF3, CLC, CISS2;607672;AR;11q13.2
CLCN1;Myotonia congenita, dominant, 160800 (3),Myotonia congenita, recessive, 255700 (3),Myotonia levior, recessive (3);CLCN1;118425;AR, AD;7q34
CLCN2;Leukoencephalopathy with ataxia, 615651 (3);CLCN2, EGMA, ECA2, EGI11, EJM8, LKPAT;600570;AR, AD;3q27.1
CLCN5;Dent disease, 300009 (3),Hypophosphatemic rickets, 300554 (3),Nephrolithiasis, type I, 310468 (3),Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3);CLCN5, CLCK2, NPHL2, DENTS, NPHL1;300008;XLR;Xp11.23
CLCN7;Osteopetrosis, autosomal dominant 2, 166600 (3),Osteopetrosis, autosomal recessive 4, 611490 (3);CLCN7, CLC7, OPTA2, OPTB4;602727;AD;16p13.3
CLCNKA;Bartter syndrome, type 4b, digenic, 613090 (3);CLCNKA;602024;DR ;1p36.13
CLCNKB;Bartter syndrome, type 3, 607364 (3),Bartter syndrome, type 4b, digenic, 613090 (3);CLCNKB;602023;AR, DR;1p36.13
CLDN1;Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 (3);CLDN1, SEMP1, ILVASC;603718;AR;3q28
CLDN14;Deafness, autosomal recessive 29, 614035 (3);CLDN14, DFNB29;605608;AR;21q22.13
CLDN16;Hypomagnesemia 3, renal, 248250 (3);CLDN16, PCLN1, HOMG3;603959;AR;3q28
CLDN19;Hypomagnesemia 5, renal, with ocular involvement, 248190 (3);CLDN19, HOMG5;610036;AR;1p34.2
CLEC4M;SARS infection, protection against (2);CLEC4M, CD209L, LSIGN, DCSIGNR;605872;-;19p13.2
CLEC7A;Candidiasis, familial, 4, autosomal recessive, 613108 (3);CLEC7A, CLECSF12, DECTIN1, CANDF4;606264;AR;12p13.2
CLIC2;?Mental retardation, X-linked, syndromic 32, 300886 (3);CLIC2, XAP121, MRXS32;300138;XLR;Xq28
CLIC5;?Deafness, autosomal recessive 103, 616042 (3);CLIC5, DFNB103;607293;AR;6p21.1
CLMP;Congenital short bowel syndrome, 615237 (3);CLMP, ASAM, ACAM, CSBS;611693;AR;11q24.1
CLN3;Ceroid lipofuscinosis, neuronal, 3, 204200 (3);CLN3, BTS;607042;AR;16p12.1
CLN5;Ceroid lipofuscinosis, neuronal, 5, 256731 (3);CLN5;608102;AR;13q22.3
CLN6;Ceroid lipofuscinosis, neuronal, 6, 601780 (3),Ceroid lipofuscinosis, neuronal, Kufs type, adult onset, 204300 (3);CLN6, CLN4A;606725;AR;15q23
CLN8;Ceroid lipofuscinosis, neuronal, 8, 600143 (3),Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 (3);CLN8, EPMR;607837;AR;8p23.3
CLP1;Pontocerebellar hypoplasia, type 10, 615803 (3);CLP1, HEAB, PCH10;608757;AR;11q12.1
CLPB;3-methylglutaconic aciduria, type VII, with cataracts, neurologic involvement and neutropenia, 616271 (3);CLPB, SKD3, MEGCANN, MGCA7;616254;AR;11q13.4
CLPP;Perrault syndrome 3, 614129 (3);CLPP, PRLTS3, DFNB81;601119;AR;19p13.3
CLRN1;Retinitis pigmentosa 61, 614180 (3),Usher syndrome, type 3A, 276902 (3);CLRN1, USH3A, USH3, RP61;606397;AR;3q25.1
CMD1B;Cardiomyopathy, dilated 1B (2);CMD1B, CMPD1, FDC;600884;AD;9q13
CMD1F;Cardiomyopathy, dilated, 1F and limb-girdle muscular dystrophy type 1D (2);CMD1F, CDCD3, LGMD1D;601419;AD, AR;6q23
CMD1H;Cardiomyopathy, dilated, 1H (2);CMD1H;604288;-;2q14-q22
CMD1K;Cardiomyopathy, dilated, 1K (2);CMD1K;605582;-;6q12-q16
CMD1Q;Cardiomyopathy, dilated, 1Q (2);CMD1Q;609915;-;7q22.3-q31.1
CMH21;Cardiomyopathy, hypertrophic, 21 (2);CMH21;614676;AD;7p12.1-q21
CMT2G;Charcot-Marie-Tooth disease, axonal, type 2G (2);CMT2G;608591;AD;12q12-q13.3
CMT2H;Charcot-Marie-Tooth disease, axonal, type 2H (2);CMT2H;607731;AR;8q13-q23
CMTDIA;Charcot-Marie-Tooth disease, dominant intermediate A (2);CMTDIA;606483;AD;10q24.1-q25.1
CMTX2;Charcot-Marie-Tooth neuropathy, X-linked recessive, 2 (2);CMTX2;302801;XLD;Xp22.2
CMTX3;Charcot-Marie-Tooth neuropathy, X-linked recessive, 3 (2);CMTX3;302802;XLR;Xq26
CNC2;Carney complex, type II (2);CNC2;605244;-;2p16
CND;Dermoids of cornea (2);CND;304730;XL;Xq24-qter
CNGA1;Retinitis pigmentosa 49, 613756 (3);CNGA1, CNCG1, RP49;123825;-;4p12
CNGA3;Achromatopsia-2, 216900 (3);CNGA3, CNG3, ACHM2;600053;AR;2q11.2
CNGB1;Retinitis pigmentosa 45, 613767 (3);CNGB1, CNCG3L, CNCG2, RP45;600724;AR;16q21
CNGB3;Achromatopsia-3, 262300 (3),Macular degeneration, juvenile, 248200 (3);CNGB3, ACHM3, ACHM1;605080;AR;8q21.3
CNNM2;Hypomagnesemia 6, renal, 613882 (3),Hypomagnesemia, seizures, and mental retardation, 616418 (3);CNNM2, ACDP2, HOMG6, HOMGSMR;607803;AD, AR;10q24.32
CNNM4;Jalili syndrome, 217080 (3);CNNM4, ACDP4;607805;AR;2q11.2
CNSN;Carnosinemia (2);CNSN;212200;AR;18q21.3
CNTN1;?Myopathy, congenital, Compton-North, 612540 (3);CNTN1, MYPCN;600016;AR;12q12
CNTN2;?Epilepsy, myoclonic, familial adult, 5, 615400 (3);CNTN2, TAX, TAX1, FAME5;190197;AR;1q32.1
CNTNAP1;Lethal congenital contracture syndrome 7, 616286 (3);CNTNAP1, CASPR, P190;602346;AR;17q21.2
CNTNAP2;Cortical dysplasia-focal epilepsy syndrome, 610042 (3),Pitt-Hopkins like syndrome 1, 610042 (3);CNTNAP2, CASPR2, NRXN4, CDFE, AUTS15, PTHSL1;604569;-;7q35-q36
COA5;?Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 3, 616500 (3);COA5, C2orf64, PET191, CEMCOX3;613920;AR;2q11.2
COA6;Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4, 616501 (3);COA6, C1orf31, CEMCOX4;614772;AR;1q42.2
COASY;Neurodegeneration with brain iron accumulation 6, 615643 (3);COASY, NBIA6;609855;AR;17q21.2
COCH;Deafness, autosomal dominant 9, 601369 (3);COCH, DFNA9;603196;AD ;14q12
COD2;Cone dystrophy, progressive X-linked, 2 (2);COD2;300085;XL;Xq27
COG1;Congenital disorder of glycosylation, type IIg, 611209 (3);COG1, LDLB, KIAA1381, CDG2G;606973;-;17q25.1
COG4;Congenital disorder of glycosylation, type IIj, 613489 (3);COG4, COD1, CDG2J;606976;AR;16q22.1
COG5;Congenital disorder of glycosylation, type IIi, 613612 (3);COG5, GOLTC1, GTC90, CDG2I;606821;-;7q22.3
COG6;Congenital disorder of glycosylation, type IIl, 614576 (3),Shaheen syndrome, 615328 (3);COG6, COD2, KIAA1134, CDG2L, SHNS;606977;AR;13q14.11
COG7;Congenital disorder of glycosylation, type IIe, 608779 (3);COG7, CDG2E;606978;-;16p12.2
COG8;Congenital disorder of glycosylation, type IIh, 611182 (3);COG8, DOR1, CDG2H;606979;-;16q22.1
COL10A1;Metaphyseal chondrodysplasia, Schmid type, 156500 (3);COL10A1;120110;AD;6q22.1
COL11A1;Fibrochondrogenesis 1, 228520 (3),Marshall syndrome, 154780 (3),Stickler syndrome, type II, 604841 (3);COL11A1, STL2;120280;AR, AD;1p21.1
COL11A2;Deafness, autosomal dominant 13, 601868 (3),Deafness, autosomal recessive 53, 609706 (3),Fibrochondrogenesis 2, 614524 (3),Otospondylomegaepiphyseal dysplasia, 215150 (3),Stickler syndrome, type III, 184840 (3),Weissenbacher-Zweymuller syndrome, 277610 (3);COL11A2, STL3, DFNA13, DFNB53, FBCG2;120290;AD, AR;6p21.32
COL12A1;?Ullrich congenital muscular dystrophy 2, 616470 (3),Bethlem myopathy 2, 616471 (3);COL12A1, UCMD2, BTHLM2;120320;-;6q13-q14
COL13A1;Myasthenic syndrome, congenital, 19, 616720 (3);COL13A1, CMS19;120350;AR;10q22.1
COL17A1;Epidermolysis bullosa, junctional, localisata variant, 226650 (3),Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3),Epithelial recurrent erosion dystrophy, 122400 (3);COL17A1, BPAG2, ERED;113811;AR, AD;10q25.1
COL18A1;Knobloch syndrome, type 1, 267750 (3);COL18A1, KNO1;120328;AR;21q22.3
COL1A1;Caffey disease, 114000 (3),Ehlers-Danlos syndrome, classic, 130000 (3),Ehlers-Danlos syndrome, type VIIA, 130060 (3),Osteogenesis imperfecta, type I, 166200 (3),Osteogenesis imperfecta, type II, 166210 (3),Osteogenesis imperfecta, type III, 259420 (3),Osteogenesis imperfecta, type IV, 166220 (3);COL1A1, OI1, OI2, OI3, OI4, EDSC;120150;AD;17q21.33
COL1A2;Ehlers-Danlos syndrome, cardiac valvular form, 225320 (3),Ehlers-Danlos syndrome, type VIIB, 130060 (3),Osteogenesis imperfecta, type II, 166210 (3),Osteogenesis imperfecta, type III, 259420 (3),Osteogenesis imperfecta, type IV, 166220 (3);COL1A2;120160;AR, AD;7q21.3
COL25A1;Fibrosis of extraocular muscles, congenital, 5, 616219 (3);COL25A1, CLAC, CFEOM5;610004;AR;4q25
COL27A1;?Steel syndrome, 615155 (3);COL27A1, KIAA1870, STLS;608461;AR;9q32
COL2A1;Achondrogenesis, type II or hypochondrogenesis, 200610 (3),Avascular necrosis of the femoral head, 608805 (3),Czech dysplasia, 609162 (3),Epiphyseal dysplasia, multiple, with myopia and deafness, 132450 (3),Kniest dysplasia, 156550 (3),Legg-Calve-Perthes disease, 150600 (3),Osteoarthritis with mild chondrodysplasia, 604864 (3),Otospondylomegaepiphyseal dysplasia, 215150 (3),Platyspondylic skeletal dysplasia, Torrance type, 151210 (3),SED congenita, 183900 (3),SMED Strudwick type, 184250 (3),Spondyloepiphyseal dysplasia, Stanescu type, 616583 (3),Spondyloperipheral dysplasia, 271700 (3),Stickler sydrome, type I, nonsyndromic ocular, 609508 (3),Stickler syndrome, type I, 108300 (3),Vitreoretinopathy with phalangeal epiphyseal dysplasia (3);COL2A1;120140;AD, AR;12q13.11
COL3A1;Ehlers-Danlos syndrome, type IV, 130050 (3);COL3A1;120180;AD;2q32.2
COL4A1;?Retinal arteries, tortuosity of, 180000 (3),Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps, 611773 (3),Brain small vessel disease with or without ocular anomalies, 607595 (3),Porencephaly 1, 175780 (3);COL4A1, POREN1, HANAC, ICH, BSVD, RATOR;120130;AD;13q34
COL4A2;Porencephaly 2, 614483 (3);COL4A2, POREN2, ICH;120090;AD;13q34
COL4A3;Alport syndrome, autosomal dominant, 104200 (3),Alport syndrome, autosomal recessive, 203780 (3),Hematuria, benign familial, 141200 (3);COL4A3;120070;AR, AD;2q36.3
COL4A3BP;Mental retardation, autosomal dominant 34, 616351 (3);COL4A3BP, GPBP, CERT, MRD34;604677;-;5q13.3
COL4A4;Alport syndrome, autosomal recessive, 203780 (3),Hematuria, familial benign (3);COL4A4;120131;AR;2q36.3
COL4A5;Alport syndrome, 301050 (3);COL4A5, ATS, ASLN;303630;XLD;Xq22.3
COL4A6;?Deafness, X-linked 6, 300914 (3);COL4A6, DELXq22.3, CXDELq22.3, DFNX6;303631;XLR;Xq22.3
COL5A1;Ehlers-Danlos syndrome, classic type, 130000 (3);COL5A1, EDSC;120215;AD;9q34.3
COL5A2;Ehlers-Danlos syndrome, classic type, 130000 (3);COL5A2, EDSC;120190;AD;2q32.2
COL6A1;Bethlem myopathy 1, 158810 (3),Ullrich congenital muscular dystrophy 1, 254090 (3);COL6A1, BTHLM1, UCHMD1;120220;AD, AR;21q22.3
COL6A2;?Myosclerosis, congenital, 255600 (3),Bethlem myopathy 1, 158810 (3),Ullrich congenital muscular dystrophy 1, 254090 (3);COL6A2, BTHLM1, UCMD1;120240;AR, AD;21q22.3
COL6A3;Bethlem myopathy 1, 158810 (3),Dystonia 27, 616411 (3),Ullrich congenital muscular dystrophy 1, 254090 (3);COL6A3, DYT27, BTHLM1, UCMD1;120250;AD, AR;2q37.3
COL7A1;EBD inversa, 226600 (3),EBD, Bart type, 132000 (3),EBD, localisata variant (3),Epidermolysis bullosa dystrophica, AD, 131750 (3),Epidermolysis bullosa dystrophica, AR, 226600 (3),Epidermolysis bullosa pruriginosa, 604129 (3),Epidermolysis bullosa, pretibial, 131850 (3),Toenail dystrophy, isolated, 607523 (3),Transient bullous of the newborn, 131705 (3);COL7A1, NDNC8;120120;AR, AD;3p21.31
COL8A2;Corneal dystrophy, Fuchs endothelial, 1, 136800 (3),Corneal dystrophy, posterior polymorphous 2, 609140 (3);COL8A2, FECD1, PPCD2;120252;AD;1p34.3
COL9A1;?Epiphyseal dysplasia, multiple, 6, 614135 (3),Stickler syndrome, type IV, 614134 (3);COL9A1, EDM6, STL4;120210;AD;6q13
COL9A2;?Stickler syndrome, type V, 614284 (3),Epiphyseal dysplasia, multiple, 2, 600204 (3);COL9A2, EDM2, STL5;120260;AR, AD;1p34.2
COL9A3;Epiphyseal dysplasia, multiple, 3, with or without myopathy, 600969 (3);COL9A3, EDM3, IDD;120270;AD;20q13.33
COLEC11;3MC syndrome 2, 265050 (3);COLEC11, CLK1, 3MC2;612502;AR;2p25.3
COLQ;Myasthenic syndrome, congenital, 5, 603034 (3);COLQ, EAD, CMS5;603033;AR;3p25.1
COMA;Oculomotor apraxia, congenital, Cogan-type (2);COMA;257550;AR;2q13
COMP;Epiphyseal dysplasia, multiple, 1, 132400 (3),Pseudoachondroplasia, 177170 (3);COMP, EDM1, MED, PSACH;600310;AD;19p13.11
COPD;Pulmonary disease, chronic obstructive, severe early-onset (2);COPD;606963;-;2q
COQ2;Coenzyme Q10 deficiency, primary, 1, 607426 (3);COQ2, COQ10D1, MSA1;609825;AR, AD;4q21.22-q21.23
COQ4;Coenzyme Q10 deficiency, primary, 7, 616276 (3);COQ4, COQ10D7;612898;AR;9q34.11
COQ6;Coenzyme Q10 deficiency, primary, 6, 614650 (3);COQ6, CGI10, COQ10D6;614647;AR;14q24.3
COQ7;?Coenzyme Q10 deficiency, primary, 8, 616733 (3);COQ7, CLK1, COQ10D8;601683;AR;16p12.3
COQ9;Coenzyme Q10 deficiency, primary, 5, 614654 (3);COQ9, C16orf49, COQ10D5;612837;AR;16q21
CORD1;Cone-rod retinal dystrophy-1 (2);CORD1, CRD1;600624;AD;18q21.1-q21.3
CORD17;Cone-rod dystrophy 17 (2);CORD17;615163;AD;10q26
CORD8;Cone-rod dystrophy 8 (2);CORD8;605549;AR;1q12-q24
CORIN;Preeclampsia/eclampsia 5, 614595 (3);CORIN, CRN, TMPRSS10, ATC2, PEE5;605236;-;4p12
CORO1A;Immunodeficiency 8, 615401 (3);CORO1A, TACO, CLIPINA, IMD8;605000;AR;16p11.2
COX10;Leigh syndrome due to mitochondrial COX4 deficiency, 256000 (3),Mitochondrial complex IV deficiency, 220110 (3);COX10;602125;Mi, AR;17p12
COX14;?Mitochondrial complex IV deficiency, 220110 (3);COX14, C12orf62;614478;AR,Mi;12q13.12
COX15;Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2, 615119 (3),Leigh syndrome due to cytochrome c oxidase deficiency, 256000 (3);COX15, CEMCOX2;603646;AR, Mi;10q24.2
COX20;Mitochondrial complex IV deficiency, 220110 (3);COX20, FAM36A;614698;Mi, AR;1q44
COX4I2;Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 (3);COX4I2;607976;AR;20q11.21
COX6A1;Charcot-Marie-Tooth disease, recessive intermediate D, 616039 (3);COX6A1, CMTRID;602072;AR;12q24.31
COX6B1;Mitochondrial complex IV deficiency, 220110 (3);COX6B1;124089;Mi, AR;19q13.12
COX7B;Linear skin defects with multiple congenital anomalies, 300887 (3);COX7B, LSDMCA2;300885;XLD;Xq21.1
COX8A;?Mitochondrial complex IV deficiency, 220110 (3);COX8A;123870;AR, Mi;11q13.1
CP;Cerebellar ataxia, 604290 (3),Hemosiderosis, systemic, due to aceruloplasminemia, 604290 (3);CP;117700;AR;3q24-q25
CPA6;Epilepsy, familial temporal lobe, 5, 614417 (3),Febrile seizures, familial, 11, 614418 (3);CPA6, CPAH, ETL5, FEB11;609562;AD, AR;8q13.2
CPN1;Carboxypeptidase N deficiency, 212070 (3);CPN1, SCPN, CPN;603103;AR;10q24.2
CPOX;Coproporphyria, 121300 (3),Harderoporphyria, 121300 (3);CPOX;612732;AD;3q11.2
CPS1;Carbamoylphosphate synthetase I deficiency, 237300 (3);CPS1, PHN;608307;AR;2q34
CPT1A;CPT deficiency, hepatic, type IA, 255120 (3);CPT1A;600528;AR;11q13.3
CPT1C;?Spastic paraplegia 73, autosomal dominant, 616282 (3);CPT1C, SPG73;608846;AD;19q13.33
CPT2;CPT II deficiency, lethal neonatal, 608836 (3),CPT deficiency, hepatic, type II, 600649 (3),Myopathy due to CPT II deficiency, 255110 (3);CPT2, IIAE4;600650;AR, AD;1p32.3
CPVT3;Ventricular tachycardia, catecholaminergic polymorphic, 3 (2);CPVT3;614021;AR;7p22-p14
CR1;CR1 deficiency (1);CR1, C3BR;120620;-;1q32.2
CR2;Immunodeficiency, common variable, 7, 614699 (3);CR2, C3DR, SLEB9, CVID7;120650;AR;1q32.2
CRADD;Mental retardation, autosomal recessive 34, 614499 (3);CRADD, RAIDD, MRT34;603454;-;12q22
CRAT;?Carnitine acetyltransferase deficiency (1);CRAT, CAT1;600184;-;9q34.11
CRB1;Leber congenital amaurosis 8, 613835 (3),Pigmented paravenous chorioretinal atrophy, 172870 (3),Retinitis pigmentosa-12, autosomal recessive, 600105 (3);CRB1, RP12, LCA8;604210;AD, AR;1q31.3
CRB2;Focal segmental glomerulosclerosis 9, 616220 (3),Ventriculomegaly with cystic kidney disease, 219730 (3);CRB2, FSGS9, VMCKD;609720;AR;9q33.3
CRBN;Mental retardation, autosomal recessive 2, 607417 (3);CRBN, MRT2;609262;AR;3p26.2
CRCL;Creatinine clearance QTL (2);CRCL;607135;-;3p
CREB1;Histiocytoma, angiomatoid fibrous, somatic, 612160 (3);CREB1;123810;-;2q33.3
CREBBP;Rubinstein-Taybi syndrome, 180849 (3);CREBBP, CBP, RSTS;600140;AD;16p13.3
CRELD1;Atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 (3);CRELD1, AVSD2;607170;AD;3p25.3
CRFB4;Inflammatory bowel disease 25, early onset, autosomal recessive, 612567 (3);CRFB4, IBD25;123889;AR;21q22.11
CRIPT;Short stature with microcephaly and distinctive facies, 615789 (3);CRIPT, SSMDF;604594;AR;2p21
CRLF1;Cold-induced sweating syndrome 1, 272430 (3);CRLF1, CISS1;604237;AR;19p13.11
CRSA;Craniosynostosis, Adelaide type (2);CRSA, CRS3;600593;?AD;4p16
CRTAP;Osteogenesis imperfecta, type VII, 610682 (3);CRTAP, CASP, OI7;605497;AR;3p22.3
CRTC1;Mucoepidermoid salivary gland carcinoma (3);CRTC1, MECT1, KIAA0616, FLJ14027;607536;-;19p13.11
CRX;Cone-rod retinal dystrophy-2, 120970 (3),Leber congenital amaurosis 7, 613829 (3);CRX, CORD2, CRD, LCA7;602225;AD;19q13.33
CRYAA;Cataract 9, multiple types, 604219 (3);CRYAA, CRYA1, CTRCT9;123580;AD;21q22.3
CRYAB;Cardiomyopathy, dilated, 1II, 615184 (3),Cataract 16, multiple types, 613763 (3),Myopathy, myofibrillar, 2, 608810 (3),Myopathy, myofibrillar, fatal infantile hypertrophy, alpha-B crystallin-related, 613869 (3);CRYAB, CRYA2, CTPP2, CMD1II, CTRCT16, MFM2;123590;AD, AR;11q23.1
CRYBA1;Cataract 10, multiple types, 600881 (3);CRYBA1, CRYB1, CTRCT10;123610;AD;17q11.2
CRYBA2;?Cataract 42, 115900 (3);CRYBA2, CTRCT42;600836;AD;2q35
CRYBA4;Cataract 23, 610425 (3);CRYBA4, CTRCT23;123631;-;22q12.1
CRYBB1;Cataract 17, multiple types, 611544 (3);CRYBB1, CATCN3, CTRCT17;600929;-;22q12.1
CRYBB2;Cataract 3, multiple types, 601547 (3);CRYBB2, CRYB2, CTRCT3, CCA2;123620;-;22q11.23
CRYBB3;Cataract 22, autosomal recessive, 609741 (3);CRYBB3, CRYB3, CATCN2, CTRCT22;123630;AD, AR;22q11.23
CRYGB;Cataract 39, multiple types, autosomal dominant, 615188 (3);CRYGB, CRYG2, CTRCT39;123670;AD;2q33.3
CRYGC;Cataract 2, multiple types, 604307 (3);CRYGC, CRYG3, CTRCT2, CCL;123680;AD;2q33.3
CRYGD;Cataract 4, multiple types, 115700 (3);CRYGD, CRYG4, CTRCT4, CACA, CCA3, PCC;123690;AD;2q33.3
CRYGS;Cataract 20, multiple types, 116100 (3);CRYGS, CRYG8, CTRCT20;123730;AD;3q27.3
CRYM;Deafness, autosomal dominant 40, 616357 (3);CRYM, DFNA40;123740;-;16p12.2
CSF1R;Leukoencephalopathy, diffuse hereditary, with spheroids, 221820 (3);CSF1R, FMS, HDLS;164770;AD;5q32
CSF2RA;Surfactant metabolism dysfunction, pulmonary, 4, 300770 (3);CSF2RA, SMDP4;306250;-;Xp22.33
CSF2RB;Surfactant metabolism dysfunction, pulmonary, 5, 614370 (3);CSF2RB, SMDP5;138981;AR;22q12.3
CSF3R;Neutropenia, severe congenital, 7, autosomal recessive, 617014 (3);CSF3R, GCSFR, SCN7;138971;AR;1p34.3
CSMF;Chondrosarcoma, extraskeletal myxoid, 612237 (3);CSMF;600542;-;9q31.1
CSNK1D;Advanced sleep-phase syndrome, familial, 2, 615224 (3);CSNK1D, ASPS, FASPS2;600864;AD;17q25.3
CSPP1;Joubert syndrome 21, 615636 (3);CSPP1, CSPP, JBTS21;611654;AR;8q13.1-q13.2
CSRP3;?Cardiomyopathy, dilated, 1M, 607482 (3),Cardiomyopathy, hypertrophic, 12, 612124 (3);CSRP3, CRP3, CLP, CMD1M, CMH12;600824;-,AD;11p15.1
CST3;Cerebral amyloid angiopathy, 105150 (3);CST3, ARMD11;604312;AD;20p11.21
CSTA;Peeling skin syndrome 4, 607936 (3);CSTA, STFA, STF1, AREI, PSS4;184600;AR;3q21.1
CSTB;Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg), 254800 (3);CSTB, STFB, EPM1, PME, EPM1A, ULD;601145;AR;21q22.3
CTC1;Cerebroretinal microangiopathy with calcifications and cysts, 612199 (3);CTC1, CRMCC, C17orf68, AAF132;613129;AR;17p13.1
CTCF;Mental retardation, autosomal dominant 21, 615502 (3);CTCF, MRD21;604167;AD;16q22.1
CTDP1;Congenital cataracts, facial dysmorphism, and neuropathy, 604168 (3);CTDP1, FCP1, CCFDN;604927;AR;18q23
CTH;Cystathioninuria, 219500 (3),Homocysteine, total plasma, elevated (3);CTH;607657;AR;1p31.1
CTHRC1;Barrett esophagus/esophageal adenocarcinoma, 614266 (3);CTHRC1;610635;-;8q22.3
CTLA4;Autoimmune lymphoproliferative syndrome, type V, 616100 (3);CTLA4, IDDM12, CELIAC3, ALPS5;123890;AD;2q33.2
CTNNA1;Macular dystrophy, patterned, 2, 608970 (3);CTNNA1, MDPT2;116805;AD;5q31.2
CTNNA3;Arrhythmogenic right ventricular dysplasia, familial, 13, 615616 (3);CTNNA3, ARVD13;607667;AD;10q21.3
CTNNB1;Colorectal cancer, somatic, 114500 (3),Hepatocellular carcinoma, somatic, 114550 (3),Mental retardation, autosomal dominant 19, 615075 (3),Ovarian cancer, somatic, 167000 (3),Pilomatricoma, somatic, 132600 (3);CTNNB1, MRD19;116806;AD;3p22.1
CTNS;Cystinosis, atypical nephropathic, 219800 (3),Cystinosis, late-onset juvenile or adolescent nephropathic, 219900 (3),Cystinosis, nephropathic, 219800 (3),Cystinosis, ocular nonnephropathic, 219750 (3);CTNS;606272;AR;17p13.2
CTPS1;Immunodeficiency 24, 615897 (3);CTPS1, CTPS, IMD24;123860;AR;1p34.2
CTRCT24;Cataract 24, anterior polar (2);CTRCT24, CTAA2;601202;AD;17p13
CTRCT25;Cataract 25 (2);CTRCT25, CCSSO;605728;-;15q21-q22
CTRCT26;Cataract 26, multiple types (2);CTRCT26, CAAR;605749;-;9q13-q22
CTRCT27;Cataract 27, nuclear progressive (2);CTRCT27, CCNP;607304;-;2p12
CTRCT29;Cataract 29, coralliform (2);CTRCT29;115800;AD;2pter-p24
CTRCT32;Cataract 32, multiple types (2);CTRCT32, CTAA1, CAP, CTPP5;115650;AD;14q22-q23
CTRCT34;Cataract 34, multiple types (2);CTRCT34, CATC3;612968;-;1p34.3-p32.2
CTRCT35;Cataract 35, congenital nuclear (2);CTRCT35, CATCN1;609376;AR;19q13
CTRCT37;Cataract 37, autosomal dominant (2);CTRCT37, CCA5;614422;AD;12q24.2-q24.3
CTRCT7;Cataract 7 (2);CTRCT7, CCA1;115660;AD;17q24
CTRCT8;Cataract 8, multiple types (2);CTRCT8, CCV;115665;AD;1pter-p36.13
CTSA;Galactosialidosis, 256540 (3);CTSA, PPGB, GSL, NGBE, GLB2;613111;AR;20q13.12
CTSC;Haim-Munk syndrome, 245010 (3),Papillon-Lefevre syndrome, 245000 (3),Periodontitis 1, juvenile, 170650 (3);CTSC, CPPI, PALS, PLS, HMS, PDON1, JPD;602365;AR;11q14.2
CTSD;Ceroid lipofuscinosis, neuronal, 10, 610127 (3);CTSD, CPSD, CLN10;116840;AR;11p15.5
CTSF;Ceroid lipofuscinosis, neuronal, 13, Kufs type, 615362 (3);CTSF, CLN13;603539;AR;11q13.2
CTSK;Pycnodysostosis, 265800 (3);CTSK;601105;AR;1q21.3
CUBN;Megaloblastic anemia-1, Finnish type, 261100 (3);CUBN, IFCR, MGA1;602997;AR;10p13
CUL3;Pseudohypoaldosteronism, type IIE, 614496 (3);CUL3, PHA2E;603136;AD;2q36.2
CUL4B;Mental retardation, X-linked, syndromic 15 (Cabezas type), 300354 (3);CUL4B, MRXSC, MRXHF2, SFM2, MRXS15;300304;XLR;Xq24
CUL7;3-M syndrome 1, 273750 (3);CUL7, 3M1;609577;AR;6p21.1
CVMRF;Cubitus valgus with mental retardation and unusual facies (2);CVMRF;300471;XLR;Chr.X
CWF19L1;?Spinocerebellar ataxia, autosomal recessive 17, 616127 (3);CWF19L1, C19L1, SCAR17;616120;AR;10q24.31
CXCR4;Myelokathexis, isolated (3),WHIM syndrome, 193670 (3);CXCR4, D2S201E, NPY3R, WHIMS;162643;AD;2q22.1
CXDUPq26.3;Chromosome Xq26.3 duplication syndrome (4);CXDUPq26.3, DUPXq26.3, XLAG;300942;XLD;Xq26.3
CYB5A;Methemoglobinemia, type IV, 250790 (3);CYB5A, MCB5;613218;AR;18q22.3
CYB5R3;Methemoglobinemia, type I, 250800 (3),Methemoglobinemia, type II, 250800 (3);CYB5R3, DIA1, B5R;613213;AR;22q13.2
CYBA;Chronic granulomatous disease, autosomal, due to deficiency of CYBA, 233690 (3);CYBA;608508;AR;16q24.2
CYBB;Chronic granulomatous disease, X-linked, 306400 (3),Immunodeficiency 34, mycobacteriosis, X-linked, 300645 (3);CYBB, CGD, AMCBX2, IMD34;300481;XLR;Xp21.1-p11.4
CYC1;Mitochondrial complex III deficiency, nuclear type 6, 615453 (3);CYC1, MC3DN6;123980;AR;8q24.3
CYCS;Thrombocytopenia 4, 612004 (3);CYCS, CYC, THC4;123970;AD;7p15.3
CYLD;Brooke-Spiegler syndrome, 605041 (3),Cylindromatosis, familial, 132700 (3),Trichoepithelioma, multiple familial, 1, 601606 (3);CYLD, CDMT, EAC, MFT1, KIAA0849, BRSS;605018;AD;16q12.1
CYP11A1;Adrenal insufficiency, congenital, with 46XY sex reversal, partial or complete, 613743 (3);CYP11A1, P450SCC;118485;-;15q24.1
CYP11B1;Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 (3),Aldosteronism, glucocorticoid-remediable, 103900 (3);CYP11B1, P450C11, FHI;610613;AR,AD;8q24.3
CYP11B2;Aldosterone to renin ratio raised (3),Hypoaldosteronism, congenital, due to CMO I deficiency, 203400 (3),Hypoaldosteronism, congenital, due to CMO II deficiency, 610600 (3);CYP11B2;124080;AR;8q24.3
CYP17A1;17,20-lyase deficiency, isolated, 202110 (3),17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3);CYP17A1, CYP17, P450C17;609300;AR;10q24.32
CYP19A1;Aromatase deficiency, 613546 (3),Aromatase excess syndrome, 139300 (3);CYP19A1, CYP19, ARO;107910;-, AD;15q21.2
CYP1B1;Glaucoma 3A, primary open angle, congenital, juvenile, or adult onset, 231300 (3),Peters anomaly, 604229 (3);CYP1B1, GLC3A;601771;AR;2p22.2
CYP21A2;Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3),Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3);CYP21A2, CYP21, CA21H;613815;AR;6p21.33
CYP24A1;Hypercalcemia, infantile, 1, 143880 (3);CYP24A1, CYP24, HCINF1;126065;AR;20q13.2
CYP26B1;Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies, 614416 (3);CYP26B1, CYP26A2, P450RAI2, RHFCA;605207;-;2p13.2
CYP26C1;Focal facial dermal dysplasia 4, 614974 (3);CYP26C1, FFDD4;608428;AR;10q23.33
CYP27A1;Cerebrotendinous xanthomatosis, 213700 (3);CYP27A1, CYP27, CTX;606530;AR;2q35
CYP27B1;Vitamin D-dependent rickets, type I, 264700 (3);CYP27B1, VDD1, PDDR;609506;AR;12q14.1
CYP2A6;Coumarin resistance, 122700 (3);CYP2A6, CYP2A3, CYP2A, P450C2A;122720;AR, AD;19q13.2
CYP2B6;Efavirenz, poor metabolism of, 614546 (3);CYP2B6, CYP2B, EFVM;123930;-;19q13.2
CYP2C;Clopidogrel, impaired responsiveness to, 609535 (3),Mephenytoin poor metabolizer, 609535 (3),Omeprazole poor metabolizer, 609535 (3),Proguanil poor metabolizer, 609535 (3);CYP2C, CYP2C19;124020;AR;10q23.33
CYP2C8;Rhabdomyolysis, cerivastatin-induced (3);CYP2C8;601129;-;10q23.33
CYP2C9;Tolbutamide poor metabolizer (3),Warfarin sensitivity, 122700 (3);CYP2C9;601130;AD;10q23.33
CYP2R1;Rickets due to defect in vitamin D 25-hydroxylation, 600081 (3);CYP2R1;608713;AR;11p15.2
CYP2U1;Spastic paraplegia 56, autosomal recessive, 615030 (3);CYP2U1, SPG56;610670;AR;4q25
CYP4F22;Ichthyosis, congenital, autosomal recessive 5, 604777 (3);CYP4F22, ARCI5, LI3;611495;AR;19p13.12
CYP4V2;Bietti crystalline corneoretinal dystrophy, 210370 (3);CYP4V2, BCD;608614;AR;4q35.1-q35.2
CYP7B1;Bile acid synthesis defect, congenital, 3, 613812 (3),Spastic paraplegia 5A, autosomal recessive, 270800 (3);CYP7B1, CBAS3, SPG5A;603711;AR;8q12.3
D2HGDH;D-2-hydroxyglutaric aciduria, 600721 (3);D2HGDH, D2HGD;609186;AR;2q37.3
DA10;Arthrogryposis, distal, type 10 (2);DA10;187370;AD;2q31.3-q32.1
DAG1;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 9, 616538 (3),Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9, 613818 (3);DAG1, DAG, MDDGC9, MDDGA9;128239;AR;3p21.31
DARS;Hypomyelination with brainstem and spinal cord involvement and leg spasticity, 615281 (3);DARS, HBSL;603084;AR;2q21.3
DARS2;Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105 (3);DARS2, ASPRS. LBSL;610956;AR;1q25.1
DAX1;46XY sex reversal 2, dosage-sensitive, 300018 (3),Adrenal hypoplasia, congenital, with hypogonadotropic hypogonadism, 300200 (3);DAX1, AHC, AHX, NR0B1, SRXY2;300473;XL,XLR;Xp21.2
DAZ;?Sertoli-cell-only syndrome (1);DAZ;400003;-;Yq11.223
DBA2;Diamond-Blackfan anemia 2 (2);DBA2;606129;-;8p23.3-p22
DBH;Dopamine beta-hydroxylase deficiency, 223360 (3);DBH;609312;AR;9q34.2
DBT;Maple syrup urine disease, type II, 248600 (3);DBT, BCATE2;248610;AR;1p21.2
DCAF17;Woodhouse-Sakati syndrome, 241080 (3);DCAF17, C20orf37;612515;AR;2q31.1
DCAF8;?Giant axonal neuropathy 2, autosomal dominant, 610100 (3);DCAF8, WDR42A, GAN2;615820;AD;1q23.2
DCC;Colorectal cancer, somatic, 114500 (3),Esophageal carcinoma, somatic 133239 (3),Mirror movements 1, 157600 (3);DCC, MRMV1;120470;AD;18q21.2
DCDC2;?Deafness, autosomal recessive 66, 610212 (3),Nephronophthisis 19, 616217 (3);DCDC2, RU2, KIAA1154, NPHP19, DFNB66;605755;AR;6p22.3
DCHS1;Mitral valve prolapse 2, 607829 (3),Van Maldergem syndrome 1, 601390 (3);DCHS1, PCDH16, FIB1, CDH19, VMLDS1, MVP2;603057;AD, AR;11p15.4
DCLRE1C;Omenn syndrome, 603554 (3),Severe combined immunodeficiency, Athabascan type, 602450 (3);DCLRE1C, ARTEMIS, SCIDA;605988;AR;10p13
DCN;Corneal dystrophy, congenital stromal, 610048 (3);DCN, CSCD;125255;AD;12q21.33
DCPS;Al-Raqad syndrome, 616459 (3);DCPS, HINT5, DCS1, ARS;610534;AR;11q24.2
DCR;Down syndrome (4);DCR, DSCR;190685;IC;21q22.3
DCTN1;Neuropathy, distal hereditary motor, type VIIB, 607641 (3),Perry syndrome, 168605 (3);DCTN1, HMN7B;601143;AD, AR;2p13.1
DCX;Lissencephaly, X-linked, 300067 (3),Subcortical laminal heteropia, X-linked, 300067 (3);DCX, DBCN, LISX;300121;XL;Xq23
DDB2;Xeroderma pigmentosum, group E, DDB-negative subtype, 278740 (3);DDB2;600811;AR;11p11.2
DDC;Aromatic L-amino acid decarboxylase deficiency, 608643 (3);DDC;107930;AR;7p12.2-p12.1
DDD3;Dowling-Degos disease 3 (2);DDD3;615674;AD;17q21.3-q22
DDH1;Developmental dysplasia of the hip 1 (2);DDH1;142700;Mu;13q22
DDH2;Developmental dysplasia of the hip 2 (2);DDH2;615612;AD;3p22.2
DDHD1;Spastic paraplegia 28, autosomal recessive, 609340 (3);DDHD1, PAPLA1, KIAA1705, SPG28;614603;AR;14q22.1
DDHD2;Spastic paraplegia 54, autosomal recessive, 615033 (3);DDHD2, KIAA0725, SPG54;615003;AR;8p11.23
DDIT3;Myxoid liposarcoma, 613488 (1);DDIT3, GADD153, CHOP10;126337;-;12q13.3
DDOST;?Congenital disorder of glycosylation, type Ir, 614507 (3);DDOST, OST, OST48, CDG1R;602202;AR;1p36.12
DDR2;Spondylometaepiphyseal dysplasia, short limb-hand type, 271665 (3);DDR2, NTRKR3, TKT;191311;AR;1q23.3
DDX11;Warsaw breakage syndrome, 613398 (3);DDX11, CHLR1, KRG2;601150;AR;12p11.21
DDX3X;Mental retardation, X-linked 102, 300958 (3);DDX3X, DDX3, DBX, MRX102;300160;XLD, XLR;Xp11.4
DDX48;Robin sequence with cleft mandible and limb anomalies, 268305 (3);DDX48, EIF4A3, MUK34, NMP265, KIAA0111, RCPS;608546;AR;17q25.3
DDX58;Singleton-Merten syndrome 2, 616298 (3);DDX58, RIGI, SGMRT2;609631;AD;9p21.1
DDX59;Orofaciodigital syndrome V, 174300 (3);DDX59, OFD5;615464;AR;1q32.1
DEAF1;Mental retardation, autosomal dominant 24, 615828 (3);DEAF1, SPN, ZMYND5, MRD24;602635;AD;11p15.5
DEC1;Esophageal squamous cell carcinoma, 133239 (1);DEC1;604767;AD;9q33.1
DEK;Leukemia, acute nonlymphocytic (2);DEK, D6S231E;125264;-;6p22.3
DEL10q23;Chromosome 10q22.3-q23.2 deletion syndrome (4);DEL10q23, C10DELq23;612242;-;10q23
DEL10q26;Chromosome 10q26 deletion syndrome (4);DEL10q26, C10q26DEL;609625;AD;10q26
DEL11p13;Chromosome 11p13 deletion syndrome, distal, 616902 (4),Wilms tumor, aniridia, genitourinary anomalies and mental retardation syndrome (4);DEL11p13, C11DELp13, WAGR;194072;Smu, AD;11p13
DEL11p15p14;Chromosome 11p15-p14 deletion syndrome (4);DEL11p15p14, C11DELp15p14;606528;AR;11p15-p14
DEL13q14;Chromosome 13q14 deletion syndrome (4);DEL13q14, C13DELq14;613884;IC, AD;13q14
DEL14q11q22;Chromosome 14q11-q22 deletion syndrome (4);DEL14q11q22, C14DELq11q22;613457;IC;14q11-q22
DEL15q11.2;Chromosome 15q11.2 deletion syndrome (4);DEL15q11.2, C15DELq11.2;615656;AD;15q11.2
DEL15q13.3;Chromosome 15q13.3 microdeletion syndrome (4);DEL15q13.3, MICRODEL15q13.3;612001;-;15q13.3
DEL15q14;Chromosome 15q14 deletion syndrome (4);DEL15q14, C15DELq14;616898;AD;15q14
DEL15q15.3;Deafness and male infertility (4);DEL15q15.3, C15DELq15.3;611102;AR;15q15.3
DEL15q24;Chromosome 15q24 deletion syndrome (4);DEL15q24, CHR15DELq24;613406;IC;15q24
DEL15q25;Chromosome 15q25 deletion syndrome (4);DEL15q25, C15DELq25;614294;AD;15q25
DEL15q26qter;Chromosome 15q26-qter deletion syndrome (4);DEL15q26qter, C15DELq26qter;612626;IC;15q26-qter
DEL16p11.2;Chromosome 16p11.2 deletion syndrome, 593kb (4);DEL16p11.2, C16DELp11.2, AUTS14A;611913;-;16p11.2
DEL16p12.1;Chromosome 16p12.1 deletion syndrome, 520kb (4);DEL16p12.1, C16DELp12.1;136570;-;16p12
DEL16p12.1p11.2;Chromosome 16p12.2-p11.2 deletion syndrome (4);DEL16p12.1p11.2, C16DELp12.1p11.2;613604;IC;16p12.2-p11.2
DEL16p13.2;Chromosome 16p13.2 deletion syndrome (4);DEL16p13.2, C16DELp13.2;616863;AD;16p13.2
DEL16p13.3;Chromosome 16p13.3 deletion syndrome (4);DEL16p13.3, RSTSS;610543;-;16p13.3
DEL17p13.1;Chromosome 17p13.1 deletion syndrome (4);DEL17p13.1, C17DELp13.1;613776;AD;17p13.1
DEL17q11.2;Chromosome 17q11.2 deletion syndrome, 1.4Mb (4);DEL17q11.2, C17DELq11.2;613675;AD;17q11.2
DEL17q12;Chromosome 17q12 deletion syndrome (4);DEL17q12, C17DELq12;614527;AD;17q12
DEL17q23.1q23.2;Chromosome 17q23.1-q23.2 deletion syndrome (4);DEL17q23.1q23.2, C17DELq23.1q23.2;613355;IC;17q23.1-q23.2
DEL18p;Chromosome 18p deletion syndrome (4);DEL18p, C18DELp;146390;AD;18p
DEL18q;Chromosome 18q deletion syndrome (4);DEL18q;601808;AD;18q
DEL19p13.13;Chromosome 19p13.13 deletion syndrome (4),Chromosome 19p13.13 duplication syndrome (4);DEL19p13.13, C19DELp13.13, DUP19p13.13, C19DUPp13.13;613638;-;19p13.13
DEL19q13.11;Chromosome 19q13.11 deletion syndrome (4);DEL19q13.11, C19DELq13.11;613026;IC;19q13.11
DEL1p32p31;Chromosome 1p32-p31 deletion syndrome (4);DEL1p32p31, C1DELp32p31;613735;IC;1p32-p31
DEL1p36;Chromosome 1p36 deletion syndrome (4);DEL1p36, C1DELp36;607872;IC;1p36
DEL1q21;Chromosome 1q21.1 deletion syndrome (4);DEL1q21, C1DELq21;612474;IC, AD;1q21.1
DEL1q41q42;Chromosome 1q41-q42 deletion syndrome (4);DEL1q41q42, C1DELq41q42;612530;IC;1q41-q42
DEL22q11.2;Chromosome 22q11.2 deletion syndrome, distal (4);DEL22q11.2, C22DELq11.2;611867;-;22q11.2
DEL2p12p11.2;Chromosome 2p12-p11.2 deletion syndrome (4);DEL2p12p11.2, C2DELp12p11.2;613564;-;2p12-p11.2
DEL2p16.1-p15;Chromosome 2p16.1-p15 deletion syndrome (4);DEL2p16.1-p15, C2DELp161-p15;612513;IC;2p16.1-p15
DEL2p21;Hypotonia-cystinuria syndrome (4);DEL2p21, C2DELp21;606407;AR;2p21
DEL2q31;Chromosome 2q31.2 deletion syndrome (4);DEL2q31;612345;-;2q31.2
DEL3pterp25;3p- syndrome (4);DEL3pterp25, C3DELpterp25;613792;AD;3pter-p25
DEL3q13.31;Chromosome 3q13.31 deletion syndrome (4);DEL3q13.31, C13DELq13.31;615433;AD;3q13.31
DEL3q29;Chromosome 3q29 microdeletion syndrome (4);DEL3q29, MICRODEL3q29;609425;IC;3q29
DEL4q21;Chromosome 4q21 deletion syndrome (4);DEL4q21, C4DELq21;613509;IC;4q21
DEL5q12;Chromosome 5q12 deletion syndrome (4);DEL5q12, C5DELq12;615668;AD;5q12
DEL6pter;Chromosome 6pter-p24 deletion syndrome (4);DEL6pter, C6DELpter;612582;IC;6pter-p24
DEL6q11q14;Chromosome 6q11-q14 deletion syndrome (4);DEL6q11q14, C6DELq11q14;613544;IC;6q11-q14
DEL6q24q25;Chromosome 6q25-q25 deletion syndrome (4);DEL6q24q25, C6DELq25q25;612863;-;6q24-q25
DEL7q11.23;Chromosome 7q11.23 deletion syndrome, distal, 1.2Mb (4);DEL7q11.23, C7DELq11.23;613729;-;7q11.23
DEL8q12q21;Bor-Duane hydrocephalus contiguous gene syndrome (4);DEL8q12q21, C8DELq12q21;600257;AD;8q12.2-q21.2
DEL8q13;Mesomelia-synostoses syndrome (4);DEL8q13, C8DELq13;600383;AD;8q13
DEL8q21.11;Chromosome 8q21.11 deletion syndrome (4);DEL8q21.11, C8DELq21.11;614230;IC, AD;8q21.11
DEL9p;Chromosome 9p deletion syndrome (4);DEL9p, C9DELp;158170;AD;9p
DEL9p24.3;46XY sex reversal 4 (4);DEL9p24.3, C9DELp24.3, SRXY4;154230;-;9p24.3
DELXp11.3;Chromosome Xp11.3 deletion syndrome (4);DELXp11.3, CXDELp11.3;300578;XLR;Xp11.3
DELXp21;Chromosome Xp21 deletion syndrome (4);DELXp21, CXDELp21;300679;-;Xp21
DELXq21;Choroideremia, deafness, and mental retardation (4);DELXq21, CXDELq21;303110;XLR;Xq21
DELYq11;Spermatogenic failure, Y-linked, 1 (4);DELYq11, CYDELq11, SPGFY1;400042;-;Yq11
DEPDC5;Epilepsy, familial focal, with variable foci, 604364 (3);DEPDC5, KIAA0645, FFEVF;614191;AD;22q12.2-q12.3
DER22t11-22;Emanuel syndrome (4);DER22t11-22;609029;ACB;22q11.2
DER22t8-22;Supernumerary der(22)t(8-22) syndrome (4);DER22t8-22;613700;-;22q11.2
DES;?Muscular dystrophy, limb-girdle, type 2R, 615325 (3),Cardiomyopathy, dilated, 1I, 604765 (3),Myopathy, myofibrillar, 1, 601419 (3),Scapuloperoneal syndrome, neurogenic, Kaeser type, 181400 (3);DES, CMD1I, MFM1, SCPNK, ARVD7, ARVC7, LGMD2R;125660;AR, AD;2q35
DFCTRPS;Deafness, cataract, retinitis pigmentosa, and sperm abnormalities (2);DFCTRPS;300719;XLR;Chr.X
DFNA16;Deafness, autosomal dominant 16 (2);DFNA16;603964;AD;2q23-q24.3
DFNA18;Deafness, autosomal dominant 18 (2);DFNA18;606012;AD;3q22
DFNA21;Deafness, autosomal dominant 21 (2);DFNA21;607017;AD;6p24.1-p22.3
DFNA24;Deafness, autosomal dominant 24 (2);DFNA24;606282;AD;4q35-qter
DFNA27;Deafness, autosomal dominant 27 (2);DFNA27;612431;AD;4q12-q13.1
DFNA30;Deafness, autosomal dominant 30 (2);DFNA30;606451;AD;15q25-q26
DFNA31;Deafness, autosomal dominant 31 (2);DFNA31;608645;AD;6p21.3
DFNA33;Deafness, autosomal dominant 33 (2);DFNA33;614211;AD;13q34
DFNA43;Deafness, autosomal dominant 43 (2);DFNA43;608394;AD;2p12
DFNA47;Deafness, autosomal dominant 47 (2);DFNA47, DFNB83;608652;AD;9p22-p21
DFNA48;Deafness, autosomal dominant 48 (2);DFNA48;607841;AD;12q13-q14
DFNA49;Deafness, autosomal dominant 49 (2);DFNA49;608372;AD;1q21-q23
DFNA5;Deafness, autosomal dominant 5, 600994 (3);DFNA5;608798;AD;7p15.3
DFNA51;Deafness, autosomal dominant 51 (4);DFNA51, C9DUPq21.11, DUP9q21.11;613558;AD;9q21.11
DFNA52;Deafness, autosomal dominant 52 (2);DFNA52, DFNA42;607683;AD;5q31.1-q32
DFNA53;Deafness, autosomal dominant 53 (2);DFNA53;609965;AD;14q11.2-q12
DFNA54;Deafness, autosomal dominant 54 (2);DFNA54;615649;AD;5q31
DFNA58;Deafness, autosomal dominant 58 (2);DFNA58;615654;AD;2p21-p12
DFNA59;Deafness, autosomal dominant 59 (2);DFNA59;612642;AD;11p14.2-q12.3
DFNA7;Deafness, autosomal dominant 7 (2);DFNA7;601412;AD;1q21-q23
DFNB13;Deafness, autosomal recessive 13 (2);DFNB13;603098;-;7q34-q36
DFNB14;Deafness, autosomal recessive 14 (2);DFNB14;603678;AR;7q31
DFNB17;Deafness, autosomal recessive 17 (2);DFNB17;603010;AR;7q31
DFNB20;Deafness, autosomal recessive 20 (2);DFNB20;604060;AR;11q25-qter
DFNB26;Deafness, autosomal recessive 26 (2);DFNB26;605428;-;4q31
DFNB27;Deafness, autosomal recessive 27 (2);DFNB27;605818;AR;2q23-q31
DFNB32;Deafness, autosomal recessive 32 (2);DFNB32;608653;AR;1p22.1-p13.3
DFNB33;Deafness, autosomal recessive 33 (2);DFNB33;607239;AR;10p11.23-q21.1
DFNB38;Deafness, autosomal recessive 38 (2);DFNB38;608219;AR;6q26-q27
DFNB40;Deafness, autosomal recessive 40 (2);DFNB40;608264;AR;22q11.21-q12.1
DFNB45;Deafness, autosomal recessive 45 (2);DFNB45;612433;-;1q43-q44
DFNB46;Deafness, autosomal recessive 46 (2);DFNB46;609647;AR;18p11.32-p11.31
DFNB47;Deafness, neurosensory, autosomal recessive 47 (2);DFNB47;609946;AR;2p25.1-p24.3
DFNB5;Deafness, autosomal recessive 5 (2);DFNB5;600792;AR;14q12
DFNB51;Deafness, autosomal recessive 51 (2);DFNB51;609941;AR;11p13-p12
DFNB55;Deafness, autosomal recessive 55 (2);DFNB55;609952;AR;4q12-q13.2
DFNB62;Deafness, autosomal recessive 62 (2);DFNB62;610143;AR;12p13.2-p11.23
DFNB65;Deafness, autosomal recessive 65 (2);DFNB65;610248;AR;20q13.2-q13.3
DFNB71;Deafness, autosomal recessive 71 (2);DFNB71;612789;AR;8p22-p21.3
DFNB83;Deafness, autosomal recessive 83 (2);DFNB83;613685;AR;9p23-p21.2
DFNB85;Deafness, autosomal recessive 85 (2);DFNB85;613392;AR;17p12-q11.2
DFNB96;Deafness, autosomal recessive 96 (2);DFNB96;614414;AR;1p36.31-p36.13
DFNX3;Deafness, X-linked 3 (2);DFNX3, DFN4;300030;XL ;Xp21.2
DFNY1;Deafness, Y-linked 1 (1);DFNY1;400043;-;Chr.Y
DGAT1;?Diarrhea 7, 615863 (3);DGAT1, ARGP1, DIAR7;604900;AR;8q24.3
DGCR2;DiGeorge syndrome/velocardiofacial syndrome complex-2 (2);DGCR2, DGS2;601362;-;10p14-p13
DGKE;Nephrotic syndrome, type 7, 615008 (3);DGKE, NPHS7, AHUS7;601440;AR;17q22
DGUOK;Mitochondrial DNA depletion syndrome 3 (hepatocerebral type), 251880 (3);DGUOK, DGK, MTDPS3;601465;AR;2p13.1
DHCR24;Desmosterolosis, 602398 (3);DHCR24, KIAA0018;606418;AR;1p32.3
DHCR7;Smith-Lemli-Opitz syndrome, 270400 (3);DHCR7, SLOS;602858;AR;11q13.4
DHDDS;Retinitis pigmentosa 59, 613861 (3);DHDDS, HDS, RP59;608172;AR;1p36.11
DHFR;Megaloblastic anemia due to dihydrofolate reductase deficiency, 613839 (3);DHFR;126060;AR;5q14.1
DHH;46XY partial gonadal dysgenesis, with minifascicular neuropathy, 607080 (3),46XY sex reversal 7, 233420 (3);DHH, SRXY7, GDXYM;605423;-,AR;12q13.12
DHMN1;Neuronopathy, distal hereditary motor, type I (2);DHMN1;182960;AD;7q34-q36
DHODH;Miller syndrome, 263750 (3);DHODH, URA1, POADS;126064;AR;16q22.2
DHS6S1;Macular dystrophy, North Carolina type, 136550 (3);DHS6S1, MCDR1;616842;AD;6q16.2
DHTKD1;2-aminoadipic 2-oxoadipic aciduria, 204750 (3),?Charcot-Marie-Tooth disease, axonal, type 2Q, 615025 (3);DHTKD1, KIAA1630, AMOXAD, CMT2Q;614984;AR,AD;10p14
DIAPH1;Deafness, autosomal dominant 1, 124900 (3),Seizures, cortical blindness, microcephaly syndrome, 616632 (3);DIAPH1, DFNA1, LFHL1, SCBMS;602121;AR, AD;5q31.3
DIAPH2;Premature ovarian failure, 300511 (3);DIAPH2, DIA, POF2;300108;-;Xq21.33
DIAPH3;Auditory neuropathy, autosomal dominant, 1, 609129 (3);DIAPH3, DIA2, DRF3, AUNA1, NSDAN;614567;AD;13q21.2
DICER1;Goiter, multinodular 1, with or without Sertoli-Leydig cell tumors, 138800 (3),Pleuropulmonary blastoma, 601200 (3),Rhabdomyosarcoma, embryonal, 2, 180295 (3);DICER1, HERNA, KIAA0928, MNG1, RMSE2;606241;AD;14q32.13
DIH1;Hernia, congenital diaphragmatic 1 (2);DIH1, HCD;142340;Mu;15q26.1
DIH2;Hernia, congenital diaphragmatic 2 (2);DIH2;222400;AR;8p23.1
DIP2B;Mental retardation, FRA12A type, 136630 (3);DIP2B, KIAA1463;611379;AD;12q13.12
DIRC2;Renal cell carcinoma, 144700 (1);DIRC2, RCC4;602773;-;3q21.1
DIS3L2;Perlman syndrome, 267000 (3);DIS3L2, PRLMNS;614184;AR;2q37.1
DISC2;Schizophrenia, 181500 (2);DISC2;606271;AD;1q42.2
DJ1;Parkinson disease 7, autosomal recessive early-onset, 606324 (3);DJ1, PARK7;602533;AR;1p36.23
DKBI;Dyskeratosis, hereditary benign intraepithelial (2);DKBI;127600;AD;4q35
DKC1;Dyskeratosis congenita, X-linked, 305000 (3);DKC1, DKCX;300126;XLR;Xq28
DLAT;Pyruvate dehydrogenase E2 deficiency, 245348 (3);DLAT, PDCE2;608770;AR;11q23.1
DLC1;Colorectal cancer, somatic, 114500 (3);DLC1;604258;-;8p22
DLD;Dihydrolipoamide dehydrogenase deficiency, 246900 (3);DLD, LAD, PHE3, DLDD;238331;AR;7q31.1
DLEC1;Esophageal cancer, 133239 (1),Lung cancer, 211980 (1);DLEC1, DLC1;604050;AD, AR;3p22.2
DLG3;Mental retardation, X-linked 90, 300850 (3);DLG3, NEDLG, SAP102, MRX90;300189;XLR;Xq13.1
DLL3;Spondylocostal dysostosis 1, autosomal recessive, 277300 (3);DLL3, SCDO1;602768;AR;19q13.2
DLL4;Adams-Oliver syndrome 6, 616589 (3);DLL4, AOS6;605185;AD;15q15.1
DLX3;Amelogenesis imperfecta, type IV, 104510 (3),Trichodontoosseous syndrome, 190320 (3);DLX3, TDO, AI4;600525;AD;17q21.33
DLX4;?Orofacial cleft 15, 616788 (3);DLX4, DLX7, DLX8, OFC15;601911;AD;17q21.33
DLX5;?Split-hand/foot malformation 1 with sensorineural hearing loss, 220600 (3);DLX5, SHFM1D;600028;AR;7q21.3
DMD;Becker muscular dystrophy, 300376 (3),Cardiomyopathy, dilated, 3B, 302045 (3),Duchenne muscular dystrophy, 310200 (3);DMD, BMD, CMD3B;300377;XLR, XL;Xp21.2-p21.1
DMGDH;Dimethylglycine dehydrogenase deficiency, 605850 (3);DMGDH, DMGDHD;605849;AR;5q14.1
DMP1;Hypophosphatemic rickets, AR, 241520 (3);DMP1, ARHR, ARHP;600980;AR;4q22.1
DMPK;Myotonic dystrophy 1, 160900 (3);DMPK, DM, DMK;605377;AD;19q13.32
DMXL2;?Polyendocrine-polyneuropathy syndrome, 616113 (3);DMXL2, RC3, KIAA0856, PEPNS;612186;AR;15q21.2
DNA2;?Seckel syndrome 8, 615807 (3),Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 6, 615156 (3);DNA2, DNA2L, KIAA0083, PEOA6, SCKL8;601810;AR, AD;10q21.3
DNAAF3;Ciliary dyskinesia, primary, 2, 606763 (3);DNAAF3, PF22, DAB1, CILD2;614566;AR;19q13.42
DNAH11;Ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3);DNAH11, DNAHC11, CILD7, DNAHBL;603339;AR;7p15.3
DNAH5;Ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 (3);DNAH5, HL1, PCD, CILD3;603335;-;5p15.2
DNAI1;Ciliary dyskinesia, primary, 1, with or without situs inversus, 244400 (3);DNAI1, CILD1, ICS, PCD;604366;AR;9p13.3
DNAI2;Ciliary dyskinesia, primary, 9, with or without situs inversus, 612444 (3);DNAI2, CILD9;605483;-;17q25.1
DNAJB2;Spinal muscular atrophy, distal, autosomal recessive, 5, 614881 (3);DNAJB2, HSJ1, HSPF3, DSMA5;604139;AR;2q35
DNAJB6;Muscular dystrophy, limb-girdle, type 1E, 603511 (3);DNAJB6, MRJ, DJ4, LGMD1E;611332;AD;7q36.3
DNAJC19;3-methylglutaconic aciduria, type V, 610198 (3);DNAJC19, TIM14;608977;AR;3q26.33
DNAJC3;?Ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, 616192 (3);DNAJC3, PRKRI, P58, ACPHD;601184;AR;13q32.1
DNAJC5;Ceroid lipofuscinosis, neuronal, 4, Parry type, 162350 (3);DNAJC5, DNAJC5A, CSP, CLN4B;611203;AD;20q13.33
DNAJC6;Parkinson disease 19, juvenile-onset, 615528 (3);DNAJC6, DJC6, KIAA0473, PARK19;608375;AR;1p31.3
DNAL1;Ciliary dyskinesia, primary, 16, 614017 (3);DNAL1, C14orf168, CILD16;610062;AR;14q24.3
DNAL4;?Mirror movements 3, 616059 (3);DNAL4, MRMV3;610565;AR;22q13.1
DNASE1L3;Systemic lupus erythematosus 16, 614420 (3);DNASE1L3, SLEB16;602244;AR;3p14.3
DNM1;Epileptic encephalopathy, early infantile, 31, 616346 (3);DNM1, EIEE31;602377;AD;9q34.11
DNM1L;Encephalopahty, lethal, due to defective mitochondrial peroxisomal fission, 614388 (3);DNM1L, DRP1, DVLP, DYMPLE, EMPF;603850;AD;12p11.21
DNM2;Charcot-Marie-Tooth disease, axonal, type 2M, 606482 (3),Charcot-Marie-Tooth disease, dominant intermediate B, 606482 (3),Lethal congenital contracture syndrome 5, 615368 (3),Myopathy, centronuclear, 160150 (3);DNM2, CMTDIB, CMTDI1, CMT2M, LCCS5;602378;AD, AR;19p13.2
DNMT1;Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, 604121 (3),Neuropathy, hereditary sensory, type IE, 614116 (3);DNMT1, MCMT, HSN1E, ADCADN;126375;AD;19p13.2
DNMT3A;Tatton-Brown-Rahman syndrome, 615879 (3);DNMT3A, TBRS;602769;AD;2p23.3
DNMT3B;Immunodeficiency-centromeric instability-facial anomalies syndrome 1, 242860 (3);DNMT3B, ICF1;602900;AR;20q11.21
DOCK2;Immunodeficiency 40, 616433 (3);DOCK2, IMD40;603122;AR;5q35.1
DOCK6;Adams-Oliver syndrome 2, 614219 (3);DOCK6, KIAA1395, AOS2;614194;AR;19p13.2
DOCK7;Epileptic encephalopathy, early infantile, 23, 615859 (3);DOCK7, KIAA1771, EIEE23;615730;AR;1p31.3
DOCK8;Hyper-IgE recurrent infection syndrome, autosomal recessive, 243700 (3);DOCK8;611432;AR;9p24.3
DOK7;?Fetal akinesia deformation sequence, 208150 (3),Myasthenic syndrome, congenital, 10, 254300 (3);DOK7, C4orf25, CMS10;610285;AR;4p16.3
DPAGT1;Congenital disorder of glycosylation, type Ij, 608093 (3),Myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 (3);DPAGT1, DPAGT2, DGPT, CDG1J, CMSTA2, CMS13;191350;AR;11q23.3
DPH1;Developmental delay with short stature, dysmorphic features, and sparse hair, 616901 (3);DPH1, DPH2L1, OVCA1, DEDSSH;603527;AR;17p13.3
DPM1;Congenital disorder of glycosylation, type Ie, 608799 (3);DPM1, MPDS, CDGIE;603503;AR;20q13.13
DPM2;Congenital disorder of glycosylation, type Iu, 615042 (3);DPM2, CDG1U;603564;AR;9q34.11
DPM3;Congenital disorder of glycosylation, type Io, 612937 (3);DPM3, CDG1O;605951;-;1q22
DPP6;Mental retardation, autosomal dominant 33, 616311 (3);DPP6, VF2, MRD33;126141;AD;7q36.2
DPY19L2;Spermatogenic failure 9, 613958 (3);DPY19L2, SPGF9;613893;AR;12q14.2
DPYD;5-fluorouracil toxicity, 274270 (3),Dihydropyrimidine dehydrogenase deficiency, 274270 (3);DPYD, DPD;612779;AR;1p21.3
DPYS;Dihydropyrimidinuria, 222748 (3);DPYS, DHP;613326;AR;8q22.3
DRAM2;Cone-rod dystrophy 21, 616502 (3);DRAM2, TMEM77, CORD21;613360;AR;1p13.3
DRC1;Ciliary dyskinesia, primary, 21, 615294 (3);DRC1, CCDC164, C2orf39, CILD21;615288;AR;2p23.3
DRD4;Autonomic nervous system dysfunction (3);DRD4;126452;AD;11p15.5
DRD5;Dystonia, primary cervical (3);DRD5, DRD1B, DRD1L2;126453;AD, IC;4p16.1
DSC2;Arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair, 610476 (3),Arrhythmogenic right ventricular dysplasia 11, 610476 (3);DSC2, DSC3, ARVD11;125645;AR, AD;18q12.1
DSC3;?Hypotrichosis and recurrent skin vesicles, 613102 (3);DSC3, DSC4;600271;AR;18q12.1
DSE;?Ehlers-Danlos syndrome, musculocontractural type 2, 615539 (3);DSE, SART2, EDSMC2;605942;AR;6q22.1
DSG1;Erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper IgE, 615508 (3),Keratosis palmoplantaris striata I, AD, 148700 (3);DSG1, PPKS1, SPPK1, EPKHE;125670;AR, AD;18q12.1
DSG2;Arrhythmogenic right ventricular dysplasia 10, 610193 (3),Cardiomyopathy, dilated, 1BB, 612877 (3);DSG2, ARVD10, ARVC10, CMD1BB;125671;AD,-;18q12.1
DSG4;Hypotrichosis 6, 607903 (3);DSG4, LAH, HYPT6;607892;AR;18q12.1
DSP;Arrhythmogenic right ventricular dysplasia 8, 607450 (3),Cardiomyopathy, dilated, with woolly hair and keratoderma, 605676 (3),Dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis, 615821 (3),Epidermolysis bullosa, lethal acantholytic, 609638 (3),Keratosis palmoplantaris striata II, 612908 (3),Skin fragility-woolly hair syndrome, 607655 (3);DSP, KPPS2, PPKS2, DCWHKTA;125647;AD, AR;6p24.3
DSPP;Deafness, autosomal dominant 39, with dentinogenesis, 605594 (3),Dentin dysplasia, type II, 125420 (3),Dentinogenesis imperfecta, Shields type II, 125490 (3),Dentinogenesis imperfecta, Shields type III, 125500 (3);DSPP, DPP, DGI1, DFNA39, DTDP2;125485;AD;4q22.1
DST;?Neuropathy, hereditary sensory and autonomic, type VI, 614653 (3),Epidermolysis bullosa simplex, autosomal recessive 2, 615425 (3);DST, BPAG1, DMH, D6S1101, HSAN6, EBSB2;113810;AR;6p12.1
DTNA;Left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3);DTNA, D18S892E, DRP3, LVNC1;601239;AD;18q12.1
DTNBP1;Hermansky-Pudlak syndrome 7, 614076 (3);DTNBP1, HPS7;607145;AR;6p22.3
DUH1;Dyschromatosis universalis hereditaria 1 (2);DUH1, DUH;127500;AD;6q24.2-q25.2
DUH2;Dyschromatosis universalis hereditaria 2 (2);DUH2;612715;-;12q21-q23
DUOX2;Thryoid dyshormonogenesis 6, 607200 (3);DUOX2, THOX2, TDH6;606759;AR;15q21.1
DUOXA2;Thyroid dyshormonogenesis 5, 274900 (3);DUOXA2, TDH5;612772;AR;15q21.1
DUP16p11.2;Chromosome 16p11.2 duplication syndrome (4);DUP16p11.2, C16DUPp11.2, AUTS14B;614671;-;16p11.2
DUP16p13.3;Chromosome 16p13.3 duplication syndrome (4);DUP16p13.3, C16DUPq13.3;613458;IC, AD;16p13.3
DUP17p13.3;Chromosome 17p13.3 duplication syndrome (4);DUP17p13.3, C17DUPp13.3;613215;-;17p13.3
DUP17q12;Chromosome 17q12 duplication syndrome (4);DUP17q12, C17DUPq12;614526;AD;17q12
DUP17q21.31;Chromosome 17q21.31 duplication syndrome (4);DUP17q21.31, C17DUPq21.31;613533;-;17q21.31
DUP17q23.1q23.2;Chromosome 17q23.1-q23.2 duplication syndrome (4);DUP17q23.1q23.2, C17DUPq23.1q23.2;613618;AD;17q23.1-q23.2
DUP18pDEL18q;Chromosome 18 pericentric inversion (4);DUP18pDEL18q, DUP18qDEL18p;609334;-;18q22
DUP1q21;Chromosome 1q21.1 duplication syndrome (4);DUP1q21, C1DUPq21;612475;IC, AD;1q21.1
DUP22q11.2;Chromosome 22q11.2 microduplication syndrome (4);DUP22q11.2;608363;IC, AD;22q11.2
DUP22q13;Chromosome 22q13 duplication syndrome, 615538 (4);DUP22q13, C22DUPq13;615538;IC ;22q13
DUP2q31.1;Chromosome 2q31.1 duplication syndrome (4);DUP2q31.1, C2DUPq31.1;613681;AD;2q31.1
DUP2q35;Syndactyly, type 1, with or without craniosynostosis (4);DUP2q35, C2DUPq35, SDTY1, SD1;185900;AD;2q34-q36
DUP3q29;Chromosome 3q29 microduplication syndrome (4);DUP3q29, MICRODUP3q29;611936;AD;3q29
DUP5p13;Chromosome 5p13 duplication syndrome (4);DUP5p13, C5DUPp13;613174;IC;5p13
DUP7q11.23;Chromosome 7q11.23 duplication syndrome (4);DUP7q11.23, C7DUPq11.23;609757;AD;7q11.23
DUP8q22.1;Leri pleonosteosis chromosome duplication syndrome (4);DUP8q22.1, C8DUPq22.1;151200;AD;8q22.1
DUPC1;Dupuytren contracture 1 (2);DUPC1;126900;AD;16q11.1-q22
DUPXp11.22;Xp11.22 microduplication syndrome (4);DUPXp11.22, MRX17, MRX31;300705;-;Xp11.22
DUPXp11.23p11.22;Chromosome Xp11.23-p11.22 duplication syndrome (4);DUPXp11.23p11.22, CXDUPp11.23p11.22;300801;XLD;Xp11.23-p11.22
DUPXq27.3q28;Chromosome Xq27.3-q28 duplication syndrome (4);DUPXq27.3q28, CXDUPq27.3q28;300869;XLR;Xq27.3-q28
DUPXq28;Chromosome Xq28 duplication syndrome (4);DUPXq28, CXq28;300815;-;Xq28
DURS1;Duane retraction syndrome 1 (2);DURS1, DUS;126800;AD;8q13
DUSP6;Hypogonadotropic hypogonadism 19 with or without anosmia, 615269 (3);DUSP6, MKP3, PYST1, HH19;602748;AD;12q21.33
DVL1;Robinow syndrome, autosomal dominant 2, 616331 (3);DVL1, DRS2;601365;AD;1p36.33
DVL3;Robinow syndrome, autosomal dominant 3, 616894 (3);DVL3, DRS3;601368;AD;3q27.1
DWS;Dandy-Walker syndrome (4);DWS, C3DELq22q24, DEL3q22q24;220200;AR;3q22-q24
DXS423E;Cornelia de Lange syndrome 2, 300590 (3);DXS423E, SMC1, CDLS2;300040;XLD;Xp11.22
DYM;Dyggve-Melchior-Clausen disease, 223800 (3),Smith-McCort dysplasia, 607326 (3);DYM, FLJ90130, DMC, SMC;607461;AR;18q21.1
DYNC1H1;Charcot-Marie-Tooth disease, axonal, type 20, 614228 (3),Mental retardation, autosomal dominant 13, 614563 (3),Spinal muscular atrophy, lower extremity-predominant 1, AD, 158600 (3);DYNC1H1, DNCL, DNECL, CMT20, MRD13, SMALED1;600112;AD;14q32.31
DYNC2H1;Short-rib thoracic dysplasia 3 with or without polydactyly, 613091 (3);DYNC2H1, DNCH2, DHC2, ATD3, SRPS2B, SRTD3;603297;DR, AR;11q22.3
DYRK1A;Mental retardation, autosomal dominant 7, 614104 (3);DYRK1A, MNBH, MNB, MRD7;600855;-;21q22.13
DYRK1B;Abdominal obesity-metabolic syndrome 3, 615812 (3);DYRK1B, MIRK, AOMS3;604556;AD;19q13.2
DYSF;Miyoshi muscular dystrophy 1, 254130 (3),Muscular dystrophy, limb-girdle, type 2B, 253601 (3),Myopathy, distal, with anterior tibial onset, 606768 (3);DYSF, LGMD2B, MMD1;603009;AR;2p13.2
DYT1;Dystonia-1, torsion, 128100 (3);DYT1, TOR1A;605204;AD;9q34.11
DYT13;Dystonia 13, torsion (2);DYT13;607671;AD;1p36.32-p36.13
DYT15;Dystonia-15, myoclonic (2);DYT15;607488;AD;18p11
DYT17;Dystonia-17, primary torsion (2);DYT17;612406;AR;20p11.2-q13.12
DYT21;Dystonia 21 (2);DYT21;614588;AD;2q14.3-q21.3
DYT7;Dystonia-7, torsion (2);DYT7;602124;AD;18p
DYX1C1;Ciliary dyskinesia, primary, 25, 615482 (3);DYX1C1, DYXC1, DYX1, CILD25;608706;AR, AD;15q21.3
EA3;Episodic ataxia, type 3 (2);EA3;606554;AD;1q42
EA7;Episodic ataxia, type 7 (2);EA7;611907;AD;19q13
EA8;Episodic ataxia, type 8 (2);EA8;616055;AD;1p36.13-p34.3
EARS2;Combined oxidative phosphorylation deficiency 12, 614924 (3);EARS2, KIAA1970, COXPD12;612799;AR;16p12.2
EBAF;Left-right axis malformations (3);EBAF, TGFB4, LEFTY2, LEFTA, LEFTYA;601877;-;1q42.12
EBP;Chondrodysplasia punctata, X-linked dominant, 302960 (3),MEND syndrome, 300960 (3);EBP, CDPX2, CPXD, CPX, MEND;300205;XLD, XLR;Xp11.23
ECA1;Epilepsy, childhood absence, 1 (2);ECA1;600131;AD;8q24
ECE1;Hirschsprung disease, cardiac defects, and autonomic dysfunction, 613870 (3);ECE1;600423;-, Mu;1p36.12
ECEL1;Arthrogryposis, distal, type 5D, 615065 (3);ECEL1, XCE, DA5D;605896;AR;2q37.1
ECHS1;Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency, 616277 (3);ECHS1, SCEH, ECHS1D;602292;AR;10q26.3
ECM1;Urbach-Wiethe disease, 247100 (3);ECM1, URBWD;602201;AR;1q21.2
ECT;Centrotemporal epilepsy (2);ECT, BECTS;117100;IC;11p13
ECTD5;Ectodermal dysplasia 5, hair/nail type (2);ECTD5;614927;AR;10q24.32-q25.1
ECTD6;Ectodermal dysplasia 6, hair/nail type (2);ECTD6;614928;AR;17p12-q21.2
ECTD8;Ectodermal dysplasia 8, hair/tooth/nail type (2);ECTD8;602401;AR;18q22.1-q22.3
EDA;Ectodermal dysplasia 1, hypohidrotic, X-linked, 305100 (3),Tooth agenesis, selective, X-linked 1, 313500 (3);EDA, ED1, ECTD1, EDA, HED1, STHAGX1;300451;XLR, XLD;Xq13.1
EDAR;Ectodermal dysplasia 10A, hypohidrotic/hair/nail type, autosomal dominant, 129490 (3),Ectodermal dysplasia 10B, hypohidrotic/hair/tooth type, autosomal recessive, 224900 (3);EDAR, DL, ED3, EDA3, HRM1, ECTD10A, ECTD10B;604095;AD, AR, -;2q13
EDARADD;Ectodermal dysplasia 11A, hypohidrotic/hair/tooth type, autosomal dominant, 614940 (3),Ectodermal dysplasia 11B, hypohidrotic/hair/tooth type, autosomal recessive, 614941 (3);EDARADD, ED3, EDA3, ECTD11B, ECTD11A;606603;AD, AR;1q42-q43
EDC3;?Mental retardation, autosomal recessive 50, 616460 (3);EDC3, YJDC, MRT50;609842;AR;15q24.1
EDN1;Auriculocondylar syndrome 3, 615706 (3),Question mark ears, isolated, 612798 (3);EDN1, ARCND3, QME, HDLCQ7;131240;AR, AD;6p24.1
EDN3;Central hypoventilation syndrome, congenital, 209880 (3),Waardenburg syndrome, type 4B, 613265 (3);EDN3, WS4B, HSCR4;131242;AD, AR, -;20q13.32
EDNRA;Mandibulofacial dysostosis with alopecia, 616367 (3);EDNRA, MFDA;131243;AD;4q31.22-q31.23
EDNRB;ABCD syndrome, 600501 (3),Waardenburg syndrome, type 4A, 277580 (3);EDNRB, HSCR2, ABCDS, WS4A;131244;AR, AD;13q22.3
EDS8;Ehlers-Danlos syndrome, type VIII (2);EDS8;130080;AD;12p13
EDSS2;Ectodermal dysplasia-syndactyly syndrome 2 (2);EDSS2;613576;AR;7p21.2-p14.3
EEC1;?EEC syndrome-1 (2);EEC1;129900;AD;7q11.2-q21.3
EEF1A2;Epileptic encephalopathy, early infantile, 33, 616409 (3),Mental retardation, autosomal dominant 38, 616393 (3);EEF1A2, EIEE33, MRD38;602959;AD;20q13.33
EEF2;?Spinocerebellar ataxia 26, 609306 (3);EEF2, EF2, SCA26;130610;AD;19p13.3
EFEMP1;Doyne honeycomb degeneration of retina, 126600 (3);EFEMP1, FBNL, DHRD;601548;AD;2p16.1
EFEMP2;Cutis laxa, autosomal recessive, type IB, 614437 (3);EFEMP2, FBLN4, UPH1, ARCL1B;604633;AR;11q13.1
EFNB1;Craniofrontonasal dysplasia, 304110 (3);EFNB1, EPLG2, CFNS, CFND;300035;XLD;Xq13.1
EFTUD2;Mandibulofacial dysostosis, Guion-Almeida type, 610536 (3);EFTUD2, KIAA0031, MFDGA;603892;AD;17q21.31
EGF;Hypomagnesemia 4, renal, 611718 (3);EGF, URG, HOMG4;131530;-;4q25
EGFR;?Inflammatory skin and bowel disease, neonatal, 2, 616069 (3),Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3),Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3);EGFR, NISBD2;131550;AR;7p11.2
EGLN1;Erythrocytosis, familial, 3, 609820 (3);EGLN1, PHD2, HIFPH2, C1orf12, ZMYND6, SM20, ECYT3, HALAH;606425;AD;1q42.2
EGR2;Charcot-Marie-Tooth disease, type 1D, 607678 (3),Dejerine-Sottas disease, 145900 (3),Neuropathy, congenital hypomyelinating, 1, 605253 (3);EGR2, KROX20;129010;AD, AR;10q21.3
EHHADH;?Fanconi renotubular syndrome 3, 615605 (3);EHHADH, PBFE, LBFP, FRTS3;607037;AD;3q27.2
EHMT1;Kleefstra syndrome, 610253 (3);EHMT1, EUHMTASE1, DEL9q34;607001;IC, AD;9q34.3
EIF2AK3;Wolcott-Rallison syndrome, 226980 (3);EIF2AK3, PEK, PERK, WRS;604032;AR;2p11.2
EIF2AK4;Pulmonary venoocclusive disease 2, 234810 (3);EIF2AK4, GCN2, KIAA1338, PVOD2;609280;AR;15q15.1
EIF2B1;Leukoencephalopathy with vanishing white matter, 603896 (3);EIF2B1, EIF2BA;606686;AR;12q24.31
EIF2B2;Leukoencephalopathy with vanishing white matter, 603896 (3),Ovarioleukodystrophy, 603896 (3);EIF2B2;606454;AR;14q24.3
EIF2B3;Leukoencephalopathy with vanishing white matter, 603896 (3);EIF2B3;606273;AR;1p34.1
EIF2B4;Leukoencephaly with vanishing white matter, 603896 (3),Ovarioleukodystrophy, 603896 (3);EIF2B4;606687;AR;2p23.3
EIF2B5;Leukoencephalopathy with vanishing white matter, 603896 (3),Ovarioleukodystrophy, 603896 (3);EIF2B5, LVWM, CACH, CLE;603945;AR;3q27.1
EIG7;Epilepsy, juvenile myoclonic (2);EIG7, EJM2;604827;AR;15q14
EJM3;Epilepsy, juvenile myoclonic 3 (2);EJM3;608816;-;6p21
EJM4;Myoclonic epilepsy, juvenile, 4 (2);EJM4;611364;AD;5q12-q14
EKD2;Episodic kinesigenic dyskinesia 2 (2);EKD2;611031;AD;16q13-q22.1
ELAC2;Combined oxidative phosphorylation deficiency 17, 615440 (3);ELAC2, HPC2, COXPD17;605367;AR;17p12
ELANE;Neutropenia, cyclic, 162800 (3),Neutropenia, severe congenital 1, autosomal dominant, 202700 (3);ELANE, ELA2, SCN1;130130;AD;19p13.3
ELAVL4;Neuropathy, paraneoplastic sensory (1);ELAVL4, HUD, PNEM;168360;-;1p33-p32
ELMOD3;?Deafness, autosomal recessive 88, 615429 (3);ELMOD3, RBED1, DFNB88;615427;AR;2p11.2
ELN;Cutis laxa, AD, 123700 (3),Supravalvar aortic stenosis, 185500 (3);ELN;130160;AD;7q11.23
ELOVL4;?Spinocerebellar ataxia 34, 133190 (3),Ichthyosis, spastic quadriplegia, and mental retardation, 614457 (3),Stargardt disease 3, 600110 (3);ELOVL4, ADMD, STGD2, STGD3, ISQMR, SCA34;605512;AD, AR;6q14.1
ELOVL5;Spinocerebellar ataxia 38, 615957 (3);ELOVL5, HELO1, SCA38;611805;AD;6p12.1
ELP4;?Aniridia, 106210 (3);ELP4, PAX6NEB, AN;606985;AD;11p13
EMC1;Cerebellar atrophy, visual impairment, and psychomotor retardation, 616875 (3);EMC1, KIAA0090, CAVIPMR;616846;AR;1p36.13
EMD;Emery-Dreifuss muscular dystrophy 1, X-linked, 310300 (3);EMD, EDMD, STA;300384;XLR;Xq28
EMG1;Bowen-Conradi syndrome, 211180 (3);EMG1, NEP1, C2F, BWCNS;611531;AR;12p13.31
EMP2;Nephrotic syndrome, type 10, 615861 (3);EMP2, NPHS10;602334;AR;16p13.13
EMWX;Episodic muscle weakness, X-linked (2);EMWX;300211;-;Xp22.3
EMX2;Schizencephaly, 269160 (3);EMX2;600035;-;10q26.11
ENAM;Amelogenesis imperfecta, type IB, 104500 (3),Amelogenesis imperfecta, type IC, 204650 (3);ENAM, AIH2, AI1C;606585;AD, AR;4q13.3
ENFL2;Epilepsy, nocturnal frontal lobe, type 2 (2);ENFL2;603204;AD;15q24
ENG;Telangiectasia, hereditary hemorrhagic, type 1, 187300 (3);ENG, END, HHT1, ORW;131195;AD;9q34.11
ENO1;Enolase deficiency (1);ENO1, PPH, MPB1;172430;-;1p36.23
ENO3;?Glycogen storage disease XIII, 612932 (3);ENO3, GSD13;131370;AR;17p13.2
ENPP1;Arterial calcification, generalized, of infancy, 1, 208000 (3),Cole disease, 615522 (3),Hypophosphatemic rickets, autosomal recessive, 2, 613312 (3);ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED;173335;AR, AD, -, Mu;6q23.2
ENTPD1;Spastic paraplegia 64, autosomal recessive, 615683 (3);ENTPD1, CD39, SPG64;601752;AR;10q24.1
ENUR1;Enuresis, nocturnal, 1 (2);ENUR1;600631;AD;13q13-q14.3
ENUR2;Enuresis, nocturnal, 2 (2);ENUR2;600808;AD;12q13-q21
EOGT;Adams-Oliver syndrome 4, 615297 (3);EOGT, EOGT1, C3orf64, AOS4;614789;AR;3p14.1
EOS;Eosinophilia, familial (2);EOS;131400;AD;5q31-q33
EP300;Colorectal cancer, somatic, 114500 (3),Rubinstein-Taybi syndrome 2, 613684 (3);EP300, RSTS2;602700;IC, AD;22q13.2
EPAS1;Erythrocytosis, familial, 4, 611783 (3);EPAS1, MOP2, HIF2A, ECYT4;603349;-;2p21
EPB41;Elliptocytosis-1, 611804 (3);EPB41, EL1;130500;-;1p35.3
EPB41L1;?Mental retardation, autosomal dominant 11, 614257 (3);EPB41L1, MRD11;602879;-;20q11.23
EPB42;Spherocytosis, type 5, 612690 (3);EPB42, SPH5;177070;-;15q15.2
EPCAM;Colorectal cancer, hereditary nonpolyposis, type 8, 613244 (3),Diarrhea 5, with tufting enteropathy, congenital, 613217 (3);EPCAM, ACSTD1, TROP1, M4S1, MIC18, DIAR5, HNPCC8;185535;-, AR;2p21
EPG5;Vici syndrome, 242840 (3);EPG5, KIAA1632, HEEW1, VICIS;615068;AR;18q12.3-q21.1
EPHA2;Cataract 6, multiple types, 116600 (3);EPHA2, ECK, ARCC2, CTPP1, CTPA, ARCC2, CTRCT6;176946;AD;1p36.13
EPHX1;?Fetal hydantoin syndrome (1),Diphenylhydantoin toxicity (1),Hypercholanemia, familial, 607748 (3);EPHX1;132810;-, AD;1q42.12
EPM2A;Epilepsy, progressive myoclonic 2A (Lafora), 254780 (3);EPM2A, MELF, EPM2;607566;AR;6q24.3
EPPS;Epilepsy, partial, with pericentral spikes (2);EPPS;607221;-;4p15
EPRPDC;Epilepsy, rolandic, with paroxysmal exercise-induced dystonia and writer's cramp (2);EPRPDC;608105;AR;16p12-p11.2
EPS8;?Deafness, autosomal recessive 102, 615974 (3);EPS8, DFNB102;600206;AR;12p12.3
ERBB2;Adenocarcinoma of lung, somatic, 211980 (3),Gastric cancer, somatic, 613659 (3),Glioblastoma, somatic, 137800 (3),Ovarian cancer, somatic, (3);ERBB2, NGL, NEU, HER2;164870;'-;17q12
ERBB3;Lethal congenital contractural syndrome 2, 607598 (3);ERBB3, LCCS2;190151;AR;12q13.2
ERBB4;Amyotrophic lateral sclerosis 19, 615515 (3);ERBB4, HER4, ALS19;600543;AD;2q34
ERCC1;Cerebrooculofacioskeletal syndrome 4, 610758 (3);ERCC1, UV20, COFS4;126380;AR;19q13.32
ERCC2;Cerebrooculofacioskeletal syndrome 2, 610756 (3),Trichothiodystrophy 1, photosensitive, 601675 (3),Xeroderma pigmentosum, group D, 278730 (3);ERCC2, EM9, XPD, COFS2, TTD1;126340;-. AR;19q13.32
ERCC3;Trichothiodystrophy 2, photosensitive, 616390 (3),Xeroderma pigmentosum, group B, 610651 (3);ERCC3, XPB, TTD2;133510;-, AR;2q14.3
ERCC4;?XFE progeroid syndrome, 610965 (3),Fanconi anemia, complementation group Q, 615272 (3),Xeroderma pigmentosum, group F, 278760 (3),Xeroderma pigmentosum, type F/Cockayne syndrome, 278760 (3);ERCC4, XPF, FANCQ, XFEPS;133520;-, AR;16p13.12
ERCC5;Cerebrooculofacioskeletal syndrome 3, 616570 (3),Xeroderma pigmentosum, group G, 278780 (3),Xeroderma pigmentosum, group G/Cockayne syndrome, 278780 (3);ERCC5, XPG, COFS3;133530;AR;13q33.1
ERCC6;Cerebrooculofacioskeletal syndrome 1, 214150 (3),Cockayne syndrome, type B, 133540 (3),De Sanctis-Cacchione syndrome, 278800 (3),Premature ovarian failure 11, 616946 (3),UV-sensitive syndrome 1, 600630 (3);ERCC6, CKN2, COFS1, CSB, ARMD5, UVSS1, POF11;609413;AR, AD;10q11.23
ERCC6L2;Bone marrow failure syndrome 2, 615715 (3);ERCC6L2, RAD26L, BMFS2;615667;AR;9q22.32
ERCC8;Cockayne syndrome, type A, 216400 (3),UV-sensitive syndrome 2, 614621 (3);ERCC8, CKN1, CSA, UVSS2;609412;AR;5q12.1
ERF;Craniosynostosis 4, 600775 (3);ERF, PE2, CRS4;611888;AD;19q13.2
ERLIN1;Spastic paraplegia 62, 615681 (3);ERLIN1, SPG62;611604;-;10q24.31
ERLIN2;Spastic paraplegia 18, autosomal recessive, 611225 (3);ERLIN2, SPFH2, C8orf2, SPG18;611605;AR;8p11.23
ERMARD;?Periventricular nodular heterotopia 6, 615544 (3);ERMARD, C6orf70, PVNH6;615532;AD;6q27
ESCO2;Roberts syndrome, 268300 (3),SC phocomelia syndrome, 269000 (3);ESCO2;609353;AR;8p21.1
ESPN;Deafness, autosomal recessive 36, 609006 (3),Deafness, neurosensory, without vestibular involvement, autosomal dominant (3);ESPN;606351;AR, -;1p36.31
ESR1;Estrogen resistance, 615363 (3);ESR1, ESR, ESTRR;133430;AR, AD;6q25.1-q25.2
ESRRB;Deafness, autosomal recessive 35, 608565 (3);ESRRB, ESRL2, DFNB35;602167;AR;14q24.3
ETFA;Glutaric acidemia IIA, 231680 (3);ETFA, GA2, MADD;608053;AR;15q24.2-q24.3
ETFB;Glutaric acidemia IIB, 231680 (3);ETFB, MADD;130410;AR;19q13.41
ETFDH;Glutaric acidemia IIC, 231680 (3);ETFDH, MADD;231675;AR;4q32.1
ETHE1;Ethylmalonic encephalopathy, 602473 (3);ETHE1, HSCO, D83198;608451;AR;19q13.31
ETL2;Epilepsy, familial temporal lobe, 2 (2);ETL2, FTLE;608096;AD;12q22-q23.3
ETL3;Epilepsy, familial temporal lobe, 3 (2);ETL3, FMTLE;611630;AD;4q13.2-q21.3
ETL4;Epilepsy, familial temporal lobe, 4 (2);ETL4, ETOLM;611631;AD;9q21-q22
ETL6;Epilepsy, familial temporal lobe, 6 (2);ETL6;615697;-;3q25-q26
ETM2;Tremor, hereditary essential, 2 (2);ETM2, ETM;602134;AD;2p25-p22
ETM3;Tremor, hereditary essential, 3 (2);ETM3;611456;-;6p23
ETV6;Leukemia, acute myeloid, somatic, 601626 (3),Thrombocytopenia 5, 616216 (3);ETV6, TEL, THC5;600618;-, AD;12p13.2
EVC;Ellis-van Creveld syndrome, 225500 (3),Weyers acrodental dysostosis, 193530 (3);EVC;604831;AR, AD;4p16.2
EVR3;Exudative vitreoretinopathy 3 (2);EVR3;605750;AD;11p13-p12
EWSR1;Ewing sarcoma, 612219 (3),Neuroepithelioma, 612219 (3);EWSR1, EWS;133450;-;22q12.2
EXOSC3;Pontocerebellar hypoplasia, type 1B, 614678 (3);EXOSC3, RRP40, PCH1B;606489;AR;9p13.2
EXOSC8;Pontocerebellar hypoplasia, type 1C, 616081 (3);EXOSC8, OIP2, RRP43, PCH1C;606019;AR;13q13.3
EXPH5;Epidermolysis bullosa, nonspecific, autosomal recessive, 615028 (3);EXPH5, SLAC2B, KIAA0624;612878;AR;11q22.3
EXT1;Chondrosarcoma, 215300 (3),Exostoses, multiple, type 1, 133700 (3);EXT1;608177;AR, AD;8q24.11
EXT2;?Seizures, scoliosis, and macrocephaly syndrome, 616682 (3),Exostoses, multiple, type 2, 133701 (3);EXT2, SSMS;608210;AR, AD;11p11.2
EXT3;Exostoses, multiple, type 3 (2);EXT3;600209;AD;19p
EYA1;?Otofaciocervical syndrome, 166780 (3),Anterior segment anomalies with or without cataract, 113650 (3),Branchiootic syndrome 1, 602588 (3),Branchiootorenal syndrome 1, with or without cataracts, 113650 (3);EYA1, BOR, BOS1, OFC1;601653;AD;8q13.3
EYA4;Cardiomyopathy, dilated, 1J, 605362 (3),Deafness, autosomal dominant 10, 601316 (3);EYA4, DFNA10, CMD1J;603550;-, AD;6q23.2
EYS;Retinitis pigmentosa 25, 602772 (3);EYS, RP25;612424;-;6q12
EZH2;Weaver syndrome, 277590 (3);EZH2, EZH1, WVS;601573;AD;7q36.1
F10;Factor X deficiency, 227600 (3);F10;613872;-;13q34
F11;Factor XI deficiency, autosomal dominant, 612416 (3),Factor XI deficiency, autosomal recessive, 612416 (3);F11;264900;-;4q35.2
F12;Angioedema, hereditary, type III, 610618 (3),Factor XII deficiency, 234000 (3);F12, HAF, HAE3;610619;AD, AR;5q35.3
F13A1;Factor XIIIA deficiency, 613225 (3);F13A1, F13A;134570;AR, AD, -;6p25.1
F13B;Factor XIIIB deficiency, 613235 (3);F13B;134580;AR;1q31.3
F2;Dysprothrombinemia, 613679 (3),Hypoprothrombinemia, 613679 (3),Thrombophilia due to thrombin defect, 188050 (3);F2, THPH1, RPRGL2;176930;AR, AD, Mu;11p11.2
F5;Factor V deficiency, 227400 (3),Thrombophilia due to activated protein C resistance, 188055 (3);F5, THPH2, RPRGL1;612309;AR, AD;1q24.2
F7;Factor VII deficiency, 227500 (3);F7;613878;AR;13q34
F8;Hemophilia A, 306700 (3);F8, F8C, HEMA;300841;XLR;Xq28
F9;Hemophilia B, 306900 (3),Thrombophilia, X-linked, due to factor IX defect, 300807 (3);F9, HEMB, THPH8;300746;XLR, -, AD;Xq27.1
FA2H;Spastic paraplegia 35, autosomal recessive, 612319 (3);FA2H, FAAH, FAXDC1, FAH1, SCS7, SPG35;611026;AR;16q23.1
FAAP95;Fanconi anemia, complementation group B, 300514 (3);FAAP95, FAAP90, FLJ34064, FANCB;300515;-;Xp22.2
FADD;Infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations, 613759 (3);FADD;602457;AR;11q13.3
FAH;Tyrosinemia, type I, 276700 (3);FAH;613871;AR;15q25.1
FAM111A;Gracile bone dysplasia, 602361 (3),Kenny-Caffey syndrome, type 2, 127000 (3);FAM111A, KIAA1895, KCS2, GCLEB;615292;AD;11q12.1
FAM111B;Poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis, 615704 (3);FAM111B, POIKTMP;615584;AD;11q12.1
FAM126A;Leukodystrophy, hypomyelinating, 5, 610532 (3);FAM126A, DRCTNNB1A, HLD5;610531;AR;7p15.3
FAM134B;Neuropathy, hereditary sensory and autonomic, type IIB, 613115 (3);FAM134B, HSAN2B;613114;AR;5p15.1
FAM161A;Retinitis pigmentosa 28, 606068 (3);FAM161A, RP28;613596;-;2p15
FAM20A;Amelogenesis imperfecta, type IG (enamel-renal syndrome), 204690 (3);FAM20A, AIGFS, AI1G;611062;AR;17q24.2
FAM20C;Raine syndrome, 259775 (3);FAM20C, DMP4;611061;AR;7p22.3
FAM58A;STAR syndrome, 300707 (3);FAM58A, STAR;300708;XLD;Xq28
FAM65B;?Deafness, autosomal recessive 104, 616515 (3);FAM65B, C6orf32, KIAA0386, PL48, DFNB104;611410;AR;6p22.3
FAM83H;Amelogenesis imperfecta, type III, 130900 (3);FAM83H, AI3;611927;AD;8q24.3
FAME1;Epilepsy, myoclonic, familial adult, 1 (2);FAME1, BAFME1, MEBA;601068;AD;8q24
FAME3;Epilepsy, myoclonic, familial adult, 3 (2);FAME3, FCMTE3;613608;AD;5p15.31-p15.1
FAME4;Epilepsy, myoclonic, familial adult, 4 (2);FAME4, FCMTE4;615127;AD;3q26.32-q28
FAN1;Interstitial nephritis, karyomegalic, 614817 (3);FAN1, MTMR15, KIAA1018, KMIN;613534;AR;15q13.3
FANCA;Fanconi anemia, complementation group A, 227650 (3);FANCA, FACA, FA1, FA, FAA;607139;AR;16q24.3
FANCC;Fanconi anemia, complementation group C, 227645 (3);FANCC, FACC;613899;AR;9q22.32
FANCD2;Fanconi anemia, complementation group D2, 227646 (3);FANCD2, FANCD, FACD, FAD;613984;AR;3p25.3
FANCE;Fanconi anemia, complementation group E, 600901 (3);FANCE, FACE;613976;AR;6p21.31
FANCF;Fanconi anemia, complementation group F, 603467 (3);FANCF;613897;-;11p14.3
FANCI;Fanconi anemia, complementation group I, 609053 (3);FANCI, KIAA1794;611360;-;15q26.1
FAR1;Peroxisomal fatty acyl-CoA reductase 1 disorder, 616154 (3);FAR1, MLSTD2, PFCRD;616107;AR;11p15.3
FARS2;Combined oxidative phosphorylation deficiency 14, 614946 (3);FARS2, FARS1, COXPD14;611592;AR;6p25.1
FAS;Autoimmune lymphoproliferative syndrome, type IA, 601859 (3),Squamous cell carcinoma, burn scar-related, somatic (3);FAS, TNFRSF6, APT1, CD95, ALPS1A;134637;AD;10q23.31
FASLG;Autoimmune lymphoproliferative syndrome, type IB, 601859 (3);FASLG, TNFSF6, APT1LG1, FASL, ALPS1B;134638;AD, AR;1q24.3
FASTKD2;?Mitochondrial complex IV deficiency, 220110 (3);FASTKD2, KIAA0971;612322;AR, Mi;2q33.3
FAT4;Hennekam lymphangiectasia-lymphedema syndrome 2, 616006 (3),Van Maldergem syndrome 2, 615546 (3);FAT4, VMLDS2, HKLLS2;612411;AR;4q28.1
FBLN1;Synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses, 608180 (4);FBLN1;135820;AD;22q13.31
FBLN5;Cutis laxa, autosomal dominant 2, 614434 (3),Cutis laxa, autosomal recessive, type IA, 219100 (3),Macular degeneration, age-related, 3, 608895 (3),Neuropathy, hereditary, with or without age-related macular degeneration, 608895 (3);FBLN5, ARMD3, ADCL2, ARCL1A, HNARMD;604580;AR, AD;14q32.12
FBN1;Acromicric dysplasia, 102370 (3),Aortic aneurysm, ascending, and dissection (3),Ectopia lentis, familial, 129600 (3),Geleophysic dysplasia 2, 614185 (3),MASS syndrome, 604308 (3),Marfan lipodystrophy syndrome, 616914 (3),Marfan syndrome, 154700 (3),Stiff skin syndrome, 184900 (3),Weill-Marchesani syndrome 2, dominant, 608328 (3);FBN1, MFS1, WMS2, SSKS, GPHYSD2, ACMICD, ECTOL1, MFLS;134797;AD;15q21.1
FBN2;Contractural arachnodactyly, congenital, 121050 (3),Macular degeneration, early-onset, 616118 (3);FBN2, CCA, EOMD;612570;AD;5q23.3
FBP1;Fructose-1,6-bisphosphatase deficiency, 229700 (3);FBP1;611570;AR;9q22.32
FBXL4;Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type), 615471 (3);FBXL4, FBL4, MTDPS13;605654;AR;6q16.1-q16.2
FBXO31;?Mental retardation, autosomal recessive 45, 615979 (3);FBXO31, FBX31, FBXO14, FBX14, MRT45;609102;AR;16q24.2
FBXO38;Neuronopathy, distal hereditary motor, type IID, 615575 (3);FBXO38, FBX38, MOKA, HMN2D;608533;AD;5q32
FBXO7;Parkinson disease 15, autosomal recessive, 260300 (3);FBXO7, FBX7, FBX, PKPS, PARK15;605648;AR;22q12.3
FCGR2C;Thrombocytopenic purpura, autoimmune, 188030 (1);FCGR2C, CD32C;612169;AD;1q23.3
FCGR3A;Immunodeficiency 20, 615707 (3);FCGR3A, CD16, IGFR3, IMD20;146740;AR;1q23.3
FCGR3B;Neutropenia, alloimmune neonatal (3);FCGR3B;610665;-;1q23.3
FCN3;Immunodeficiency due to ficolin 3 deficiency, 613860 (3);FCN3, HAKA1;604973;AR;1p36.11
FCYT;Polycystic kidney and hepatic disease, 263200 (3);FCYT, PKHD1, ARPKD;606702;AR;6p12.3-p12.2
FDPS;Porokeratosis 9, multiple types, 616631 (3);FDPS, FPS, POROK9;134629;-;1q22
FEB1;Febrile seizures, familial, 1 (2);FEB1;121210;AD;8q13-q21
FEB10;Febrile seizures, familial, 10 (2);FEB10;612637;-;3q26.2-q26.33
FEB2;Febrile seizures, familial, 2 (2);FEB2;602477;AD;19p13.3
FEB5;Febrile seizures, familial, 5 (2);FEB5;609255;AD;6q22-q24
FEB6;Febrile seizures, familial, 6 (2);FEB6;609253;AD;18p11.2
FEB7;Febrile seizures, familial, 7 (2);FEB7;611515;-;21q22
FEB9;Febrile seizures, familial, 9 (2);FEB9;611634;AD;3p24.2-p23
FECD2;Corneal dystrophy, Fuchs endothelial, 2 (2);FECD2, FCD1;610158;AD;13pter-q12.13
FECD5;Corneal dystrophy, Fuchs endothelial, 5 (2);FECD5, FCD3;613269;-;5q33.1-q35.2
FECD7;Corneal dystrophy, Fuchs endothelial, 7 (2);FECD7, FCD4;613271;-;9p24.1-p22.1
FECH;Protoporphyria, erythropoietic, autosomal recessive, 177000 (3);FECH, FCE;612386;AR;18q21.31
FEZF1;Hypogonadotropic hypogonadism 22, with or without anosmia, 616030 (3);FEZF1, FEZ, ZNF312B, HH22;613301;AR;7q31.32
FGA;Afibrinogenemia, congenital, 202400 (3),Amyloidosis, familial visceral, 105200 (3),Dysfibrinogenemia, congenital, 616004 (3),Hypodysfibrinogenemia, congenital, 616004 (3);FGA;134820;AR, AD;4q31.3
FGB;Afibrinogenemia, congenital, 202400 (3),Dysfibrinogenemia, congenital, 616004 (3),Hypofibrinogenemia, congenital, 202400 (3);FGB;134830;AR, -;4q31.3
FGD1;Aarskog-Scott syndrome, 305400 (3),Mental retardation, X-linked syndromic 16, 305400 (3);FGD1, FGDY, AAS, MRXS16;300546;XLR,XLR;Xp11.22
FGD4;Charcot-Marie-Tooth disease, type 4H, 609311 (3);FGD4, FRABIN, CMT4H;611104;AR;12p11.21
FGF10;Aplasia of lacrimal and salivary glands, 180920 (3),LADD syndrome, 149730 (3);FGF10;602115;AD;5p12
FGF14;Spinocerebellar ataxia 27, 609307 (3);FGF14, FHF4, SCA27;601515;AD;13q33.1
FGF16;Metacarpal 4-5 fusion, 309630 (3);FGF16, MF4;300827;XLR;Xq21.1
FGF17;Hypogonadotropic hypogonadism 20 with or without anosmia, 615270 (3);FGF17, HH20;603725;AD;8p21.3
FGF20;?Renal hypodysplasia/aplasia 2, 615721 (3);FGF20, RHDA2;605558;AR;8p22
FGF23;Hypophosphatemic rickets, autosomal dominant, 193100 (3),Osteomalacia, tumor-induced (1),Tumoral calcinosis, hyperphosphatemic, familial, 211900 (3);FGF23, ADHR, HPDR2, PHPTC;605380;AD, AR;12p13.32
FGF3;Deafness, congenital with inner ear agenesis, microtia, and microdontia, 610706 (3);FGF3, INT2;164950;AR;11q13.3
FGF5;Trichomegaly, 190330 (3);FGF5, TCMGLY;165190;AR;4q21.21
FGF8;Hypogonadotropic hypogonadism 6 with or without anosmia, 612702 (3);FGF8, HH6;600483;-;10q24.32
FGF9;?Multiple synostoses syndrome 3, 612961 (3);FGF9, SYNS3;600921;-;13q12.11
FGFR1;Encephalocraniocutaneous lipomatosis, 613001 (3),Hartsfield syndrome, 615465 (3),Hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3),Jackson-Weiss syndrome, 123150 (3),Osteoglophonic dysplasia, 166250 (3),Pfeiffer syndrome, 101600 (3),Trigonocephaly 1, 190440 (3);FGFR1, FLT2, OGD, KAL2, HH2, HRTFDS, ECCL;136350;Smo, AD;8p11.23
FGFR1OP;Myeloproliferative disorder (2);FGFR1OP, FOP;605392;-;6q27
FGFR2;Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3),Apert syndrome, 101200 (3),Beare-Stevenson cutis gyrata syndrome, 123790 (3),Bent bone dysplasia syndrome, 614592 (3),Craniofacial-skeletal-dermatologic dysplasia, 101600 (3),Craniosynostosis, nonspecific (3),Crouzon syndrome, 123500 (3),Gastric cancer, somatic, 613659 (3),Jackson-Weiss syndrome, 123150 (3),LADD syndrome, 149730 (3),Pfeiffer syndrome, 101600 (3),Saethre-Chotzen syndrome, 101400 (3),Scaphocephaly and Axenfeld-Rieger anomaly (3),Scaphocephaly, maxillary retrusion, and mental retardation, 609579 (3);FGFR2, BEK, CFD1, JWS, TK14, BBDS;176943;AR, AD, -;10q26.13
FGFR3;Achondroplasia, 100800 (3),Bladder cancer, somatic, 109800 (3),CATSHL syndrome, 610474 (3),Cervical cancer, somatic, 603956 (3),Colorectal cancer, somatic, 114500 (3),Crouzon syndrome with acanthosis nigricans, 612247 (3),Hypochondroplasia, 146000 (3),LADD syndrome, 149730 (3),Muenke syndrome, 602849 (3),Nevus, epidermal, somatic, 162900 (3),SADDAN, 616482 (3),Spermatocytic seminoma, somatic, 273300 (3),Thanatophoric dysplasia, type I, 187600 (3),Thanatophoric dysplasia, type II, 187601 (3);FGFR3, ACH;134934;AR, AD, -;4p16.3
FGG;Afibrinogenemia, congenital, 202400 (3),Dysfibrinogenemia, congenital, 616004 (3),Hypodysfibrinogenemia, 616004 (3),Hypofibrinogenemia, congenital, 202400 (3);FGG;134850;AR;4q32.1
FGS3;FG syndrome 3 (2);FGS3;300406;-;Xp22.3
FGS5;FG syndrome 5 (2);FGS5;300581;-;Xq22.3
FH;Fumarase deficiency, 606812 (3),Leiomyomatosis and renal cell cancer, 150800 (3);FH, HLRCC, MCUL1, FMRD;136850;AR, AD;1q43
FHII;Hyperaldosteronism, familial, type II (2);FHII;605635;-;7p22
FHL1;Emery-Dreifuss muscular dystrophy 6, X-linked, 300696 (3),Hemophagocytic lymphohistiocytosis, familial, 1 (2),Myopathy, X-linked, with postural muscle atrophy, 300696 (3),Reducing body myopathy, X-linked 1a, severe, infantile or early childhood onset, 300717 (3),Reducing body myopathy, X-linked 1b, with late childhood or adult onset, 300718 (3),Scapuloperoneal myopathy, X-linked dominant, 300695 (3);FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B, RBMX1A, RBMX1B;300163;XLR, XLD, XL;Xq26.3
FIG4;?Polymicrogyria, bilateral temporooccipital, 612691 (3),Amyotrophic lateral sclerosis 11, 612577 (3),Charcot-Marie-Tooth disease, type 4J, 611228 (3),Yunis-Varon syndrome, 216340 (3);FIG4, KIAA0274, SAC3, ALS11, YVS, BTOP;609390;AR, AD;6q21
FIGLA;Premature ovarian failure 6, 612310 (3);FIGLA, POF6;608697;-;2p13.3
FKBP10;Bruck syndrome 1, 259450 (3),Osteogenesis imperfecta, type XI, 610968 (3);FKBP10, FKBP65, OI11, BRKS1;607063;AR;17q21.2
FKBP14;Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss, 614557 (3);FKBP14, EDSKMH;614505;AR;7p14.3
FKRP;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5, 613153 (3),Muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5, 606612 (3),Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5, 607155 (3);FKRP, MDC1C, LGMD2I, MDDGA5, MDDGB5, MDDGC5;606596;AR;19q13.32
FKTN;Cardiomyopathy, dilated, 1X, 611615 (3),Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4, 253800 (3),Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4, 613152 (3),Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4, 611588 (3);FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4;607440;AR;9q31.2
FLAD1;Lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency, 255100 (3);FLAD1, FADS, LSMFLAD;610595;AR;1q21.3
FLCN;Birt-Hogg-Dube syndrome, 135150 (3),Colorectal cancer, somatic, 114500 (3),Pneumothorax, primary spontaneous, 173600 (3),Renal carcinoma, chromophobe, somatic, 144700 (3);FLCN, BHD;607273;AD, -;17p11.2
FLG;Ichthyosis vulgaris, 146700 (3);FLG, ATOD2;135940;AD, -;1q21.3
FLJ22792;Premature ovarian failure 2B, 300604 (3);FLJ22792, POF1B, POF2B;300603;-;Xq21.1
FLNA;Cardiac valvular dysplasia, X-linked, 314400 (3),Congenital short bowel syndrome, 300048 (3),FG syndrome 2, 300321 (3),Frontometaphyseal dysplasia, 305620 (3),Heterotopia, periventricular, 300049 (3),Heterotopia, periventricular, ED variant, 300537 (3),Intestinal pseudoobstruction, neuronal, 300048 (3),Melnick-Needles syndrome, 309350 (3),Otopalatodigital syndrome, type I, 311300 (3),Otopalatodigital syndrome, type II, 304120 (3),Terminal osseous dysplasia, 300244 (3);FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1, CSBS;300017;XLR, XLD, -;Xq28
FLNB;Atelosteogenesis, type I, 108720 (3),Atelosteogenesis, type III, 108721 (3),Boomerang dysplasia, 112310 (3),Larsen syndrome, 150250 (3),Spondylocarpotarsal synostosis syndrome, 272460 (3);FLNB, SCT, AOI, LRS1;603381;AD, AR;3p14.3
FLNC;Myopathy, distal, 4, 614065 (3),Myopathy, myofibrillar, 5, 609524 (3);FLNC, FLN2, ABPA, ABPL, MFM5, MPD4;102565;-, AD;7q32.1
FLRT3;Hypogonadotropic hypogonadism 21 with anosmia, 615271 (3);FLRT3, HH21;604808;AD;20p12.1
FLT3;Leukemia, acute lymphoblastic, somatic, 613065 (3),Leukemia, acute myeloid, reduced survival in, somatic, 601626 (3),Leukemia, acute myeloid, somatic, 601626 (3);FLT3;136351;-;13q12.2
FLT4;Hemangioma, capillary infantile, somatic, 602089 (3),Lymphedema, hereditary, IA, 153100 (3);FLT4, VEGFR3, PCL, LMPH1A;136352;-, AD;5q35.3
FLVCR1;Ataxia, posterior column, with retinitis pigmentosa, 609033 (3);FLVCR1, AXPC1, PCARP;609144;AR;1q32.3
FLVCR2;Proliferative vasculopathy and hydraencephaly-hydrocephaly syndrome, 225790 (3);FLVCR2, C14orf58, CCT, PVHH, EPV;610865;AR;14q24.3
FMN2;Mental retardation, autosomal recessive 47, 616193 (3);FMN2, MRT47;606373;AR;1q43
FMO3;Trimethylaminuria, 602079 (3);FMO3, TMAU;136132;AR;1q24.3
FMR1;Fragile X syndrome, 300624 (3),Fragile X tremor/ataxia syndrome, 300623 (3),Premature ovarian failure 1, 311360 (3);FMR1, FRAXA, POF1;309550;AR;Xq27.3
FN1;Glomerulopathy with fibronectin deposits 2, 601894 (3),Plasma fibronectin deficiency, 614101 (1);FN1, FN, LETS, FNZ, GFND2;135600;AD;2q35
FOLR1;Neurodegeneration due to cerebral folate transport deficiency, 613068 (3);FOLR1;136430;AR;11q13.4
FOXC1;Axenfeld-Rieger syndrome, type 3, 602482 (3),Iridogoniodysgenesis, type 1, 601631 (3),Iris hypoplasia and glaucoma, 601631 (3),Rieger or Axenfeld anomalies, 602482 (3);FOXC1, FKHL7, FREAC3, IRID1, RIEG3;601090;AD;6p25.3
FOXC2;Lymphedema-distichiasis syndrome with renal disease and diabetes mellitus, 153400 (3),Lymphedema-distichiasis syndrome, 153400 (3);FOXC2, FKHL14, MFH1;602402;AD;16q24.1
FOXE1;Bamforth-Lazarus syndrome, 241850 (3);FOXE1, FKHL15, TITF2, TTF2, NMTC4;602617;AR, AD;9q22.33
FOXE3;Anterior segment mesenchymal dysgenesis, 107250 (3),Aphakia, congenital primary, 610256 (3);FOXE3, FKHL12, ASMD;601094;AD,AR;1p33
FOXF1;Alveolar capillary dysplasia with misalignment of pulmonary veins, 265380 (3);FOXF1, FKHL5, ACDMPV;601089;AD;16q24.1
FOXG1;Rett syndrome, congenital variant, 613454 (3);FOXG1, FOXG1B, FKHL1, FKH2, QIN, BF1;164874;IC;14q12
FOXI1;Enlarged vestibular aqueduct, 600791 (3);FOXI1, FKHL10, FREAC6;601093;AR;5q35.1
FOXL2;Blepharophimosis, epicanthus inversus, and ptosis, type 1, 110100 (3),Blepharophimosis, epicanthus inversus, and ptosis, type 2, 110100 (3),Premature ovarian failure 3, 608996 (3);FOXL2, BPES, BPES1, PFRK, POF3;605597;AD, -;3q22.3
FOXN1;T-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 (3);FOXN1, WHN;600838;AR;17q11.2
FOXO1A;Rhabdomyosarcoma, alveolar, 268220 (3);FOXO1A, FKHR;136533;AR;13q14.11
FOXP1;Mental retardation with language impairment and with or without autistic features, 613670 (3);FOXP1, QRF1;605515;AD;3p13
FOXP2;Speech-language disorder-1, 602081 (3);FOXP2, SPCH1, TNRC10, CAGH44;605317;AD;7q31.1
FOXP3;Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked, 304790 (3);FOXP3, IPEX, AIID, XPID, PIDX;300292;XLR, AR;Xp11.23
FOXRED1;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3),Mitochondrial complex I deficiency, 252010 (3);FOXRED1;613622;Mi, AR, XLD;11q24.2
FPH1;Hyperpigmentation, familial progressive, 1 (2);FPH1, MUH, HPP;614233;-;19pter-p13.1
FRAS1;Fraser syndrome, 219000 (3);FRAS1;607830;AR;4q21.21
FRDA2;Friedreich ataxia 2 (2);FRDA2;601992;AR;9p23-p11
FREM1;Bifid nose with or without anorectal and renal anomalies, 608980 (3),Manitoba oculotrichoanal syndrome, 248450 (3),Trigonocephaly 2, 614485 (3);FREM1, C9orf154, BNAR, MOTA, TRIGNO2;608944;AR, AD;9p22.3
FREM2;Fraser syndrome, 219000 (3);FREM2;608945;AR;13q13.3
FRIASS;Frias syndrome (4);FRIASS, DEL14q22, C14DELq22;609640;AD;14q22.1-q22.3
FRMD4A;?Corpus callosum, agenesis of, with facial anomalies and cerebellar ataxia, 616819 (3);FRMD4A, KIAA1294, CCAFCA;616305;AR;10p13
FRMD7;Nystagmus 1, congenital, X-linked, 310700 (3),Nystagmus, infantile periodic alternating, X-linked, 310700 (3);FRMD7, NYS1, XIPAN;300628;XL;Xq26.2
FRRS1L;Epileptic encephalopathy, early infantile, 37, 616981 (3);FRRS1L, C9orf4, CG6, EIEE37;604574;AR;9q31.3
FRTS1;Fanconi renotubular syndrome 1 (2);FRTS1, FRTS, RFS;134600;AD;15q15.3
FSCN2;Retinitis pigmentosa 30, 607921 (3);FSCN2, RFSN, RP30;607643;-;17q25.3
FSHB;Hypogonadotropic hypogonadism 24 without anosmia, 229070 (3);FSHB, HH24;136530;AR;11p14.1
FSHD1;Facioscapulohumeral muscular dystrophy 1 (4);FSHD1, FSHD1A;158900;AD;4q35
FSHR;Ovarian dysgenesis 1, 233300 (3),Ovarian hyperstimulation syndrome, 608115 (3),Ovarian response to FSH stimulation, 276400 (3);FSHR, ODG1;136435;AR, AD;2p16.3
FTCD;Glutamate formiminotransferase deficiency, 229100 (3);FTCD;606806;AR;21q22.3
FTH1;?Hemochromatosis, type 5, 615517 (3);FTH1, FTHL6, HFE5;134770;AD;11q12.3
FTL;Hyperferritinemia-cataract syndrome, 600886 (3),L-ferritin deficiency, dominant and recessive, 615604 (3),Neurodegeneration with brain iron accumulation 3, 606159 (3);FTL, NBIA3, LFTD;134790;AD, AR;19q13.33
FTO;Growth retardation, developmental delay, facial dysmorphism, 612938 (3);FTO, GDFD, BMIQ14;610966;AR;16q12.2
FTSJ1;Mental retardation, X-linked 9, 309549 (3);FTSJ1, JM23, SPB1, MRX44, MRX9;300499;-;Xp11.23
FUCA1;Fucosidosis, 230000 (3);FUCA1;612280;AR;1p36.11
FUS;Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, 608030 (3),Tremor, hereditary essential, 4, 614782 (3);FUS, TLS, ALS6, ETM4;137070;-, AD;16p11.2
FUT6;Fucosyltransferase 6 deficiency, 613852 (3);FUT6;136836;-;19p13.3
FUZ;Neural tube defects, 182940 (3);FUZ, NTD;610622;AD;19q13.33
FVT1;Lymphoma/leukemia, B-cell, variant (1);FVT1;136440;-;18q21.33
FWS;Forsythe-Wakeling syndrome (2);FWS;613606;AR;1p33-p31.1
FXN;Friedreich ataxia with retained reflexes, 229300 (3),Friedreich ataxia, 229300 (3);FXN, FRDA, FARR, X25;606829;AR;9q21.11
FXYD2;Hypomagnesemia 2, renal, 154020 (3);FXYD2, ATP1G1, HOMG2;601814;AD;11q23.3
FYCO1;Cataract 18, autosomal recessive, 610019 (3);FYCO1, CATC2, CTRCT18;607182;AR;3p21.31
FZD4;Exudative vitreoretinopathy 1, 133780 (3),Retinopathy of prematurity, 133780 (3);FZD4, EVR1;604579;AD;11q14.2
FZD6;Nail disorder, nonsyndromic congenital, 10, (claw-shaped nails), 614157 (3);FZD6, NDNC10;603409;AR;8q22.3
G6PC;Glycogen storage disease Ia, 232200 (3);G6PC, G6PT;613742;AR;17q21.31
G6PC3;Dursun syndrome, 612541 (3),Neutropenia, severe congenital 4, autosomal recessive, 612541 (3);G6PC3, UGRP, SCN4;611045;AR;17q21.31
G6PD;Favism, 134700 (3),Hemolytic anemia due to G6PD deficiency, 300908 (3);G6PD, G6PD1;305900;AD, -;Xq28
GAA;Glycogen storage disease II, 232300 (3);GAA;606800;AR;17q25.3
GABRA1;Epileptic encephalopathy, early infantile, 19, 615744 (3);GABRA1, EJM5, ECA4, EIEE19;137160;AD, -;5q34
GABRG2;Epilepsy, generalized, with febrile seizures plus, type 3, 611277 (3),Febrile seizures, familial, 8, 611277 (3);GABRG2, GEFSP3, CAE2, ECA2;137164;AD;5q34
GAD1;?Cerebral palsy, spastic quadriplegic, 1, 603513 (3);GAD1, SCP, CPSQ1;605363;AR;2q31.1
GAL;?Epilepsy, familial temporal lobe, 8, 616461 (3);GAL, GALN, GLNN, ETL8;137035;AD;11q13.2
GALC;Krabbe disease, 245200 (3);GALC;606890;AD;14q31.3
GALE;Galactose epimerase deficiency, 230350 (3);GALE;606953;AR;1p36.11
GALK1;Galactokinase deficiency with cataracts, 230200 (3);GALK1;604313;AR;17q25.1
GALNS;Mucopolysaccharidosis IVA, 253000 (3);GALNS, MPS4A;612222;AR;16q24.3
GALNT3;Tumoral calcinosis, hyperphosphatemic, familial, 211900 (3);GALNT3, HHS, HFTC;601756;AR;2q24.3
GALT;Galactosemia, 230400 (3);GALT;606999;AR;9p13.3
GAMT;Cerebral creatine deficiency syndrome 2, 612736 (3);GAMT, CCDS2;601240;AR;19p13.3
GAN;Giant axonal neuropathy-1, 256850 (3);GAN, GAN1;605379;AR;16q23.2
GARS;Charcot-Marie-Tooth disease, type 2D, 601472 (3),Neuropathy, distal hereditary motor, type VA, 600794 (3);GARS, SMAD1, CMT2D, HMN5;600287;AD;7p14.3
GAS8;Ciliary dyskinesia, primary, 33, 616726 (3);GAS8, GAS11, CILD33;605178;AR;16q24.3
GATA1;Anemia, X-linked, with/without neutropenia and/or platelet abnormalities, 300835 (3),Leukemia, megakaryoblastic, with or without Down syndrome, somatic, 190685 (3),Thrombocytopenia with beta-thalassemia, X-linked, 314050 (3),Thrombocytopenia, X-linked, with or without dyserythropoietic anemia, 300367 (3);GATA1, GF1, ERYF1, NFE1, XLTDA, XLTT, XLANP;305371;XLR, -;Xp11.23
GATA2;Emberger syndrome, 614038 (3),Immunodeficiency 21, 614172 (3);GATA2, DCML, MONOMAC, IMD21;137295;AD, -;3q21.3
GATA3;Hypoparathyroidism, sensorineural deafness, and renal dysplasia, 146255 (3);GATA3, HDR, HDRS;131320;AD;10p14
GATA4;?Testicular anomalies with or without congenital heart disease, 615542 (3),Atrial septal defect 2, 607941 (3),Atrioventricular septal defect 4, 614430 (3),Tetralogy of Fallot, 187500 (3),Ventricular septal defect 1, 614429 (3);GATA4, ASD2, VSD1, TACHD, TOF;600576;AD;8p23.1
GATA6;Atrial septal defect 9, 614475 (3),Atrioventricular septal defect 5, 614474 (3),Pancreatic agenesis and congenital heart defects, 600001 (3),Persistent truncus arteriosus, 217095 (3),Tetralogy of Fallot, 187500 (3);GATA6, AVSD5, ASD9, AVSD5, PACHD;601656;AD, -;18q11.2
GATAD1;?Cardiomyopathy, dilated, 2B, 614672 (3);GATAD1, ODAG, CMD2B;614518;AR;7q21.2
GATAD2B;Mental retardation, autosomal dominant 18, 615074 (3);GATAD2B, KIAA1150, p68, MRD18;614998;-;1q21.3
GATM;Cerebral creatine deficiency syndrome 3, 612718 (3);GATM, AGAT, CCDS3;602360;AR;15q21.1
GBA;Gaucher disease, perinatal lethal, 608013 (3),Gaucher disease, type I, 230800 (3),Gaucher disease, type II, 230900 (3),Gaucher disease, type III, 231000 (3),Gaucher disease, type IIIC, 231005 (3);GBA;606463;AR, IC, Mu, AD;1q22
GBA2;Spastic paraplegia 46, autosomal recessive, 614409 (3);GBA2, KIAA1605, SPG46;609471;AR;9p13.3
GBD2;Gallbladder disease 2 (2);GBD2;609918;-;1p36.21
GBD3;Gallbladder disease 3 (2);GBD3;609919;-;1p34.3
GBE1;Glycogen storage disease IV, 232500 (3),Polyglucosan body disease, adult form, 263570 (3);GBE1, GSD4, APBD;607839;AR;3p12.2
GCCD3;Glucocorticoid deficiency 3 (2);GCCD3, FGD3, GCCD2;609197;AR;8q11.2-q13.2
GCDH;Glutaricaciduria, type I, 231670 (3);GCDH;608801;AR;19p13.13
GCH1;Dystonia, DOPA-responsive, with or without hyperphenylalaninemia, 128230 (3),Hyperphenylalaninemia, BH4-deficient, B, 233910 (3);GCH1, DYT5, HPABH4B;600225;AD, AR;14q22.2
GCK;Diabetes mellitus, noninsulin-dependent, late onset, 125853 (3),Diabetes mellitus, permanent neonatal, 606176 (3),Hyperinsulinemic hypoglycemia, familial, 3, 602485 (3),MODY, type II, 125851 (3);GCK, HHF3;138079;AD;7p13
GCLC;Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 (3);GCLC, GLCLC;606857;AR, -;6p12.1
GCM2;Hypoparathyroidism, familial isolated, 146200 (3);GCM2, GCMB;603716;AD;6p24.2
GCNT2;Adult i phenotype without cataract, 110800 (3),Cataract 13 with adult i phenotype, 116700 (3);GCNT2, Ii, CTRCT13;600429;AD,AR;6p24.3-p24.2
GCSH;Glycine encephalopathy, 605899 (3);GCSH, NKH;238330;AR;16q23.2
GDAP1;Charcot-Marie-Tooth disease, axonal, type 2K, 607831 (3),Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, 607706 (3),Charcot-Marie-Tooth disease, recessive intermediate, A, 608340 (3),Charcot-Marie-Tooth disease, type 4A, 214400 (3);GDAP1, CMT4A, CMT2K, CMTRIA;606598;AR, AD;8q21.11
GDF1;Double-outlet right ventricle, 217095 (3),Right atrial isomerism, 208530 (3),Tetralogy of Fallot, 187500 (3),Transposition of great arteries, dextro-looped 3, 613854 (3);GDF1, DTGA3, DORV, RAI;602880;-, AR, AD;19p13.11
GDF2;Telangiectasia, hereditary hemorrhagic, type 5, 615506 (3);GDF2, BMP9, HHT5;605120;AD;10q11.22
GDF3;Klippel-Feil syndrome 3, autosomal dominant, 613702 (3),Microphthalmia with coloboma 6, 613703 (3),Microphthalmia, isolated 7, 613704 (3);GDF3, KFS3, MCOPCB6, MCOP7;606522;-;12p13.31
GDF5;?Acromesomelic dysplasia, Hunter-Thompson type, 201250 (3),Brachydactyly, type A1, C, 615072 (3),Brachydactyly, type A2, 112600 (3),Brachydactyly, type C, 113100 (3),Chondrodysplasia, Grebe type, 200700 (3),Du Pan syndrome, 228900 (3),Multiple synostoses syndrome 2, 610017 (3),Symphalangism, proximal, 1B, 615298 (3);GDF5, CDMP1, SYNS2, OS5, BDA1C, SYM1B;601146;AR, AD;20q11.22
GDF6;Klippel-Feil syndrome 1, autosomal dominant, 118100 (3),Leber congenital amaurosis 17, 615360 (3),Microphthalmia with coloboma 6, digenic, 613703 (3),Microphthalmia, isolated 4, 613094 (3);GDF6, MCOP4, KFS1, MCOPCB6, LCA17;601147;AR, AD,-;8q22.1
GDF8;Muscle hypertrophy, 614160 (3);GDF8, MSTN, MSLHP;601788;-;2q32.2
GDI1;Mental retardation, X-linked 41, 300849 (3);GDI1, RABGD1A, MRX41, MRX48;300104;-;Xq28
GDNF;Central hypoventilation syndrome, 209880 (3);GDNF, HSCR3;600837;AD, -;5p13.2
GEFSP4;Epilepsy, generalized, with febrile seizures plus, type 4 (2);GEFSP4;609800;AD;2p24
GEFSP6;Epilepsy, generalized, with febrile seizures plus, type 6 (2);GEFSP6;612279;-;8p23-p21
GEFSP8;Epilespy, generalized, with febrile seizures plus, type 8 (2);GEFSP8;613828;-;6q16.3-q22.31
GER;Gastroesophageal reflux (2);GER;109350;AD;13q14
GFAP;Alexander disease, 203450 (3);GFAP, ALXDRD;137780;AD;17q21.31
GFER;Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay, 613076 (3);GFER, ERV1, ALR;600924;-;16p13.3
GFI1;Neutropenia, nonimmune chronic idiopathic, of adults, 607847 (3),Neutropenia, severe congenital 2, autosomal dominant, 613107 (3);GFI1, ZNF163, SCN2;600871;-;1p22.1
GFI1B;Bleeding disorder, platelet-type, 17, 187900 (3);GFI1B, BDPLT17;604383;AD;9q34.13
GFM1;Combined oxidative phosphorylation deficiency 1, 609060 (3);GFM1, EFG1, GFM, COXPD1;606639;AR;3q25.32
GFND1;Glomerulopathy with fibronectin deposits 1 (2);GFND1;137950;AD;1q32
GFPT1;Myasthenia, congenital, 12, with tubular aggregates, 610542 (3);GFPT1, GFAT1, GFPT1L, MSLG, CMS12, CMSTA1;138292;AR;2p13.3
GGCX;Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency, 610842 (3),Vitamin K-dependent clotting factors, combined deficiency of, 1, 277450 (3);GGCX, VKCFD1;137167;-, AR;2p11.2
GGT1;Glutathioninuria (1);GGT1, GTG;231950;-;22q11.1-q11.2
GH1;Growth hormone deficiency, isolated, type IA, 262400 (3),Growth hormone deficiency, isolated, type IB, 612781 (3),Growth hormone deficiency, isolated, type II, 173100 (3),Kowarski syndrome, 262650 (3);GH1, GHN, IGHD1B;139250;AR, -;17q23.3
GHR;Growth hormone insensitivity, partial, 604271 (3),Increased responsiveness to growth hormone (3),Laron dwarfism, 262500 (3);GHR, GHIP;600946;-, AR, AD;5p13-p12
GHRH;?Isolated growth hormone deficiency due to defect in GHRF (1),Gigantism due to GHRF hypersecretion (1);GHRH, GHRF;139190;-;20q11.23
GHRHR;Growth hormone deficiency, isolated, type IB, 612781 (3);GHRHR, GHRFR, IGHD1B;139191;-;7p14.3
GHSR;Growth hormone deficiency, isolated partial, 615925 (3);GHSR, GHDP;601898;AD, AR;3q26.31
GIF;Intrinsic factor deficiency, 261000 (3);GIF, IF;609342;AR;11q12.1
GINGF2;Fibromatosis, gingival, 2 (2);GINGF2, GGF2, HGF2;605544;-;5q13-q22
GINGF3;Fibromatosis, gingival, 3 (2);GINGF3, HGF3, GGF3;609955;-;2p23.3-p22.3
GINGF4;Fibromatosis, gingival, 4 (2);GINGF4, HGF4, GGF4;611010;-;11p15
GIPC3;Deafness, autosomal recessive 15, 601869 (3);GIPC3, DFNB15, DFNB72, DFNB95;608792;AR;19p13.3
GJA1;Atrioventricular septal defect 3, 600309 (3),Craniometaphyseal dysplasia, autosomal recessive, 218400 (3),Erythrokeratodermia variabilis et progressiva, 133200 (3),Hypoplastic left heart syndrome 1, 241550 (3),Oculodentodigital dysplasia, 164200 (3),Oculodentodigital dysplasia, autosomal recessive, 257850 (3),Palmoplantar keratoderma with congenital alopecia, 104100 (3),Syndactyly, type III, 186100 (3);GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR, EKVP;121014;AD, AR;6q22.31
GJA3;Cataract 14, multiple types, 601885 (3);GJA3, CX46, CZP3, CAE3, CTRCT14;121015;AD;13q12.11
GJA5;Atrial fibrillation, familial, 11, 614049 (3),Atrial standstill, digenic (GJA5/SCN5A), 108770 (3);GJA5, CX40, ATFB11;121013;AD;1q21.2
GJA8;Cataract 1, multiple types, 116200 (3);GJA8, CX50, CTRCT1, CZP1, CAE1;600897;AD;1q21.2
GJB1;Charcot-Marie-Tooth neuropathy, X-linked dominant, 1, 302800 (3);GJB1, CX32, CMTX1;304040;XLD ;Xq13.1
GJB2;Bart-Pumphrey syndrome, 149200 (3),Deafness, autosomal dominant 3A, 601544 (3),Deafness, autosomal recessive 1A, 220290 (3),Hystrix-like ichthyosis with deafness, 602540 (3),Keratitis-ichthyosis-deafness syndrome, 148210 (3),Keratoderma, palmoplantar, with deafness, 148350 (3),Vohwinkel syndrome, 124500 (3);GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID;121011;AD, DD, AR;13q12.11
GJB3;Deafness, autosomal dominant 2B, 612644 (3),Deafness, autosomal dominant, with peripheral neuropathy (3),Deafness, autosomal recessive (3),Deafness, digenic, GJB2/GJB3, 220290 (3),Erythrokeratodermia variabilis et progressiva, 133200 (3);GJB3, CX31, DFNA2B;603324;AD, DD, AR;1p34.3
GJB4;Erythrokeratodermia variabilis with erythema gyratum repens, 133200 (3);GJB4, CX30.3;605425;AD, AR;1p34.3
GJB6;Deafness, autosomal dominant 3B, 612643 (3),Deafness, autosomal recessive 1B, 612645 (3),Deafness, digenic GJB2/GJB6, 220290 (3),Ectodermal dysplasia 2, Clouston type, 129500 (3);GJB6, CX30, DFNA3B, DFNB1B, ECTD2, HED2;604418;AD, AR, DD ;13q12.11
GJC2;Leukodystrophy, hypomyelinating, 2, 608804 (3),Lymphedema, hereditary, IC, 613480 (3),Spastic paraplegia 44, autosomal recessive, 613206 (3);GJC2, GJA12, CX47, PMLDAR, HLD2, SPG44, LMPH1C;608803;AR, AD;1q42.13
GK;Glycerol kinase deficiency, 307030 (3);GK;300474;XLR;Xp21.2
GLA;Fabry disease, 301500 (3),Fabry disease, cardiac variant, 301500 (3);GLA;300644;XL;Xq22.1
GLB1;GM1-gangliosidosis, type I, 230500 (3),GM1-gangliosidosis, type II, 230600 (3),GM1-gangliosidosis, type III, 230650 (3),Mucopolysaccharidosis type IVB (Morquio), 253010 (3);GLB1, MPS4B;611458;AR;3p22.3
GLC1B;Glaucoma 1B, primary open angle, adult onset, (2);GLC1B;606689;-;2cen-q13
GLC1C;Glaucoma 1C, primary open angle (2);GLC1C;601682;AD;3q21-q24
GLC1D;Glaucoma 1D, primary open angle (2);GLC1D;602429;-;8q23
GLC1H;Glaucoma 1, open angle, H (2);GLC1H;611276;-;2p16-p15
GLC1I;Glaucoma 1, open angle, I (2);GLC1I;609745;-;15q11-q13
GLC1K;Glaucoma 1K, primary open angle, juvenile-onset (2);GLC1K, JOAG3;608696;-;20p12
GLC1M;Glaucoma 1, open angle, M (2);GLC1M;610535;AD;5q22.1-q32
GLC1N;Glaucoma 1, open angle, N (2);GLC1N;611274;-;15q22-q24
GLC1P;Glaucoma 1, open angle, P (4);GLC1P;177700;AD;12q14
GLC3B;Glaucoma 3, primary infantile, B (2);GLC3B;600975;AR;1p36.2-p36.1
GLC3C;Glaucoma 3, primary congenital, C (2);GLC3C;613085;-;14q24.3
GLDC;Glycine encephalopathy, 605899 (3);GLDC, HYGN1, GCSP, GCE, NKH;238300;AR;9p24.1
GLE1;Arthrogryposis, lethal, with anterior horn cell disease, 611890 (3),Lethal congenital contracture syndrome 1, 253310 (3);GLE1, GLE1L, LCCS, LCCS1;603371;-, AR;9q34.11
GLI2;Culler-Jones syndrome, 615849 (3),Holoprosencephaly 9, 610829 (3);GLI2, HPE9, CJS;165230;AD;2q14.2
GLI3;Greig cephalopolysyndactyly syndrome, 175700 (3),Pallister-Hall syndrome, 146510 (3),Polydactyly, postaxial, types A1 and B, 174200 (3),Polydactyly, preaxial, type IV, 174700 (3);GLI3, PAPA, PAPB;165240;AD;7p14.1
GLIS2;Nephronophthisis 7, 611498 (3);GLIS2, NPHP7;608539;-;16p13.3
GLIS3;Diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 (3);GLIS3, ZNF515, NDH;610192;AR;9p24.2
GLML;Glomuvenous malformations, 138000 (3);GLML, GVM, VMGLOM;601749;AD;1p22.1
GLRA1;Hyperekplexia, hereditary 1, autosomal dominant or recessive, 149400 (3);GLRA1, STHE, HKPX1;138491;AD, AR;5q33.1
GLRB;Hyperekplexia 2, autosomal recessive, 614619 (3);GLRB, HKPX2;138492;-;4q32.1
GLRX5;Anemia, sideroblastic, 3, pyridoxine-refractory, 616860 (3),Spasticity, childhood-onset, with hyperglycinemia, 616859 (3);GLRX5, C14orf87, PRO1238, FLB4739, PRSA, SIDBA3, SPAHGC;609588;AR;14q32.13
GLUD1;Hyperinsulinism-hyperammonemia syndrome, 606762 (3);GLUD1;138130;AD;10q23.2
GLUL;Glutamine deficiency, congenital, 610015 (3);GLUL, GLNS;138290;AR;1q25.3
GLYCTK;D-glyceric aciduria, 220120 (3);GLYCTK, GLYCTK1;610516;AR;3p21.2
GM2A;GM2-gangliosidosis, AB variant, 272750 (3);GM2A;613109;AR;5q33.1
GMNN;Meier-Gorlin syndrome 6, 616835 (3);GMNN, MGORS6;602842;-;6p22.3
GMPPA;Alacrima, achalasia, and mental retardation syndrome, 615510 (3);GMPPA, AAMR;615495;AR;2q35
GMPPB;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14, 615350 (3),Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 14, 615351 (3),Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14, 615352 (3);GMPPB, KIAA1851, MDDGA14, MDDGB14, MDDGC14;615320;AR;3p21.31
GNA11;Hypocalcemia, autosomal dominant 2, 615361 (3),Hypocalciuric hypercalcemia, type II, 145981 (3);GNA11, HHC2, HYPOC2;139313;AD;19p13.3
GNAI2;Pituitary ACTH-secreting adenoma (3),Ventricular tachycardia, idiopathic, 192605 (3);GNAI2, GNAI2B, GIP;139360;-, AD;3p21.31
GNAI3;Auriculocondylar syndrome 1, 602483 (3);GNAI3, ARCND1;139370;AD;1p13.3
GNAL;Dystonia 25, 615073 (3);GNAL, DYT25;139312;AD;18p11.21
GNAO1;Epileptic encephalopathy, early infantile, 17, 615473 (3);GNAO1, EIEE17;139311;AD;16q13
GNAQ;Capillary malformations, congenital, 1, somatic, mosaic, 163000 (3),Sturge-Weber syndrome, somatic, mosaic, 185300 (3);GNAQ, SWS, CMC1;600998;-;9q21.2
GNAS;ACTH-independent macronodular adrenal hyperplasia, 219080 (3),Acromegaly, somatic, 102200 (3),McCune-Albright syndrome, somatic, mosaic 174800 (3),Osseous heteroplasia, progressive, 166350 (3),Pseudohypoparathyroidism Ia, 103580 (3),Pseudohypoparathyroidism Ib, 603233 (3),Pseudohypoparathyroidism Ic, 612462 (3),Pseudopseudohypoparathyroidism, 612463 (3);GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C;139320;IC, AD, -;20q13.32
GNASAS1;Pseudohypoparathyroidism, type IB, 603233 (3);GNASAS1, GNASAS, SANG, NESPAS;610540;AD;20q13.32
GNAT1;?Night blindness, congenital stationary, type 1G, 616389 (3),Night blindness, congenital stationary, autosomal dominant 3, 610444 (3);GNAT1, CSNBAD3, CSNB1G;139330;AR, AD;3p21.31
GNAT2;Achromatopsia-4, 613856 (3);GNAT2, ACHM4;139340;-;1p13.3
GNB1;Leukemia, acute lymphoblastic, somatic, 613065 (3),Mental retardation, autosomal dominant 42, 616973 (3);GNB1, MRD42;139380;-, AD;1p36.33
GNB3;Night blindness, congenital stationary, type 1H, 617024 (3);GNB3, CSNB1H;139130;AR, Mu;12p13.31
GNB4;Charcot-Marie-Tooth disease, dominant intermediate F, 615185 (3);GNB4, CMTD1F;610863;AD;3q26.33
GNE;Nonaka myopathy, 605820 (3),Sialuria, 269921 (3);GNE, GLCNE, IBM2, DMRV, NM;603824;AR, AD;9p13.3
GNMT;Glycine N-methyltransferase deficiency, 606664 (3);GNMT;606628;AR;6p21.1
GNPAT;Rhizomelic chondrodysplasia punctata, type 2, 222765 (3);GNPAT, DHAPAT, RCDP2;602744;AR;1q42.2
GNPTAB;Mucolipidosis II alpha/beta, 252500 (3),Mucolipidosis III alpha/beta, 252600 (3);GNPTAB, GNPTA;607840;AR;12q23.2
GNPTAG;Mucolipidosis III gamma, 252605 (3);GNPTAG;607838;AR;16p13.3
GNRH1;?Hypogonadotropic hypogonadism 12 with or without anosmia, 614841 (3);GNRH1, LNRH, HH12;152760;AR;8p21.2
GNRHR;Hypogonadotropic hypogonadism 7 without anosmia, 146110 (3);GNRHR, LHRHR, HH7;138850;AR;4q13.2
GNS;Mucopolysaccharidosis type IIID, 252940 (3);GNS, G6S;607664;AR;12q14.3
GORAB;Geroderma osteodysplasticum, 231070 (3);GORAB, SCYL1BP1, NTKLBP1, GO;607983;AR;1q24.2
GOSR2;Epilepsy, progressive myoclonic 6, 614018 (3);GOSR2, GS27, EPM6;604027;AR;17q21.32
GOT1;Aspartate aminotransferase, serum level of, QTL1, 614419 (3);GOT1, ASTQTL1;138180;-;10q24.2
GP1BA;Bernard-Soulier syndrome, type A1 (recessive), 231200 (3),Bernard-Soulier syndrome, type A2 (dominant), 153670 (3);GP1BA, BSS, BDPLT1, VWDP, BDPLT3;606672;AR, AD;17p13.2
GP1BB;Bernard-Soulier syndrome, type B, 231200 (3),Giant platelet disorder, isolated, 231200 (3);GP1BB, BS, BDPLT1;138720;AR;22q11.21
GP6;Bleeding disorder, platelet-type, 11, 614201 (3);GP6, GPIV, BDPLT11;605546;AR;19q13.42
GP9;Bernard-Soulier syndrome, type C, 231200 (3);GP9;173515;AR;3q21.3
GPC3;Simpson-Golabi-Behmel syndrome, type 1, 312870 (3),Wilms tumor, somatic, 194070 (3);GPC3, SDYS, SGBS1;300037;XLR, -;Xq26.2
GPC6;Omodysplasia 1, 258315 (3);GPC6, OMIMD1;604404;AR;13q31.3-q32.1
GPD1;Hypertriglyceridemia, transient infantile, 614480 (3);GPD1, HTGTI;138420;AR;12q13.12
GPD1L;Brugada syndrome 2, 611777 (3);GPD1L, KIAA0089;611778;-;3p22.3
GPDS1;Pigment dispersion syndrome (2);GPDS1, PDS1;600510;AD;7q35-q36
GPHN;Molybdenum cofactor deficiency C, 615501 (3);GPHN, GPH, KIAA1385, GEPH, MOCODC;603930;-;14q23.3-q24.1
GPI;Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency, 613470 (3);GPI;172400;AR;19q13.11
GPIHBP1;Hyperlipoproteinemia, type 1D, 615947 (3);GPIHBP1, HYPL1D;612757;AR;8q24.3
GPR101;Pituitary adenoma, growth hormone-secreting 2, 300943 (3);GPR101, PAGH2;300393;-;Xq26.3
GPR126;Lethal congenital contracture syndrome 9, 616503 (3);GPR126, VIGR, LCCS9;612243;AR;6q24.2
GPR143;Nystagmus 6, congenital, X-linked, 300814 (3),Ocular albinism, type I, Nettleship-Falls type, 300500 (3);GPR143, OA1, NYS6;300808;-, XL;Xp22.2
GPR179;Night blindness, congenital stationary (complete), 1E, autosomal recessive, 614565 (3);GPR179, GPR158L, GPR158L1, CSNB1E;614515;AR;17q12
GPR56;Polymicrogyria, bilateral frontoparietal, 606854 (3),Polymicrogyria, bilateral perisylvian, 615752 (3);GPR56, TM7XN1, BFPP, BPPR;604110;AR;16q21
GPR88;?Chorea, childhood-onset, with psychomotor retardation, 616939 (3);GPR88, STRG, COCPMR;607468;AR;1p21.2
GPSM2;Chudley-McCullough syndrome, 604213 (3);GPSM2, LGN, PINS, DFNB82, CMCS;609245;AR;1p13.3
GPT2;?Mental retardation, autosomal recessive 49, 616281 (3);GPT2, ALT2, MRT49;138210;-;16q11.2
GPX1;Hemolytic anemia due to glutathione peroxidase deficiency, 614164 (1);GPX1, GPXD;138320;AR;3p21.31
GPX4;Spondylometaphyseal dysplasia, Sedaghatian type, 250220 (3);GPX4, SMDS;138322;AR;19p13.3
GRHL2;Deafness, autosomal dominant 28, 608641 (3),Ectodermal dysplasia/short stature syndrome, 616029 (3);GRHL2, TFCP2L3, DFNA28, ECTDS;608576;AD, AR;8q22.3
GRHL3;Van der Woude syndrome 2, 606713 (3);GRHL3, SOM, TFCP2L4, VWS2;608317;AD;1p36.11
GRHPR;Hyperoxaluria, primary, type II, 260000 (3);GRHPR, GLXR;604296;AR;9p13.2
GRIA3;Mental retardation, X-linked 94, 300699 (3);GRIA3, GLUR3, MRX94;305915;XLR;Xq25
GRID2;Spinocerebellar ataxia, autosomal recessive 18, 616204 (3);GRID2, SCAR18;602368;AR;4q22.1-q22.2
GRIK2;Mental retardation, autosomal recessive, 6, 611092 (3);GRIK2, GLUR6, MRT6;138244;AR;6q16.3
GRIN1;Mental retardation, autosomal dominant 8, 614254 (3);GRIN1, NMDAR1, MRD8;138249;-;9q34.3
GRIN2A;Epilepsy, focal, with speech disorder and with or without mental retardation, 245570 (3);GRIN2A, NMDAR2A, FESD, LKS;138253;AD;16p13.2
GRIN2B;Epileptic encephalopathy, early infantile, 27, 616139 (3),Mental retardation, autosomal dominant 6, 613970 (3);GRIN2B, NMDAR2B, MRD6, EIEE27;138252;AD, -;12p13.1
GRIP1;Fraser syndrome, 219000 (3);GRIP1;604597;AR;12q14.3
GRK1;Oguchi disease-2, 613411 (3);GRK1, RHOK, RK;180381;-;13q34
GRM1;Spinocerebellar ataxia, autosomal recessive 13, 614831 (3);GRM1, MGLUR1, GRM1A, SCAR13;604473;AR;6q24.3
GRM6;Night blindness, congenital stationary (complete), 1B, autosomal recessive, 257270 (3);GRM6, MGLUR6, CSNB1B;604096;AR;5q35.3
GRN;Aphasia, primary progressive, 607485 (3),Ceroid lipofuscinosis, neuronal, 11, 614706 (3),Frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 (3);GRN, CLN11;138945;AD, AR;17q21.31
GRXCR1;Deafness, autosomal recessive 25, 613285 (3);GRXCR1;613283;AR;4p13
GRXCR2;?Deafness, autosomal recessive 101, 615837 (3);GRXCR2, DFNB101;615762;AR;5q32
GSC;Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities, 602471 (3);GSC, SAMS;138890;AR;14q32.13
GSM1;Geniospasm (2);GSM1, GSP;190100;AD;9q13-q21
GSN;Amyloidosis, Finnish type, 105120 (3);GSN;137350;AD;9q33.2
GSR;Hemolytic anemia due to glutathione reductase deficiency (1);GSR;138300;AD;8p12
GSS;Glutathione synthetase deficiency, 266130 (3),Hemolytic anemia due to glutathione synthetase deficiency, 231900 (3);GSS, GSHS;601002;AR;20q11.22
GSTZ1;Tyrosinemia, type Ib (1);GSTZ1, MAAI;603758;-;14q24.3
GTF2E2;Trichothiodystrophy 6, nonphotosensitive, 616943 (3);GTF2E2, TTD6;189964;AR;8p12
GTF2H5;Trichothiodystrophy 3, photosensitive, 616395 (3);GTF2H5, TTD3, TFB5, C6orf175, TTDA;608780;-;6q25.3
GTPBP3;Combined oxidative phosphorylation deficiency 23, 616198 (3);GTPBP3, MSS1, COXPD23;608536;AR;19p13.11
GTS;Tourette syndrome (2);GTS;137580;AD;11q23
GUCA1A;Cone dystrophy-3, 602093 (3),Cone-rod dystrophy 14, 602093 (3);GUCA1A, GCAP, COD3, CORD14;600364;AD;6p21.1
GUCA1B;Retinitis pigmentosa 48, 613827 (3);GUCA1B, GCAP2, GUCA2, RP48;602275;-;6p21.1
GUCY1A3;Moyamoya 6 with achalasia, 615750 (3);GUCY1A3, GUC1A3, GUCSA3, MYMY6;139396;AR;4q32.1
GUCY2C;Diarrhea 6, 614616 (3),Meconium ileus, 614665 (3);GUCY2C, GUC2C, DIAR6, MECIL;601330;AD, AR;12p12.3
GUCY2D;Cone-rod dystrophy 6, 601777 (3),Leber congenital amaurosis 1, 204000 (3);GUCY2D, GUC2D, LCA1, CORD6, RCD2;600179;AD, AR;17p13.1
GULOP;Scurvy (3);GULOP, GULO;240400;-;8p21.1
GUSB;Mucopolysaccharidosis VII, 253220 (3);GUSB, MPS7;611499;AR;7q11.21
GUST;Gustavson syndrome (2);GUST;309555;XL;Xq26
GYG1;?Glycogen storage disease XV, 613507 (3),Polyglucosan body myopathy 2, 616199 (3);GYG1, GSD15;603942;AR;3q24
GYS1;Glycogen storage disease 0, muscle, 611556 (3);GYS1, GYS;138570;AR;19q13.33
GYS2;Glycogen storage disease 0, liver, 240600 (3);GYS2;138571;AR;12p12.1
H19;Beckwith-Wiedemann syndrome, 130650 (3),Silver-Russell syndrome, 180860 (3),Wilms tumor 2, 194071 (3);H19, D11S813E, ASM1, BWS, WT2;103280;AD, IC, Smu;11p15.5
H6PD;Cortisone reductase deficiency 1, 604931 (3);H6PD, GDH, G6PDH, CORTRD1;138090;AR;1p36.22
HACE1;Spastic paraplegia and psychomotor retardation with or without seizures, 616756 (3);HACE1, KIAA1320, SPPRS;610876;AR;6q16.3
HADHA;Fatty liver, acute, of pregnancy, 609016 (3),HELLP syndrome, maternal, of pregnancy, 609016 (3),LCHAD deficiency, 609016 (3),Trifunctional protein deficiency, 609015 (3);HADHA, MTPA;600890;-, AR;2p23.3
HADHB;Trifunctional protein deficiency, 609015 (3);HADHB;143450;AR;2p23.3
HADHSC;3-hydroxyacyl-CoA dehydrogenase deficiency, 231530 (3),Hyperinsulinemic hypoglycemia, familial, 4, 609975 (3);HADHSC, SCHAD, HHF4;601609;AR;4q25
HAMP;Hemochromatosis, type 2B, 613313 (3);HAMP, LEAP1, HEPC, HFE2B;606464;-;19q13.12
HARS;Charcot-Marie-Tooth disease, axonal, type 2W, 616625 (3),Usher syndrome type 3B, 614504 (3);HARS, USH3B, CMT2W;142810;AD, AR;5q31.3
HARS2;?Perrault syndrome 2, 614926 (3);HARS2, HARSL, HARSR, HO3, PRLTS2;600783;AR;5q31.3
HAX1;Neutropenia, severe congenital 3, autosomal recessive, 610738 (3);HAX1, SCN3;605998;AR;1q21.3
HBA1;Erythremias, alpha- (3),Heinz body anemias, alpha-, 140700 (3),Hemoglobin H disease, nondeletional, 613978 (3),Methemoglobinemias, alpha- (3),Thalassemias, alpha-, 604131 (3);HBA1, HBH;141800;AD, -;16p13.3
HBA2;Erythrocytosis (3),Heinz body anemia, 140700 (3),Hemoglobin H disease, nondeletional, 613978 (3),Hypochromic microcytic anemia (3),Thalassemia, alpha-, 604131 (3);HBA2, HBH;141850;AD, -;16p13.3
HBB;Delta-beta thalassemia, 141749 (3),Erythremias, beta- (3),Heinz body anemias, beta-, 140700 (3),Hereditary persistence of fetal hemoglobin, 141749 (3),Methemoglobinemias, beta- (3),Sickle cell anemia, 603903 (3),Thalassemia-beta, dominant inclusion-body, 603902 (3),Thalassemias, beta-, 613985 (3);HBB;141900;AD, AR, -;11p15.4
HBD;Thalassemia due to Hb Lepore (3),Thalassemia, delta- (3);HBD;142000;-;11p15.4
HBFQTL2;Fetal hemoglobin quantitative trait locus 2 (2);HBFQTL2, FCP;142470;AD;6q22.3-q23.1
HBFQTL3;Fetal hemoglobin quantitative trait locus 3 (2);HBFQTL3, FCP1, FCPX, FCP;305435;XL;Xp22.2
HBFQTL4;Fetal hemoglobin quantitative trait locus 4 (2);HBFQTL4;606789;-;8q
HBG1;Fetal hemoglobin quantitative trait locus 1, 141749 (3);HBG1;142200;AD;11p15.4
HBG2;Cyanosis, transient neonatal, 613977 (3),Fetal hemoglobin quantitative trait locus 1, 141749 (3);HBG2, TNCY;142250;AD;11p15.4
HBHR;Alpha-thalassemia/mental retardation syndrome, type 1 (4);HBHR, ATR1;141750;AD;16pter-p13.3
HBT;Telangiectasia, hereditary benign (2);HBT;187260;AD;5q14
HCA1;Hypercalciuria, absorptive (2);HCA1;607258;-;4q33-qter
HCCS;Linear skin defects with multiple congenital anomalies 1, 309801 (3);HCCS, MCOPS7, LSDMCA1;300056;XLD;Xp22.2
HCF2;Thrombophilia due to heparin cofactor II deficiency, 612356 (3);HCF2, HC2, SERPIND1, THPH10;142360;AD;22q11.21
HCFC1;Mental retardation, X-linked 3 (methylmalonic acidemia and homocysteinemia, cblX type ), 309541 (3);HCFC1, HCF1, MRX3;300019;XLR;Xq28
HCFP1;Facial paresis, hereditary congenital, 1 (2);HCFP1, MBS2;601471;AD;3q21-q22
HCFP2;Facial paresis, hereditary congenital, 2 (2);HCFP2;604185;AD;10q21.3-q22.1
HCN1;Epileptic encephalopathy, early infantile, 24, 615871 (3);HCN1, BCNG1, EIEE24;602780;AD;5p12
HCN4;Brugada syndrome 8, 613123 (3),Sick sinus syndrome 2, 163800 (3);HCN4, SSS2;605206;-, AD;15q24.1
HCRT;?Narcolepsy 1, 161400 (3);HCRT, OX, NRCLP1;602358;AD;17q21.2
HDAC6;?Chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia, 300863 (3);HDAC6, CPBHM;300272;XLD;Xp11.23
HDAC8;Cornelia de Lange syndrome 5, 300882 (3),Wilson-Turner syndrome, 309585 (3);HDAC8, WTS, MRXS6, CDLS5;300269;XLD;Xq13.1
HDCPH1;?Hydrocephalus, autosomal dominant (2);has;123155;AD;8q12.2-q21.2
HDL3;Huntington disease-like 3 (2);HDL3, HLN2;604802;AR;4p15.3
HDLCQ14;High density lipoprotein cholesterol level QTL14 (2);HDLCQ14, HYLAP;605201;-;11q23.3
HEATR2;Ciliary dyskinesia, primary, 18, 614874 (3);HEATR2, CILD18;614864;AR;7p22.3
HELLS;Immunodeficiency-centromeric instability-facial anomalies syndrome 4, 616911 (3);HELLS, LSH, ICF4;603946;AR;10q23.33
HEPACAM;Megalencephalic leukoencephalopathy with subcortical cysts 2A, 613925 (3),Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without mental retardation, 613926 (3);HEPACAM, MLC2A, MLC2B;611642;AR, AD;11q24.2
HERC1;Macrocephaly, dysmorphic facies, and psychomotor retardation, 617011 (3);HERC1, MDFPMR;605109;AR;15q22.31
HERC2;Mental retardation, autosomal recessive 38, 615516 (3);HERC2, SHEP1, MRT38;605837;AR;15q13.1
HES7;Spondylocostal dysostosis 4, autosomal recessive, 613686 (3);HES7, SCDO4;608059;AR;17p13.1
HESX1;Growth hormone deficiency with pituitary anomalies, 182230 (3),Pituitary hormone deficiency, combined, 5, 182230 (3),Septooptic dysplasia, 182230 (3);HESX1, RPX, CPHD5;601802;AD, AR;3p14.3
HEXA;GM2-gangliosidosis, several forms, 272800 (3),Tay-Sachs disease, 272800 (3);HEXA, TSD;606869;AR;15q23
HEXB;Sandhoff disease, infantile, juvenile, and adult forms, 268800 (3);HEXB;606873;AR;5q13.3
HEY;?Hairy ears, Y-linked (2);HEY;425500;YL;Yq
HFE;Hemochromatosis, 235200 (3);HFE, HLA-H, HFE1, MVCD7, TFQTL2;613609;AR, AD;6p22.2
HFM;Hemifacial microsomia (2);HFM;164210;AD;14q32
HFM1;Premature ovarian failure 9, 615724 (3);HFM1, MER3, POF9;615684;AR;1p22.2
HGD;Alkaptonuria, 203500 (3);HGD, AKU;607474;AR;3q13.33
HGF;Deafness, autosomal recessive 39, 608265 (3);HGF, DFNB39;142409;AR;7q21.11
HGSNAT;Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930 (3),Retinitis pigmentosa 73, 616544 (3);HGSNAT, TMEM76, MPS3C, RP73;610453;AR;8p11.2-p11.1
HHPP;Hyperhidrosis palmaris et plantaris (2);HHPP;144110;AD;14q11.2-q13
HHT3;Telangiectasia, hereditary hemorrhagic, type 3 (2);HHT3, ORW3;601101;-;5q31.3-q32
HHT4;Telangiectasia, hereditary hemorrhagic, type 4 (2);HHT4;610655;AD;7p14
HIBCH;3-hydroxyisobutryl-CoA hydrolase deficiency, 250620 (3);HIBCH;610690;AR;2q32.2
HINT1;Neuromyotonia and axonal neuropathy, autosomal recessive, 137200 (3);HINT1, PRKCNH1, NMAN;601314;AR;5q23.3
HIVEP2;Mental retardation, autosomal dominant 43, 616977 (3);HIVEP2, MRD43;143054;AD;6q24.2
HJCD;Histiocytosis-lymphadenopathy plus syndrome, 602782 (3);HJCD, HCLAP;602782;AR;11q25
HJV;Hemochromatosis, type 2A, 602390 (3);HJV, HFE2A;608374;-;1q21.1
HK1;Hemolytic anemia due to hexokinase deficiency, 235700 (3),Neuropathy, hereditary motor and sensory, Russe type, 605285 (3);HK1, HKD, HMSNR;142600;AR;10q22.1
HLCS;Holocarboxylase synthetase deficiency, 253270 (3);HLCS, HCS;609018;AR;21q22.13
HMBS;Porphyria, acute intermittent, 176000 (3),Porphyria, acute intermittent, nonerythroid variant, 176000 (3);HMBS, PBGD, UPS;609806;AD;11q23.3
HMGA2;Leiomyoma, uterine, somatic, 150699 (1);HMGA2, HMGIC, BABL;600698;-;12q14.3
HMGB3;?Microphthalmia, syndromic 13, 300915 (3);HMGB3, HMG4, HMG2A, MCOPS13;300193;XL;Xq28
HMGCL;HMG-CoA lyase deficiency, 246450 (3);HMGCL;613898;AR;1p36.11
HMGCS2;HMG-CoA synthase-2 deficiency, 605911 (3);HMGCS2;600234;-;1p12
HMOX1;Heme oxygenase-1 deficiency, 614034 (3);HMOX1, HMOX1D;141250;-;22q12.3
HMPS1;Polyposis syndrome, mixed hereditary 1 (4);HMPS1, CRAC1, CRCS4, DUP15q, C15DUPq;601228;AD;15q15.3-q22.1
HMSN5;Hereditary motor and sensory neuropathy V (2);HMSN5;600361;AD;4q34.3-q35.2
HMX1;Oculoauricular syndrome, 612109 (3);HMX1, H6;142992;AR;4p16.1
HNF1A;Diabetes mellitus, insulin-dependent, 20, 612520 (3),Hepatic adenoma, somatic, 142330 (3),MODY, type III, 600496 (3),Renal cell carcinoma, 144700 (3);HNF1A, TCF1, MODY3, IDDM20;142410;-, AR, AD;12q24.31
HNF1B;Diabetes mellitus, noninsulin-dependent, 125853 (3),Renal cysts and diabetes syndrome, 137920 (3);HNF1B, TCF2, HNF2, MODY5, FJHN, HPC11;189907;AD, -;17q12
HNF4A;Fanconi renotubular syndrome 4, with maturity-onset diabetes of the young, 616026 (3),MODY, type I, 125850 (3);HNF4A, TCF14, MODY1, FRTS4;600281;AD;20q13.12
HNFJ3;Hyperuricemic nephropathy, familial juvenile, 3 (2);HNFJ3;614227;AD;2p22.1-p21
HNMT;Mental retardation, autosomal recessive 51, 616739 (3);HNMT, MRT51;605238;AR, AD;2q22.1
HNP1;Hypertensive nephropathy (2);HNP1;608026;-;9q31-q32
HNRNPA1;?Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3, 615424 (3),Amyotrophic lateral sclerosis 20, 615426 (3);HNRNPA1, IBMPFD3, ALS20;164017;AD;12q13.13
HNRNPDL;Muscular dystrophy, limb-girdle, type 1G, 609115 (3);HNRNPDL, HNRPDL, JKTBP, LGMD1G;607137;AD;4q21.22
HNRNPK;Au-Kline syndrome, 616580 (3);HNRNPK, HNRPK, AUKS;600712;AD;9q21.32
HNRPA2B1;?Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2, 615422 (3);HNRPA2B1, IBMPFD2;600124;-;7p15.2
HOGA1;Hyperoxaluria, primary, type III, 613616 (3);HOGA1, DHDPSL, HP3;613597;-;10q24.2
HOMER2;?Deafness, autosomal dominant 68, 616707 (3);HOMER2, HOMER2B, HOMER2A, DFNA68;604799;AD;15q25.2
HOXA1;Athabaskan brainstem dysgenesis syndrome, 601536 (3),Bosley-Salih-Alorainy syndrome, 601536 (3);HOXA1, HOX1F, BSAS;142955;-;7p15.2
HOXA11;Radioulnar synostosis with amegakaryocytic thrombocytopenia 1, 605432 (3);HOXA11, HOX1I, RUSAT1;142958;AD;7p15.2
HOXA13;Guttmacher syndrome, 176305 (3),Hand-foot-uterus syndrome, 140000 (3);HOXA13, HOX1J;142959;AD;7p15.2
HOXA2;?Microtia with or without hearing impairment (AD), 612290 (3),?Microtia, hearing impairment, and cleft palate (AR), 612290 (3);HOXA2, MCOHI;604685;AD, AR;7p15.2
HOXB1;Facial paresis, hereditary congenital, 3, 614744 (3);HOXB1, HOX2I, HCFP3;142968;AR;17q21.32
HOXC13;Ectodermal dysplasia 9, hair/nail type, 614931 (3);HOXC13, HOX3G, ECTD9;142976;AR;12q13.13
HOXD10;Charcot-Marie-Tooth disease, foot deformity of, 192950 (3),Vertical talus, congenital, 192950 (3);HOXD10, HOX4D;142984;AD;2q31.1
HOXD13;?Brachydactyly-syndactyly syndrome, 610713 (3),Brachydactyly, type D, 113200 (3),Brachydactyly, type E, 113300 (3),Syndactyly, type V, 186300 (3),Synpolydactyly 1, 186000 (3);HOXD13, HOX4I, SPD1, BDSD;142989;AD;2q31.1
HPCA;Dystonia 2, torsion, autosomal recessive, 224500 (3);HPCA, DYT2;142622;AR;1p35.1
HPD;Hawkinsinuria, 140350 (3),Tyrosinemia, type III, 276710 (3);HPD;609695;AR, AD;12q24.31
HPE1;Holoprosencephaly 1 (2);HPE1;236100;IC, AD ;21q22.3
HPE6;Holoprosencephaly 6 (2);HPE6;605934;-;2q37.1-q37.3
HPE8;Holoprosencephaly 8 (2);HPE8;609408;-;14q13
HPGD;Cranioosteoarthropathy, 259100 (3),Digital clubbing, isolated congenital, 119900 (3),Hypertrophic osteoarthropathy, primary, autosomal recessive 1, 259100 (3);HPGD, PGDH1, PHOAR1;601688;AR, AD;4q34.1
HPPD;Hypertelorism, preauricular sinus, punctal pits, and deafness (2);HPPD;614187;AD;14q31
HPRHP;Hypophosphatemic rickets and hyperparathyroidism (2);HPRHP;612089;AD;13q13.1
HPRT1;HPRT-related gout, 300323 (3),Lesch-Nyhan syndrome, 300322 (3);HPRT1, HPRT;308000;XLR;Xq26.2-q26.3
HPS1;Hermansky-Pudlak syndrome 1, 203300 (3);HPS1;604982;AR;10q24.2
HPS3;Hermansky-Pudlak syndrome 3, 614072 (3);HPS3;606118;-;3q24
HPS4;Hermansky-Pudlak syndrome 4, 614073 (3);HPS4;606682;-;22q12.1
HPS5;Hermansky-Pudlak syndrome 5, 614074 (3);HPS5, RU2, KIAA1017;607521;-;11p15.1
HPS6;Hermansky-Pudlak syndrome 6, 614075 (3);HPS6, RU;607522;-;10q24.32
HPSE2;Urofacial syndrome 1, 236730 (3);HPSE2, HPA2, UFS1;613469;AR;10q24.2
HPT;Hypoparathyroidism, X-linked (2);HPT, HPTX, HYPX;307700;XL;Xq26-q27
HR;Alopecia universalis, 203655 (3),Atrichia with papular lesions, 209500 (3),Hypotrichosis 4, 146550 (3);HR, AU, MUHH1, HYPT4;602302;AR, AD;8p21.3
HRAS;Congenital myopathy with excess of muscle spindles, 218040 (3),Costello syndrome, 218040 (3),Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3);HRAS;190020;IC, AD , -;11p15.5
HRG;Thrombophilia due to HRG deficiency, 613116 (3),Thrombophilia due to elevated HRG, 613116 (1);HRG, THPH11;142640;AD;3q27.3
HRM2;Hair, curly (2);HRM2;139450;AD;1q21.3
HRPT2;Hyperparathyroidism, familial primary, 145000 (3),Hyperparathyroidism-jaw tumor syndrome, 145001 (3),Parathyroid adenoma with cystic changes, 145001 (3),Parathyroid carcinoma, 608266 (3);HRPT2, C1orf28;607393;AD;1q31.2
HRPT3;Hyperparathyroidism 3 (2);HRPT3;610071;-;2p14-p13.3
HSD11B1;Cortisone reductase deficiency 2, 614662 (3);HSD11B1, HSD11, HSD11L, CORTRD2;600713;AD;1q32.2
HSD11B2;Apparent mineralocorticoid excess, 218030 (3);HSD11B2, HSD11K, AME;614232;AR;16q22.1
HSD17B10;17-beta-hydroxysteroid dehydrogenase X deficiency, 300438 (3),?Mental retardation, X-linked syndromic 10, 300220 (3);HSD17B10, HADH2, ERAB, MRXS10;300256;XLD,XLR;Xp11.22
HSD17B3;Pseudohermaphroditism, male, with gynecomastia, 264300 (3);HSD17B3, EDH17B3;605573;AR;9q22.32
HSD17B4;D-bifunctional protein deficiency, 261515 (3),Perrault syndrome 1, 233400 (3);HSD17B4, PRLTS1;601860;AR;5q23.1
HSD3B2;Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency, 201810 (3);HSD3B2;613890;AR;1p12
HSD3B7;Bile acid synthesis defect, congenital, 1, 607765 (3);HSD3B7, CBAS1;607764;AR;16p11.2
HSF4;Cataract 5, multiple types, 116800 (3);HSF4, CTM, CTRCT5;602438;AD;16q22.1
HSN1B;Neuropathy, hereditary sensory, type IB (2);HSN1B;608088;AD;3p24-p22
HSPA9;Anemia, sideroblastic, 4, 182170 (3),Even-plus syndrome, 616854 (3);HSPA9, HSPA9B, MOT2, GRP75, EVPLS, SIDBA4;600548;AD, AR;5q31.2
HSPB1;Charcot-Marie-Tooth disease, axonal, type 2F, 606595 (3),Neuropathy, distal hereditary motor, type IIB, 608634 (3);HSPB1, HSP27, CMT2F, HMN2B;602195;AD;7q11.23
HSPB3;?Neuronopathy, distal hereditary motor, type IIC, 613376 (3);HSPB3, HSPL27, HMN2C, DHMN2C;604624;AD;5q11.2
HSPB8;Charcot-Marie-Tooth disease, axonal, type 2L, 608673 (3),Neuropathy, distal hereditary motor, type IIA, 158590 (3);HSPB8, H11, E2IG1, DHMN2, CMT2L, HMN2A;608014;AD;12q24.23
HSPD1;Leukodystrophy, hypomyelinating, 4, 612233 (3),Spastic paraplegia 13, autosomal dominant, 605280 (3);HSPD1, SPG13, HSP60, HLD4;118190;AR, AD;2q33.1
HSPG2;Dyssegmental dysplasia, Silverman-Handmaker type, 224410 (3),Schwartz-Jampel syndrome, type 1, 255800 (3);HSPG2, PLC, SJS, SJA, SJS1;142461;AR;1p36.12
HT;Hashimoto thyroiditis (2);HT;140300;AD;8q23-q24
HTC1;?Hypertrichosis universalis congenita, Ambras type (2);HTC1;145701;AD;8q22
HTC2;Hypertrichosis, congenital generalized (4);HTC2, HCG, CGH, CXINSq27.1,;307150;XLD;Xq27.1
HTGH;Hypertrichosis terminalis, generalized, with or without gingival hyperplasia (4);HTGH, DEL17q24;135400;AR;17q24.2-q24.3
HTR1A;Periodic fever, menstrual cycle dependent, 614674 (3);HTR1A, ADRB2RL1, PFMCD;109760;AD;5q12.3
HTRA1;CARASIL syndrome, 600142 (3),Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2, 616779 (3);HTRA1, PRSS11, ARMD7, CARASIL, CADASIL2;602194;AR, AD, -;10q26.13
HTT;Huntington disease, 143100 (3);HTT, HD, IT15;613004;AD;4p16.3
HTX3;?Heterotaxy, visceral, 3, autosomal (2);HTX3;606325;-;6q21
HUWE1;Mental retardation, X-linked syndromic, Turner type, 300706 (3);HUWE1, UREB1, KIAA0312, LASU1;300697;-;Xp11.22
HWE1;Epilepsy, hot water, 1 (2);HWE1;613339;AD;10q21.3-q22.3
HWE2;Epilepsy, hot water, 2 (2);HWE2;613340;-;4q24-q28
HYAL1;?Mucopolysaccharidosis type IX, 601492 (3);HYAL1, MPS9;607071;AR;3p21.31
HYDIN;Ciliary dyskinesia, primary, 5, 608647 (3);HYDIN, HYDIN1, CILD5;610812;AR;16q22.2
HYLS1;Hydrolethalus syndrome, 236680 (3);HYLS1, FLJ32915;610693;AR;11q24.2
HYPLIP2;Hyperlipidemia, combined, 2 (2);HYPLIP2;604499;-;11p
HYPT10;Hypotrichosis 10 (2);HYPT10;614238;-;7p22.3-p21.3
HYPT5;Hypotrichosis 5 (2);HYPT5, MUHH2;612841;-;1p21.1-q21.3
HYPT9;Hypotrichosis 9 (2);HYPT9;614237;-;10q11.23-q22.3
HYSP3;Hypospadias 3, autosomal (2);HYSP3;146450;Mu, AD;7q32.2-q36.1
IARS2;?Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia, 616007 (3);IARS2, CAGSSS;612801;AR;1q41
IBA57;?Multiple mitochondrial dysfunctions syndrome 3, 615330 (3),?Spastic paraplegia 74, autosomal recessive, 616451 (3);IBA57, C1orf69, MMDS3, SPG74;615316;AR,AR;1q42.13
IBGC2;Basal ganglia calcification, idiopathic, 2 (2);IBGC2;606656;-;2q37
ICK;Endocrine-cerebroosteodysplasia, 612651 (3);ICK, MRK, KIAA0936, ECO;612325;AR;6p12.1
ICOS;Immunodeficiency, common variable, 1, 607594 (3);ICOS, AILIM, CVID1;604558;AR;2q33.2
ICR1;Beckwith-Wiedemann syndrome, 130650 (3);ICR1;616186;AD;11p15.5
IDH2;D-2-hydroxyglutaric aciduria 2, 613657 (3);IDH2, IDPM, D2HGA2;147650;-;15q26.1
IDH3B;Retinitis pigmentosa 46, 612572 (3);IDH3B, RP46;604526;-;20p13
IDS;Mucopolysaccharidosis II, 309900 (3);IDS, MPS2, SIDS;300823;XLR;Xq28
IDUA;Mucopolysaccharidosis Ih, 607014 (3),Mucopolysaccharidosis Ih/s, 607015 (3),Mucopolysaccharidosis Is, 607016 (3);IDUA, IDA;252800;AR;4p16.3
IER3IP1;Microcephaly, epilepsy, and diabetes syndrome, 614231 (3);IER3IP1, MEDS;609382;AR;18q21.1
IFIH1;Aicardi-Goutieres syndrome 7, 615846 (3),Singleton-Merten syndrome 1, 182250 (3);IFIH1, MDA5, AGS7, SGMRT1;606951;AD;2q24.2
IFITM5;Osteogenesis imperfecta, type V, 610967 (3);IFITM5, OI5;614757;AD;11p15.5
IFNA1;Interferon, alpha, deficiency (1);IFNA1, IFNA@;147660;-;9p21.3
IFNAR2;?Immunodeficiency 45, 616669 (3);IFNAR2, IMD45;602376;AR;21q22.11
IFNGR1;Immunodeficiency 27A, mycobacteriosis, AR, 209950 (3),Immunodeficiency 27B, mycobacteriosis, AD, 615978 (3);IFNGR1, IMD27A, IMD27B;107470;AR, AD, -;6q23.3
IFNGR2;Immunodeficiency 28, mycobacteriosis, 614889 (3);IFNGR2, IFNGT1, IFGR2, IMD28;147569;AR;21q22.11
IFT122;Cranioectodermal dysplasia 1, 218330 (3);IFT122, WDR10, CED1;606045;AR;3q21.3-q22.1
IFT140;Short-rib thoracic dysplasia 9 with or without polydactyly, 266920 (3);IFT140, KIAA0590, SRTD9, MZSDS;614620;AR;16p13.3
IFT172;Retinitis pigmentosa 71, 616394 (3),Short-rib thoracic dysplasia 10 with or without polydactyly, 615630 (3);IFT172, SLB, KIAA1179, SRTD10, RP71;607386;AR;2p23.3
IFT27;?Bardet-Biedl syndrome 19, 615996 (3);IFT27, RABL4, BBS19;615870;AR;22q12.3
IFT43;Cranioectodermal dysplasia 3, 614099 (3);IFT43, C14orf179, CED3;614068;AR;14q24.3
IFT80;Short-rib thoracic dysplasia 2 with or without polydactyly, 611263 (3);IFT80, KIAA1374, WDR56, SRTD2, ATD2;611177;AR;3q25.33
IGAD1;Immunoglobulin A deficiency (2);IGAD1;137100;IC, AD, AR;6p21.3
IGBP1;Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia, 300472 (3);IGBP1;300139;XLR;Xq13.1
IGF1;Growth retardation with deafness and mental retardation due to IGF1 deficiency, 608747 (3);IGF1;147440;AR;12q23.2
IGF1R;Insulin-like growth factor I, resistance to, 270450 (3);IGF1R;147370;AD, AR;15q26.3
IGF2;?Growth restriction, severe, with distinctive facies, 616489 (3);IGF2, GRDF;147470;XLR;11p15.5
IGF2R;Hepatocellular carcinoma, somatic, 114550 (3);IGF2R, MPRI;147280;AD, AR;6q25.3
IGFALS;Acid-labile subunit, deficiency of, 615961 (3);IGFALS, ALS, ACLSD;601489;-;16p13.3
IGFBP7;Retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 (3);IGFBP7, MAC25, RAMSVPS;602867;AR;4q12
IGHG2;IgG2 deficiency, selective (3);IGHG2;147110;-;14q32.33
IGHM;Agammaglobulinemia 1, 601495 (3);IGHM, MU, AGM1;147020;AR;14q32.33
IGHMBP2;Charcot-Marie-Tooth disease, axonal, type 2S, 616155 (3),Neuronopathy, distal hereditary motor, type VI, 604320 (3);IGHMBP2, SMUBP2, CATF1, SMARD1, HMN6, CMT2S;600502;AR;11q13.3
IGHR;?Hyperimmunoglobulin G1 syndrome (2);IGHR;144120;AD;14q32.33
IGKC;Kappa light chain deficiency, 614102 (3);IGKC, IGKCD;147200;AR;2p11.2
IGLL1;Agammaglobulinemia 2, 613500 (3);IGLL1, IGO, IGL5, VPREB2, AGM2;146770;AR;22q11.23
IGSF1;Hypothyroidism, central, and testicular enlargement, 300888 (3);IGSF1, IGDC1, CHTE;300137;XLR;Xq26.1
IGSF3;?Lacrimal duct defect, 149700 (3);IGSF3, LCDD;603491;AR;1p13.1
IH;Hemihypertrophy (2);IH, HHP;235000;AD;11p15
IHH;Acrocapitofemoral dysplasia, 607778 (3),Brachydactyly, type A1, 112500 (3);IHH, BDA1;600726;AR, AD;2q35
IHPS1;Pyloric stenosis, infantile hypertrophic 1 (2);IHPS1, IHPS;179010;Mu, AD;12q
IHPS2;Pyloric stenosis, infantile hypertrophic, 2 (2);IHPS2;610260;-;16p13-p12
IHPS3;Pyloric stenosis, infantile hypertrophic, 3 (2);IHPS3;612017;-;11q14-q22
IHPS4;Pyloric stenosis, infantile hypertrophic, 4 (2);IHPS4;300711;-;Xq23
IHPS5;Pyloric stenosis, infantile hypertrophic, 5 (2);IHPS5;612525;-;16q24.3
IKBKAP;Dysautonomia, familial, 223900 (3);IKBKAP, IKAP;603722;AR;9q31.3
IKBKB;Immunodeficiency 15, 615592 (3);IKBKB, NFKBIKB, IMD15;603258;AR;8p11.21
IKBKG;Ectodermal dysplasia, hypohidrotic, with immune deficiency, 300291 (3),Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency, 300301 (3),Immunodeficiency 33, 300636 (3),Immunodeficiency, isolated, 300584 (3),Incontinentia pigmenti, 308300 (3),Invasive pneumococcal disease, recurrent isolated, 2, 300640 (3);IKBKG, NEMO, FIP3, IP, IPD2, AMCBX1, IMD33;300248;-, XLR, XLD;Xq28
IKZF1;Immunodeficiency, common variable, 13, 616873 (3);IKZF1, ZNFN1A1, IK1, LYF1, CVID13;603023;AD;7p12.2
IL10RA;Inflammatory bowel disease 28, early onset, autosomal recessive, 613148 (3);IL10RA, IL10R, IBD28;146933;AR;11q23.3
IL11RA;Craniosynostosis and dental anomalies, 614188 (3);IL11RA, CRSDA;600939;AR;9p13.3
IL12B;Immunodeficiency 29, mycobacteriosis, 614890 (3);IL12B, NKSF2, IMD29;161561;AR;5q33.3
IL12RB1;Immunodeficiency 30, 614891 (3);IL12RB1, IMD30;601604;AR;19p13.11
IL17F;?Candidiasis, familial, 6, autosomal dominant, 613956 (3);IL17F, ML1, CANDF6;606496;-;6p12.2
IL17RA;?Candidiasis, familial, 5, autosomal recessive, 613953 (3);IL17RA, IL17R, CANDF5;605461;-;22q11.1
IL17RC;Candidiasis, familial, 9, 616445 (3);IL17RC, IL17RL, CANDF9;610925;AR;3p25.3
IL17RD;Hypogonadotropic hypogonadism 18 with or without anosmia, 615267 (3);IL17RD, SEF, HH18;606807;AD;3p14.3
IL1RAPL1;Mental retardation, X-linked 21/34, 300143 (3);IL1RAPL1, IL1R8, MRX21, MRX34;300206;XLR;Xp21.3-p21.2
IL1RN;Interleukin 1 receptor antagonist deficiency, 612852 (3);IL1RN, MVCD4, DIRA;147679;AR, AD, -;2q14.1
IL2;Severe combined immunodeficiency due to IL2 deficiency (1);IL2;147680;-;4q27
IL21;?Immunodeficiency, common variable, 11, 615767 (3);IL21, CVID11;605384;AR;4q27
IL21R;Immunodeficiency, primary, autosomal recessive, IL21R-related, 615207 (3);IL21R;605383;AR, AD;16p12.1
IL2RA;Immunodeficiency 41 with lymphoproliferation and autoimmunity, 606367 (3);IL2RA, CD25, IL2R, IDDM10, IMD41;147730;AR;10p15.1
IL2RG;Combined immunodeficiency, X-linked, moderate, 312863 (3),Severe combined immunodeficiency, X-linked, 300400 (3);IL2RG, SCIDX1, SCIDX, IMD4;308380;XLR;Xq13.1
IL31RA;Amyloidosis, primary localized cutaneous, 2, 613955 (3);IL31RA, GLMR, GPL, PLCA2;609510;-;5q11.2
IL36RN;Psoriasis 14, pustular, 614204 (3);IL36RN, IL1F5, FIL1D, IL1HY1, IL1RP3, PSORP, PSORS14;605507;AR;2q14.1
IL7R;Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type, 608971 (3);IL7R, IL7RA, CD127;146661;AR;5p13.2
ILDR1;Deafness, autosomal recessive 42, 609646 (3);ILDR1, DFNB42;609739;AR;3q13.33
IMPAD1;Chondrodysplasia with joint dislocations, GPAPP type, 614078 (3);IMPAD1, GPAPP, IMPA3;614010;AR;8q12.1
IMPDH1;Leber congenital amaurosis 11, 613837 (3),Retinitis pigmentosa 10, 180105 (3);IMPDH1, RP10, LCA11;146690;-, AD;7q32.1
IMPG1;Macular dystrophy, vitelliform, 4, 616151 (3);IMPG1, IPM150, VMD4;602870;AD;6q14.1
IMPG2;Macular dystrophy, vitelliform, 5, 616152 (3),Retinitis pigmentosa 56, 613581 (3);IMPG2, IPM200, RP56, VMD5;607056;AR, AD;3q12.3
INDX;Wood neuroimmunologic syndrome (2);INDX;300076;XLD;Xq26-qter
INF2;Charcot-Marie-Tooth disease, dominant intermediate E, 614455 (3),Glomerulosclerosis, focal segmental, 5, 613237 (3);INF2, FSGS5, C14orf173, CMTDIE;610982;AD, -;14q32.33
ING1;Squamous cell carcinoma, head and neck, somatic, 275355 (3);ING1;601566;-;13q34
INPP5E;Joubert syndrome 1, 213300 (3),Mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 (3);INPP5E, MORMS, JBTS1, CORS1;613037;AR;9q34.3
INPPL1;Opsismodysplasia, 258480 (3);INPPL1, OPSMD;600829;AR;11q13.4
INS;Diabetes mellitus, insulin-dependent, 2, 125852 (3),Diabetes mellitus, permanent neonatal, 606176 (3),Hyperproinsulinemia, 616214 (3),Maturity-onset diabetes of the young, type 10, 613370 (3);INS, MODY10, IDDM2;176730;AD;11p15.5
INSL3;Cryptorchidism, 219050 (3);INSL3;146738;AD;19p13.11
INSR;Diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 (3),Hyperinsulinemic hypoglycemia, familial, 5, 609968 (3),Leprechaunism, 246200 (3),Rabson-Mendenhall syndrome, 262190 (3);INSR, HHF5;147670;AD, AR;19p13.2
INVS;Nephronophthisis 2, infantile, 602088 (3);INVS, INV, NPHP2, NPH2;243305;AR;9q31.1
IPF1;MODY, type IV, 606392 (3),Pancreatic agenesis 1, 260370 (3);IPF1, MODY4, PAGEN1;600733;AR, AD;13q12.2
IQCB1;Senior-Loken syndrome 5, 609254 (3);IQCB1, NPHP5, KIAA0036;609237;AR;3q13.33
IQSEC2;Mental retardation, X-linked 1/78, 309530 (3);IQSEC2, KIAA0522, MRX1, MRX78;300522;XLD;Xp11.22
IRAK4;IRAK4 deficiency, 607676 (3),Invasive pneumococcal disease, recurrent isolated, 1, 610799 (3);IRAK4, REN64, IPD1;606883;-;12q12
IRF1;Gastric cancer, somatic, 613659 (3),Myelodysplastic syndrome, preleukemic (3),Myelogenous leukemia, acute (3),Nonsmall cell lung cancer, somatic, 211980 (3);IRF1, MAR;147575;-;5q31.1
IRF6;Popliteal pterygium syndrome 1, 119500 (3);IRF6, VWS, LPS, PIT, PPS1, OFC6;607199;AD, IC;1q32.2
IRF7;?Immunodeficiency 39, 616345 (3);IRF7, IRF7A, IRF7B, IRF7C, IRF7H, IMD39;605047;AR;11p15.5
IRF8;Immunodeficiency 32A, mycobacteriosis, autosomal dominant, 614893 (3),Immunodeficiency 32B, monocyte and dendritic cell deficiency, autosomal recessive, 614894 (3);IRF8, ICSBP1, IMD32A, IMD32B;601565;AD, AR;16q24.1
IRGM;Inflammatory bowel disease 19, 612278 (3);IRGM, LRG47, IFI1, IBD19;608212;-;5q33.1
IRX5;Hamamy syndrome, 611174 (3);IRX5, HMMS;606195;AR;16q12.2
IS1;Scoliosis, idiopathic 1 (2);IS1, AIS;181800;AD;19p13.3
IS2;Scoliosis, idiopathic 2 (2);IS2, AIS2;607354;-;17p11.2
ISCA2;Multiple mitochondrial dysfunctions syndrome 4, 616370 (3);ISCA2, MMDS4;615317;AR;14q24.3
ISCU;Myopathy with lactic acidosis, hereditary, 255125 (3);ISCU, HML;611911;AR;12q23.3
ISG15;Immunodeficiency 38, 616126 (3);ISG15, G1P2, IFI15, IMD38;147571;AR;1p36.33
ISPD;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, 614643 (3),Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 7, 616052 (3);ISPD, MDDGA7, MDDGC7;614631;AR;7p21.2
ITCH;Autoimmune disease, multisystem, with facial dysmorphism, 613385 (3);ITCH, AIP4, NAPP1, ADMFD;606409;AR;20q11.22
ITGA2;?Glycoprotein Ia deficiency, 614200 (1);ITGA2, CD49B, BR, BDPLT9;192974;AD;5q11.2
ITGA2B;Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 (3),Glanzmann thrombasthenia, 273800 (3),Thrombocytopenia, neonatal alloimmune, BAK antigen related (3);ITGA2B, GP2B, CD41B, GT, BDPLT2, BDPLT16;607759;AD, AR, -;17q21.31
ITGA3;Interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital, 614748 (3);ITGA3, CD49C, GAPB3, ILNEB;605025;AR;17q21.33
ITGA6;Epidermolysis bullosa, junctional, with pyloric stenosis, 226730 (3);ITGA6;147556;AR;2q31.1
ITGA7;Muscular dystrophy, congenital, due to ITGA7 deficiency, 613204 (3);ITGA7;600536;AR;12q13.2
ITGA8;Renal hypodysplasia/aplasia 1, 191830 (3);ITGA8, RHDA1;604063;AR;10p13
ITGB2;Leukocyte adhesion deficiency, 116920 (3);ITGB2, CD18, LCAMB, LAD;600065;AR;21q22.3
ITGB3;Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 (3),Glanzmann thrombasthenia, 273800 (3),Purpura, posttransfusion (3),Thrombocytopenia, neonatal alloimmune (3);ITGB3, GP3A, GT, BDPLT2, BDPLT16;173470;AD, AR, -;17q21.32
ITGB4;Epidermolysis bullosa of hands and feet, 131800 (3),Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3),Epidermolysis bullosa, junctional, with pyloric atresia, 226730 (3);ITGB4;147557;AD, AR;17q25.1
ITGB6;Amelogenesis imperfecta, type IH, 616221 (3);ITGB6, AI1H;147558;AR;2q24.2
ITK;Lymphoproliferative syndrome 1, 613011 (3);ITK, EMT, LPFS1;186973;AR;5q33.3
ITM2B;?Retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities, 616079 (3),Dementia, familial British, 176500 (3),Dementia, familial Danish, 117300 (3);ITM2B, BRI, ABRI, FBD, RDGCA;603904;AD;13q14.2
ITPA;Epileptic encephalopathy, early infantile, 35, 616647 (3);ITPA, EIEE35;147520;AR, -;20p13
ITPR1;Gillespie syndrome, 206700 (3),Spinocerebellar ataxia 15, 606658 (3),Spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3);ITPR1, SCA15, SCA16, SCA29;147265;-, AD;3p26.1
ITPR2;?Anhidrosis, isolated, with normal sweat glands, 106190 (3);ITPR2, ANHD;600144;AR;12p11.23
ITS;Insulinoma (1);ITS;606960;-;22q12.1-q12.2
IVD;Isovaleric acidemia, 243500 (3);IVD;607036;AR;15q15.1
IYD;Thyroid dyshormonogenesis 4, 274800 (3);IYD, DEHAL1, TDH4;612025;AR;6q25.1
JAG1;?Deafness, congenital heart defects, and posterior embryotoxon (3),Alagille syndrome, 118450 (3),Tetralogy of Fallot, 187500 (3);JAG1, AGS, AHD;601920;-, AD;20p12.2
JAGN1;Neutropenia, severe congenital, 6, autosomal recessive, 616022 (3);JAGN1, SCN6;616012;AR;3p25.3
JAK2;Erythrocytosis, somatic, 133100 (3),Leukemia, acute myeloid, somatic, 601626 (3),Myelofibrosis, somatic, 254450 (3),Polycythemia vera, somatic, 263300 (3),Thrombocythemia 3, 614521 (3);JAK2, THCYT3;147796;-, AD, Smu;9p24.1
JAK3;SCID, autosomal recessive, T-negative/B-positive type, 600802 (3);JAK3, JAKL;600173;AR;19p13.11
JAM3;Hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 (3);JAM3;606871;AR;11q25
JBS;Jacobsen syndrome (4);JBS;147791;IC ;11q23
JOAG2;Glaucoma, primary open angle, juvenile-onset, 2 (2);JOAG2;608695;-;9q22
JPH1;?Charcot-Marie-Tooth disease, axonal, autosomal dominant, type 2K, 607831 (3);JPH1, JP1, CMT2K;605266;AD, AR;8q21.11
JPH2;Cardiomyopathy, hypertrophic, 17, 613873 (3);JPH2, JP2, CMH17;605267;AD;20q13.12
JPH3;Huntington disease-like 2, 606438 (3);JPH3, JP3, HDL2;605268;AD;16q24.2
JUP;Arrhythmogenic right ventricular dysplasia 12, 611528 (3),Naxos disease, 601214 (3);JUP, DP3, PDGB, ARVD12;173325;AD, AR;17q21.2
KAL1;Hypogonadotropic hypogonadism 1 with or without anosmia (Kallmann syndrome 1), 308700 (3);KAL1, KMS, ADMLX, HH1;300836;XL;Xp22.31
KANK1;Cerebral palsy, spastic quadriplegic, 2, 612900 (3);KANK1, KANK, ANKRD15, KIAA0172, CPSQ2;607704;-;9p24.3
KANK2;Palmoplantar keratoderma and woolly hair, 616099 (3);KANK2, ANKRD25, KIAA1518, PPKWH;614610;AR;19p13.2
KANSL1;Koolen-De Vries syndrome, 610443 (3);KANSL1, KIAA1267, MSL1V1, KDVS;612452;AD;17q21.31
KAOGS;Kagami-Ogata syndrome (4);KAOGS;608149;IC;14q32
KARS;?Charcot-Marie-Tooth disease, recessive intermediate, B, 613641 (3),Deafness, autosomal recessive 89, 613916 (3);KARS, CMTRIB, DFNB89;601421;AR;16q23.1
KAT6A;Mental retardation, autosomal dominant 32, 616268 (3);KAT6A, MYST3, MOZ, ZNF220, MRD32;601408;AD;8p11.21
KAT6B;Genitopatellar syndrome, 606170 (3),SBBYSS syndrome, 603736 (3);KAT6B, MYST4, MORF, GTPTS;605880;AD;10q22.2
KATNB1;Lissencephaly 6, with microcephaly, 616212 (3);KATNB1, LIS6;602703;AR;16q21
KATNIP;?Joubert syndrome 26, 616784 (3);KATNIP, KIAA0556;616650;AR;16p12.1
KBTBD13;Nemaline myopathy 6, autosomal dominant, 609273 (3);KBTBD13, NEM6;613727;AD;15q22.31
KCNA1;Episodic ataxia/myokymia syndrome, 160120 (3);KCNA1, AEMK, EA1;176260;AD;12p13.32
KCNA2;Epileptic encephalopathy, early infantile, 32, 616366 (3);KCNA2, EIEE32;176262;AD;1p13.3
KCNA5;Atrial fibrillation, familial, 7, 612240 (3);KCNA5, ATFB7;176267;AD;12p13.32
KCNB1;Epileptic encephalopathy, early infantile, 26, 616056 (3);KCNB1, EIEE26;600397;AD;20q13.13
KCNC1;Epilepsy, progressive myoclonic 7, 616187 (3);KCNC1, EPM7;176258;AD;11p15.1
KCNC3;Spinocerebellar ataxia 13, 605259 (3);KCNC3, SCA13;176264;AD;19q13.33
KCND3;Brugada syndrome 9, 616399 (3),Spinocerebellar ataxia 19, 607346 (3);KCND3, KCND3S, KCND3L, SCA19, SCA22, BRGDA9;605411;AD;1p13.2
KCNE1;Jervell and Lange-Nielsen syndrome 2, 612347 (3),Long QT syndrome 5, 613695 (3);KCNE1, JLNS, LQT5, JLNS2;176261;AR, AD;21q22.12
KCNE2;Atrial fibrillation, familial, 4, 611493 (3),Long QT syndrome 6, 613693 (3);KCNE2, MIRP1, LQT6, ATFB4;603796;-, AD;21q22.11
KCNE3;Brugada syndrome 6, 613119 (3);KCNE3, HOKPP, HYPP;604433;-;11q13.4
KCNH1;Temple-Baraitser syndrome, 611816 (3),Zimmermann-Laband syndrome 1, 135500 (3);KCNH1, EAG, TMBTS, ZLS1;603305;AD;1q32.2
KCNH2;Long QT syndrome 2, 613688 (3),Short QT syndrome 1, 609620 (3);KCNH2, LQT2, HERG, SQT1;152427;AD, -;7q36.1
KCNJ1;Bartter syndrome, type 2, 241200 (3);KCNJ1, ROMK1;600359;AR;11q24.3
KCNJ10;Enlarged vestibular aqueduct, digenic, 600791 (3),SESAME syndrome, 612780 (3);KCNJ10, SESAME;602208;AR;1q23.2
KCNJ11;Diabetes mellitus, permanent neonatal, with neurologic features, 606176 (3),Diabetes mellitus, transient neonatal, 3, 610582 (3),Diabetes, permanent neonatal, 606176 (3),Hyperinsulinemic hypoglycemia, familial, 2, 601820 (3),Maturity-onset diabetes of the young, type 13, 616329 (3);KCNJ11, BIR, PHHI, HHF2, TNDM3, MODY13;600937;AD, AR, -;11p15.1
KCNJ13;Leber congenital amaurosis 16, 614186 (3),Snowflake vitreoretinal degeneration, 193230 (3);KCNJ13, SVD, LCA16;603208;AR, AD;2q37.1
KCNJ2;Andersen syndrome, 170390 (3),Atrial fibrillation, familial, 9, 613980 (3),Short QT syndrome 3, 609622 (3);KCNJ2, HHIRK1, KIR2.1, IRK1, LQT7, SQT3, ATFB9;600681;AD, -;17q24.3
KCNJ5;Hyperaldosteronism, familial, type III, 613677 (3),Long QT syndrome 13, 613485 (3);KCNJ5, GIRK4, KATP1, LQT13;600734;AD;11q24.3
KCNJ6;Keppen-Lubinsky syndrome, 614098 (3);KCNJ6, GIRK2, KCNJ7, KPLBS;600877;AD;21q22.13
KCNK3;Pulmonary hypertension, primary, 4, 615344 (3);KCNK3, TASK, PPH4;603220;AD;2p23.3
KCNK9;Birk-Barel mental retardation dysmorphism syndrome, 612292 (3);KCNK9, TASK3;605874;-;8q24.3
KCNMA1;Generalized epilepsy and paroxysmal dyskinesia, 609446 (3);KCNMA1, SLO;600150;AD;10q22.3
KCNN4;Dehydrated hereditary stomatocytosis 2, 616689 (3);KCNN4, KCA4, SK4, DHS2;602754;AD;19q13.31
KCNQ1;Atrial fibrillation, familial, 3, 607554 (3),Jervell and Lange-Nielsen syndrome, 220400 (3),Long QT syndrome 1, 192500 (3),Short QT syndrome 2, 609621 (3);KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2;607542;AD, AR;11p15.5-p15.4
KCNQ1OT1;Beckwith-Wiedemann syndrome, 130650 (3);KCNQ1OT1, LIT1;604115;AD;11p15.5
KCNQ2;Epileptic encephalopathy, early infantile, 7, 613720 (3),Myokymia, 121200 (3),Seizures, benign neonatal, 1, 121200 (3);KCNQ2, EBN1, EIEE7, BFNS1;602235;AD;20q13.33
KCNQ3;Seizures, benign neonatal, type 2, 121201 (3);KCNQ3, EBN2, BFNC2;602232;AD;8q24.22
KCNQ4;Deafness, autosomal dominant 2A, 600101 (3);KCNQ4, DFNA2A;603537;AD;1p34.2
KCNT1;Epilepsy, nocturnal frontal lobe, 5, 615005 (3),Epileptic encephalopathy, early infantile, 14, 614959 (3);KCNT1, KIAA1422, EIEE14, ENFL5;608167;AD;9q34.3
KCNV2;Retinal cone dystrophy 3B, 610356 (3);KCNV2, KV11.1, RCD3B;607604;AR;9p24.2
KCTD1;Scalp-ear-nipple syndrome, 181270 (3);KCTD1, SENS;613420;AD;18q11.2
KCTD17;Dystonia 26, myoclonic, 616398 (3);KCTD17;616386;AD;22q12.3
KCTD7;Epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726 (3);KCTD7, EPM3, CLN14;611725;AR;7q11.21
KDM1A;Cleft palate, psychomotor retardation, and distinctive facial features, 616728 (3);KDM1A, LSD1, AOF2, BHC110, KIAA0601, CPRF;609132;AD;1p36.12
KDM5C;Mental retardation, X-linked, syndromic, Claes-Jensen type, 300534 (3);KDM5C, JARID1C, SMCX, DXS1272E, XE169, MRXSCJ;314690;XLR;Xp11.22
KDM6A;Kabuki syndrome 2, 300867 (3);KDM6A, UTX, KABUK2;300128;XLD;Xp11.3
KDR;Hemangioma, capillary infantile, somatic, 602089 (3);KDR;191306;-, AD;4q12
KERA;Cornea plana congenita, recessive, 217300 (3);KERA, CNA2;603288;AR;12q21.33
KHDC3L;Hydatidiform mole, recurrent, 2, 614293 (3);KHDC3L, C6orf221, ECAT1, HYDM2;611687;AR;6q13
KIAA0196;Ritscher-Schinzel syndrome 1, 220210 (3),Spastic paraplegia 8, autosomal dominant, 603563 (3);KIAA0196, SPG8, RTSC1;610657;AR, AD;8q24.13
KIAA0442;Mental retardation, autosomal dominant 26, 615834 (3);KIAA0442, MRD26;607270;AD;7q11.22
KIAA0586;Joubert syndrome 23, 616490 (3),Short-rib thoracic dysplasia 14 with polydactyly, 616546 (3);KIAA0586, TALPID3, JBTS23, SRTD14;610178;AR;14q23.1
KIAA1033;?Mental retardation, autosomal recessive 43, 615817 (3);KIAA1033, SWIP, MRT43;615748;AR;12q23.3
KIAA1279;Goldberg-Shprintzen megacolon syndrome, 609460 (3);KIAA1279;609367;AR;10q22.1
KIAA2022;Mental retardation, X-linked 98, 300912 (3);KIAA2022, MRX98;300524;XLR;Xq13.3
KIF11;Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950 (3);KIF11, KNSL1, MCLMR;148760;AD;10q23.33
KIF14;?Meckel syndrome 12, 616258 (3);KIF14, KIAA0042, MKS12;611279;AR;1q32.1
KIF1A;Mental retardation, autosomal dominant 9, 614255 (3),Neuropathy, hereditary sensory, type IIC, 614213 (3),Spastic paraplegia 30, autosomal recessive, 610357 (3);KIF1A, ATSV, UNC104, SPG30, HSN2C, MRD9;601255;AD, AR;2q37.3
KIF1B;?Charcot-Marie-Tooth disease, type 2A1, 118210 (3),Pheochromocytoma, 171300 (3);KIF1B, CMT2A, CMT2A1, NBLST1;605995;AD, IC;1p36.22
KIF1C;Spastic ataxia 2, autosomal recessive, 611302 (3);KIF1C, LTXS1, KIAA0706, SPAX2;603060;AR;17p13.2
KIF21A;Fibrosis of extraocular muscles, congenital, 1, 135700 (3),Fibrosis of extraocular muscles, congenital, 3B, 135700 (3);KIF21A, KIAA1708, FEOM1, CFEOM1, CFEOM3B;608283;AD;12q12
KIF22;Spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 (3);KIF22, KNSL4, KID, OBP, SEMDJL2;603213;AD;16p11.2
KIF2A;Cortical dysplasia, complex, with other brain malformations 3, 615411 (3);KIF2A, CDCBM3;602591;AD;5q12.1
KIF4A;?Mental retardation, X-linked 100, 300923 (3);KIF4A, KIF4, MRX100;300521;XLR;Xq13.1
KIF5A;Spastic paraplegia 10, autosomal dominant, 604187 (3);KIF5A, NKHC, SPG10;602821;AD;12q13.3
KIF5C;Cortical dysplasia, complex, with other brain malformations 2, 615282 (3);KIF5C, NKHC2, CDCBM2;604593;AD;2q23.1-q23.2
KIF7;?Al-Gazali-Bakalinova syndrome, 607131 (3),?Hydrolethalus syndrome 2, 614120 (3),Acrocallosal syndrome, 200990 (3),Joubert syndrome 12, 200990 (3);KIF7, HLS2, ACLS, JBTS12, AGBK;611254;AR;15q26.1
KIND1;Kindler syndrome, 173650 (3);KIND1, URP1, C20orf42;607900;AR;20p12.3
KIND3;Leukocyte adhesion deficiency, type III, 612840 (3);KIND3, URP2, MIG2B, FERMT3;607901;AR;11q13.1
KIRREL3;Mental retardation, autosomal dominant 4, 612581 (3);KIRREL3, NEPH2, KIAA1867, KIRRE, MRD4;607761;-;11q24.2
KISS1;?Hypogonadotropic hypogonadism 13 with or without anosmia, 614842 (3);KISS1, HH13;603286;AR;1q32.1
KISS1R;?Precocious puberty, central, 1, 176400 (3),Hypogonadotropic hypogonadism 8 with or without anosmia, 614837 (3);KISS1R, GPR54, HH8, CPPB1;604161;AR, AD;19p13.3
KIT;Gastrointestinal stromal tumor, familial, 606764 (3),Germ cell tumors, 273300 (3),Leukemia, acute myeloid, 601626 (3),Mast cell disease, 154800 (3),Piebaldism, 172800 (3);KIT, PBT;164920;IC, AD, SMu;4q12
KITLG;Deafness, autosomal dominant 69, unilateral or asymmetric, 616697 (3),Hyperpigmentation with or without hypopigmentation, 145250 (3);KITLG, MGF, SF, SCF, SHEP7, FPHH, DCUA, DFNA69;184745;AD, -;12q21.32
KIZ;Retinitis pigmentosa 69, 615780 (3);KIZ, KIZUNA, C20orf19, RP69;615757;AR;20p11.23
KL;Tumoral calcinosis, hyperphosphatemic, 211900 (3);KL, KLOTHO;604824;AR, -;13q13.1
KLC2;Spastic paraplegia, optic atrophy, and neuropathy, 609541 (3);KLC2, SPOAN;611729;AR;11q13.2
KLF1;Blood group--Lutheran inhibitor, 111150 (3),Dyserythropoietic anemia, congenital, type IV, 613673 (3);KLF1, EKLF, INLU, HBFQTL6, CDAN4;600599;-, AD;19p13.13
KLF11;Maturity-onset diabetes of the young, type VII, 610508 (3);KLF11, TIEG2, FKLF1, FKLF, MODY7;603301;-;2p25.1
KLF6;Gastric cancer, somatic, 613659 (3),Prostate cancer, somatic, 176807 (3);KLF6, COPEB, BCD1, ZF9;602053;-;10p15.2
KLHL10;Spermatogenic failure 11, 615081 (3);KLHL10, SPGF11;608778;AD;17q21.2
KLHL3;Pseudohypoaldosteronism, type IID, 614495 (3);KLHL3, PHA2D;605775;AR, AD;5q31.2
KLHL40;Nemaline myopathy 8, autosomal recessive, 615348 (3);KLHL40, SYRP, KBTBD5, NEM8;615340;-;3p22.1
KLHL41;Nemaline myopathy 9, 615731 (3);KLHL41, KBTBD10, SARCOSIN, NEM9;607701;AR;2q31.1
KLHL7;Retinitis pigmentosa 42, 612943 (3);KLHL7, RP42;611119;-, AD;7p15.3
KLK4;Amelogenesis imperfecta, type IIA1, 204700 (3);KLK4, EMSP1, PRSS17, AI2A1;603767;AR;19q13.41
KLKB1;Fletcher factor (prekallikrein) deficiency, 612423 (3);KLKB1, KLK3, PKKD;229000;AR;4q35.2
KLLN;Cowden syndrome 4, 615107 (3);KLLN, CWS4;612105;-;10q23.31
KMT2A;Leukemia, myeloid/lymphoid or mixed-lineage (2),Wiedemann-Steiner syndrome, 605130 (3);KMT2A, MLL, HRX, HTRX1, WDSTS;159555;AD;11q23.3
KMT2D;Kabuki syndrome 1, 147920 (3);KMT2D, MLL2, ALR, KABUK1;602113;AD;12q13.12
KONDS;Kondoh syndrome (2);KONDS;606242;AR;1p36.32-p35.3
KPTN;Mental retardation, autosomal recessive 41, 615637 (3);KPTN, 2E4, MRT41;615620;AR;19q13.32
KRAS;Bladder cancer, somatic, 109800 (3),Breast cancer, somatic, 114480 (3),Cardiofaciocutaneous syndrome 2, 615278 (3),Gastric cancer, somatic, 137215 (3),Leukemia, acute myeloid, 601626 (3),Lung cancer, somatic, 211980 (3),Noonan syndrome 3, 609942 (3),Pancreatic carcinoma, somatic, 260350 (3),RAS-associated autoimmune leukoproliferative disorder, 614470 (3),Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3);KRAS, KRAS2, RASK2, NS, CFC2, RALD;190070;-, AD;12p12.1
KRT1;Epidermolytic hyperkeratosis, 113800 (3),Ichthyosis histrix, Curth-Macklin type, 146590 (3),Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3),Keratosis palmoplantaris striata III, 607654 (3),Palmoplantar keratoderma, epidermolytic, 144200 (3),Palmoplantar keratoderma, nonepidermolytic, 600962 (3);KRT1, EPPK, NEPPK, EHK;139350;AD, -;12q13.13
KRT10;Epidermolytic hyperkeratosis, 113800 (3),Ichthyosis with confetti, 609165 (3),Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3);KRT10, EHK, BCIE, BIE;148080;AD;17q21.2
KRT12;Meesmann corneal dystrophy, 122100 (3);KRT12;601687;AD;17q21.2
KRT13;White sponge nevus 2, 615785 (3);KRT13, WSN2;148065;AD;17q21.2
KRT14;Dermatopathia pigmentosa reticularis, 125595 (3),Epidermolysis bullosa simplex, Dowling-Meara type, 131760 (3),Epidermolysis bullosa simplex, Koebner type, 131900 (3),Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 (3),Epidermolysis bullosa simplex, recessive 1, 601001 (3),Naegeli-Franceschetti-Jadassohn syndrome, 161000 (3);KRT14;148066;AD;17q21.2
KRT16;Pachyonychia congenita 1, 167200 (3),Palmoplantar keratoderma, nonepidermolytic, focal, 613000 (3);KRT16, FNEPPK, PC1;148067;AD;17q21.2
KRT17;Pachyonychia congenita 2, 167210 (3),Steatocystoma multiplex, 184500 (3);KRT17, PC2, PCHC1;148069;AD;17q21.2
KRT18;Cirrhosis, cryptogenic, 215600 (3);KRT18;148070;AR;12q13.13
KRT2;Ichthyosis bullosa of Siemens, 146800 (3);KRT2, KRT2A, KRT2E;600194;AD;12q13.13
KRT25;Woolly hair, autosomal recessive 3, 616760 (3);KRT25, K25, KRT24IRS1, ARWH3;616646;AR;17q21.2
KRT3;Meesmann corneal dystrophy, 122100 (3);KRT3;148043;AD;12q13.13
KRT4;White sponge nevus 1, 193900 (3);KRT4, CYK4, WSN1;123940;AD;12q13.13
KRT5;Dowling-Degos disease 1, 179850 (3),Epidermolysis bullosa simplex, Dowling-Meara type, 131760 (3),Epidermolysis bullosa simplex, Koebner type, 131900 (3),Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 (3),Epidermolysis bullosa simplex, recessive 1, 601001 (3),Epidermolysis bullosa simplex-MP, 131960 (3),Epidermylysis bullosa simplex-MCR, 609352 (3);KRT5, DDD1;148040;AD, AR;12q13.13
KRT6A;Pachyonychia congenita 3, 615726 (3);KRT6A, PC3;148041;-;12q13.13
KRT6B;Pachyonychia congenita 4, 615728 (3);KRT6B, PC4;148042;-;12q13.13
KRT6C;Palmoplantar keratoderma, nonepidermolytic, focal or diffuse, 615735 (3);KRT6C, PPKNEFD;612315;AD;12q13.13
KRT71;?Hypotrichosis 13, 615896 (3);KRT71, K6IRS1, KRT6IRS1, HYPT13;608245;AD;12q13.13
KRT74;?Ectodermal dysplasia 7, hair/nail type, 614929 (3),?Hypotrichosis 3, 613981 (3),Woolly hair, autosomal dominant, 194300 (3);KRT74, K6IRS4, KRT6IRS4, HTSS2, HYPT3, ADWH;608248;AR, AD;12q13.13
KRT8;Cirrhosis, cryptogenic, 215600 (3);KRT8;148060;AR;12q13.13
KRT81;Monilethrix, 158000 (3);KRT81, KRTHB1, HB1;602153;AD;12q13.13
KRT83;?Monilethrix, 158000 (3);KRT83, KRTHB3, HB3;602765;AD;12q13.13
KRT85;Ectodermal dysplasia 4, hair/nail type, 602032 (3);KRT85, KRTHB5, HB5, ECTD4;602767;AR;12q13.13
KRT86;Monilethrix, 158000 (3);KRT86, KRTHB6, HB6;601928;AD;12q13.13
KRT9;Palmoplantar keratoderma, epidermolytic, 144200 (3);KRT9, EPPK;607606;AD;17q21.2
KTCN2;Keratoconus 2 (2);KTCN2;608932;-;16q22.3-q23.1
KTCN3;Keratoconus 3 (2);KTCN3;608586;-;3p14-q13
KTCN4;Keratoconus 4 (2);KTCN4;609271;-;2p24
KTCN5;Keratoconus 5 (2);KTCN5;614622;AD;5q14.1-q21.3
KTCN6;Keratoconus 6 (2);KTCN6;614623;AD;9q34
KTCN7;Keratoconus 7 (2);KTCN7;614629;AD;13q32
KTCN8;Keratoconus 8 (2);KTCN8;614628;AD;14q24.3
KTU;Ciliary dyskinesia, primary, 10, 612518 (3);KTU, C14orf104, CILD10;612517;-;14q21.3
KTWS;Klippel-Trenaunay-Weber syndrome (2);KTWS, KTS;149000;IC;8q22.3
KWE;Keratolytic winter erythema (2);KWE;148370;AD;8p23-p22
KYNU;?Hydroxykynureninuria, 236800 (3);KYNU, KYNUU;605197;AR;2q22.2
KYPSC1;Kyphoscoliosis 1 (2);KYPSC1;610170;-;5p13
L1CAM;CRASH syndrome, 303350 (3),Corpus callosum, partial agenesis of, 304100 (3),Hydrocephalus due to aqueductal stenosis, 307000 (3),Hydrocephalus with Hirschsprung disease, 307000 (3),Hydrocephalus with congenital idiopathic intestinal pseudoobstruction, 307000 (3),MASA syndrome, 303350 (3);L1CAM, CAML1, HSAS1, MASA, SPG1;308840;XL, XLR;Xq28
L2HGDH;L-2-hydroxyglutaric aciduria, 236792 (3);L2HGDH, C14orf160, L2HGA;609584;AR;14q21.3
LAG5;Neutropenia, neonatal alloimmune (1);LAG5;151450;-;Chr.4
LALL;Leukemia, acute lymphoblastic (2);LALL;247640;AR;9p22-p21
LAMA1;Poretti-Boltshauser syndrome, 615960 (3);LAMA1, PTBHS;150320;AR;18p11.31
LAMA2;Muscular dystrophy, congenital merosin-deficient, 607855 (3),Muscular dystrophy, congenital, due to partial LAMA2 deficiency, 607855 (3);LAMA2, LAMM;156225;AR;6q22.33
LAMA3;Epidermolysis bullosa, generalized atrophic benign, 226650 (3),Epidermolysis bullosa, junctional, Herlitz type, 226700 (3),Laryngoonychocutaneous syndrome, 245660 (3);LAMA3, LOCS;600805;AR;18q11.2
LAMA4;Cardiomyopathy, dilated, 1JJ, 615235 (3);LAMA4, LAMA3, CMD1JJ;600133;AD;6q21
LAMB1;Lissencephaly 5, 615191 (3);LAMB1, LIS5;150240;AR;7q31.1
LAMB2;Nephrotic syndrome, type 5, with or without ocular abnormalities, 614199 (3),Pierson syndrome, 609049 (3);LAMB2, LAMS, NPHS5;150325;-, AR;3p21.31
LAMB3;Amelogenesis imperfecta, type IA, 104530 (3),Epidermolysis bullosa, junctional, Herlitz type, 226700 (3),Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3);LAMB3, AI1A;150310;AD, AR;1q32.2
LAMC2;Epidermolysis bullosa, junctional, Herlitz type, 226700 (3),Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3);LAMC2, LAMNB2, LAMB2T;150292;AR;1q25.3
LAMC3;Cortical malformations, occipital, 614115 (3);LAMC3, OCCM;604349;AR;9q34.12
LAMP2;Danon disease, 300257 (3);LAMP2, LAMPB, LGP110;309060;XLD;Xq24
LAMTOR2;Immunodeficiency due to defect in MAPBP-interacting protein, 610798 (3);LAMTOR2, MAPBPIP, p14;610389;AR;1q22
LAP;?Laryngeal adductor paralysis (2);LAP;150270;AD;6p21.3-p21.2
LARGE;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6, 613154 (3),Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 6, 608840 (3);LARGE, KIAA0609, MDC1D, MDDGA6, MDDGB6;603590;AR;22q12.3
LARP7;Alazami syndrome, 615071 (3);LARP7, PIP7S, ALAZS;612026;AR;4q25
LARS;?Infantile liver failure syndrome 1, 615438 (3);LARS, LFIS, ILFS1;151350;AR;5q32
LARS2;Perrault syndrome 4, 615300 (3);LARS2, PRLTS4;604544;AR;3p21.31
LBN;Ellis-van Creveld syndrome, 225500 (3),Weyers acrofacial dysostosis, 193530 (3);LBN, EVC2, WAD;607261;AR, AD;4p16.2
LBR;?Reynolds syndrome, 613471 (3),Greenberg skeletal dysplasia, 215140 (3),Pelger-Huet anomaly, 169400 (3);LBR, PHA;600024;AR, AD;1q42.12
LCA5;Leber congenital amaurosis 5, 604537 (3);LCA5, C6orf152;611408;-;6q14.1
LCAT;Fish-eye disease, 136120 (3),Norum disease, 245900 (3);LCAT;606967;AR;16q22.1
LCK;?Immunodeficiency 22, 615758 (3);LCK, IMD22;153390;AR;1p35.2
LCO;?Hepatocellular carcinoma (1);LCO;165320;-;2q14-q21
LCRB;Thalassemia, Hispanic gamma-delta-beta, 613985 (3);LCRB;152424;-;11p15.4
LCS1;Cholestasis-lymphedema syndrome (2);LCS1, CHLS;214900;AR;15q
LCT;Lactase deficiency, congenital, 223000 (3);LCT, LAC, LPH;603202;AR;2q21.3
LDB3;Cardiomyopathy, dilated, 1C, with or without LVNC, 601493 (3),Cardiomyopathy, hypertrophic, 24, 601493 (3),Left ventricular noncompaction 3, 601493 (3),Myopathy, myofibrillar, 4, 609452 (3);LDB3, ZASP, CYPHER, KIAA01613, MFM4, CMD1C, CMH24, LVNC3;605906;AD;10q23.2
LDHA;Glycogen storage disease XI, 612933 (3);LDHA, LDH1, GSD11;150000;AR;11p15.1
LDLR;Hypercholesterolemia, familial, 143890 (3),LDL cholesterol level QTL2, 143890 (3);LDLR, FHC, FH, LDLCQ2;606945;AD;19p13.2
LDLRAP1;Hypercholesterolemia, familial, autosomal recessive, 603813 (3);LDLRAP1, ARH, FHCB2, FHCB1;605747;-;1p36.11
LECD;Corneal dystrophy, Lisch epithelial (2);LECD;300778;XLD;Xp22.3
LEF1;Sebaceous tumors, somatic (3);LEF1;153245;-;4q25
LEMD2;Cataract 46, juvenile-onset, 212500 (3);LEMD2, NET25, CTRCT42;616312;AR;6p21.31
LEMD3;Buschke-Ollendorff syndrome, 166700 (3),Melorheostosis with osteopoikilosis, 155950 (3),Osteopoikilosis, 166700 (3);LEMD3, MAN1;607844;-;12q14.3
LEP;Obesity, morbid, due to leptin deficiency, 614962 (3);LEP, OB, LEPD;164160;AR;7q32.1
LEPR;Obesity, morbid, due to leptin receptor deficiency, 614963 (3);LEPR, OBR, LEPRD;601007;-;1p31.3
LFNG;?Spondylocostal dysostosis 3, autosomal recessive, 609813 (3);LFNG, SCDO3;602576;-;7p22.3
LFS3;Li-Fraumeni syndrome 3 (2);LFS3;609266;-;1q23
LGI1;Epilepsy, familial temporal lobe, 1, 600512 (3);LGI1, EPT, ETL1, ADLTE, ADPEAF;604619;AD;10q23.33
LGMD1H;Muscular dystrophy, limb-girdle, type 1H (2);LGMD1H;613530;AD;3p25.1-p23
LHB;Hypogonadotropic hypogonadism 23 with or without anosmia, 228300 (3);LHB, HH23;152780;AR;19q13.33
LHCGR;Leydig cell adenoma, somatic, with precocious puberty, 176410 (3),Leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3),Leydig cell hypoplasia with pseudohermaphroditism, 238320 (3),Luteinizing hormone resistance, female, 238320 (3),Precocious puberty, male, 176410 (3);LHCGR, LHR, LCGR;152790;-, AR, AD;2p16.3
LHFPL5;Deafness, autosomal recessive 67, 610265 (3);LHFPL5, TMHS, DFNB67;609427;AR;6p21.31
LHX3;Pituitary hormone deficiency, combined, 3, 221750 (3);LHX3, CPHD3;600577;AR;9q34.3
LHX4;Pituitary hormone deficiency, combined, 4, 262700 (3);LHX4, CPHD4;602146;AD;1q25.2
LIAS;Hyperglycinemia, lactic acidosis, and seizures, 614462 (3);LIAS, PDHLD, HGCLAS;607031;AR;4p14
LIFR;Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome, 601559 (3);LIFR, STWS, SWS, SJS2;151443;AR;5p13.1
LIG1;DNA ligase I deficiency (3);LIG1;126391;-;19q13.33
LIG4;LIG4 syndrome, 606593 (3);LIG4, LIG4S;601837;-;13q33.3
LIM2;Cataract 19, multiple types, 615277 (3);LIM2, MP19, CTRCT19;154045;AR;19q13.41
LIMS2;Muscular dystrophy, limb-girdle, type 2W, 616827 (3);LIMS2, PINCH2, LGMD2W;607908;AR;2q14.3
LINS1;Mental retardation, autosomal recessive 27, 614340 (3);LINS1, WINS1, FLJ10583, MRT27;610350;AR;15q26.3
LIPA;Cholesteryl ester storage disease, 278000 (3),Wolman disease, 278000 (3);LIPA, CESD;613497;AR;10q23.31
LIPC;Hepatic lipase deficiency, 614025 (3);LIPC, HL, LIPH, HDLCQ12;151670;AR, -, AD;15q21.3
LIPE;Lipodystrophy, familial partial, type 6, 615980 (3);LIPE, LHS, FPLD6;151750;AR;19q13.2
LIPH;Hypotrichosis 7, 604379 (3),Woolly hair, autosomal recessive 2 with or without hypotrichosis, 604379 (3);LIPH, LAH2, ARWH2, HYPT7;607365;AR;3q27.2
LIPN;Ichthyosis, congenital, autosomal recessive 8, 613943 (3);LIPN, LIPL4, ARCI8, LI4;613924;AR;10q23.31
LIPT1;Lipoyltransferase 1 deficiency, 616299 (3);LIPT1, LIPT1D;610284;AR;2q11.2
LITAF;Charcot-Marie-Tooth disease, type 1C, 601098 (3);LITAF, CMT1C;603795;AD;16p13.13
LKMCD;Leukoencephalopathy with metaphyseal chondrodysplasia (2);LKMCD;300660;XLR;Xq25-q27
LMAN1;Combined factor V and VIII deficiency, 227300 (3);LMAN1, ERGIC53, F5F8D, MCFD1;601567;AR;18q21.32
LMAN2L;?Mental retardation, autosomal recessive, 52, 616887 (3);LMAN2L, VIPL, MRT52;609552;AR;2q11.2
LMBR1;Acheiropody, 200500 (3),Hypoplastic or aplastic tibia with polydactyly, 188740 (3),Laurin-Sandrow syndrome, 135750 (3),Polydactyly, preaxial type II, 174500 (3),Syndactyly, type IV, 186200 (3),Triphalangeal thumb, type I, 174500 (3),Triphalangeal thumb-polysyndactyly syndrome, 174500 (3);LMBR1, ACHP, C7orf2, PPD2, THYP, LSS;605522;AR, AD;7q36.3
LMBRD1;Methylmalonic aciduria and homocystinuria, cblF type, 277380 (3);LMBRD1, LMBD1, NESI, MAHCF;612625;AR;6q13
LMF1;Lipase deficiency, combined, 246650 (3);LMF1, TMEM112;611761;AR;16p13.3
LMNA;Cardiomyopathy, dilated, 1A, 115200 (3),Charcot-Marie-Tooth disease, type 2B1, 605588 (3),Emery-Dreifuss muscular dystrophy 2, AD, 181350 (3),Emery-Dreifuss muscular dystrophy 3, AR, 616516 (3),Heart-hand syndrome, Slovenian type, 610140 (3),Hutchinson-Gilford progeria, 176670 (3),Lipodystrophy, familial partial, type 2, 151660 (3),Malouf syndrome, 212112 (3),Mandibuloacral dysplasia, 248370 (3),Muscular dystrophy, congenital, 613205 (3),Muscular dystrophy, limb-girdle, type 1B, 159001 (3),Restrictive dermopathy, lethal, 275210 (3);LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS, LGMD1B;150330;AR, AD;1q22
LMNB1;Leukodystrophy, adult-onset, autosomal dominant, 169500 (3);LMNB1, ADLD;150340;AD;5q23.2
LMNB2;?Epilepsy, progressive myoclonic, 9, 616540 (3);LMNB2, LMN2, EPM9;150341;AR;19p13.3
LMO1;Leukemia, T-cell acute lymphoblastic (2);LMO1, RBTN1, RHOM1;186921;AD;11p15.4
LMO2;Leukemia, acute T-cell (2);LMO2, RBTNL1, RHOM2, TTG2;180385;AD;11p13
LMOD3;Nemaline myopathy 10, 616165 (3);LMOD3, NEM10;616112;AR;3p14.1
LMPH1B;Lymphedema, hereditary, IB (2);LMPH1B;611944;AD;6q16.2-q22.1
LMX1B;Nail-patella syndrome, 161200 (3);LMX1B, NPS1;602575;AD;9q33.3
LONP1;CODAS syndrome, 600373 (3);LONP1, PRSS15, LON, CODASS;605490;AR;19p13.3
LOR;Vohwinkel syndrome with ichthyosis, 604117 (3);LOR;152445;AD;1q21.3
LOXHD1;Deafness, autosomal recessive 77, 613079 (3);LOXHD1, DFNB77;613072;AR;18q21.1
LPAR6;Hypotrichosis 8, 278150 (3),Woolly hair, autosomal recessive 1, with or without hypotrichosis, 278150 (3);LPAR6, P2RY5, P2Y5, LAH3, ARWH1, HYPT8;609239;AR;13q14.2
LPIN1;Myoglobinuria, acute recurrent, autosomal recessive, 268200 (3);LPIN1;605518;AR;2p25.1
LPIN2;Majeed syndrome, 609628 (3);LPIN2;605519;-;18p11.31
LPL;Combined hyperlipidemia, familial, 144250 (3),Lipoprotein lipase deficiency, 238600 (3);LPL, LIPD, HDLCQ11;609708;AD, AR, -;8p21.3
LPP;Leukemia, acute myeloid, 601626 (3),Lipoma (3);LPP;600700;AD, -;3q27-q28
LPSA;Liposarcoma (1);LPSA, D19S381E;164953;-;19p13.2-q13.3
LRAT;Leber congenital amaurosis 14, 613341 (3),Retinal dystrophy, early-onset severe, 613341 (3),Retinitis pigmentosa, juvenile, 613341 (3);LRAT, LCA14;604863;AR;4q32.1
LRBA;Immunodeficiency, common variable, 8, with autoimmunity, 614700 (3);LRBA, LBA, CDC4L, CVID8;606453;AR;4q31.3
LRIG2;Urofacial syndrome 2, 615112 (3);LRIG2, LIG2, KIAA0806, UFS2;608869;AR;1p13.2
LRIT3;Night blindness, congenital stationary (complete), 1F, autosomal recessive, 615058 (3);LRIT3, FIGLER4, CSNB1F;615004;AR;4q25
LRP2;Donnai-Barrow syndrome, 222448 (3);LRP2, DBS;600073;AR;2q31.1
LRP4;?Myasthenic syndrome, congenital, 17, 616304 (3),Cenani-Lenz syndactyly syndrome, 212780 (3),Sclerosteosis 2, 614305 (3);LRP4, MEGF7, CLSS, SOST2, CMS17;604270;AR, AD;11p11.2
LRP5;Exudative vitreoretinopathy 4, 601813 (3),Hyperostosis, endosteal, 144750 (3),Osteopetrosis, autosomal dominant 1, 607634 (3),Osteoporosis-pseudoglioma syndrome, 259770 (3),Osteosclerosis, 144750 (3);LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4;603506;AD, AR;11q13.2
LRP6;Tooth agenesis, selective, 7, 616724 (3);LRP6, ADCAD2, STHAG7;603507;AD;12p13.2
LRPAP1;Myopia 23, autosomal recessive, 615431 (3);LRPAP1, A2MRAP, MYP23;104225;AR;4p16.3
LRPPRC;Leigh syndrome, French-Canadian type, 220111 (3);LRPPRC, LRP130, LSFC;607544;AR;2p21
LRRC50;Ciliary dyskinesia, primary, 13, 613193 (3);LRRC50, ODA7, CILD13;613190;AR;16q24.1
LRRC6;Ciliary dyskinesia, primary, 19, 614935 (3);LRRC6, LRTP, CILD19;614930;AR;8q24.22
LRRC8A;?Agammaglobulinemia 5, 613506 (3);LRRC8A, KIAA1437, AGM5;608360;AD;9q34.11
LRSAM1;Charcot-Marie-Toothe disease, axonal, type 2P, 614436 (3);LRSAM1, TAL, RIFLE, CMT2P;610933;AR, AD;9q33.3-q34.1
LRSL;Larsen-like syndrome (2);LRSL;608545;IC;6p25
LRTOMT;Deafness, autosomal recessive 63, 611451 (3);LRTOMT, LRTOMT1, LRTOMT2, DFNB63;612414;AR;11q13.4
LSS;Cataract 44, 616509 (3);LSS, OSC, CTRCT44;600909;AR;21q22.3
LTBP2;Glaucoma 3, primary congenital, D, 613086 (3),Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 (3),Weill-Marchesani syndrome 3, recessive, 614819 (3);LTBP2, LTBP3, GLC3D, MSPKA, WMS3;602091;-, AR;14q24.3
LTBP3;Dental anomalies and short stature, 601216 (3);LTBP3, LTBP2, DASS;602090;AR;11q13.1
LTBP4;Cutis laxa, autosomal recessive, type IC, 613177 (3);LTBP4, LTBP4S, LTBP4L, ARCL1C;604710;AR;19q13.2
LTC4S;Leukotriene C4 synthase deficiency, 614037 (1);LTC4S;246530;AR;5q35.3
LVNC2;Left ventricular noncompaction 2 (2);LVNC2;609470;-;11p15
LVSKS;Levy-Shanske syndrome (4);LVSKS;614846;-;15q26-qter
LYL1;Leukemia, T-cell acute lymphoblastoid (2);LYL1;151440;-;19p13.13
LYRM4;?Combined oxidative phosphorylation deficiency 19, 615595 (3);LYRM4, ISD11, C6orf149, COXPD19;613311;AR;6p25.1
LYRM7;Mitochondrial complex III deficiency, nuclear type 8, 615838 (3);LYRM7, MZM1L, MC3DN8;615831;AR;5q23.3-q31.1
LYST;Chediak-Higashi syndrome, 214500 (3);LYST, CHS1;606897;AR;1q42.3
LYZ;Amyloidosis, renal, 105200 (3);LYZ;153450;AD;12q15
LZTFL1;Bardet-Biedl syndrome 17, 615994 (3);LZTFL1, BBS17;606568;AR;3p21.31
LZTR1;Noonan syndrome 10, 616564 (3);LZTR1, SWNTS2, NS10;600574;AD;22q11.21
LZTS1;Esophageal squamous cell carcinoma, 133239 (3);LZTS1, F37, FEZ1;606551;AD;8p21.3
MAB21L2;Microphthalmia, syndromic 14, 615877 (3);MAB21L2, MCOPS14;604357;AR, AD;4q31.3
MACST;Macrostomia (2);MACST;613545;-;1p34-p32
MAD1L1;Lymphoma, somatic (3),Prostate cancer, somatic, 176807 (3);MAD1L1, TXBP181;602686;-;7p22.3
MADH4;Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, 175050 (3),Myhre syndrome, 139210 (3),Pancreatic cancer, somatic, 260350 (3),Polyposis, juvenile intestinal, 174900 (3);MADH4, DPC4, SMAD4, JIP, MYHRS;600993;AD;18q21.2
MADH9;Pulmonary hypertension, primary, 2, 615342 (3);MADH9, SMAD9, MADH6, PPH2;603295;AD;13q13.3
MAF;Ayme-Gripp syndrome, 601088 (3),Cataract 21, multiple types, 610202 (3);MAF, CCA4, CTRCT21, AYGRP;177075;0,AD;16q23.2
MAFB;Multicentric carpotarsal osteolysis syndrome, 166300 (3);MAFB, KRML, MCTO;608968;AD;20q12
MAFD4;Major affective disorder 4 (2);MAFD4, BPAD;611247;-;16p12
MAG;Spastic paraplegia 75, autosomal recessive, 616680 (3);MAG, GMA, SPG75;159460;AR;19q13.12
MAGED2;Bartter syndrome, type 5, antenatal, transient, 300971 (3);MAGED2, MAGED, BARTS5;300470;XLR;Xp11.21
MAGEL2;Schaaf-Yang syndrome, 615547 (3);MAGEL2, NDNL1, SHFYNG;605283;AD;15q11.2
MAGT1;Immunodeficiency, X-linked, with magnesium defect, Epstein-Barr virus infection and neoplasia, 300853 (3);MAGT1, IAP, XMEN;300715;-;Xq21.1
MAK;Retinitis pigmentosa 62, 614181 (3);MAK, RP62;154235;AR;6p24.2
MALT1;Immunodeficiency 12, 615468 (3);MALT1, MLT, IMD12;604860;AR;18q21.32
MAML2;Mucoepidermoid salivary gland carcinoma (3);MAML2, MAM3;607537;-;11q21
MAMLD1;Hypospadias 2, X-linked, 300758 (3);MAMLD1, CXorf6, F18, HYSP2;300120;XLR;Xq28
MAN1B1;Mental retardation, autosomal recessive 15, 614202 (3);MAN1B1, MRT15;604346;AR;9q34.3
MAN2B1;Mannosidosis, alpha-, types I and II, 248500 (3);MAN2B1, MANB;609458;AR;19p13.13
MANBA;Mannosidosis, beta, 248510 (3);MANBA, MANB1;609489;AR;4q24
MAOA;Brunner syndrome, 300615 (3);MAOA;309850;XLR;Xp11.3
MAP2K1;Cardiofaciocutaneous syndrome 3, 615279 (3);MAP2K1, PRKMK1, MKK1, MEK1, CFC3;176872;-;15q22.31
MAP2K2;Cardiofaciocutaneous syndrome 4, 615280 (3);MAP2K2, PRKMK2, MEK2, MKK2, CFC4;601263;-;19p13.3
MAP3K1;46XY sex reversal 6, 613762 (3);MAP3K1, MEKK1, MEKK, SRXY6;600982;AD;5q11.2
MAP3K8;Lung cancer, somatic, 211980 (3);MAP3K8, COT, EST, TPL2;191195;-;10p11.23
MAPRE2;Symmetric circumferential skin creases, congenital, 2, 616734 (3);MAPRE2, EB2, RP1, CSCSC2;605789;AD;18q12.1-q12.2
MAPT;Dementia, frontotemporal, with or without parkinsonism, 600274 (3),Pick disease, 172700 (3),Supranuclear palsy, progressive atypical, 260540 (3),Supranuclear palsy, progressive, 601104 (3);MAPT, MTBT1, DDPAC, MSTD;157140;AD, IC, AR, Mu;17q21.31
MARS;Charcot-Marie-Tooth disease, axonal, type 2U, 616280 (3),Interstitial lung and liver disease, 615486 (3);MARS, MTRNS, METRS, ILLD, CMT2U;156560;AD, AR;12q13.3
MARS2;?Combined oxidative phosphorylation deficiency 25, 616430 (3),Spastic ataxia 3, autosomal recessive, 611390 (3);MARS2, SPAX3, COXPD25;609728;AR;2q33.1
MARVELD2;Deafness, autosomal recessive 49, 610153 (3);MARVELD2, MARVD2, TRIC, DFNB49;610572;AR;5q13.2
MASP1;3MC syndrome 1, 257920 (3);MASP1, CRARF, 3MC1;600521;AR;3q27.3
MASP2;MASP2 deficiency, 613791 (3);MASP2;605102;AR;1p36.22
MASTL;?Thrombocytopenia-2, 188000 (3);MASTL, FLJ14813, GWL, THC2;608221;AD;10p12.1
MAT1A;Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency, 250850 (3),Methionine adenosyltransferase deficiency, autosomal recessive, 250850 (3);MAT1A, MATA1, SAMS1;610550;AD, AR;10q22.3
MATN3;Epiphyseal dysplasia, multiple, 5, 607078 (3),Spondyloepimetaphyseal dysplasia, 608728 (3);MATN3, EDM5, HOA, OS2;602109;AD, AR;2p24.1
MATR3;Amyotrophic lateral sclerosis 21, 606070 (3);MATR3, MPD2, ALS21;164015;AD;5q31.2
MBD5;Mental retardation, autosomal dominant 1, 156200 (3);MBD5, KIAA1461, MRD1;611472;AD;2q23.1
MBS;?Moebius syndrome (2);MBS, MBS1;157900;IC, AD ;13q12.2-q13
MBTPS2;?Olmsted syndrome, X-linked, 300918 (3),IFAP syndrome with or without BRESHECK syndrome, 308205 (3),Keratosis follicularis spinulosa decalvans, X-linked, 308800 (3);MBTPS2, S2P, IFAP, KFSDX, OLMSX;300294;XLR;Xp22.12
MC2R;Glucocorticoid deficiency, due to ACTH unresponsiveness, 202200 (3);MC2R;607397;AR;18p11.21
MC4R;Obesity, autosomal dominant, 601665 (3);MC4R;155541;Mu, AD, AR;18q21.32
MCC;Colorectal cancer, somatic, 114500 (3);MCC;159350;-;5q22.2
MCCC1;3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200 (3);MCCC1, MCCA;609010;AR;3q27.1
MCCC2;3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210 (3);MCCC2, MCCB;609014;AR;5q13.2
MCDR3;Macular dystrophy, retinal, 3 (2);MCDR3;608850;AD;5p15.33-p13.1
MCEE;Methylmalonyl-CoA epimerase deficiency, 251120 (3);MCEE;608419;AR;2p13.3
MCFD2;Factor V and factor VIII, combined deficiency of, 613625 (3);MCFD2, F5F8D2;607788;-;2p21
MCM2;?Deafness, autosomal dominant 70, 616968 (3);MCM2, CDCL1, DFNA70;116945;AD;3q21.3
MCM4;Natural killer cell and glucocorticoid deficiency with DNA repair defect, 609981 (3);MCM4, NKGCD, NKCD;602638;AR;8q11.21
MCM6;Lactase persistence/nonpersistence, 223100 (3);MCM6;601806;AR;2q21.3
MCM8;?Premature ovarian failure 10, 612885 (3);MCM8, POF10;608187;AR;20p12.3
MCM9;Ovarian dysgenesis 4, 616185 (3);MCM9, MCMDC1, ODG4;610098;AR;6q22.31
MCOLN1;Mucolipidosis IV, 252650 (3);MCOLN1, ML4;605248;AR;19p13.2
MCOP1;Microphthalmia, isolated 1 (2);MCOP1;251600;AR;14q32
MCOPCB1;Microphthalmia with coloboma 1 (2);MCOPCB1;300345;-;Chr.X
MCOPCB2;Microphthalmia with coloboma 2 (2);MCOPCB2;605738;-;15q12-q15
MCOPCT1;Microphthalmia with cataract 1 (2);MCOPCT1;156850;AD;16p13.3
MCOPS4;?Microphthalmia, syndromic 4 (2);MCOPS4, ANOP1;301590;XL;Xq27-q28
MCOPS8;Microphthalmia, syndromic 8 (2);MCOPS8, MMEP;601349;?AD;6q21
MCOR;Microcoria, congenital (4);MCOR, C13DELq32, DEL13q32;156600;AD;13q32
MCPH1;Microcephaly 1, primary, autosomal recessive, 251200 (3);MCPH1;607117;AR;8p23.1
MCS;Miles-Carpenter syndrome (2);MCS, MRXS4;309605;XL;Xq13-q22
MDBS2;Macular dystrophy, butterfly-shaped pigmentary, 2 (2);MDBS2;608970;AD;5q21.3-q33.2
MDC1B;Muscular dystrophy, congenital, 1B (2);MDC1B;604801;AR;1q42
MDCMP;Muscular dystrophy, congenital, merosin-positive (2);MDCMP;609456;AR;4p16.3
MDD1;Major depressive disorder 1, 608516 (2);MDD1;608520;-;12q22-q23.2
MDD2;Major depressive disorder 2, 608516 (2);MDD2;608691;-;15q25.3-q26.2
MDDC;Macular dystrophy, dominant cystoid (2);MDDC;153880;AD;7p21-p15
MDLS;Miller-Dieker lissencephaly syndrome (4);MDLS, MDS, MDCR, DEL17p13.3, C17DELp13.3;247200;AD;17p13.3
MDNS;Mammary-digital-nail syndrome (2);MDNS;613689;AD;22q12.3-q13.1
MDRV;Muscular dystrophy with rimmed vacuoles (2);MDRV;601846;AD;19p13.3
MDS1;Myelodysplasia syndrome-1 (3);MDS1;600049;-;3q26
MECOM;Radioulnar synostosis with amegakaryocytic thrombocytopenia 2, 616738 (3);MECOM, EVI1, RUSAT2;165215;AD;3q26.2
MECP2;Encephalopathy, neonatal severe, 300673 (3),Mental retardation, X-linked syndromic, Lubs type, 300260 (3),Mental retardation, X-linked, syndromic 13, 300055 (3),Rett syndrome, 312750 (3),Rett syndrome, atypical, 312750 (3),Rett syndrome, preserved speech variant, 312750 (3);MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16;300005;XLR, XLD, XL, IC, Mu;Xq28
MED12;Lujan-Fryns syndrome, 309520 (3),Ohdo syndrome, X-linked, 300895 (3),Opitz-Kaveggia syndrome, 305450 (3);MED12, TNRC11, TRAP230, HOPA, KIAA0192, OKS, FGS1, OHDOX;300188;XLR;Xq13.1
MED13L;Mental retardation and distinctive facial features with or without cardiac defects, 616789 (3),Transposition of the great arteries, dextro-looped 1, 608808 (3);MED13L, THRAP2, PROSIT240, TRAP240L, KIAA1025, MRFACD;608771;AD;12q24.21
MED17;Microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3);MED17, CRSP6, CRSP77, TRAP80, DRIP80;603810;AR;11q21
MED23;Mental retardation, autosomal recessive 18, 614249 (3);MED23, MRT18;605042;-;6q23.2
MED25;?Charcot-Marie-Tooth disease, type 2B2, 605589 (3),Basel-Vanagait-Smirin-Yosef syndrome, 616449 (3);MED25, PTOV2, ARC92, CMT2B2, BVSYS;610197;AR;19q13.33
MEF2C;Chromosome 5q14.3 deletion syndrome, 613443 (4),Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations, 613443 (3);MEF2C, C5DELq14.3, DEL5q14.3;600662;AD;5q14.3
MEFV;Familial Mediterranean fever, AD, 134610 (3),Familial Mediterranean fever, AR, 249100 (3);MEFV, MEF, FMF;608107;AD, AR;16p13.3
MEGF10;Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, 614399 (3),Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, mild variant, 614399 (3);MEGF10, KIAA1780, EMARDD;612453;AR, AD;5q23.2
MEGF8;Carpenter syndrome 2, 614976 (3);MEGF8, EGFL4, CRPT2;604267;AR;19q13.2
MEHMO;MEHMO syndrome (2);MEHMO;300148;-;Xp22.13-p21.1
MEN1;Adrenal adenoma, somatic (3),Angiofibroma, somatic (3),Carcinoid tumor of lung (3),Lipoma, somatic (3),Multiple endocrine neoplasia 1, 131100 (3),Parathyroid adenoma, somatic (3);MEN1;613733;-, AD;11q13.1
MEOX1;Klippel-Feil syndrome 2, 214300 (3);MEOX1, MOX1, KFS2;600147;AR;17q21.31
MERTK;Retinitis pigmentosa 38, 613862 (3);MERTK, RP38;604705;AR;2q13
MESP2;Spondylocostal dysostosis 2, autosomal recessive, 608681 (3);MESP2, SCDO2;605195;-;15q26.1
MET;?Deafness, autosomal recessive 97, 616705 (3),Hepatocellular carcinoma, childhood type, somatic, 114550 (3),Renal cell carcinoma, papillary, 1, familial and somatic, 605074 (3);MET, DFNB97, OSFD;164860;AR,  -, AD;7q31.2
METTL23;Mental retardation, autosomal recessive 44, 615942 (3);METTL23, C17orf95, MRT44;615262;AR;17q25.1
MFAP5;Aortic aneurysm, familial thoracic 9, 616166 (3);MFAP5, MAGP2, AAT9;601103;AD;12p13.31
MFHAS1;Malignant fibrous histiocytoma (2);MFHAS1, MASL1;605352;-;8p23.1
MFN2;Charcot-Marie-Tooth disease, type 2A2, 609260 (3),Hereditary motor and sensory neuropathy VIA, 601152 (3);MFN2, KIAA0214, CMT2A2, HMSN6A;608507;AD, -;1p36.22
MFRP;Microphthalmia, isolated 5, 611040 (3),Nanophthalmos 2, 609549 (3);MFRP, MCOP5, NNO2;606227;AR, -;11q23.3
MFSD2A;Microcephaly 15, primary, autosomal recessive, 616486 (3);MFSD2A, MCPH15;614397;AR;1p34.2
MFSD8;Ceroid lipofuscinosis, neuronal, 7, 610951 (3),Macular dystrophy with central cone involvement, 616170 (3);MFSD8, MGC33302, CLN7, CCMD;611124;AR;4q28.2
MFT2;Trichoepithelioma, multiple familial, 2 (2);MFT2, TEM;612099;-;9p21
MGAT2;Congenital disorder of glycosylation, type IIa, 212066 (3);MGAT2, CDGS2, CDG2A;602616;AR;14q21.3
MGCT;Male germ cell tumor (2);MGCT;273300;SMu;12q22
MGME1;Mitochondrial DNA depletion syndrome 11, 615084 (3);MGME1, C20orf72, MTDPS11;615076;AR;20p11.23
MGP;Keutel syndrome, 245150 (3);MGP;154870;AR;12p12.3
MGS;Mungan syndrome (2);MGS;611376;AR;8q23-q24
MHC2TA;Bare lymphocyte syndrome, type II, complementation group A, 209920 (3);MHC2TA, C2TA;600005;AR, -;16p13.13
MIB1;Left ventricular noncompaction 7, 615092 (3);MIB1, MIB, DIP1, KIAA1323, LVNC7;608677;AD;18q11.2
MICU1;Myopathy with extrapyramidal signs, 615673 (3);MICU1, CBARA1, MPXPS;605084;AD;10q22.1
MID1;Opitz GBBB syndrome, type I, 300000 (3);MID1, OGS1, BBBG1, FXY, OSX;300552;XLR;Xp22.2
MID2;?Mental retardation, X-linked 101, 300928 (3);MID2, MRX101;300204;XLR;Xq22.3
MINPP1;Thyroid carcinoma, follicular, 188470 (3);MINPP1, HIPER1;605391;AD;10q23.2
MIP;Cataract 15, multiple types, 615274 (3);MIP, AQP0, CTRCT15;154050;-;12q13.3
MIR17HG;Feingold syndrome 2, 614326 (3);MIR17HG, MIRH1, MIHG1, MIRHG1, C13orf25, FGLDS2;609415;AD;13q31.3
MIR184;EDICT syndrome, 614303 (3);MIR184, MIRN184, KTCNCT, EDICT;613146;AD;15q25.1
MIR204;?Retinal dystrophy and iris coloboma with or without cataract, 616722 (3);MIR204, MIRN204, RDICC;610942;AD;9q21.12
MIR96;Deafness, autosomal dominant 50, 613074 (3);MIR96, MIRN96, DFNA50;611606;AD;7q32.2
MITF;Tietz albinism-deafness syndrome, 103500 (3),Waardenburg syndrome, type 2A, 193510 (3),Waardenburg syndrome/ocular albinism, digenic, 103470 (3);MITF, WS2A, CMM8;156845;AD, -;3p13
MKKS;Bardet-Biedl syndrome 6, 605231 (3),McKusick-Kaufman syndrome, 236700 (3);MKKS, HMCS, KMS, MKS, BBS6;604896;AR;20p12.2
MKL1;Megakaryoblastic leukemia, acute (3);MKL1, AMKL, MAL;606078;-;22q13.1-q13.2
MKRN3;Precocious puberty, central, 2, 615346 (3);MKRN3, ZFP127, ZNF127, CPPB2;603856;AD;15q11.2
MKS1;Bardet-Biedl syndrome 13, 615990 (3),Meckel syndrome 1, 249000 (3);MKS1, MKS, BBS13;609883;AR, -;17q22
MLC1;Megalencephalic leukoencephalopathy with subcortical cysts, 604004 (3);MLC1, LVM, VL;605908;AR;22q13.33
MLF1;Leukemia, acute myeloid, 601626 (1);MLF1;601402;AD;3q25.32
MLH1;Colorectal cancer, hereditary nonpolyposis, type 2, 609310 (3),Mismatch repair cancer syndrome, 276300 (3),Muir-Torre syndrome, 158320 (3);MLH1, COCA2, HNPCC2;120436;-, AR, AD;3p22.2
MLH3;Colorectal cancer, hereditary nonpolyposis, type 7, 614385 (3),Colorectal cancer, somatic, 114500 (3);MLH3, HNPCC7;604395;-;14q24.3
MLPH;Griscelli syndrome, type 3, 609227 (3);MLPH;606526;AR;2q37.3
MLSM7;Myelodysplasia and leukemia syndrome with monosomy 7 (4);MLSM7, DEL7q, C7DELq;252270;AR;7q
MLYCD;Malonyl-CoA decarboxylase deficiency, 248360 (3);MLYCD, MCD;606761;AR;16q23.3
MMAA;Methylmalonic aciduria, vitamin B12-responsive, 251100 (3);MMAA;607481;AR;4q31.21
MMAB;Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type, 251110 (3);MMAB;607568;AR;12q24.11
MMACHC;Methylmalonic aciduria and homocystinuria, cblC type, 277400 (3);MMACHC;609831;AR;1p34.1
MMD2;Miyoshi muscular dystrophy 2 (2);MMD2;613318;-;8q22.3
MMDK;Mesomelic dysplasia, Kantaputra type (2);MMDK, MDK;156232;AD;2q24-q32
MME;Charcot-Marie-Tooth disease, axonal, type 2T, 617017 (3);MME, CD10, CALLA, NEP, CMT2T;120520;AD, AR;3q25.2
MMP1;COPD, rate of decline of lung function in, 606963 (3);MMP1, CLG;120353;-;11q22.2
MMP13;Metaphyseal anadysplasia 1, 602111 (3),Spondyloepimetaphyseal dysplasia, Missouri type, 602111 (3);MMP13, CLG3, MANDP1;600108;AR, AD;11q22.2
MMP14;?Winchester syndrome, 277950 (3);MMP14, WNCHRS;600754;-;14q11.2
MMP19;Cavitary optic disc anomalies, 611543 (3);MMP19, MMP18, CODA;601807;AD;12q13.2
MMP2;Multicentric osteolysis, nodulosis, and arthropathy, 259600 (3);MMP2, CLG4A, MONA;120360;AR;16q12.2
MMP20;Amelogenesis imperfecta, type IIA2, 612529 (3);MMP20, AI2A2;604629;AR;11q22.2
MMP21;Heterotaxy, visceral, 7, autosomal, 616749 (3);MMP21, HTX7;608416;AR;10q26.2
MMP9;Metaphyseal anadysplasia 2, 613073 (3);MMP9, CLG4B, MANDP2;120361;-;20q13.12
MMVP1;Mitral valve prolapse, myxomatous 1 (2);MMVP1, MVP, PMV;157700;AD;16p12.1-p11.2
MMVP3;Mitral valve prolapse, myxomatous 3 (2);MMVP3;610840;AD;13q31.3-q32.1
MN1;Meningioma, 607174 (3);MN1, MGCR;156100;AD;22q12.1
MNDEC;Microtia with nasolacrimal duct imperforation and eye coloboma (1);MNDEC;611863;-;4p16-p15
MNG2;Goiter, multinodular, 2 (2);MNG2;300273;XLD;Xp22
MNG3;Goiter, multinodular, 3 (2);MNG3;606082;-;3q26.1-q26.3
MNRI;Meningioma, radiation-induced (2);MNRI;606190;-;1p11
MNX1;Currarino syndrome, 176450 (3);MNX1, HLXB9, HOXHB9, SCRA1;142994;AD;7q36.3
MOCS1;Molybdenum cofactor deficiency A, 252150 (3);MOCS1, MOCODA;603707;AR;6p21.2
MOCS2;Molybdenum cofactor deficiency B, 252160 (3);MOCS2, MPTS, MOCODB;603708;AR;5q11.2
MOG;?Narcolepsy 7, 614250 (3);MOG, NRCLP7;159465;AD;6p22.1
MOGS;Congenital disorder of glycosylation, type IIb, 606056 (3);MOGS, GCS1, CDG2B;601336;AR;2p13.1
MORC2;Charcot-Marie-Tooth disease, axonal, type 2Z, 616688 (3);MORC2, ZCW3, ZCWCC1, KIAA0852, CMT2Z;616661;AD;22q12.2
MPD3;Myopathy, distal 3 (2);MPD3;610099;AD;8p22-q11
MPDU1;Congenital disorder of glycosylation, type If, 609180 (3);MPDU1, SL15, CDGIF;604041;AR;17p13.1
MPDZ;Hydrocephalus, nonsyndromic, autosomal recessive 2, 615219 (3);MPDZ, MUPP1, HYC2;603785;AR;9p23
MPI;Congenital disorder of glycosylation, type Ib, 602579 (3);MPI, PMI1, CDG1B;154550;AR;15q24.1
MPL;Myelofibrosis with myeloid metaplasia, somatic, 254450 (3),Thrombocythemia 2, 601977 (3),Thrombocytopenia, congenital amegakaryocytic, 604498 (3);MPL, TPOR, MPLV, THCYT2;159530;-, AD, SMu, AR;1p34.2
MPLKIP;Trichothiodystrophy 4, nonphotosensitive, 234050 (3);MPLKIP, C7orf11, ABHS, TTDN1, TTD4;609188;AR;7p14.1
MPO;Myeloperoxidase deficiency, 254600 (3);MPO;606989;AR, AD, -;17q22
MPV17;Mitochondrial DNA depletion syndrome 6 (hepatocerebral type), 256810 (3);MPV17, MTDPS6;137960;AR;2p23.3
MPVQTL4;Mean platelet volume QTL4 (2);MPVQTL4;614644;-;6p21.3-p21.2
MPVQTL5;Mean platelet volume QTL5 (2);MPVQTL5;614645;-;6q23.3
MPVQTL6;Mean platelet volume QTL6 (2);MPVQTL6;614646;-;7q22.3
MPZ;Charcot-Marie-Tooth disease, dominant intermediate D, 607791 (3),Charcot-Marie-Tooth disease, type 1B, 118200 (3),Charcot-Marie-Tooth disease, type 2I, 607677 (3),Charcot-Marie-Tooth disease, type 2J, 607736 (3),Dejerine-Sottas disease, 145900 (3),Neuropathy, congenital hypomyelinating, 605253 (3),Roussy-Levy syndrome, 180800 (3);MPZ, CMT1B, CMTDID, CHM, DSS;159440;AD, AR;1q23.3
MR1;Paroxysmal nonkinesigenic dyskinesia, 118800 (3);MR1, TAHCCP2, KIPP1184, BRP17, PNKD, FPD1, PDC, DYT8;609023;AD;2q35
MRAP;Glucocorticoid deficiency 2, 607398 (3);MRAP, FALP, C21orf61, GCCD2, FGD2;609196;AR;21q22.11
MRD2;Mental retardation, autosomal dominant 2 (4);MRD2;614113;AD;9p24
MRE11A;Ataxia-telangiectasia-like disorder, 604391 (3);MRE11A, MRE11, ATLD;600814;AR;11q21
MROS;?Melkersson-Rosenthal syndrome (2);MROS;155900;AD;9p11
MRPL3;Combined oxidative phosphorylation deficiency 9, 614582 (3);MRPL3, MRL3, COXPD9;607118;AR;3q22.1
MRPL44;?Combined oxidative phosphorylation deficiency 16, 615395 (3);MRPL44, COXPD16;611849;AR;2q36.1
MRPS16;Combined oxidative phosphorylation deficiency 2, 610498 (3);MRPS16, COXPD2;609204;AR;10q22.2
MRPS22;Combined oxidative phosphorylation deficiency 5, 611719 (3);MRPS22, C3orf5, COXPD5;605810;AR;3q23
MRSD;Mental retardation-skeletal dysplasia (2);MRSD, CHRS;309620;XL;Xq28
MRSS;Mental retardation, X-linked, with short stature (2);MRSS;300360;XLR;Xq24
MRST;Mental retardation, severe, with spasticity and tapetoretinal degeneration (2);MRST;602685;-;15q24
MRT10;Mental retardation, autosomal recessive 10/20 (2);MRT10, MRT20;611096;-;16p12.2-q12.1
MRT11;Mental retardation, autosomal recessive, 11 (2);MRT11;611097;-;19q13.2-q13.3
MRT16;Mental retardation, autosomal recessive 16 (2);MRT16;614208;-;9p23-p13.3
MRT19;Mental retardation, autosomal recessive 19 (2);MRT19;614343;-;18p11.3
MRT23;Mental retardation, autosomal recessive 23 (2);MRT23;614344;-;11p13-q14.1
MRT24;Mental retardation, autosomal recessive 24 (2);MRT24;614345;-;6p12.2-q12
MRT25;Mental retardation, autosomal recessive 25 (2);MRT25;614346;-;12q13.11-q15
MRT28;Mental retardation, autosomal recessive 28 (2);MRT28;614347;-;6q26-q27
MRT29;Mental retardation, autosomal recessive 29 (2);MRT29;614333;-;4q27-q28.2
MRT30;Mental retardation, autosomal recessive 30 (2);MRT30;614342;-;6q12-q15
MRT31;Mental retardation, autosomal recessive 31 (2);MRT31;614329;AR;4q12-q13.1
MRT32;Mental retardation, autosomal recessive 32 (2);MRT32;614339;-;14q32.13-q32.2
MRT33;Mental retardation, autosomal recessive 33 (2);MRT33;614341;-;17p13.2-p13.1
MRT35;Mental retardation, autosomal recessive 35 (2);MRT35;615162;-;17q21.31-q22
MRT4;Mental retardation, autosomal recessive, 4 (2);MRT4;611107;AR;1p21.1-p13.3
MRT8;Mental retardation, autosomal recessive, 8 (2);MRT8;611094;-;10q22
MRT9;Mental retardation, autosomal recessive, 9/26 (2);MRT9, MRT26;611095;-;14q11.2-q12
MRX14;Mental retardation, X-linked 14 (2);MRX14;300062;XL;Xp11.3-q13.3
MRX2;Mental retardation, X-linked 2 (2);MRX2;300428;XL;Xp22.3
MRX20;Mental retardation, X-linked 20 (2);MRX20;300047;XL;Xp11-q21
MRX23;Mental retardation, X-linked 23 (2);MRX23;300046;XL;Xq23-q24
MRX42;Mental retardation, X-linked 42 (2);MRX42;300372;-;Xq26
MRX49;Mental retardation, X-linked 49 (2);MRX49;300114;XLR;Xp22.3
MRX50;Mental retardation, X-linked 50 (2);MRX50;300115;XL;Xp11.3-p11.21
MRX52;Mental retardation, X-linked 52 (2);MRX52;300504;-;Xp11.21-q22.3
MRX53;Mental retardation, X-linked 53 (2);MRX53;300324;XLD;Xq22.2-q26
MRX73;Mental retardation, X-linked 73 (2);MRX73;300355;XLR;Xp22.2
MRX77;Mental retardation, X-linked 77 (2);MRX77;300454;-;Xq12-q21.3
MRX78;Mental retardation, X-linked 78 (2);MRX78;300551;XLD;Xp11.4-q21.1
MRX81;Mental retardation, X-linked 81 (2);MRX81;300433;XLD;Xp11.2-q12
MRX82;Mental retardation, X-linked 82 (2);MRX82;300518;-;Xq24-q25
MRX84;Mental retardation, X-linked 84 (2);MRX84;300505;XLD;Xp11.3-q22.3
MRX88;Mental retardation, X-linked 88 (2);MRX88;300852;-;Xq24
MRX89;Mental retardation, X-linked 89 (2);MRX89;300848;XLD;Xp11.3
MRX92;Mental retardation, X-linked 92 (2);MRX92;300851;XLR;Xp11.3
MRX95;Mental retardation, X-linked 95 (2);MRX95;300716;XLD;Chr.X
MRXS12;?Mental retardation, X-linked, syndromic 12 (2);MRXS12;309545;XL;Xp11
MRXS17;Mental retardation, X-linked, syndromic 17 (2);MRXS17;300858;XLR;Xp21.1-p11.23
MRXS7;Mental retardation, X-linked syndromic 7 (2);MRXS7;300218;-;Xp11.3-q22
MRXS9;Mental retardation, X-linked, syndromic 9 (2);MRXS9;300709;-;Xq12-q21.31
MRXSA;Mental retardation syndrome, X-linked, Armfield type (2);MRXSA;300261;XLR;Xq28
MRXSAB;Mental retardation, X-linked syndromic, Abidi type (2);MRXSAB;300262;-;Xq13.2
MRXSBWB;Brooks-Wisniewski-Brown syndrome (2);MRXSBWB;300612;XLR;Chr.X
MRXSCS;Mental retardation, X-linked, syndromic, Chudley-Schwartz type, (2);MRXSCS;300861;XLR;Xq21.33-q23
MRXSMP;Mental retardation, X-linked, syndromic, Martin-Probst type (2);MRXSMP;300519;XLR;Chr.X
MS4A1;Immunodeficiency, common variable, 5, 613495 (3);MS4A1, CD20, CVID5;112210;AR;11q12.2
MSH2;Colorectal cancer, hereditary nonpolyposis, type 1, 120435 (3),Mismatch repair cancer syndrome, 276300 (3),Muir-Torre syndrome, 158320 (3);MSH2, COCA1, FCC1, HNPCC1;609309;AD, AR;2p21-p16
MSH3;Endometrial carcinoma, somatic, 608089 (3);MSH3;600887;AR;5q14.1
MSH6;Colorectal cancer, hereditary nonpolyposis, type 5, 614350 (3),Endometrial cancer, familial, 608089 (3),Mismatch repair cancer syndrome, 276300 (3);MSH6, GTBP, HNPCC5;600678;AD, -, AR;2p16.3
MSMO1;Microcephaly, congenital cataract, and psoriasiform dermatitis, 616834 (3);MSMO1, SC4MOL, ERG25, MCCPD;607545;AR;4q32.3
MSPC;Palmoplantar carcinoma, multiple self-healing (2);MSPC;616964;AD;17p13.3-p12
MSR1;Barrett esophagus/esophageal adenocarcinoma, 614266 (3),Prostate cancer, hereditary, 176807 (3);MSR1, SCARA1, SRA;153622;-, AD;8p22
MSRB3;Deafness, autosomal recessive 74, 613718 (3);MSRB3, DFNB74;613719;AR;12q14.3
MSX1;Ectodermal dysplasia 3, Witkop type, 189500 (3),Orofacial cleft 5, 608874 (3),Tooth agenesis, selective, 1, with or without orofacial cleft, 106600 (3);MSX1, HOX7, HYD1, OFC5, STHAG1, ECTD3;142983;AD, -;4p16.2
MSX2;Craniosynostosis, type 2, 604757 (3),Parietal foramina 1, 168500 (3),Parietal foramina with cleidocranial dysplasia, 168550 (3);MSX2, CRS2, HOX8;123101;AD;5q35.2
MTAP;Diaphyseal medullary stenosis with malignant fibrous histiocytoma, 112250 (3);MTAP, DMSMFH;156540;AD;9p21.3
MTFMT;Combined oxidative phosphorylation deficiency 15, 614947 (3);MTFMT, COXPD15;611766;AR;15q22.31
MTHFR;Homocystinuria due to MTHFR deficiency, 236250 (3);MTHFR;607093;AR, AD;1p36.22
MTM1;Myotubular myopathy, X-linked, 310400 (3);MTM1, MTMX;300415;XLR;Xq28
MTMR2;Charcot-Marie-Tooth disease, type 4B1, 601382 (3);MTMR2, CMT4B1;603557;AR;11q21
MTO1;Combined oxidative phosphorylation deficiency 10, 614702 (3);MTO1, COXPD10;614667;AR;6q13
MTOR;Smith-Kingsmore syndrome, 616638 (3);MTOR, FRAP1, SKS;601231;AD;1p36.22
MTP;Abetalipoproteinemia, 200100 (3);MTP;157147;AR;4q23
MTPAP;Ataxia, spastic, 4, 613672 (3);MTPAP, PAPD1, SPAX4;613669;AR;10p11.23
MTR;Homocystinuria-megaloblastic anemia, cblG complementation type, 250940 (3);MTR, HMAG;156570;AR;1q43
MTRR;Homocystinuria-megaloblastic anemia, cbl E type, 236270 (3);MTRR;602568;AR;5p15.31
MUC1;Medullary cystic kidney disease 1, 174000 (3);MUC1, PUM, MCKD1;158340;AD;1q22
MUSK;Fetal akinesia deformation sequence, 208150 (3),Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency, 616325 (3);MUSK, CMS9, FADS;601296;AR;9q31.3
MUSTQTL1;Muscle strength quantitative trait locus 1 (2);MUSTQTL1;612083;-;14q24.3
MUT;Methylmalonic aciduria, mut(0) type, 251000 (3);MUT, MCM;609058;AR;6p12.3
MUTYH;Adenomas, multiple colorectal, 608456 (3),Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas, 132600 (3),Gastric cancer, somatic, 613659 (3);MUTYH, MYH;604933;-, SMu;1p34.1
MVD;Porokeratosis 7, multiple types, 614714 (3);MVD, MPD, POROK7;603236;AD;16q24.2
MVK;Hyper-IgD syndrome, 260920 (3),Mevalonic aciduria, 610377 (3),Porokeratosis 3, multiple types, 175900 (3);MVK, MVLK, POROK3;251170;AR, AD;12q24.11
MXI1;Neurofibrosarcoma (3);MXI1;600020;-, AD;10q25.2
MYAS1;Myasthenia gravis with thymus hyperplasia (2);MYAS1;607085;-;6p21.3
MYBPC1;Arthrogryposis, distal, type 1B, 614335 (3),Lethal congenital contracture syndrome 4, 614915 (3);MYBPC1, LCCS4;160794;-, AR;12q23.2
MYBPC3;Cardiomyopathy, dilated, 1MM, 615396 (3),Cardiomyopathy, hypertrophic, 4, 115197 (3),Left ventricular noncompaction 10, 615396 (3);MYBPC3, CMH4, CMD1MM, LVNC10;600958;AD;11p11.2
MYC;Burkitt lymphoma, 113970 (3);MYC;190080;IC ;8q24.21
MYCN;Feingold syndrome, 164280 (3);MYCN, NMYC, ODED, MODED;164840;AD;2p24.3
MYD88;Macroglobulinemia, Waldenstrom, somatic, 153600 (3),Pyogenic bacterial infections, recurrent, due to MYD88 deficiency, 612260 (3);MYD88, MYD88D;602170;-;3p22.2
MYF6;Myopathy, centronuclear, 3, 614408 (3);MYF6, CNM3;159991;AD;12q21.31
MYH11;Aortic aneurysm, familial thoracic 4, 132900 (3);MYH11, AAT4, FAA4;160745;AD;16p13.11
MYH14;?Peripheral neuropathy, myopathy, hoarseness, and hearing loss, 614369 (3),Deafness, autosomal dominant 4A, 600652 (3);MYH14, KIAA2034, DFNA4A, PNMHH;608568;AD;19q13.33
MYH2;Proximal myopathy and ophthalmoplegia, 605637 (3);MYH2, MYPOP;160740;AD, AR;17p13.1
MYH3;Arthrogryposis, distal, type 2A, 193700 (3),Arthrogryposis, distal, type 2B, 601680 (3),Arthrogryposis, distal, type 8, 178110 (3);MYH3, DA2A, DA2B, DA8;160720;AD;17p13.1
MYH6;Atrial septal defect 3, 614089 (3),Cardiomyopathy, dilated, 1EE, 613252 (3),Cardiomyopathy, hypertrophic, 14, 613251 (3);MYH6, ASD3, MYHCA, CMD1EE, CMH14, SSS3;160710;-;14q11.2
MYH7;Cardiomyopathy, dilated, 1S, 613426 (3),Cardiomyopathy, hypertrophic, 1, 192600 (3),Left ventricular noncompaction 5, 613426 (3),Liang distal myopathy, 160500 (3),Myopathy, myosin storage, autosomal dominant, 608358 (3),Myopathy, myosin storage, autosomal recessive, 255160 (3),Scapuloperoneal syndrome, myopathic type, 181430 (3);MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD;160760;AD, AR;14q11.2
MYH8;Carney complex variant, 608837 (3),Trismus-pseudocamptodactyly syndrome, 158300 (3);MYH8, DA7;160741;-, AD;17p13.1
MYH9;Deafness, autosomal dominant 17, 603622 (3),Epstein syndrome, 153650 (3),Fechtner syndrome, 153640 (3),Macrothrombocytopenia and progressive sensorineural deafness, 600208 (3),May-Hegglin anomaly, 155100 (3),Sebastian syndrome, 605249 (3);MYH9, MHA, FTNS, DFNA17, BDPLT6;160775;AD;22q12.3
MYL2;Cardiomyopathy, hypertrophic, 10, 608758 (3);MYL2, CMH10;160781;-;12q24.11
MYL3;Cardiomyopathy, hypertrophic, 8, 608751 (3);MYL3, CMH8;160790;-;3p21.31
MYLK;Aortic aneurysm, familial thoracic 7, 613780 (3);MYLK, MLCK, AAT7;600922;AD;3q21.1
MYLK2;Cardiomyopathy, hypertrophic, 1, digenic, 192600 (3);MYLK2, MLCK;606566;AD;20q11.21
MYMY1;Moyamoya disease (2);MYMY1, MYMY;252350;AR;3p26-p24.2
MYMY3;Moyamoya disease 3 (2);MYMY3;608796;-;8q23
MYMY4;Moyamoya disease 4 (4);MYMY4, CXDELq38;300845;XLR;Xq28
MYO15A;Deafness, autosomal recessive 3, 600316 (3);MYO15A, DFNB3;602666;AR;17p11.2
MYO18B;Klippel-Feil syndrome 4, autosomal recessive, with myopathy and facial dysmorphism, 616549 (3);MYO18B, KFS4;607295;AR;22q12.1
MYO1E;Glomerulosclerosis, focal segmental, 6, 614131 (3);MYO1E, MYO1C, FSGS6;601479;AR;15q22.2
MYO3A;Deafness, autosomal recessive 30, 607101 (3);MYO3A, DFNB30;606808;AR;10p12.1
MYO5A;Griscelli syndrome, type 1, 214450 (3);MYO5A, MYH12, GS1;160777;AR;15q21.2
MYO5B;Microvillus inclusion disease, 251850 (3);MYO5B, KIAA1119;606540;AR;18q21.1
MYO6;Deafness, autosomal dominant 22, 606346 (3),Deafness, autosomal dominant 22, with hypertrophic cardiomyopathy, 606346 (3),Deafness, autosomal recessive 37, 607821 (3);MYO6, DFNA22, DFNB37;600970;AD, AR;6q14.1
MYO7A;Deafness, autosomal dominant 11, 601317 (3),Deafness, autosomal recessive 2, 600060 (3),Usher syndrome, type 1B, 276900 (3);MYO7A, USH1B, DFNB2, DFNA11;276903;AD, AR;11q13.5
MYOC;Glaucoma 1A, primary open angle, 137750 (3);MYOC, TIGR, GLC1A, JOAG, GPOA;601652;AD;1q24.3
MYOT;Muscular dystrophy, limb-girdle, type 1A, 159000 (3),Myopathy, myofibrillar, 3, 609200 (3),Myopathy, spheroid body, 182920 (3);MYOT, TTOD, MFM3;604103;AD;5q31.2
MYOZ2;Cardiomyopathy, hypertrophic, 16, 613838 (3);MYOZ2, CMH16;605602;AD;4q26
MYP1;Myopia-1 (2);MYP1;310460;XLR;Xq28
MYP10;Myopia 10 (2);MYP10;609259;Mu ;8p23
MYP11;Myopia 11 (2);MYP11;609994;-;4q22-q27
MYP12;Myopia 12 (2);MYP12;609995;-;2q37.1
MYP13;Myopia 13 (2);MYP13;300613;-;Xq23-q27.2
MYP14;Myopia 14 (2);MYP14;610320;-;1p36
MYP15;Myopia 15 (2);MYP15;612717;AD;10q21.1
MYP16;Myopia 16 (2);MYP16;612554;-;5p15.33-p15.2
MYP17;Myopia 17 (2);MYP17, MYP4;608367;AD;7p15
MYP18;Myopia 18 (2);MYP18;255500;AR;14q22.1-q24.2
MYP19;Myopia 19 (2);MYP19;613969;AD;5p15.1-p13.3
MYP2;Myopia-2 (2);MYP2;160700;AD;18p11.31
MYP20;Myopia 20, autosomal dominant (2);MYP20;614166;-;13q12.12
MYP3;Myopia-3 (2);MYP3;603221;AD;12q21-q23
MYP5;Myopia 5 (2);MYP5;608474;AD;17q21-q22
MYP7;Myopia 7 (2);MYP7;609256;Mu ;11p13
MYP8;Myopia 8 (2);MYP8;609257;Mu ;3q26
MYP9;Myopia 9 (2);MYP9;609258;Mu ;4q12
MYPN;Cardiomyopathy, dilated, 1KK, 615248 (3),Cardiomyopathy, familial restrictive, 4, 615248 (3),Cardiomyopathy, hypertrophic, 22, 615248 (3);MYPN, CMD1DD, CMH22, RCM4;608517;AD;10q21.3
MYT1L;Mental retardation, autosomal dominant 39, 616521 (3);MYT1L, KIAA1106, MRD39;613084;AD;2p25.3
NAA10;?Microphthalmia, syndromic 1, 309800 (3),Ogden syndrome, 300855 (3);NAA10, ARD1A, ARD1, TE2, NATD, OGDNS, MCOPS1;300013;XL, XLR, XLD;Xq28
NADK2;?2,4-dienoyl-CoA reductase deficiency, 616034 (3);NADK2, C5orf33, DECRD;615787;AR;5p13.2
NAGA;Kanzaki disease, 609242 (3),Schindler disease, type I, 609241 (3),Schindler disease, type III, 609241 (3);NAGA;104170;AR;22q13.2
NAGLU;?Charcot-Marie-Tooth disease, axonal, type 2V, 616491 (3),Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 (3);NAGLU, MPS3B, CMT2V;609701;AD, AR;17q21.2
NAGS;N-acetylglutamate synthase deficiency, 237310 (3);NAGS;608300;AR;17q21.31
NALCN;Congenital contractures of the limbs and face, hypotonia, and developmental delay, 616266 (3),Hypotonia, infantile, with psychomotor retardation and characteristic facies 1, 615419 (3);NALCN, IHPRF1, CLIFAHDD;611549;AR, AD;13q32.3-q33.1
NALP7;Hydatidiform mole, recurrent, 1, 231090 (3);NALP7, NOD12, PYPAF3, HYDM;609661;AR;19q13.42
NANOS1;Spermatogenic failure 12, 615413 (3);NANOS1, NOS1, SPGF12;608226;AD;10q26.11
NANS;Spondyloepimetaphyseal dysplasia, Genevieve type, 610442 (3);NANS, SAS, SEMDG;605202;AR;9q22.33
NARS2;Combined oxidative phosphorylation deficiency 24, 616239 (3);NARS2, COXPD24;612803;AR;11q14.1
NAT8L;?N-acetylaspartate deficiency, 614063 (3);NAT8L, CML3, NACED;610647;-;4p16.3
NBAS;Infantile liver failure syndrome 2, 616483 (3),Short stature, optic nerve atrophy, and Pelger-Huet anomaly, 614800 (3);NBAS, NAG, SOPH, ILFS2;608025;AR;2p24.3
NBEAL2;Gray platelet syndrome, 139090 (3);NBEAL2, KIAA0540, GPS, BDPLT4;614169;AR;3p21.31
NBN;Aplastic anemia, 609135 (3),Leukemia, acute lymphoblastic, 613065 (3),Nijmegen breakage syndrome, 251260 (3);NBN, NBS1;602667;-, AR;8q21.3
NCF1;Chronic granulomatous disease due to deficiency of NCF-1, 233700 (3);NCF1;608512;AR;7q11.23
NCF2;Chronic granulomatous disease due to deficiency of NCF-2, 233710 (3);NCF2;608515;AR;1q25.3
NCF4;?Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type III, 613960 (3);NCF4, P40PHOX, CGD3;601488;AR;22q12.3
NCSTN;Acne inversa, familial, 1, 142690 (3);NCSTN;605254;AD;1q23.2
NDE1;?Microhydranencephaly, 605013 (3),Lissencephaly 4 (with microcephaly), 614019 (3);NDE1, NUDE, LIS4, MHAC;609449;AR;16p13.11
NDN;Prader-Willi syndrome, 176270 (3);NDN;602117;IC;15q11.2
NDNC7;Nail disorder, nonsyndromic congenital, 7 (2);NDNC7;605779;AD;17p13
NDNC9;Nail disorder, nonsyndromic congenital, 9 (2);NDNC9;614149;AR;17q25.1-q25.3
NDP;Exudative vitreoretinopathy 2, X-linked, 305390 (3),Norrie disease, 310600 (3);NDP, ND, EVR2;300658;-, XLR;Xp11.3
NDRG1;Charcot-Marie-Tooth disease, type 4D, 601455 (3);NDRG1, HMSNL, CMT4D;605262;AR;8q24.22
NDST1;Mental retardation, autosomal recessive 46, 616116 (3);NDST1, HSST, MRT46;600853;AR;5q33.1
NDUFA1;Mitochondrial complex I deficiency, 252010 (3);NDUFA1, MWFE;300078;Mi, XLD, AR;Xq24
NDUFA10;?Leigh syndrome, 256000 (3);NDUFA10;603835;Mi, AR;2q37.3
NDUFA11;Mitochondrial complex I deficiency, 252010 (3);NDUFA11;612638;Mi, XLD, AR;19p13.3
NDUFA12;Leigh syndrome due to mitochondrial complex 1 deficiency, 256000 (3);NDUFA12;614530;Mi, AR;12q22
NDUFA2;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3);NDUFA2;602137;Mi, AR;5q31.3
NDUFA9;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3);NDUFA9;603834;Mi, AR;12p13.32
NDUFAF1;Mitochondrial complex I deficiency, 252010 (3);NDUFAF1, CIA30, CGI65;606934;Mi, XLD, AR;15q15.1
NDUFAF2;Leigh syndrome, 256000 (3),Mitochondrial complex I deficiency, 252010 (3);NDUFAF2, NDUFA12L, MMTN, B17.2L;609653;Mi, AR, XLD;5q12.1
NDUFAF3;Mitochondrial complex I deficiency, 252010 (3);NDUFAF3;612911;Mi, XLD, AR;3p21.31
NDUFAF4;Mitochondrial complex I deficiency, 252010 (3);NDUFAF4, HRPAP20, C6orf66;611776;Mi, XLD, AR;6q16.1
NDUFAF5;Mitochondrial complex 1 deficiency, 252010 (3);NDUFAF5, C20orf7;612360;Mi, XLD, AR;20p12.1
NDUFAF6;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3);NDUFAF6, C8orf38;612392;Mi, AR;8q22.1
NDUFB11;Linear skin defects with multiple congenital anomalies 3, 300952 (3);NDUFB11, LSDMCA3;300403;XLD;Xp11.3
NDUFB3;Mitochondrial complex I deficiency, 252010 (3);NDUFB3;603839;Mi, XLD, AR;2q33.1
NDUFB9;?Mitochondrial complex I deficiency, 252010 (3);NDUFB9, UQOR22;601445;Mi, XLD, AR;8q24.13
NDUFS1;Mitochondrial complex I deficiency, 252010 (3);NDUFS1;157655;Mi, XLD, AR;2q33.3
NDUFS2;Mitochondrial complex I deficiency, 252010 (3);NDUFS2;602985;Mi, XLD, AR;1q23.3
NDUFS3;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3),Mitochondrial complex I deficiency, 252010 (3);NDUFS3;603846;Mi, AR, XLD;11p11.2
NDUFS4;Leigh syndrome, 256000 (3),Mitochondrial complex I deficiency, 252010 (3);NDUFS4, AQDQ;602694;Mi, AR, XLD;5q11.2
NDUFS6;Mitochondrial complex I deficiency, 252010 (3);NDUFS6;603848;Mi, XLD, AR;5p15.33
NDUFS7;Leigh syndrome, 256000 (3);NDUFS7, PSST;601825;Mi, AR;19p13.3
NDUFS8;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3);NDUFS8;602141;Mi, AR;11q13.2
NDUFV1;Mitochondrial complex I deficiency, 252010 (3);NDUFV1, UQOR1;161015;Mi, XLD, AR;11q13.2
NDUFV2;Mitochondrial complex I deficiency, 252010 (3);NDUFV2;600532;Mi, XLD, AR;18p11.22
NEB;Nemaline myopathy 2, autosomal recessive, 256030 (3);NEB, NEM2;161650;AR;2q23.3
NECAP1;?Epileptic encephalopathy, early infantile, 21, 615833 (3);NECAP1, EIEE21;611623;AR;12p13.31
NECTIN1;Cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3),Orofacial cleft 7, 225060 (3);NECTIN1, PVRL1, HVEC, PVRR1, PRR1, ED4, OFC7, CLPED1;600644;AR;11q23.3
NEDE;Nephropathy, progressive, with deafness (2);NEDE;609469;-;11q24
NEFH;?{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3),Charcot-Marie-Tooth disease, axonal, type 2CC, 616924 (3);NEFH, CMT2CC;162230;AD, AR;22q12.2
NEFL;Charcot-Marie-Tooth disease, type 1F, 607734 (3),Charcot-Marie-Tooth disease, type 2E, 607684 (3);NEFL, CMT2E, CMT1F;162280;AD, AR;8p21.2
NEK1;Short-rib thoracic dysplasia 6 with or without polydactyly, 263520 (3);NEK1, SRTD6, SRPS2A;604588;DR, AR;4q33
NEK2;?Retinitis pigmentosa 67, 615565 (3);NEK2, RP67;604043;AR;1q32.3
NEK8;?Nephronophthisis 9, 613824 (3),?Renal-hepatic-pancreatic dysplasia 2, 615415 (3);NEK8, JCK, NPHP9, RHPD2;609799;-,AR;17q11.2
NEK9;?Arthrogryposis, Perthes disease, and upward gaze palsy, 614262 (3),Lethal congenital contracture syndrome 10, 617022 (3),Nevus comedonicus, somatic, 617025 (3);NEK9, NERCC1, LCCS10, APUG, NC;609798;AR, -;14q24.3
NEU1;Sialidosis, type I, 256550 (3),Sialidosis, type II, 256550 (3);NEU1, NEU, SIAL1;608272;AR;6p21.33
NEUROD1;Maturity-onset diabetes of the young 6, 606394 (3);NEUROD1, NIDDM;601724;-, AD;2q31.3
NEUROG3;Diarrhea 4, malabsorptive, congenital, 610370 (3);NEUROG3, NGN3, ATOH5;604882;AR;10q22.1
NEXN;Cardiomyopathy, dilated, 1CC, 613122 (3),Cardiomyopathy, hypertrophic, 20, 613876 (3);NEXN, NELIN, CMD1CC, CMH20;613121;-,AD;1p31.1
NF1;Leukemia, juvenile myelomonocytic, 607785 (3),Neurofibromatosis, familial spinal, 162210 (3),Neurofibromatosis, type 1, 162200 (3),Neurofibromatosis-Noonan syndrome, 601321 (3),Watson syndrome, 193520 (3);NF1, VRNF, WSS, NFNS;613113;AD, SMu;17q11.2
NF2;Meningioma, NF2-related, somatic, 607174 (3),Neurofibromatosis, type 2, 101000 (3),Schwannomatosis, 162091 (3);NF2;607379;-, AD;22q12.2
NFIX;Marshall-Smith syndrome, 602535 (3),Sotos syndrome 2, 614753 (3);NFIX, NF1A, SOTOS2, MRSHSS;164005;AD;19p13.13
NFKB1;Immunodeficiency, common variable, 12, 616576 (3);NFKB1, CVID12;164011;AD;4q24
NFKB2;Immunodeficiency, common variable, 10, 615577 (3);NFKB2, LYT10, CVID10;164012;AD;10q24.32
NFKBIA;Ectodermal dysplasia, anhidrotic, with T-cell immunodeficiency, 612132 (3);NFKBIA, IKBA;164008;AD;14q13.2
NFU1;Multiple mitochondrial dysfunctions syndrome 1, 605711 (3);NFU1, HIRIP, MMDS1;608100;AR;2p13.3
NGF;Neuropathy, hereditary sensory and autonomic, type V, 608654 (3);NGF, NGFB, HSAN5;162030;AR;1p13.2
NGLY1;Congenital disorder of deglycosylation, 615273 (3);NGLY1, PNG1, CDDG, CDG1V;610661;AR;3p24.2
NHEJ1;Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 (3);NHEJ1, XLF;611290;-;2q35
NHLRC1;Epilepsy, progressive myoclonic 2B (Lafora), 254780 (3);NHLRC1, EPM2A, EPM2B;608072;AR;6p22.3
NHS;Cataract 40, X-linked, 302200 (3),Nance-Horan syndrome, 302350 (3);NHS, CXN, CTRCT40;300457;XL, XLD ;Xp22.2-p22.1
NIDDM2;Diabetes mellitus, noninsulin-dependent, 2 (2);NIDDM2;601407;-;12q24.2
NIN;?Seckel syndrome 7, 614851 (3);NIN, KIAA1565, SCKL7;608684;AR;14q22.1
NIPA1;Spastic paraplegia 6, autosomal dominant, 600363 (3);NIPA1, SPG6;608145;AD;15q11.2
NIPAL4;Ichthyosis, congenital, autosomal recessive 6, 612281 (3);NIPAL4, ICHYN, ARCI6;609383;AR;5q33.3
NIPBL;Cornelia de Lange syndrome 1, 122470 (3);NIPBL, CDLS1;608667;AD;5p13.2
NKX2-1;Chorea, hereditary benign, 118700 (3),Choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3);NKX2-1, TITF1, NKX2A, TTF1, NMTC1;600635;AD;14q13.3
NKX2-5;Atrial septal defect 7, with or without AV conduction defects, 108900 (3),Conotruncal heart malformations, variable, 217095 (3),Hypoplastic left heart syndrome 2, 614435 (3),Hypothyroidism, congenital nongoitrous, 5, 225250 (3),Tetrology of Fallot, 187500 (3),Ventricular septal defect 3, 614432 (3);NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2;600584;AD, -;5q35.1
NKX2-6;Conotruncal heart malformations, 217095 (3),Persistent truncus arteriosus, 217095 (3);NKX2-6, CSX2, CTHM;611770;-;8p21.2
NKX3-2;Spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 (3);NKX3-2, BAPX1, SMMD;602183;AR;4p15.33
NLGN4;Mental retardation, X-linked, 300495 (3);NLGN4, KIAA1260, AUTSX2, ASPGX2;300427;XL, ICM Mu;Xp22.32-p22.31
NLRC4;?Familial cold autoinflammatory syndrome 4, 616115 (3),Autoinflammation with infantile enterocolitis, 616050 (3);NLRC4, CARD12, CLAN, IPAF, AIFEC, FCAS4;606831;AD;2p22.3
NLRP1;?Corneal intraepithelial dyskeratosis and ectodermal dysplasia, 615225 (3);NLRP1, NALP1, KIAA0926, DEFCAP, CARD7, SLEV1, VAMAS1, CIDED;606636;AD;17p13.2
NLRP12;Familial cold autoinflammatory syndrome 2, 611762 (3);NLRP12, NALP12, PYPAF7, RNO, FCAS2;609648;AD;19q13.42
NLRP3;CINCA syndrome, 607115 (3),Familial cold-induced inflammatory syndrome 1, 120100 (3),Muckle-Wells syndrome, 191900 (3);NLRP3, CIAS1, FCU, FCAS1, NALP3, PYPAF1;606416;AD, -;1q44
NM;?Neutrophil chemotactic response, abnormal (2);NM, NCR;162820;AD;7q22-qter
NME1;Neuroblastoma, 256700 (3);NME1, NM23;156490;IC, AD;17q21.33
NME8;Ciliary dyskinesia, primary, 6, 610852 (3);NME8, TXNDC3, SPTRX2, CILD6;607421;AR;7p14.1
NMLFS;Nablus mask-like facial syndrome (4);NMLFS, DEL8q22.1, C8DELq22.1;608156;IC, AR;8q22.1
NMNAT1;Leber congenital amaurosis 9, 608553 (3);NMNAT1, NMNAT, PNAT1, LCA9;608700;AR;1p36.22
NNMT;Homocysteine plasma level (2);NNMT;600008;-;11q23.2
NNO1;Nanophthalmos-1 (2);NNO1;600165;AD;11p
NNO3;Nanophthalmos 3 (2);NNO3;611897;-;2q11-q14
NNT;Glucocorticoid deficiency 4, 614736 (3);NNT, GCCD4;607878;AR;5p12
NOBOX;Premature ovarian failure 5, 611548 (3);NOBOX, POF5;610934;AD;7q35
NOD2;Blau syndrome, 186580 (3),Sarcoidosis, early-onset, 609464 (3);NOD2, CARD15, IBD1, CD, ACUG, PSORAS1;605956;AD, Mu, -;16q12.1
NODAL;Heterotaxy, visceral, 5, 270100 (3);NODAL, HTX5;601265;AD;10q22.1
NOG;Brachydactyly, type B2, 611377 (3),Multiple synostoses syndrome 1, 186500 (3),Stapes ankylosis with broad thumb and toes, 184460 (3),Symphalangism, proximal, 1A, 185800 (3),Tarsal-carpal coalition syndrome, 186570 (3);NOG, SYM1, SYNS1A;602991;AD;17q22
NOL3;Myoclonus, familial cortical, 614937 (3);NOL3, NOP, MYC, ARC, FCM;605235;AD;16q22.1
NOLA2;Dyskeratosis congenita, autosomal recessive 2, 613987 (3);NOLA2, NHP2, DKCB2;606470;AR;5q35.3
NOLA3;Dyskeratosis congenita, autosomal recessive 1, 224230 (3);NOLA3, NOP10, DKCB1;606471;AR;15q14
NONO;Mental retardation, X-linked, syndromic 34, 300967 (3);NONO, NRB54, MRXS34;300084;AD;Xq13.1
NOP56;Spinocerebellar ataxia 36, 614153 (3);NOP56, SCA36;614154;AD;20p13
NOTCH1;Adams-Oliver syndrome 5, 616028 (3),Aortic valve disease 1, 109730 (3);NOTCH1, TAN1, AOS5, AOVD1;190198;AD;9q34.3
NOTCH2;Alagille syndrome 2, 610205 (3),Hajdu-Cheney syndrome, 102500 (3);NOTCH2, AGS2, HJCYS;600275;AD;1p12
NOTCH3;?Myofibromatosis, infantile 2, 615293 (3),Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1, 125310 (3),Lateral meningocele syndrome, 130720 (3);NOTCH3, CADASIL1, CASIL, IMF2, LMNS;600276;AD;19p13.12
NPC1;Niemann-Pick disease, type C1, 257220 (3),Niemann-Pick disease, type D, 257220 (3);NPC1, NPC;607623;AR;18q11.2
NPC2;Niemann-pick disease, type C2, 607625 (3);NPC2, HE1;601015;AR;14q24.3
NPHP1;Joubert syndrome 4, 609583 (3),Nephronophthisis 1, juvenile, 256100 (3),Senior-Loken syndrome-1, 266900 (3);NPHP1, NPH1, SLSN1, JBTS4;607100;AR;2q13
NPHP3;Meckel syndrome 7, 267010 (3),Nephronophthisis 3, 604387 (3),Renal-hepatic-pancreatic dysplasia 1, 208540 (3);NPHP3, NPH3, RHPD1, MKS7;608002;AR;3q22.1
NPHP4;Nephronophthisis 4, 606966 (3),Senior-Loken syndrome 4, 606996 (3);NPHP4, SLSN4;607215;AR;1p36.31
NPHS1;Nephrotic syndrome, type 1, 256300 (3);NPHS1, NPHN;602716;AR;19q13.12
NPM1;Leukemia, acute myeloid, somatic, 601626 (3);NPM1;164040;-;5q35.1
NPPA;Atrial fibrillation, familial, 6, 612201 (3),Atrial standstill 2, 615745 (3);NPPA, PND, ANP, ATFB6, ATRST2;108780;AD, AR;1p36.22
NPR2;Acromesomelic dysplasia, Maroteaux type, 602875 (3),Epiphyseal chondrodysplasia, Miura type, 615923 (3),Short stature with nonspecific skeletal abnormalities, 616255 (3);NPR2, ANPRB, AMDM, ECDM, SNSK;108961;AD, AR;9p13.3
NPR3;?Hypertension, salt-resistant (1);NPR3, ANPRC;108962;-;5p13.3
NR0B2;Obesity, mild, early-onset, 601665 (3);NR0B2, SHP;604630;Mu, AD, AR;1p36.11
NR2E3;Enhanced S-cone syndrome, 268100 (3),Retinitis pigmentosa 37, 611131 (3);NR2E3, PNR, ESCS, RP37;604485;AR, AD;15q23
NR2F1;Bosch-Boonstra-Schaaf optic atrophy syndrome, 615722 (3);NR2F1, TFCOUP1, ERBAL3, EAR3, BBSOAS;132890;AD;5q15
NR2F2;Congenital heart defects, multiple types, 4, 615779 (3);NR2F2, TFCOUP2, ARP1, CHTD4;107773;AD;15q26.2
NR3C1;Glucocorticoid resistance, 615962 (3);NR3C1, GCR, GRL, GCRST;138040;AD;5q31.3
NR3C2;Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy, 605115 (3),Pseudohypoaldosteronism type I, autosomal dominant, 177735 (3);NR3C2, MLR, MCR;600983;-, AD;4q31.23
NR5A1;46XY sex reversal 3, 612965 (3),Adrenocortical insufficiency (3),Premature ovarian failure 7, 612964 (3),Spermatogenic failure 8, 613957 (3);NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7, SRXY3, SPGF8;184757;AD, AR;9q33.3
NRAS;?RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic, 614470 (3),Colorectal cancer, somatic, 114500 (3),Epidermal nevus, somatic, 162900 (3),Melanocytic nevus syndrome, congenital, somatic, 137550 (3),Neurocutaneous melanosis, somatic, 249400 (3),Noonan syndrome 6, 613224 (3),Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3),Thyroid carcinoma, follicular, somatic, 188470 (3);NRAS, ALPS4, NS6, CMNS, NCMS;164790;AD, -;1p13.2
NRCLP2;Narcolepsy 2 (2);NRCLP2;605841;-;4p13-q21
NRCLP3;Narcolepsy 3 (2);NRCLP3;609039;AD;21q11.2
NRCLP6;Narcolepsy 6 (2);NRCLP6;614223;-;19p13.2
NRL;Retinal degeneration, autosomal recessive, clumped pigment type (3),Retinitis pigmentosa 27, 613750 (3);NRL, D14S46E, RP27;162080;-, AD;14q11-q12
NRXN1;Pitt-Hopkins-like syndrome 2, 614325 (3);NRXN1, PTHSL2, SCZD17;600565;AR, -;2p16.3
NSD1;Beckwith-Wiedemann syndrome, 130650 (3),Leukemia, acute myeloid, 601626 (1),Sotos syndrome 1, 117550 (3);NSD1, ARA267, STO, SOTOS1;606681;AD;5q35.3
NSDHL;CHILD syndrome, 308050 (3),CK syndrome, 300831 (3);NSDHL;300275;XLD,XLR;Xq28
NSMF;Hypogonadotropic hypogonadism 9 with or without anosmia, 614838 (3);NSMF, NELF, HH9;608137;-;9q34.3
NSUN2;Mental retardation, autosomal recessive 5, 611091 (3);NSUN2, TRM4, SAKI, MISU, MRT5;610916;AR;5p15.31
NT5C2;Spastic paraplegia 45, autosomal recessive, 613162 (3);NT5C2, NT5B, PNT5, SPG45;600417;AR;10q24.32-q24.33
NT5C3A;Anemia, hemolytic, due to UMPH1 deficiency, 266120 (3);NT5C3A, NT5C3, UMPH1, PSN1;606224;AR;7p14.3
NT5E;Calcification of joints and arteries, 211800 (3);NT5E, NT5;129190;AR;6q14.3
NTF4 ;Glaucoma 1, open angle, 1O, 613100 (3);NTF4 , NTF5, NT5, NT4, GLC1O;162662;-;19q13.33
NTHL1;Familial adenomatous polyposis 3, 616415 (3);NTHL1, OCTS3, FAP3;602656;AR;16p13.3
NTRK1;Insensitivity to pain, congenital, with anhidrosis, 256800 (3),Medullary thyroid carcinoma, familial, 155240 (3);NTRK1, TRKA, MTC;191315;AR, AD;1q23.1
NTRK2;?Obesity, hyperphagia, and developmental delay, 613886 (3);NTRK2, TRKB;600456;-;9q21.33
NUBPL;Mitochondrial complex I deficiency, 252010 (3);NUBPL, IND1;613621;Mi, XLD, AR;14q12
NUMA1;Leukemia, acute promyelocytic, somatic, 612376 (3);NUMA1;164009;-;11q13.4
NUP107;Nephrotic syndrome, type 11, 616730 (3);NUP107, NUP84, NPHS11;607617;AR;12q15
NUP155;?Atrial fibrillation 15, 615770 (3);NUP155, KIAA0791, ATFB15;606694;AR;5p13.2
NUP205;?Nephrotic syndrome, type 13, 616893 (3);NUP205, C7orf14, KIAA0225, NPHS13;614352;-;7q33
NUP214;Leukemia, T-cell acute lymphoblastic, somatic, 613065 (3),Leukemia, acute myeloid, somatic, 601626 (3);NUP214, D9S46E, CAN, CAIN;114350;-;9q34.13
NUP62;Striatonigral degeneration, infantile, 271930 (3);NUP62, SNDI, IBSN;605815;AR;19q13.33
NUP93;Nephrotic syndrome, type 12, 616892 (3);NUP93, NIC96, KIAA0095, NPHS12;614351;AR;16q13
NYS2;Nystagmus 2, congenital, autosomal dominant (2);NYS2, NYSA;164100;AD;6p12
NYS3;Nystagmus 3, congenital, autosomal dominant (2);NYS3;608345;AD;7p11.2
NYS4;Nystagmus 4, congenital, autosomal dominant (2);NYS4;193003;AD;13q31-q33
NYS5;Nystagmus 5, congenital, X-linked (2);NYS5;300589;XLD;Xp11.4
NYS7;Nystagmus 7, congenital, autosomal dominant (2);NYS7;614826;AD;1q31.3-q32.1
NYX;Night blindness, congenital stationary (complete), 1A, X-linked, 310500 (3);NYX, CSNB1A, NBM1;300278;XLR;Xp11.4
OASD;Ocular albinism with sensorineural deafness (2);OASD;300650;XL;Xp22.3
OAT;Gyrate atrophy of choroid and retina with or without ornithinemia, 258870 (3);OAT, GACR;613349;AR;10q26.13
OBSL1;3-M syndrome 2, 612921 (3);OBSL1, KIAA0657, 3M2;610991;-;2q35
OCA2;Albinism, brown oculocutaneous, 203200 (3),Albinism, oculocutaneous, type II, 203200 (3);OCA2, P, PED, D15S12, BOCA, EYCL3, HCL3, SHEP1;611409;AR,AR;15q12-q13
OCA5;Albinism, oculocutaneous, type V (2);OCA5;615312;AR;4q24
OCLN;Band-like calcification with simplified gyration and polymicrogyria, 251290 (3);OCLN, BLCPMG;602876;AR;5q13.2
OCRL;Dent disease 2, 300555 (3),Lowe syndrome, 309000 (3);OCRL, LOCR, OCRL1, NPHL2;300535;XLR;Xq26.1
OFC1;Orofacial cleft-1 (2);OFC1, CL;119530;AD;6p24.3
OFC12;Orofacial cleft 12 (2);OFC12;612858;-;8q24.3
OFC13;Orofacial cleft 13 (2);OFC13;613857;AD;1p33
OFC14;Orofacial cleft 14 (2);OFC14;615892;AR;1p31
OFC2;Orofacial cleft-2 (2);OFC2;602966;-;2p13
OFC3;Orofacial cleft-3 (2);OFC3;600757;?AD;19q13
OFC4;Orofacial cleft 4 (2);OFC4;608371;-;4q21-q31
OFC9;Orofacial cleft 9 (2);OFC9;610361;-;13q33.1-q34
OFD1;?Retinitis pigmentosa 23, 300424 (3),Joubert syndrome 10, 300804 (3),Orofaciodigital syndrome I, 311200 (3),Simpson-Golabi-Behmel syndrome, type 2, 300209 (3);OFD1, CXorf5, SGBS2, JBTS10, RP23;300170;XLR, XLD;Xp22.2
OGDH;Alpha-ketoglutarate dehydrogenase deficiency, 203740 (1);OGDH;613022;AR;7p13
OGG1;Renal cell carcinoma, clear cell, somatic, 144700 (3);OGG1;601982;-;3p25.3
OHDS;Orthostatic hypotensive disorder of Streeten (2);OHDS;143850;AD;18q
OI16;Osteogenesis imperfecta, type XVI (4);OI16, C16DELp11.2, DEL16p11.2;616229;AR;11p11.2
OPA1;?Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type), 616896 (3),Behr syndrome, 210000 (3),Optic atrophy 1, 165500 (3),Optic atrophy plus syndrome, 125250 (3);OPA1, NTG, NPG, BERHS, MTDPS14;605290;AR, AD;3q29
OPA2;Optic atrophy 2, X-linked (2);OPA2;311050;XL;Xp11.4-p11.21
OPA3;3-methylglutaconic aciduria, type III, 258501 (3),Optic atrophy 3 with cataract, 165300 (3);OPA3, MGA3;606580;AR, AD;19q13.32
OPA4;Optic atrophy 4 (2);OPA4;605293;-;18q12.2-q12.3
OPA5;Optic atrophy 5 (2);OPA5;610708;AD;22q12.1-q13.1
OPA6;Optic atrophy 6 (2);OPA6;258500;AR;8q21-q22
OPA8;Optic atroph 8 (2);OPA8;616648;AD;16q21-q22
OPHLC;Omphalocele due to duplication of 1p31.3 (4);OPHLC, C1DUPp31.3, DUP1p31.3;164750;AD;1p31.3
OPHN1;Mental retardation, X-linked, with cerebellar hypoplasia and distinctive facial appearance, 300486 (3);OPHN1, MRX60;300127;XLR;Xq12
OPLAH;5-oxoprolinase deficiency, 260005 (3);OPLAH, OPLAHD;614243;AR;8q24.3
OPN1LW;Blue cone monochromacy, 303700 (3),Colorblindness, protan, 303900 (3);OPN1LW, RCP, CBP, CBBM;300822;XLR, XL ;Xq28
OPN1MW;Blue cone monochromacy, 303700 (3),Colorblindness, deutan, 303800 (3);OPN1MW, GCP, CBD, CBBM;300821;XLR, XL ;Xq28
OPN1SW;Colorblindness, tritan, 190900 (3);OPN1SW, BCP, CBT;613522;AD;7q32.1
OPTN;Amyotrophic lateral sclerosis 12, 613435 (3),Glaucoma 1, open angle, E, 137760 (3);OPTN, GLC1E, FIP2, HYPL, NRP, ALS12;602432;-, AD;10p13
ORAI1;Immunodeficiency 9, 612782 (3),Myopathy, tubular aggregate, 2, 615883 (3);ORAI1, TMEM142A, CRACM1, IMD9, TAM2;610277;AR, AD;12q24.31
ORC1;Meier-Gorlin syndrome 1, 224690 (3);ORC1, ORC1L;601902;AR;1p32.3
ORC4;Meier-Gorlin syndrome 2, 613800 (3);ORC4, ORC4L;603056;AR;2q23.1
ORC6;Meier-Gorlin syndrome 3, 613803 (3);ORC6, ORC6L;607213;AR;16q11.2
OSBPL2;Deafness, autosomal dominant 67, 616340 (3);OSBPL2, ORP2, KIAA0772, DNFA67;606731;AD;20q13.33
OSMR;Amyloidosis, primary localized cutaneous, 1, 105250 (3);OSMR, OSMRB, PLCA1;601743;AD;5p13.1
OSTM1;Osteopetrosis, autosomal recessive 5, 259720 (3);OSTM1, GL, OPTB5;607649;AR;6q21
OTC;Ornithine transcarbamylase deficiency, 311250 (3);OTC;300461;XLR;Xp11.4
OTDD;Otodental dysplasia chromsome deletion syndrome (4);OTDD, DEL11q13, C11DELq13;166750;AD;11q13
OTOA;Deafness, autosomal recessive 22, 607039 (3);OTOA, DFNB22;607038;AR;16p12.2
OTOF;Auditory neuropathy, autosomal recessive, 1, 601071 (3),Deafness, autosomal recessive 9, 601071 (3);OTOF, DFNB9, NSRD9, AUNB1;603681;AR;2p23.3
OTOG;Deafness, autosomal recessive 18B, 614945 (3);OTOG, OTGN, DFNB18B;604487;AR;11p15.1
OTOGL;Deafness, autosomal recessive 84B, 614944 (3);OTOGL, C12orf64, DFNB84B;614925;AR;12q21.31
OTSC1;Otosclerosis 1 (2);OTSC1, OTS;166800;AD;15q26.1-qter
OTSC10;Otosclerosis 10 (2);OTSC10;615589;AD;1q41-q44
OTSC2;Otosclerosis 2 (2);OTSC2;605727;-;7q34-q36
OTSC3;Otosclerosis 3 (2);OTSC3;608244;AD;6p22.3-p21.3
OTSC5;Otosclerosis 5 (2);OTSC5;608787;-;3q22-q24
OTSC7;Otosclerosis 7 (2);OTSC7;611572;AD;6q13-q16.1
OTSC8;Otosclerosis 8 (2);OTSC8;612096;AD;9p13.1-q21.11
OTX2;Microphthalmia, syndromic 5, 610125 (3),Pituitary hormone deficiency, combined, 6, 613986 (3),Retinal dystrophy, early-onset, with or without pituitary dysfunction, 610125 (3);OTX2, MCOPS5, CPHD6;600037;AD;14q22.3
OVOL2;Corneal dystrophy, posterior polymorphous, 1, 122000 (3);OVOL2, ZNF339, PPCD1;616441;AD;20p11.23
OXCT1;Succinyl CoA:3-oxoacid CoA transferase deficiency, 245050 (3);OXCT1, OXCT, SCOT;601424;-;5p13.1
P2RX1;Bleeding disorder due to P2RX1 defect, somatic, 609821 (3);P2RX1, P2X1;600845;-;17p13.2
P2RX2;Deafness, autosomal dominant 41, 608224 (3);P2RX2, P2X2, DFNA41;600844;AD;12q24.33
P2RY12;Bleeding disorder, platelet-type, 8, 609821 (3);P2RY12, P2Y12, BDPLT8;600515;AR;3q25.1
P3H1;Osteogenesis imperfecta, type VIII, 610915 (3);P3H1, LEPRE1, GROS1, OI8;610339;AR;1p34.2
P3H2;Myopia, high, with cataract and vitreoretinal degeneration, 614292 (3);P3H2, LEPREL1, MCVD;610341;AR;3q28
P4HB;Cole-Carpenter syndrome 1, 112240 (3);P4HB, PROHB, CLCRP1;176790;AD;17q25.3
PABPN1;Oculopharyngeal muscular dystrophy, 164300 (3);PABPN1, PABP2, PAB2;602279;AD;14q11.2
PACS1;Mental retardation, autosomal dominant 17, 615009 (3);PACS1, MRD17;607492;AD;11q13.1-q13.2
PAFAH1B1;Lissencephaly 1, 607432 (3),Subcortical laminar heterotopia, 607432 (3);PAFAH1B1, LIS1;601545;IC;17p13.3
PAFC;?Preauricular fistulae, congenital (2);PAFC;128700;AD;8q11.1-q13.3
PAH;Phenylketonuria, 261600 (3);PAH, PKU1;612349;AR;12q23.2
PAI1;Plasminogen activator inhibitor-1 deficiency, 613329 (3);PAI1, PLANH1, SERPINE1;173360;AR, AD, -;7q22.1
PAK3;Mental retardation, X-linked 30/47, 300558 (3);PAK3, MRX30, MRX47;300142;XLR;Xq23
PALB2;Fanconi anemia, complementation group N, 610832 (3);PALB2, FANCN, PNCA3;610355;-, AD;16p12.2
PAM16;Spondylometaphyseal dysplasia, Megarbane-Dagher-Melike type, 613320 (3);PAM16, MAGMAS, SMDMDM;614336;AR;16p13.3
PAND1;Panic disorder syndrome 1 (2);PAND1;167870;?AD;13q22-q32
PAND2;Panic disorder 2 (2);PAND2;607853;-;9q31
PAND3;Panic disorder 3 (2);PAND3;609985;-;4q31-q34
PANK2;HARP syndrome, 607236 (3),Neurodegeneration with brain iron accumulation 1, 234200 (3);PANK2, NBIA1, PKAN, HARP;606157;AR;20p13
PAOD1;Peripheral arterial occlusive disease 1 (2);PAOD1;606787;-;1p31
PAPA2;Postaxial polydactyly, type A2 (2);PAPA2;602085;AD;13q21-q32
PAPA3;Polydactyly, postaxial, type A3 (2);PAPA3;607324;-;19p13.2-p13.1
PAPA4;Polydactyly, postaxial, type A4 (2);PAPA4;608562;-;7q22
PAPA5;Polydactyly, postaxial, type A5 (2);PAPA5;263450;AR;13q13.3-q21
PAPSS2;Brachyolmia 4 with mild epiphyseal and metaphyseal changes, 612847 (3);PAPSS2, ATPSK2, BCYM4;603005;AR;10q23.2-q23.3
PARN;Dyskeratosis congenita, autosomal recessive 6, 616353 (3),Pulmonary fibrosis and/or bone marrow failure, telomere-related, 4, 616371 (3);PARN, DAN, DKCB6, PFBMFT4;604212;AR, AD;16p13.12
PAURT1;Preauricular tag, isolated, autosomal dominant, 1 (2);PAURT1;610420;AD;14q11.2-q12
PAX1;?Otofaciocervical syndrome 2, 615560 (3);PAX1, OFC2;167411;AR;20p11.22
PAX2;Glomerulosclerosis, focal segmental, 7, 616002 (3),Papillorenal syndrome, 120330 (3);PAX2, PAPRS, FSGS7;167409;AD;10q24.31
PAX3;Craniofacial-deafness-hand syndrome, 122880 (3),Rhabdomyosarcoma 2, alveolar, 268220 (3),Waardenburg syndrome, type 1, 193500 (3),Waardenburg syndrome, type 3, 148820 (3);PAX3, WS1, HUP2, CDHS, WS3;606597;AR, AD;2q36.1
PAX4;Diabetes mellitus, type 2, 125853 (3),Maturity-onset diabetes of the young, type IX, 612225 (3);PAX4, MODY9, KPD;167413;AD, -;7q32.1
PAX6;?Morning glory disc anomaly, 120430 (3),Aniridia, 106210 (3),Cataract with late-onset corneal dystrophy, 106210 (3),Coloboma of optic nerve, 120430 (3),Coloboma, ocular, 120200 (3),Foveal hypoplasia 1, 136520 (3),Keratitis, 148190 (3),Optic nerve hypoplasia, 165550 (3),Peters anomaly, 604229 (3);PAX6, AN2, MGDA, FVH1;607108;AD;11p13
PAX7;Rhabdomyosarcoma 2, alveolar, 268220 (3);PAX7, RMS2;167410;AR;1p36.13
PAX8;Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, 218700 (3);PAX8;167415;AD;2q14.1
PAX9;Tooth agenesis, selective, 3, 604625 (3);PAX9, STHAG3;167416;AD;14q13.3
PBC1;Biliary cirrhosis, primary, 1 (2);PBC1;109720;AD;3p12-q13.2
PBC4;Biliary cirrhosis, primary, 4 (2);PBC4;614220;-;7q32
PBC5;Biliary cirrhosis, primary, 5 (2);PBC5;614221;-;17q12
PBCA;?Diabetes mellitus, insulin-dependent, neonatal (2);PBCA;600089;AR;6p21.3
PBCRA;Chorioretinal atrophy, progressive bifocal (2);PBCRA, CRAPB;600790;AD;6q14-q16.2
PBLT;Panbronchiolitis, diffuse (2);PBLT;604809;Mu ;6p21.3
PBX1;Leukemia, acute pre-B-cell (2);PBX1;176310;-;1q23.3
PC;Pyruvate carboxylase deficiency, 266150 (3);PC;608786;AR;11q13.2
PCBD1;Hyperphenylalaninemia, BH4-deficient, D, 264070 (3);PCBD1, DCOH;126090;AR;10q22.1
PCCA;Propionicacidemia, 606054 (3);PCCA;232000;AR;13q32.3
PCCB;Propionicacidemia, 606054 (3);PCCB;232050;AR;3q22.3
PCDH15;Deafness, autosomal recessive 23, 609533 (3),Usher syndrome, type 1D/F digenic, 601067 (3),Usher syndrome, type 1F, 602083 (3);PCDH15, DFNB23, USH1F;605514;AR, DR;10q21.1
PCDH19;Epileptic encephalopathy, early infantile, 9, 300088 (3);PCDH19, KIAA1313, EFMR, EIEE9;300460;XL;Xq22.1
PCK1;?Phosphoenolpyruvate carboxykinase-1, cytosolic, deficiency, 261680 (1);PCK1;614168;AR;20q13.31
PCK2;PEPCK deficiency, mitochondrial, 261650 (1);PCK2, PEPCK2;614095;AR;14q11-q12
PCLO;?Pontocerebellar hypoplasia, type 3, 608027 (3);PCLO, PCH3;604918;AR;7q21.11
PCNA;?Ataxia-telangiectasia-like disorder, 615919 (3);PCNA, ATLD2;176740;AR;20p12.3
PCNT;Microcephalic osteodysplastic primordial dwarfism, type II, 210720 (3);PCNT, PCNT2, KEN, SCKL4, MOPD2;605925;AR;21q22.3
PCOS1;Polycystic ovary syndrome 1 (2);PCOS1, PCO1, PCO;184700;AD;19p13.2
PCSK1;Obesity with impaired prohormone processing, 600955 (3);PCSK1, NEC1, PC1, PC3, BMIQ12;162150;IC, -;5q15
PCSK9;Hypercholesterolemia, familial, 3, 603776 (3);PCSK9, NARC1, HCHOLA3, FH3, LDLCQ1;607786;-;1p32.3
PCYT1A;Spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 (3);PCYT1A, CTPCT, PCYT1, SMDCRD;123695;AR;3q29
PDB4;Paget disease of bone 4 (2);PDB4;606263;AD;5q31
PDCD10;Cerebral cavernous malformations 3, 603285 (3);PDCD10, TFAR15, CCM3;609118;-;3q26.1
PDCN;Nephrotic syndrome, type 2, 600995 (3);PDCN, NPHS2, SRN1;604766;AR;1q25.2
PDE10A;Dyskinesia, limb and orofacial, infantile-onset, 616921 (3),Striatal degeneration, autosomal dominant, 616922 (3);PDE10A, IOLOD, ADSD2;610652;AR, AD;6q27
PDE11A;Pigmented nodular adrenocortical disease, primary, 2, 610475 (3);PDE11A, PDE11A1, PDE11A2, PDE11A3, PPNAD2;604961;AD;2q31.2
PDE3A;Hypertension and brachydactyly syndrome, 112410 (3);PDE3A, HTNB;123805;AD;12p12.2
PDE4D;Acrodysostosis 2, with or without hormone resistance, 614613 (3);PDE4D, DPDE3, STRK1, ACRDYS2;600129;AD;5q11.2-q12.1
PDE6A;Retinitis pigmentosa 43, 613810 (3);PDE6A, PDEA, RP43;180071;-;5q32
PDE6B;Night blindness, congenital stationary, autosomal dominant 2, 163500 (3),Retinitis pigmentosa-40, 613801 (3);PDE6B, PDEB, RP40, CSNBAD2;180072;AD, AR;4p16.3
PDE6C;Cone dystrophy 4, 613093 (3);PDE6C, PDEA2, COD4;600827;AR;10q23.33
PDE6D;?Joubert syndrome 22, 615665 (3);PDE6D, JBTS22;602676;AR;2q37.1
PDE6G;Retinitis pigmentosa 57, 613582 (3);PDE6G, PDEG, RP57;180073;AR;17q25.3
PDE6H;Achromatopsia 6, 610024 (3),Retinal cone dystrophy 3, 610024 (3);PDE6H, RCD3, ACHM6;601190;AD, AR;12p12.3
PDE8B;Pigmented nodular adrenocortical disease, primary, 3, 614190 (3),Striatal degeneration, autosomal dominant, 609161 (3);PDE8B, PPNAD3, ADSD;603390;-, AD;5q13.3
PDGFB;Basal ganglia calcification, idiopathic, 5, 615483 (3),Dermatofibrosarcoma protuberans, 607907 (3),Meningioma, SIS-related, 607174 (3);PDGFB, SIS, IBGC5;190040;-, AD;22q13.1
PDGFRA;Gastrointestinal stromal tumor, somatic, 606764 (3),Hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 (3);PDGFRA;173490;-, IC, Smu;4q12
PDGFRB;Basal ganglia calcification, idiopathic, 4, 615007 (3),Kosaki overgrowth syndrome, 616592 (3),Myeloproliferative disorder with eosinophilia, 131440 (4),Myofibromatosis, infantile, 1, 228550 (3),Premature aging syndrome, Penttinen type, 601812 (3);PDGFRB, PDGFR, IBGC4, IMF1, PENTT, KOGS;173410;AD;5q32
PDGFRL;Colorectal cancer, somatic, 114500 (3),Hepatocellular cancer, somatic, 114550 (3);PDGFRL, PDGRL, PRLTS;604584;-;8p22
PDHA1;Pyruvate dehydrogenase E1-alpha deficiency, 312170 (3);PDHA1, PHE1A, PDHAD;300502;XLD;Xp22.12
PDHB;Pyruvate dehydrogenase E1-beta deficiency, 614111 (3);PDHB, PDHBD;179060;-;3p14.3
PDK3;?Charcot-Marie-Tooth disease, X-linked dominant, 6, 300905 (3);PDK3, CMTX6;300906;XLD;Xp22.11
PDON2;Periodontitis, aggressive, 2 (2);PDON2;608526;-;1q25
PDP1;Pyruvate dehydrogenase phosphatase deficiency, 608782 (3);PDP1, PPM2C, PDP1, PDPC;605993;AR;8q22.1
PDR;Pigment disorder, reticulate (2);PDR;301220;XLR;Xp22-p21
PDSS1;Coenzyme Q10 deficiency, primary, 2, 614651 (3);PDSS1, TPT, COQ1, COQ10D2;607429;AR;10p12.1
PDSS2;Coenzyme Q10 deficiency, primary, 3, 614652 (3);PDSS2, DLP1, C6orf210, COQ10D3;610564;AR;6q21
PDX1;Lacticacidemia due to PDX1 deficiency, 245349 (3);PDX1;608769;AR;11p13
PDYN;Spinocerebellar ataxia 23, 610245 (3);PDYN, SCA23;131340;AD;20p13
PDZD7;Usher syndrome, type IIC, GPR98/PDZD7 digenic, 605472 (3);PDZD7;612971;DD, AR;10q24.31
PEE1;Preeclampsia/eclampsia 1 (2);PEE1, PREG1;189800;AD;2p13
PEE2;Preeclampsia/eclampsia 2 (2);PEE2;609402;-;2p25
PEE3;Preeclampsia/eclampsia 3 (2);PEE3;609403;-;9p13
PEPD;Prolidase deficiency, 170100 (3);PEPD;613230;AR;19q13.11
PER2;Advanced sleep phase syndrome, familial, 1, 604348 (3);PER2, FASPS1, KIAA0347;603426;AD;2q37.3
PER3;?Advanced sleep phase syndrome, familial, 3, 616882 (3);PER3, FASPS3;603427;AD;1p36.23
PET100;Mitochondrial complex IV deficiency, 220110 (3);PET100, C19orf79;614770;Mi, AR;19p13.2
PEX1;Heimler syndrome 1, 234580 (3),Peroxisome biogenesis disorder 1A (Zellweger), 214100 (3),Peroxisome biogenesis disorder 1B (NALD/IRD), 601539 (3);PEX1, ZWS1, PBD1A, PBD1B, HMLR1;602136;AR, -;7q21.2
PEX10;Peroxisome biogenesis disorder 6A (Zellweger), 614870 (3),Peroxisome biogenesis disorder 6B, 614871 (3);PEX10, NALD, PBD6A, PBD6B;602859;AR;1p36.32
PEX11B;Peroxisome biogenesis disorder 14B, 614920 (3);PEX11B, PEX14B;603867;-;1q21.1
PEX12;Peroxisome biogenesis disorder 3A (Zellweger), 614859 (3),Peroxisome biogenesis disorder 3B, 266510 (3);PEX12, PBD3A;601758;AR;17q12
PEX13;Peroxisome biogenesis disorder 11A (Zellweger), 614883 (3),Peroxisome biogenesis disorder 11B, 614885 (3);PEX13, ZWS, NALD, PBD11A, PBD11B;601789;-;2p15
PEX14;Peroxisome biogenesis disorder 13A (Zellweger), 614887 (3);PEX14, PBD13A;601791;AR;1p36.22
PEX16;Peroxisome biogenesis disorder 8A, (Zellweger), 614876 (3),Peroxisome biogenesis disorder 8B, 614877 (3);PEX16, PBD8A, PBD8B;603360;-;11p11.2
PEX19;Peroxisome biogenesis disorder 12A (Zellweger), 614886 (3);PEX19, PXF, HK33, D1S2223E, PBD12A;600279;-;1q23.2
PEX2;Peroxisome biogenesis disorder 5A (Zellweger), 614866 (3),Peroxisome biogenesis disorder 5B, 614867 (3);PEX2, PAF1, PMP35, PBD5A, PBD5B, PXMP3;170993;AR;8q21.13
PEX26;Peroxisome biogenesis disorder 7A (Zellweger), 614872 (3),Peroxisome biogenesis disorder 7B, 614873 (3);PEX26, PBD7A, PBD7B;608666;-;22q11.21
PEX3;Peroxisome biogenesis disorder 10A (Zellweger), 614882 (3);PEX3, PBD10A;603164;-;6q24.2
PEX5;Peroxisome biogenesis disorder 2A (Zellweger), 214110 (3),Peroxisome biogenesis disorder 2B, 202370 (3),Rhizomelic chondrodysplasia punctata, type 5, 616716 (3);PEX5, PXR1, PTS1R, PBD2A, PBD2B, RCDP5;600414;AR;12p13.31
PEX6;Heimler syndrome 2, 616617 (3),Peroxisome biogenesis disorder 4A (Zellweger), 614862 (3),Peroxisome biogenesis disorder 4B, 614863 (3);PEX6, PXAAA1, PAF2, PBD4A, PDB4B, HMLR2;601498;AR;6p21.1
PEX7;Peroxisome biogenesis disorder 9B, 614879 (3),Rhizomelic chondrodysplasia punctata, type 1, 215100 (3);PEX7, RCDP1, PBD9B;601757;-, AR;6q23.3
PFC;Properdin deficiency, X-linked, 312060 (3);PFC, PFD;300383;XLR;Xp11.23
PFHB2;Progressive familial heart block, type II (2);PFHB2;140400;AD;1q32
PFKL;Hemolytic anemia due to phosphofructokinase deficiency (1);PFKL;171860;-;21q22.3
PFKM;Glycogen storage disease VII, 232800 (3);PFKM, GSD7;610681;AR;12q13.11
PFN1;Amyotrophic lateral sclerosis 18, 614808 (3);PFN1, ALS18;176610;-;17p13.2
PGAM2;Glycogen storage disease X, 261670 (3);PGAM2, PGAMM, GSD10;612931;AR;7p13
PGAP1;Mental retardation, autosomal recessive 42, 615802 (3);PGAP1, MRT42;611655;AR;2q33.1
PGAP2;Hyperphosphatasia with mental retardation syndrome 3, 614207 (3);PGAP2, FRAG1, HPMRS3, MRT17, MRT21;615187;AR;11p15.4
PGAP3;Hyperphosphatasia with mental retardation syndrome 4, 615716 (3);PGAP3, PERLD1, CAB2, MGC9753, HPMRS4;611801;AR;17q12
PGK1;Phosphoglycerate kinase 1 deficiency, 300653 (3);PGK1, PGKA;311800;XLR;Xq21.1
PGM1;Congenital disorder of glycosylation, type It, 614921 (3);PGM1, GSD14, CDG1T;171900;AR;1p31.3
PGM3;Immunodeficiency 23, 615816 (3);PGM3, AGM1, IMD23;172100;AR;6q14.1
PGN;Spastic paraplegia 7, autosomal recessive, 607259 (3);PGN, SPG7, CMAR, CAR;602783;AD, AR;16q24.3
PGR;?Progesterone resistance, 264080 (2);PGR;607311;AR;11q22.1
PHA2A;Pseudohypoaldosteronism, type IIA (2);PHA2A, PHA2;145260;AD;1q31-q42
PHC1;?Microcephaly 11, primary, autosomal recessive, 615414 (3);PHC1, EDR1, HPH1, RAE28, MCPH11;602978;AR;12p13.31
PHEX;Hypophosphatemic rickets, X-linked dominant, 307800 (3);PHEX, HYP, HPDR1, LXHR;300550;XLD;Xp22.11
PHF6;Borjeson-Forssman-Lehmann syndrome, 301900 (3);PHF6, BFLS;300414;XLR;Xq26.2
PHF8;Mental retardation syndrome, X-linked, Siderius type, 300263 (3);PHF8, ZNF422, KIAA1111, MRXSSD;300560;XLR;Xp11.22
PHF9;Fanconi anemia, complementation group L, 614083 (3);PHF9, FANCL;608111;AR;2p16.1
PHGDH;Neu-Laxova syndrome 1, 256520 (3),Phosphoglycerate dehydrogenase deficiency, 601815 (3);PHGDH, NLS1, PHGDHD;606879;AR;1p12
PHKA1;Muscle glycogenosis, 300559 (3);PHKA1;311870;XLR;Xq13.1
PHKA2;Glycogen storage disease, type IXa1, 306000 (3),Glycogen storage disease, type IXa2, 306000 (3);PHKA2, PHK, XLG, PHK, PYKL, GSD9A;300798;XLR;Xp22.13
PHKB;Phosphorylase kinase deficiency of liver and muscle, autosomal recessive, 261750 (3);PHKB;172490;AR;16q12.1
PHKG2;Cirrhosis due to liver phosphorylase kinase deficiency (3),Glycogen storage disease IXc, 613027 (3);PHKG2, GSD9C;172471;-, AR;16p11.2
PHOBS;Phobia, specific (2);PHOBS;608251;-;Chr.14
PHOX2A;Fibrosis of extraocular muscles, congenital, 2, 602078 (3);PHOX2A, ARIX, CFEOM2;602753;AR;11q13.4
PHYH;Refsum disease, 266500 (3);PHYH, PAHX;602026;AR;10p13
PI4KA;Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis, 616531 (3);PI4KA, PIK4CA, PMGYCHA;600286;AR;22q11.21
PICALM;Leukemia, acute myeloid, somatic, 601626 (3);PICALM, CALM, CLTH, LAP;603025;-;11q14.2
PIEZO1;Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, 194380 (3),Lymphedema, hereditary, III, 616843 (3);PIEZO1, FAM38A, MIB, DHS, LMPH3;611184;AD, AR;16q24.3
PIEZO2;?Marden-Walker syndrome, 248700 (3),Arthrogryposis, distal, type 3, 114300 (3),Arthrogryposis, distal, type 5, 108145 (3);PIEZO2, FAM38B, DA5, DA3, MWKS;613629;AD;18p11.22-p11.21
PIGA;Multiple congenital anomalies-hypotonia-seizures syndrome 2, 300868 (3),Paroxysmal nocturnal hemoglobinuria, somatic, 300818 (3);PIGA, PNH1, MCAHS2;311770;XLR, -;Xp22.2
PIGG;Mental retardation, autosomal recessive 53, 616917 (3);PIGG, GPI7, MRT53;616918;AR;4p16.3
PIGL;CHIME syndrome, 280000 (3);PIGL, CHIME;605947;AR;17p11.2
PIGM;Glycosylphosphatidylinositol deficiency, 610293 (3);PIGM;610273;AR;1q23.2
PIGN;Multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080 (3);PIGN, MCAHS1;606097;AR;18q21.33
PIGO;Hyperphosphatasia with mental retardation syndrome 2, 614749 (3);PIGO, HPMRS2;614730;AR;9p13.3
PIGT;?Paroxysmal nocturnal hemoglobinuria 2, 615399 (3),Multiple congenital anomalies-hypotonia-seizures syndrome 3, 615398 (3);PIGT, NDAP, PNH2, MCAHS3;610272;AD, Smu, AR;20q13.12
PIGV;Hyperphosphatasia with mental retardation syndrome 1, 239300 (3);PIGV, HPMRS1;610274;AR;1p36.11
PIGW;?Hyperphosphatasia with mental retardation syndrome 5, 616025 (3);PIGW, HPMRS5;610275;AR;17q12
PIGY;Hyperphosphatasia with mental retardation syndrome 6, 616809 (3);PIGY, HPMRS6;610662;AR;4q22.1
PIK3CA;Breast cancer, somatic, 114480 (3),CLOVE syndrome, somatic, 612918 (3),Colorectal cancer, somatic, 114500 (3),Cowden syndrome 5, 615108 (3),Gastric cancer, somatic, 613659 (3),Hepatocellular carcinoma, somatic, 114550 (3),Keratosis, seborrheic, somatic, 182000 (3),Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic, 602501 (3),Nevus, epidermal, somatic, 162900 (3),Nonsmall cell lung cancer, somatic, 211980 (3),Ovarian cancer, somatic, 167000 (3);PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5;171834;-;3q26.32
PIK3CD;Immunodeficiency 14, 615513 (3);PIK3CD, APDS, IMD14;602839;AD;1p36.22
PIK3R1;?Agammaglobulinemia 7, autosomal recessive, 615214 (3),Immunodeficiency 36, 616005 (3),SHORT syndrome, 269880 (3);PIK3R1, GRB1, AGM7, SHORT, IMD36;171833;AR, AD;5q13.1
PIK3R2;Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, 603387 (3);PIK3R2, MPPH1;603157;AD;19p13.11
PIK3R5;Ataxia-oculomotor apraxia 3, 615217 (3);PIK3R5, p101;611317;AR;17p13.1
PIKFYVE;Corneal fleck dystrophy, 121850 (3);PIKFYVE, PIP5K3;609414;AD;2q34
PINK1;Parkinson disease 6, early onset, 605909 (3);PINK1, PARK6;608309;AR;1p36.12
PIP5K1C;Lethal congenital contractural syndrome 3, 611369 (3);PIP5K1C, LCCS3;606102;AR;19p13.3
PITPNM3;Cone-rod dystrophy 5, 600977 (3);PITPNM3, NIR1, CORD5;608921;AD;17p13.2-p13.1
PITX1;Clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly, 119800 (3),Liebenberg syndrome, 186550 (4);PITX1, PTX1, BFT, POTX, CCF, LBNBG;602149;AD;5q31.1
PITX2;Axenfeld-Rieger syndrome, type 1, 180500 (3),Iridogoniodysgenesis, type 2, 137600 (3),Peters anomaly, 604229 (3),Ring dermoid of cornea, 180550 (3);PITX2, IDG2, RIEG1, RGS, IGDS2;601542;AD;4q25
PITX3;Anterior segment mesenchymal dysgenesis, 107250 (3),Cataract 11, multiple types, 610623 (3),Cataract 11, syndromic, 610623 (3);PITX3, CTPP4, CTRCT11;602669;AD;10q24.32
PJVK;Deafness, autosomal recessive 59, 610220 (3);PJVK, DFNB59;610219;AR;2q31.2
PKD1;Polycystic kidney disease, adult type I, 173900 (3);PKD1;601313;AD;16p13.3
PKD2;Polycystic kidney disease 2, 613095 (3);PKD2;173910;-;4q22.1
PKDTS;Polycystic kidney disease, infantile severe, with tuberous sclerosis (4);PKDTS;600273;AD;16p13.3
PKLR;Adenosine triphosphate, elevated, of erythrocytes, 102900 (3),Pyruvate kinase deficiency, 266200 (3);PKLR, PK1;609712;AD, AR;1q22
PKP1;Ectodermal dysplasia/skin fragility syndrome, 604536 (3);PKP1;601975;-;1q32.1
PKP2;Arrhythmogenic right ventricular dysplasia 9, 609040 (3);PKP2, ARVD9;602861;AD;12p11.21
PKS;Pallister-Killian syndrome (4);PKS;601803;Smo;12p
PLA2G4A;Phospholipase A2, group IV A, deficiency of (3);PLA2G4A, PLA2G4;600522;-;1q31.1
PLA2G6;Infantile neuroaxonal dystrophy 1, 256600 (3),Neurodegeneration with brain iron accumulation 2B, 610217 (3),Parkinson disease 14, autosomal recessive, 612953 (3);PLA2G6, IPLA2, INAD1, NBIA2B, NBIA2A, PARK14;603604;AR;22q13.1
PLA2G7;Platelet-activating factor acetylhydrolase deficiency, 614278 (3);PLA2G7, PAFAH, PAFAD;601690;-, AD;6p12.3
PLAG1;Adenomas, salivary gland pleomorphic, somatic, 181030 (3);PLAG1, SGPA, PSA;603026;-;8q12.1
PLAT;Hyperfibrinolysis, familial, due to increased release of PLAT, 612348 (1),Thrombophilia, familial, due to decreased release of PLAT, 612348 (1);PLAT, TPA;173370;-;8p11.21
PLAU;Quebec platelet disorder, 601709 (3);PLAU, URK, QPD, BDPLT5;191840;AD;10q22.2
PLCB1;Epileptic encephalopathy, early infantile, 12, 613722 (3);PLCB1, KIAA0581, PLCB1A, PLCB1B, EIEE12;607120;AR;20p12.3
PLCB2;Platelet PLC beta-2 deficiency (1);PLCB2;604114;-;15q15.1
PLCB4;Auriculocondylar syndrome 2, 614669 (3);PLCB4, ARCND2;600810;AD, AR;20p12.3-p12.2
PLCD1;Nail disorder, nonsyndromic congenital, 3, (leukonychia), 151600 (3);PLCD1, NDNC3;602142;AD, AR;3p22.2
PLCE1;Nephrotic syndrome, type 3, 610725 (3);PLCE1, KIAA1516, NPHS3;608414;AR;10q23.33
PLCG2;Autoinflammation, antibody deficiency, and immune dysregulation syndrome, 614878 (3),Familial cold autoinflammatory syndrome 3, 614468 (3);PLCG2, FCAS3, APLAID;600220;AD;16q23.3
PLEC1;?Epidermolysis bullosa simplex with nail dystrophy, 616487 (3),Epidermolysis bullosa simplex with muscular dystrophy, 226670 (3),Epidermolysis bullosa simplex with pyloric atresia, 612138 (3),Epidermolysis bullosa simplex, Ogna type, 131950 (3),Muscular dystrophy, limb-girdle, type 2Q, 613723 (3);PLEC1, PLEC, PLTN, EBS1, LGMD2Q, EBSOG, EBSPA, EBSMD, EBSND;601282;AR, AD;8q24.3
PLEKHG2;Leukodystrophy and acquired microcephaly with or without dystonia, 616763 (3);PLEKHG2, CLG, LDAMD;611893;AR;19q13.2
PLEKHG5;Charcot-Marie-Tooth disease, recessive intermediate C, 615376 (3),Spinal muscular atrophy, distal, autosomal recessive, 4, 611067 (3);PLEKHG5, KIAA0720, DSMA4, CMTRIC;611101;AR;1p36.31
PLEKHM1;Osteopetrosis, autosomal recessive 6, 611497 (3);PLEKHM1, AP162, KIAA0356, OPTB6;611466;-;17q21.31
PLG;Dysplasminogenemia, 217090 (3),Plasminogen deficiency, type I, 217090 (3);PLG;173350;AR;6q26
PLI;Alpha-2-plasmin inhibitor deficiency, 262850 (3);PLI, SERPINF2;613168;AR;17p13.3
PLIN1;Lipodystrophy, familial partial, type 4, 613877 (3);PLIN1, PLIN, FPLD4;170290;AD;15q26.1
PLK4;Microcephaly and chorioretinopathy, autosomal recessive, 2, 616171 (3);PLK4, STK18, SAK, MCCRP2;605031;AR;4q28.1
PLN;Cardiomyopathy, dilated, 1P, 609909 (3),Cardiomyopathy, hypertrophic, 18, 613874 (3);PLN, PLB, CMD1P, CMH18;172405;-,AD;6q22.31
PLOD1;Ehlers-Danlos syndrome, type VI, 225400 (3);PLOD1, LH1, LLH, EDS6;153454;AR;1p36.22
PLOD2;Bruck syndrome 2, 609220 (3);PLOD2, LH2, TLH, BRKS2;601865;AR;3q24
PLOD3;Lysyl hydroxylase 3 deficiency, 612394 (3);PLOD3, LH3;603066;AR;7q22.1
PLP1;Pelizaeus-Merzbacher disease, 312080 (3),Spastic paraplegia 2, X-linked, 312920 (3);PLP1, PMD, HLD1, SPG2;300401;XLR;Xq22.2
PLS3;Bone mineral density QTL18, osteoporosis, 300910 (3);PLS3, BMND18;300131;XLD;Xq23
PLSA1;Primary lateral sclerosis, adult, 1 (2);PLSA1, PLSA;611637;AD;4p16
PML;Leukemia, acute promyelocytic, PML/RARA type (3);PML, MYL;102578;-;15q24.1
PMM2;Congenital disorder of glycosylation, type Ia, 212065 (3);PMM2, CDG1A;601785;AR;16p13.2
PMP22;Charcot-Marie-Tooth disease, type 1A, 118220 (3),Charcot-Marie-Tooth disease, type 1E, 118300 (3),Dejerine-Sottas disease, 145900 (3),Neuropathy, inflammatory demyelinating, 139393 (3),Neuropathy, recurrent, with pressure palsies, 162500 (3),Roussy-Levy syndrome, 180800 (3);PMP22, CMT1A, CMT1E, DSS;601097;AD, AR, ?AD;17p12
PMPCA;Spinocerebellar ataxia, autosomal recessive 2, 213200 (3);PMPCA, KIAA0123, SCAR2;613036;AR;9q34.3
PMS2;Colorectal cancer, hereditary nonpolyposis, type 4, 614337 (3),Mismatch repair cancer syndrome, 276300 (3);PMS2, PMSL2, HNPCC4;600259;-, AR;7p22.1
PMVK;Porokeratosis 1, multiple types, 175800 (3);PMVK, PMK, POROK1;607622;AD;1q21.3
PMX2B;Central hypoventilation syndrome, congenital, with or without Hirschsprung disease, 209880 (3),Neuroblastoma with Hirschsprung disease, 613013 (3);PMX2B, NBPHOX, PHOX2B, NBLST2;603851;AD, -;4p13
PNKD2;Paroxysmal nonkinesigenic dyskinesia 2 (2);PNKD2;611147;AD;2q31
PNKP;Ataxia-oculomotor apraxia 4, 616267 (3),Microcephaly, seizures, and developmental delay, 613402 (3);PNKP, PNK, MCSZ, EIEE10, MCSZ, AOA4;605610;AR;19q13.33
PNLIP;Pancreatic lipase deficiency, 614338 (1);PNLIP, PNLIPD;246600;AR;10q25.3
PNP;Immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 (3);PNP, NP;164050;AR;14q11.2
PNPLA1;Ichthyosis, congenital, autosomal recessive 10, 615024 (3);PNPLA1, ARCI10;612121;AR;6p21.31
PNPLA2;Neutral lipid storage disease with myopathy, 610717 (3);PNPLA2, TTS2, ATGL;609059;AR;11p15.5
PNPLA6;?Laurence-Moon syndrome, 245800 (3),Boucher-Neuhauser syndrome, 215470 (3),Oliver-McFarlane syndrome, 275400 (3),Spastic paraplegia 39, autosomal recessive, 612020 (3);PNPLA6, NTE, SPG39, NTEMND, BNHS, LNMS, OMCS;603197;AR;19p13.2
PNPLA8;?Mitochondrial myopathy with lactic acidosis, 251950 (3);PNPLA8, MMLA;612123;AR;7q31.1
PNPO;Pyridoxamine 5'-phosphate oxidase deficiency, 610090 (3);PNPO;603287;AR;17q21.32
PNPT1;Combined oxidative phosphorylation deficiency 13, 614932 (3),Deafness, autosomal recessive 70, 614934 (3);PNPT1, OLD35, COXPD13, DFNB70;610316;AR;2p16.1
POC1A;Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 (3);POC1A, PIX2, SOFT;614783;AR;3p21.2
POC1B;Cone-rod dystrophy 20, 615973 (3);POC1B, PIX1, CORD20;614784;AR;12q21.33
POFUT1;Dowling-Degos disease 2, 615327 (3);POFUT1, OFUCT1, KIAA0180, DDD2;607491;AD;20q11.21
POGLUT1;Dowling-Degos disease 4, 615696 (3);POGLUT1, CLP46, KTELC1, RUMI, C3orf9, DDD4;615618;AD;3q13.33
POGZ;White-Sutton syndrome, 616364 (3);POGZ, KIAA0461, MRD37, WHSUS;614787;AD;1q21.3
POLA1;?N syndrome, 310465 (1);POLA1;312040;XLR;Xp22.1-p21.3
POLD1;Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome, 615381 (3);POLD1, CRCS10, MDPL;174761;AD;19q13.33
POLE1;FILS syndrome, 615139 (3);POLE1, CRCS12, FILS;174762;AR, AD;12q24.33
POLG;Mitochondrial DNA depletion syndrome 4A (Alpers type), 203700 (3),Mitochondrial DNA depletion syndrome 4B (MNGIE type), 613662 (3),Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE), 607459 (3),Progressive external ophthalmoplegia, autosomal dominant 1, 157640 (3),Progressive external ophthalmoplegia, autosomal recessive 1, 258450 (3);POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS;174763;AR, AD;15q26.1
POLG2;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4, 610131 (3);POLG2, POLGB, PEOA4;604983;AD;17q23.3
POLH;Xeroderma pigmentosum, variant type, 278750 (3);POLH, XPV;603968;AR;6p21.1
POLR1A;Acrofacial dysostosis, Cincinnati type, 616462 (3);POLR1A, RPA194, AFDCIN;616404;AD;2p11.2
POLR1C;Leukodystrophy, hypomyelinating, 11, 616494 (3),Treacher Collins syndrome 3, 248390 (3);POLR1C, RPA39, RPA40, RPAC1, RPA5, TCS3, HLD11;610060;AR;6p21.1
POLR1D;Treacher Collins syndrome 2, 613717 (3);POLR1D, RPA16, RPAC2, TCS2;613715;AD;13q12.2
POLR3A;Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 (3);POLR3A, RPC1, RPC155, ADDH, HLD7;614258;AR;10q22.3
POLR3B;Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 (3);POLR3B, RPC2, C128, HLD8;614366;AR;12q23.3
POMC;Obesity, adrenal insufficiency, and red hair due to POMC deficiency, 609734 (3);POMC;176830;-, Mu, AD, AR;2p23.3
POMGNT1;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3, 253280 (3),Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3, 613151 (3),Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3, 613157 (3);POMGNT1, MEB, MDDGA3, MDDGB3, MDDGC3;606822;AR;1p34.1
POMGNT2;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 8, 614830 (3);POMGNT2, GTDC2, C3orf39, AGO61, MDDGA8;614828;AR;3p22.1
POMK;?Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 12, 616094 (3),Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12, 615249 (3);POMK, SGK196, MDDGA12, MDDGC12;615247;AR;8p11.21
POMP;Keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 (3);POMP, UMP1;613386;AR;13q12.3
POMT1;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1, 236670 (3),Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 1, 613155 (3),Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1, 609308 (3);POMT1, MDDGA1, MDDGB1, MDDGC1;607423;AR;9q34.13
POMT2;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2, 613150 (3),Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2, 613156 (3),Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2, 613158 (3);POMT2, MDDGA2, MDDGB2, MDDGC2;607439;AR;14q24.3
POR;Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 (3),Disordered steroidogenesis due to cytochrome P450 oxidoreductase, 613571 (3);POR;124015;AR, -;7q11.23
PORCN;Focal dermal hypoplasia, 305600 (3);PORCN, PORC, DHOF, FODH;300651;XLD;Xp11.23
POROK2;Porokeratosis 2, palmar, plantar, and disseminated (2);POROK2, PPPD1;175850;AD;12q24.1-q24.2
POROK4;Porokeratosis 4, disseminated superficial actinic (2);POROK4, DSAP2;607728;-;15q25.1-q26.1
POROK5;Porokeratosis 5, disseminated superficial actinic (2);POROK5, DSAP3;612293;-;1p31.3-p31.1
POROK6;Porokeratosis 6, multiple types (2);POROK6, DSAP4;612353;AD;18p11.3
POU1F1;Pituitary hormone deficiency, combined, 1, 613038 (3);POU1F1, PIT1, CPHD1;173110;AD, AR;3p11.2
POU3F4;Deafness, X-linked 2, 304400 (3);POU3F4, DFN3, DFNX2;300039;XLR;Xq21.1
POU4F3;Deafness, autosomal dominant 15, 602459 (3);POU4F3, BRN3C;602460;AD;5q32
PPARG;Carotid intimal medial thickness 1, 609338 (3),Insulin resistance, severe, digenic, 604367 (3),Lipodystrophy, familial partial, type 3, 604367 (3),Obesity, severe, 601665 (3);PPARG, PPARG1, PPARG2, CIMT1, GLM1;601487;AD, Mu, AR;3p25.2
PPIB;Osteogenesis imperfecta, type IX, 259440 (3);PPIB, CYPB, OI9;123841;AR;15q22.31
PPKP1B;Keratoderma, palmoplantar, punctate type IB (2);PPKP1B;614936;AD;8q24.13-q24.21
PPKP3;?Keratoderma, palmoplantar, punctate type 3 (2);PPKP3;101850;AD;2p25-p12
PPM1D;Breast cancer, 114480 (3);PPM1D, WIP1;605100;AD;17q23.2
PPM1K;?Maple syrup urine disease, mild variant, 615135 (3);PPM1K, PP2CM, PTMP, MSUDMV;611065;-;4q22.1
PPNAD4;Pigmented nodular adrenocortical disease, primary, 4 (4);PPNAD4;615830;AD;19p13
PPOX;Porphyria variegata, 176200 (3);PPOX;600923;AD;1q23.3
PPP1R15B;Microcephaly, short stature, and impaired glucose metabolism 2, 616817 (3);PPP1R15B, CREP, MSSGM2;613257;AR;1q32.1
PPP1R3A;Insulin resistance, severe, digenic, 125853 (3);PPP1R3A, PPP1R3;600917;AD;7q31.1
PPP2R1A;Mental retardation, autosomal dominant 36, 616362 (3);PPP2R1A, MRD36;605983;AD;19q13.41
PPP2R1B;Lung cancer, 211980 (3);PPP2R1B;603113;AR;11q23.1
PPP2R2B;Spinocerebellar ataxia 12, 604326 (3);PPP2R2B;604325;AD;5q32
PPP2R5D;Mental retardation, autosomal dominant 35, 616355 (3);PPP2R5D, MRD35;601646;AD;6p21.1
PPR1;Photoparoxysmal response 1 (2);PPR1;132100;AD;6p21.1
PPR2;Photoparoxysmal response 2 (2);PPR2;609572;-;13q31.3
PPR3;Photoparoxysmal response 3 (2);PPR3;609573;-;7q32
PPT1;Ceroid lipofuscinosis, neuronal, 1, 256730 (3);PPT1, CLN1;600722;AR;1p34.2
PQBP1;Renpenning syndrome, 309500 (3);PQBP1, NPW38, SHS, MRX55, MRXS3, RENS1, MRXS8;300463;XLR;Xp11.23
PRBNS;Pierre Robin syndrome (2);PRBNS;261800;AR;17q24.3-q25.1
PRCC;Renal cell carcinoma, papillary, 605074 (3);PRCC, RCCP1;179755;-;1q23.1
PRCD;Retinitis pigmentosa 36, 610599 (3);PRCD, RP36;610598;-;17q25.1
PRDM12;Neuropathy, hereditary sensory and autonomic, type VIII, 616488 (3);PRDM12, HSAN8;616458;AR;9q34.12
PRDM16;Cardiomyopathy, dilated, 1LL, 615373 (3),Left ventricular noncompaction 8, 615373 (3);PRDM16, MEL1, LVNC8, CMD1LL;605557;AD;1p36.32
PRDM5;Brittle cornea syndrome 2, 614170 (3);PRDM5, BCS2;614161;AR;4q27
PRDM8;?Epilepsy, progressive myoclonic, 10, 616640 (3);PRDM8, EPM10;616639;AR;4q21.21
PRF1;Aplastic anemia, 609135 (3),Hemophagocytic lymphohistiocytosis, familial, 2, 603553 (3),Lymphoma, non-Hodgkin, 605027 (3);PRF1, HPLH2, FLH2;170280;-, AR;10q22.1
PRG4;Camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3);PRG4, CACP, MSF, SZP, HAPO;604283;AR;1q31.1
PRICKLE1;Epilepsy, progressive myoclonic 1B, 612437 (3);PRICKLE1, RILP, EPM1B;608500;AR;12q12
PRKACA;Cushing syndrome, ACTH-independent adrenal, somatic, 615830 (3);PRKACA;601639;-;19p13.12
PRKACG;?Bleeding disorder, platelet-type, 19, 616176 (3);PRKACG, BDPLT19;176893;AR;9q21.11
PRKAG2;Cardiomyopathy, hypertrophic 6, 600858 (3),Glycogen storage disease of heart, lethal congenital, 261740 (3),Wolff-Parkinson-White syndrome, 194200 (3);PRKAG2, WPWS, CMH6;602743;AD, ?AD;7q36.1
PRKAR1A;Acrodysostosis 1, with or without hormone resistance, 101800 (3),Adrenocortical tumor, somatic, (3),Carney complex, type 1, 160980 (3),Myxoma, intracardiac, 255960 (3),Pigmented nodular adrenocortical disease, primary, 1, 610489 (3);PRKAR1A, TSE1, CNC1, CAR, PPNAD1, ACRDYS1;188830;AD, -, AR;17q24.2
PRKCA;Pituitary tumor, invasive (3);PRKCA, PKCA;176960;-;17q24.2
PRKCD;Autoimmune lymphoproliferative syndrome, type III, 615559 (3);PRKCD, CVID9, ALPS3;176977;AR;3p21.1
PRKCG;Spinocerebellar ataxia 14, 605361 (3);PRKCG, PKCC, PKCG, SCA14;176980;AD;19q13.42
PRKCSH;Polycystic liver disease, 174050 (3);PRKCSH, G19P1, PCLD;177060;AD;19p13.2
PRKDC;Immunodeficiency 26, with or without neurologic abnormalities, 615966 (3);PRKDC, HYRC1, DNPK1, IMD26;600899;AR;8q11.21
PRKG1;Aortic aneurysm, familial thoracic 8, 615436 (3);PRKG1, PRKG1B, PRKGR1B, AAT8;176894;AD;10q11.2-q21.1
PRKN;Adenocarcinoma of lung, somatic, 211980 (3),Adenocarcinoma, ovarian, somatic, 167000 (3),Parkinson disease, juvenile, type 2, 600116 (3);PRKN, PARK2, PDJ, LPRS2;602544;-, AR;6q26
PRKRA;Dystonia 16, 612067 (3);PRKRA, PACT, RAX, DYT16;603424;AR;2q31.2
PRLR;?Hyperprolactinemia, 615555 (3),Multiple fibroadenomas of the breast, 615554 (3);PRLR, MFAB, HPRL;176761;AD;5p13.2
PRNP;Cerebral amyloid angiopathy, PRNP-related, 137440 (3),Creutzfeldt-Jakob disease, 123400 (3),Gerstmann-Straussler disease, 137440 (3),Huntington disease-like 1, 603218 (3),Insomnia, fatal familial, 600072 (3),Prion disease with protracted course, 606688 (3);PRNP, PRIP, KURU, CJD;176640;AD;20p13
PROC;Thrombophilia due to protein C deficiency, autosomal dominant, 176860 (3),Thrombophilia due to protein C deficiency, autosomal recessive, 612304 (3);PROC, PC, THPH3, THPH4;612283;AR;2q14.3
PRODH;Hyperprolinemia, type I, 239500 (3);PRODH, PRODH2, SCZD4;606810;AR, AD;22q11.21
PROK2;Hypogonadotropic hypogonadism 4 with or without anosmia, 610628 (3);PROK2, PK2, BV8, HH4;607002;AD;3p13
PROKR2;Hypogonadotropic hypogonadism 3 with or without anosmia, 244200 (3);PROKR2, PKR2, GPR73L1, HH3;607123;AD;20p12.3
PROM1;Cone-rod dystrophy 12, 612657 (3),Macular dystrophy, retinal, 2, 608051 (3),Retinitis pigmentosa 41, 612095 (3),Stargardt disease 4, 603786 (3);PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4;604365;-, AD, AR;4p15.32
PROP1;Pituitary hormone deficiency, combined, 2, 262600 (3);PROP1, CPHD2;601538;AR;5q35.3
PROS1;Thrombophilia due to protein S deficiency, autosomal dominant, 612336 (3),Thrombophilia due to protein S deficiency, autosomal recessive, 614514 (3);PROS1, THPH5, THPH6;176880;AD, AR;3q11.1
PRPF3;Retinitis pigmentosa 18, 601414 (3);PRPF3, HPRP3, RP18;607301;AD;1q21.2
PRPF31;Retinitis pigmentosa 11, 600138 (3);PRPF31, PRP31, RP11;606419;AD;19q13.42
PRPF4;Retinitis pigmentosa 70, 615922 (3);PRPF4, PRP4, HPRP4, RP70;607795;AD;9q32
PRPF6;Retinitis pigmentosa 60, 613983 (3);PRPF6, PRP6, ANT1, TOM, C20orf14;613979;AD;20q13.33
PRPF8;Retinitis pigmentosa 13, 600059 (3);PRPF8, PRPC8, RP13;607300;AD;17p13.3
PRPH2;Choriodal dystrophy, central areolar 2, 613105 (3),Leber congenital amaurosis 18, 608133 (3),Macular dystrophy, patterned, 1, 169150 (3),Macular dystrophy, vitelliform, 3, 608161 (3),Retinitis pigmentosa 7 and digenic, 608133 (3),Retinitis punctata albescens, 136880 (3);PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2, MDBS1;179605;AD, AR;6p21.1
PRPS1;Arts syndrome, 301835 (3),Charcot-Marie-Tooth disease, X-linked recessive, 5, 311070 (3),Deafness, X-linked 1, 304500 (3),Gout, PRPS-related, 300661 (3),Phosphoribosylpyrophosphate synthetase superactivity, 300661 (3);PRPS1, CMTX5, DFNX1, DFN2;311850;XLR, XL;Xq22.3
PRRT2;Convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3),Episodic kinesigenic dyskinesia 1, 128200 (3),Seizures, benign familial infantile, 2, 605751 (3);PRRT2, PKC, DYT10, EKD1, BFIS2, BFIC2, ICCA;614386;AD;16p11.2
PRRX1;Agnathia-otocephaly complex, 202650 (3);PRRX1, PMX1, PHOX1, AGOTC;167420;AR, AD;1q24.2
PRS;Prieto syndrome (2);PRS, MRXS2;309610;XLR;Xp11-q21
PRSS1;Pancreatitis, hereditary, 167800 (3),Trypsinogen deficiency, 614044 (1);PRSS1, TRY1;276000;AD, AR;7q34
PRSS12;Mental retardation, autosomal recessive 1, 249500 (3);PRSS12, BSSP3, MRT1;606709;AR;4q26
PRSS56;Microphthalmia, isolated 6, 613517 (3);PRSS56, MCOP6;613858;AR;2q37.1
PRSS7;Enterokinase deficiency, 226200 (3);PRSS7, ENTK;606635;AR;21q21.1
PRX;Charcot-Marie-Tooth disease, type 4F, 614895 (3),Dejerine-Sottas disease, 145900 (3);PRX, CMT4F;605725;AR, AD;19q13.2
PSAP;Combined SAP deficiency, 611721 (3),Gaucher disease, atypical, 610539 (3),Krabbe disease, atypical, 611722 (3),Metachromatic leukodystrophy due to SAP-b deficiency, 249900 (3);PSAP, SAP1;176801;AR;10q22.1
PSAT1;?Phosphoserine aminotransferase deficiency, 610992 (3),Neu-Laxova syndrome 2, 616038 (3);PSAT1, PSAT, EPIP, PSATD, NLS2;610936;AR;9q21.2
PSC;Cholangitis, primary sclerosing (2);PSC;613806;-;3p21
PSEN1;Acne inversa, familial, 3, 613737 (3),Alzheimer disease, type 3, 607822 (3),Alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3),Alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3),Cardiomyopathy, dilated, 1U, 613694 (3),Dementia, frontotemporal, 600274 (3),Pick disease, 172700 (3);PSEN1, AD3;104311;AD, IC;14q24.2
PSEN2;Alzheimer disease-4, 606889 (3),Cardiomyopathy, dilated, 1V, 613697 (3);PSEN2, AD4, STM2, CMD1V;600759;AD;1q42.13
PSENEN;Acne inversa, familial, 2, 613736 (3);PSENEN, PEN2;607632;AD;19q13.12
PSHK2;Pseudohyperkalemia, familial, 2, due to red cell leak (2);PSHK2;609153;AD;2q35-q36
PSMB8;Autoinflammation, lipodystrophy, and dermatosis syndrome, 256040 (3);PSMB8, LMP7, RING10, JMP, NKJO, ALDD;177046;AR;6p21.32
PSMC3IP;Ovarian dysgenesis 3, 614324 (3);PSMC3IP, TBPIP, GT198, HOP2, ODG3;608665;AR;17q21.2
PSMNSW;Parasomnia, sleepwalking type (2);PSMNSW;613938;Mu, AD ;20q12-q13.12
PSNP2;Supranuclear palsy, progressive, 2 (2);PSNP2;609454;AD;1q31.1
PSNP3;Supranuclear palsy, progressive, 3 (2);PSNP3;610898;-;11p12-p11
PSPH;Phosphoserine phosphatase deficiency, 614023 (3);PSPH, PSP, PSPHD;172480;AR;7p11.2
PSS;Potocki-Shaffer syndrome (4);PSS;601224;-;11p11.2
PSTPIP1;Pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3);PSTPIP1, PSTPIP, CD2BP1, PAPAS;606347;AD;15q24.3
PTCH1;Basal cell carcinoma, somatic, 605462 (3),Basal cell nevus syndrome, 109400 (3),Holoprosencephaly 7, 610828 (3);PTCH1, NBCCS, BCNS, HPE7;601309;-, AD;9q22.32
PTCH2;Basal cell carcinoma, somatic, 605462 (3),Basal cell nevus syndrome, 109400 (3),Medulloblastoma, 155255 (3);PTCH2;603673;-, AD;1p34.1
PTCPRN;Thyroid carcinoma, papillary, with papillary renal neoplasia (2);PTCPRN, PRN1;605642;-;1q21
PTDSS1;Lenz-Majewski hyperostotic dwarfism, 151050 (3);PTDSS1, PSS1, KIAA0024, LMHD;612792;AD;8q22.1
PTEN;Bannayan-Riley-Ruvalcaba syndrome, 153480 (3),Cowden syndrome 1, 158350 (3),Endometrial carcinoma, somatic, 608089 (3),Lhermitte-Duclos syndrome, 158350 (3),Macrocephaly/autism syndrome, 605309 (3),Malignant melanoma, somatic, 155600 (3),PTEN hamartoma tumor syndrome (3),Squamous cell carcinoma, head and neck, somatic, 275355 (3),VATER association with macrocephaly and ventriculomegaly, 276950 (3);PTEN, MMAC1, GLM2, CWS1;601728;AD, AR, -;10q23.31
PTF1A;Pancreatic agenesis 2, 615935 (3),Pancreatic and cerebellar agenesis, 609069 (3);PTF1A, PACA, PAGEN2;607194;AR;10p12.2
PTGIS;Hypertension, essential, 145500 (3);PTGIS, CYP8A1, PGIS, CYP8;601699;Mu ;20q13.13
PTH;Hypoparathyroidism, autosomal dominant, 146200 (3),Hypoparathyroidism, autosomal recessive, 146200 (3);PTH;168450;AD;11p15.3
PTHB1;Bardet-Biedl syndrome 9, 615986 (3);PTHB1, BBS9;607968;AR;7p14.3
PTHLH;Brachydactyly, type E2, 613382 (3),Humoral hypercalcemia of malignancy (1);PTHLH, BDE2;168470;AD, -;12p11.22
PTHR1;Chondrodysplasia, Blomstrand type, 215045 (3),Eiken syndrome, 600002 (3),Failure of tooth eruption, primary, 125350 (3),Metaphyseal chondrodysplasia, Murk Jansen type, 156400 (3);PTHR1, PTHR, PFE;168468;AD, AR;3p21.31
PTLAH;Patella aplasia or hypoplasia (2);PTLAH, FPAH;168860;AD;17q21-q22
PTLS;Potocki-Lupski syndrome (4);PTLS;610883;IC;17p11.2
PTOS1;Ptosis, hereditary congenital, 1 (2);PTOS1;178300;AD;1p34.1-p32
PTOS2;Ptosis, hereditary congenital 2 (2);PTOS2, PTOSX;300245;XLD;Xq24-q27.1
PTPN11;LEOPARD syndrome 1, 151100 (3),Leukemia, juvenile myelomonocytic, somatic, 607785 (3),Metachondromatosis, 156250 (3),Noonan syndrome 1, 163950 (3);PTPN11, PTP2C, SHP2, NS1, JMML, METCDS;176876;AD;12q24.13
PTPN12;Colon cancer, somatic, 114500 (3);PTPN12, PTPG1;600079;-;7q11.23
PTPN14;Choanal atresia and lymphedema, 613611 (3);PTPN14, PEZ;603155;AR;1q32-q41
PTPRC;Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 (3);PTPRC, CD45, LCA;151460;AR, -;1q31.3-q32.1
PTPRF;?Breasts and/or nipples, aplasia or hypoplasia of, 2, 616001 (3);PTPRF, LAR, BNAH2;179590;AR;1p34.2
PTPRJ;Colon cancer, somatic, 114500 (3);PTPRJ, DEP1;600925;-;11p11.2
PTPRO;Nephrotic syndrome, type 6, 614196 (3);PTPRO, GLEPP1, NPHS6;600579;AR;12p12.3
PTPRQ;Deafness, autosomal recessive 84A, 613391 (3);PTPRQ, PTPGMC1, DFNB84A;603317;AR;12q21.31
PTRF;Lipodystrophy, congenital generalized, type 4, 613327 (3);PTRF, CAVIN, CGL4;603198;AR;17q21.2
PTRH2;Infantile-onset multisystem neurologic, endocrine, and pancreatic disease, 616263 (3);PTRH2, BIT1, IMNEPD;608625;AR;17q23.1
PTS;Hyperphenylalaninemia, BH4-deficient, A, 261640 (3);PTS;612719;AR;11q23.1
PUF60;Verheij syndrome, 615583 (3);PUF60, FIR, SIAHBP1, VRJS;604819;AD;8q24.3
PURA;Mental retardation, autosomal dominant 31, 616158 (3);PURA, PUR1, MRD31;600473;AD;5q31.3
PUS1;Myopathy, lactic acidosis, and sideroblastic anemia 1, 600462 (3);PUS1, MLASA1;608109;AR;12q24.33
PVNH3;Periventricular nodular heterotopia 3 (2);PVNH3;608098;-;5p15.1
PVNH5;Periventricular nodular heterotopia 5 (4);PVNH5;612881;-;5q14.3-q15
PVRL4;Ectodermal dysplasia-syndactyly syndrome 1, 613573 (3);PVRL4, PRR4, EDSS1;609607;-;1q23.3
PXDN;Corneal opacification and other ocular anomalies, 269400 (3);PXDN, D2S448E, KIAA0230, PRG2, PXN, COPOA;605158;AR;2p25.3
PYCR1;Cutis laxa, autosomal recessive, type IIB, 612940 (3),Cutis laxa, autosomal recessive, type IIIB, 614438 (3);PYCR1, PRO3, ARCL2B, ARCL3B;179035;AR, -;17q25.3
PYCR2;Leukodystrophy, hypomyelinating, 10, 616420 (3);PYCR2, HLD10;616406;AR;1q42.12
PYGL;Glycogen storage disease VI, 232700 (3);PYGL;613741;AR;14q22.1
PYGM;McArdle disease, 232600 (3);PYGM;608455;AR;11q13.1
QARS;Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy, 615760 (3);QARS, GLNRS, MSCCA;603727;AR;3p21.31
QDPR;Hyperphenylalaninemia, BH4-deficient, C, 261630 (3);QDPR, DHPR;612676;AR;4p15.32
RAB18;Warburg micro syndrome 3, 614222 (3);RAB18, WARBM3;602207;AR;10p12.1
RAB23;Carpenter syndrome, 201000 (3);RAB23;606144;AR;6p12.1-p11.2
RAB27A;Griscelli syndrome, type 2, 607624 (3);RAB27A, RAM, GS2;603868;AR;15q21.3
RAB28;Cone-rod dystrophy 18, 615374 (3);RAB28, CORD18;612994;AR;4p15.33
RAB33B;Smith-McCort dysplasia 2, 615222 (3);RAB33B, SMC2;605950;AR;4q31.1
RAB39B;?Waisman syndrome, 311510 (3),Mental retardation, X-linked 72, 300271 (3);RAB39B, MRX72, WSMN;300774;XLR;Xq28
RAB3GAP1;Warburg micro syndrome 1, 600118 (3);RAB3GAP1, WARBM1, P130;602536;AR;2q21.3
RAB3GAP2;Martsolf syndrome, 212720 (3),Warburg micro syndrome 2, 614225 (3);RAB3GAP2, RAB3GAP150, p150, KIAA0839, WARBM2;609275;AR;1q41
RAB7;Charcot-Marie-Tooth disease, type 2B, 600882 (3);RAB7, CMT2B, PSN;602298;AD;3q21.3
RAC2;Neutrophil immunodeficiency syndrome, 608203 (3);RAC2;602049;-;22q13.1
RAD21;Cornelia de Lange syndrome 4, 614701 (3);RAD21, SCC1, NXP1, KIAA0078, CDLS4;606462;AD;8q24.11
RAD50;Nijmegen breakage syndrome-like disorder, 613078 (3);RAD50, NBSLD;604040;-;5q31.1
RAD51A;Mirror movements 2, 614508 (3);RAD51A, RECA, MRMV2;179617;AD;15q15.1
RAD51C;Fanconi anemia, complementation group O, 613390 (3);RAD51C, FANCO, BROVCA3;602774;AR, -;17q22
RAD54B;Colon cancer, somatic, 114500 (3),Lymphoma, non-Hodgkin, somatic, 605027 (3);RAD54B;604289;-;8q22.1
RAD54L;Adenocarcinoma, colonic, somatic (3),Lymphoma, non-Hodgkin, somatic, 605027 (3);RAD54L, HR54, HRAD54;603615;-, AD;1p34.1
RAF1;Cardiomyopathy, dilated, 1NN, 615916 (3),LEOPARD syndrome 2, 611554 (3),Noonan syndrome 5, 611553 (3);RAF1, CRAF, NS5, CMD1NN;164760;AD, -;3p25.2
RAG1;Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 (3),Combined cellular and humoral immune defects with granulomas, 233650 (3),Omenn syndrome, 603554 (3),Severe combined immunodeficiency, B cell-negative, 601457 (3);RAG1;179615;-, AR;11p12
RAG2;Combined cellular and humoral immune defects with granulomas, 233650 (3),Omenn syndrome, 603554 (3),Severe combined immunodeficiency, B cell-negative, 601457 (3);RAG2;179616;AR;11p12
RAI1;Smith-Magenis syndrome, 182290 (3);RAI1, SMCR, SMS;607642;IC, AD;17p11.2
RAP1GDS1;Lymphocytic leukemia, acute T-cell (3);RAP1GDS1;179502;-;4q23
RAPSN;Fetal akinesia deformation sequence, 208150 (3),Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency, 616326 (3);RAPSN, CMS1D, CMS11, FADS;601592;AR;11p11.2
RARA;Leukemia, acute promyelocytic, 612376 (1);RARA;180240;-;17q21.2
RARB;Microphthalmia, syndromic 12, 615524 (3);RARB, HAP, MCOPS12;180220;AD;3p24.2
RARS;Leukodystrophy, hypomyelinating, 9, 616140 (3);RARS, HLD9;107820;AR;5q34
RARS2;Pontocerebellar hypoplasia, type 6, 611523 (3);RARS2, RARSL, PCH6;611524;AR;6q15
RASA1;Basal cell carcinoma, somatic, 605462 (3),Capillary malformation-arteriovenous malformation, 608354 (3),Parkes Weber syndrome, 608355 (3);RASA1, GAP, CMAVM, PKWS;139150;-, AD;5q14.3
RASGRP2;?Bleeding disorder, platelet-type, 18, 615888 (3);RASGRP2, CDC25L;605577;AR;11q13.1
RASSF1;Lung cancer, 211980 (2);RASSF1;605082;AR;3p21.31
RAX;Microphthalmia, isolated 3, 611038 (3);RAX, RX, MCOP3;601881;AR;18q21.32
RAX2;?Macular degeneration, age-related, 6, 613757 (3),Cone-rod dystrophy 11, 610381 (3);RAX2, RAXL1, QRX, CORD11, ARMD6;610362;-, AD;19p13.3
RB1;Bladder cancer, somatic, 109800 (3),Osteosarcoma, somatic, 259500 (3),Retinoblastoma, 180200 (3),Retinoblastoma, trilateral, 180200 (3),Small cell cancer of the lung, somatic, 182280 (3);RB1;614041;-, AD, Smu;13q14.2
RB1CC1;Breast cancer, somatic, 114480 (3);RB1CC1, CC1, KIAA0203;606837;-;8q11.23
RBBP8;Jawad syndrome, 251255 (3),Pancreatic carcinoma, somatic (3),Seckel syndrome 2, 606744 (3);RBBP8, RIM, SCKL2, JWDS;604124;AR, -;18q11.2
RBCK1;Polyglucosan body myopathy 1 with or without immunodeficiency, 615895 (3);RBCK1, HOIL1, PGBM1, PBMEI;610924;AR;20p13
RBM10;TARP syndrome, 311900 (3);RBM10, DXS8237E, KIAA0122, TARPS;300080;XLR;Xp11.3
RBM15;Megakaryoblastic leukemia, acute (2);RBM15, SPEN, OTT;606077;-;1p13.3
RBM20;Cardiomyopathy, dilated, 1DD, 613172 (3);RBM20;613171;AD;10q25.2
RBM28;?Alopecia, neurologic defects, and endocrinopathy syndrome, 612079 (3);RBM28, ANES;612074;AR;7q32.1
RBM8A;Thrombocytopenia-absent radius syndrome, 274000 (3);RBM8A, RBM8B, TAR, C1DELq21.1, DEL1q21.1;605313;AR;1q21.1
RBMX;?Mental retardation, X-linked, syndromic 11, Shashi type, 300238 (3);RBMX, MRXS11;300199;XLR;Xq26.3
RBP3;?Retinitis pigmentosa 66, 615233 (3);RBP3, RP66;180290;AR;10q11.22
RBP4;Microphthalmia, isolated, with coloboma 10, 616428 (3),Retinal dystrophy, iris coloboma, and comedogenic acne syndrome, 615147 (3);RBP4, RDCCAS, MCOPCB10;180250;AD, AR;10q23.33
RBPJ;Adams-Oliver syndrome 3, 614814 (3);RBPJ, RBPSUH, IGKJRB1, AOS3;147183;AD;4p15.2
RC14S;Ring chromosome 14 syndrome (4);RC14S;616606;IC ;Chr.14
RCD1;?Retinal cone dystrophy-1 (2);RCD1;180020;AD;6q25-q26
RCHTS;?Roifman-Chitayat syndrome (2);RCHTS;613328;AR;15q11-q21.1
RCM2;Cardiomyopathy, familial restrictive, 2 (2);RCM2;609578;-;10q23.3
RD3;Leber congenital amaurosis 12, 610612 (3);RD3, LCA12, C1orf36;180040;AR;1q32.3
RDH11;?Retinal dystrophy, juvenile cataracts, and short stature syndrome, 616108 (3);RDH11, PSDR1, RALR1, RDJCSS;607849;AR;14q24.1
RDH12;Leber congenital amaurosis 13, 612712 (3);RDH12, LCA13;608830;AR;14q24.1
RDH5;Fundus albipunctatus, 136880 (3);RDH5;601617;AD, AR;12q13.2
RDX;Deafness, autosomal recessive 24, 611022 (3);RDX, DFNB24;179410;AR;11q22.3
RECQL2;Werner syndrome, 277700 (3);RECQL2, RECQ3, WRN;604611;AR;8p12
RECQL3;Bloom syndrome, 210900 (3);RECQL3, RECQ2, BLM, BS;604610;AR;15q26.1
RECQL4;Baller-Gerold syndrome, 218600 (3),RAPADILINO syndrome, 266280 (3),Rothmund-Thomson syndrome, 268400 (3);RECQL4, RTS, RECQ4;603780;AR;8q24.3
REEP1;?Neuronopathy, distal hereditary motor, type VB, 614751 (3),Spastic paraplegia 31, autosomal dominant, 610250 (3);REEP1, C2ORF23, SPG31, HMN5B;609139;AD;2p11.2
REEP2;?Spastic paraplegia 72, autosomal dominant, 615625 (3),?Spastic paraplegia 72, autosomal recessive, 615625 (3);REEP2, C5orf19, SPG72;609347;AR,AD;5q31.2
RELN;Lissencephaly 2 (Norman-Roberts type), 257320 (3);RELN, RL, LIS2, ETL7;600514;AR, AD;7q22.1
REN;Hyperuricemic nephropathy, familial juvenile 2, 613092 (3),Renal tubular dysgenesis, 267430 (3);REN, HNFJ2;179820;AR, AD;1q32.1
RERE;Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, 616975 (3);RERE, NEDBEH;605226;AD;1p36.23
RET;Central hypoventilation syndrome, congenital, 209880 (3),Medullary thyroid carcinoma, 155240 (3),Multiple endocrine neoplasia IIA, 171400 (3),Multiple endocrine neoplasia IIB, 162300 (3),Pheochromocytoma, 171300 (3);RET, MEN2A, HSCR1;164761;AD;10q11.21
RFH1;Nephropathy-hypertension (2);RFH1, AORF;161900;AD;1q21
RFT1;Congenital disorder of glycosylation, type In, 612015 (3);RFT1, CDG1N;611908;AR;3p21.1
RFX5;Bare lymphocyte syndrome, type II, complementation group C, 209920 (3),Bare lymphocyte syndrome, type II, complementation group E, 209920 (3);RFX5;601863;AR;1q21.3
RFX6;Mitchell-Riley syndrome, 615710 (3);RFX6, RFXDC1, MTCHRS;612659;AR;6q22.1
RFXANK;MHC class II deficiency, complementation group B, 209920 (3);RFXANK;603200;AR;19p13.11
RFXAP;Bare lymphocyte syndrome, type II, complementation group D, 209920 (3);RFXAP;601861;AR;13q13.3
RGR;Retinitis pigmentosa 44, 613769 (3);RGR, RP44;600342;-;10q23.1
RGS9;Bradyopsia, 608415 (3);RGS9, PERRS;604067;-;17q24.1
RGS9BP;Bradyopsia, 608415 (3);RGS9BP, R9AP, RGS9, PERRS;607814;-;19q13.11
RHAG;Anemia, hemolytic, Rh-null, regulator type, 268150 (3),Overhydrated hereditary stomatocytosis, 185000 (3),Rh-mod syndrome (3);RHAG, RH50A, OHST;180297;AR, AD;6p12.3
RHBDF2;Tylosis with esophageal cancer, 148500 (3);RHBDF2, IRHOM2, TOC;614404;AD;17q25.1
RHCE;Rh-null disease, amorph type (3);RHCE;111700;-;1p36.11
RHO;Night blindness, congenital stationary, autosomal dominant 1, 610445 (3),Retinitis pigmentosa 4, autosomal dominant or recessive, 613731 (3),Retinitis punctata albescens, 136880 (3);RHO, RP4, OPN2, CSNBAD1;180380;-, AD, AR;3q22.1
RIEG2;Rieger syndrome, type 2 (2);RIEG2, RGS2;601499;AD;13q14
RIMS1;Cone-rod dystrophy 7, 603649 (3);RIMS1, RIM1, RIM, KIAA0340, CORD7;606629;-;6q13
RIN2;Macrocephaly, alopecia, cutis laxa, and scoliosis, 613075 (3);RIN2, MACS;610222;AR;20p11.23
RIPK4;Popliteal pterygium syndrome, Bartsocas-Papas type, 263650 (3);RIPK4, NKRD3, DIK, PPS2;605706;AR;21q22.3
RIPPLY2;?Spondylocostal dysostosis 6, 616566 (3);RIPPLY2, C6orf59, SCDO6;609891;AR;6q14.2
RIT1;Noonan syndrome 8, 615355 (3);RIT1, RIT, ROC1, NS8;609591;AD;1q22
RJBS;Rajab syndrome (2);RJBS;613658;AR;2q36.2
RLBP1;Bothnia retinal dystrophy, 607475 (3),Fundus albipunctatus, 136880 (3),Newfoundland rod-cone dystrophy, 607476 (3),Retinitis punctata albescens, 136880 (3);RLBP1;180090;AR, AD;15q26.1
RMD1;Rippling muscle disease-1 (2);RMD1;600332;AD;1q41
RMND1;Combined oxidative phosphorylation deficiency 11, 614922 (3);RMND1, COXPD11;614917;AR;6q25.1
RMRP;Anauxetic dysplasia, 607095 (3),Cartilage-hair hypoplasia, 250250 (3),Metaphyseal dysplasia without hypotrichosis, 250460 (3);RMRP, RMRPR, CHH;157660;AR;9p13.3
RNASEH1;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2, 616479 (3);RNASEH1, PEOB2;604123;AR;2p25.3
RNASEH2A;Aicardi-Goutieres syndrome 4, 610333 (3);RNASEH2A, RNHIA, AGS4;606034;AR;19p13.13
RNASEH2B;Aicardi-Goutieres syndrome 2, 610181 (3);RNASEH2B, DLEU8, FLJ11712, AGS2;610326;AR;13q14.3
RNASEH2C;Aicardi-Goutieres syndrome 3, 610329 (3);RNASEH2C, AYP1, FLJ20974, AGS3;610330;AR;11q13.1
RNASEL;Prostate cancer 1, 601518 (3);RNASEL, RNS4, PRCA1, HPC1;180435;AD;1q25.3
RNASET2;Leukoencephalopathy, cystic, without megalencephaly, 612951 (3);RNASET2, RNASE6PL;612944;AR;6q27
RNF113A;?Trichothiodystrophy 5, nonphotosensitive, 300953 (3);RNF113A, ZNF183, TTD5;300951;XLD;Xq24
RNF125;Tenorio syndrome, 616260 (3);RNF125, TRAC1, TNORS;610432;AD;18q12.1
RNF135;Macrocephaly, macrosomia, facial dysmorphism syndrome, 614192 (3);RNF135, MMFD;611358;-;17q11.2
RNF139;Renal cell carcinoma, 144700 (3);RNF139, TRC8, RCA1;603046;-;8q24.13
RNF168;RIDDLE syndrome, 611943 (3);RNF168;612688;AR;3q29
RNF170;Ataxia, sensory, 1, autosomal dominant, 608984 (3);RNF170, SNAX1;614649;AD;8p11.21
RNF212;Recombination rate QTL 1, 612042 (3);RNF212, ZHP3;612041;-;4p16.3
RNF216;Cerebellar ataxia and hypogonadotropic hypogonadism, 212840 (3);RNF216, TRIAD3, ZIN, CAHH;609948;AR;7p22.1
RNF6;Esophageal carcinoma, somatic, 133239 (3);RNF6;604242;-;13q12.13
RNU4ATAC;Microcephalic osteodysplastic primordial dwarfism, type I, 210710 (3),Roifman syndrome, 616651 (3);RNU4ATAC, U4ATAC, MOPD1, TALS, RFMN;601428;AR;2q14.2
ROBO2;Vesicoureteral reflux 2, 610878 (3);ROBO2, SAX3, KIAA1568;602431;-;3p12.3
ROBO3;Gaze palsy, horizontal, with progressive scoliosis, 607313 (3);ROBO3, RBIG1, RIG1, HGPPS;608630;AR;11q24.2
ROGDI;Kohlschutter-Tonz syndrome, 226750 (3);ROGDI, KTZS;614574;AR;16p13.3
ROM1;Retinitis pigmentosa 7, digenic, 608133 (3);ROM1, ROSP1, RP7;180721;AD, AR;11q12.3
ROR2;Brachydactyly, type B1, 113000 (3),Robinow syndrome, autosomal recessive, 268310 (3);ROR2, BDB1, BDB, NTRKR2;602337;AD, AR;9q22.31
RORC;Immunodeficiency 42, 616622 (3);RORC, RORG, RZRG, IMD42;602943;AR;1q21.3
RP1;Retinitis pigmentosa 1, 180100 (3);RP1, ORP1;603937;AD, AR;8q11.2-q12.1
RP1L1;Occult macular dystrophy, 613587 (3);RP1L1;608581;AD;8p23.1
RP2;Retinitis pigmentosa 2, 312600 (3);RP2;300757;XLR;Xp11.3
RP22;Retinitis pigmentosa 22 (2);RP22;602594;-;16p12.3-p12.1
RP24;Retinitis pigmentosa 24 (2);RP24;300155;-;Xq26-q27
RP29;Retinitis pigmentosa 29 (2);RP29;612165;AR;4q32-q34
RP32;Retinitis pigmentosa 32 (2);RP32;609913;-;1p21.3-p13.3
RP34;Retinitis pigmentosa 34 (2);RP34;300605;-;Xq28
RP6;?Retinitis pigmentosa, X-linked recessive, 6 (2);RP6;312612;XLR;Xp21.3-p21.2
RP63;Retinitis pigmentosa 63 (2);RP63;614494;AD;6q23
RP9;?Retinitis pigmentosa 9, 180104 (3);RP9, PAP1;607331;AD;7p14.3
RPE65;Leber congenital amaurosis 2, 204100 (3),Retinitis pigmentosa 20, 613794 (3);RPE65, RP20, LCA2;180069;AR, -;1p31.3
RPGR;Cone-rod dystrophy, X-linked, 1, 304020 (3),Macular degeneration, X-linked atrophic, 300834 (3),Retinitis pigmentosa 3, 300029 (3),Retinitis pigmentosa, X-linked, and sinorespiratory infections, with or without deafness, 300455 (3);RPGR, RP3, CRD, RP15, COD1, CORDX1;312610;XL, XLR, -;Xp11.4
RPGRIP1;Cone-rod dystrophy 13, 608194 (3),Leber congenital amaurosis 6, 613826 (3);RPGRIP1, LCA6, CORD13;605446;-;14q11.2
RPGRIP1L;COACH syndrome, 216360 (3),Joubert syndrome 7, 611560 (3),Meckel syndrome 5, 611561 (3);RPGRIP1L, KIAA1005, JBTS7, MKS5;610937;AR;16q12.2
RPIA;?Ribose 5-phosphate isomerase deficiency, 608611 (3);RPIA, RPI, RPIAD;180430;AR;2p11.2
RPL11;Diamond-Blackfan anemia 7, 612562 (3);RPL11, DBA7;604175;-;1p36.11
RPL15;?Diamond-Blackfan anemia 12, 615550 (3);RPL15, DBA12;604174;AD;3p24.2
RPL21;Hypotrichosis 12, 615885 (3);RPL21, HYPT12;603636;AD;13q12.2
RPL26;?Diamond-Blackfan anemia 11, 614900 (3);RPL26, DBA11;603704;AD;17p13.1
RPL35A;Diamond-Blackfan anemia 5, 612528 (3);RPL35A, DBA5;180468;-;3q29
RPL5;Diamond-Blackfan anemia 6, 612561 (3);RPL5, DBA6;603634;-;1p22.1
RPS10;Diamond-Blackfan anemia 9, 613308 (3);RPS10, DBA9;603632;-;6p21.31
RPS14;Macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 (3);RPS14, EMTB;130620;-;5q33.1
RPS17;Diamond-Blackfan anemia 4, 612527 (3);RPS17, RPS17L1, RPS17L2, DBA4;180472;-;15q25.2
RPS19;Diamond-Blackfan anemia 1, 105650 (3);RPS19, DBA, DBA1;603474;AD;19q13.2
RPS24;Diamond-blackfan anemia 3, 610629 (3);RPS24, DBA3;602412;-;10q22.3
RPS26;Diamond-Blackfan anemia 10, 613309 (3);RPS26, DBA10;603701;AD;12q13.2
RPS28;Diamond Blackfan anemia 15 with mandibulofacial dysostosis, 606164 (3);RPS28, DBA15;603685;AD;19p13.2
RPS29;Diamond-Blackfan anemia 13, 615909 (3);RPS29, DBA13;603633;AD;14q21.3
RPS6KA3;Coffin-Lowry syndrome, 303600 (3),Mental retardation, X-linked 19, 300844 (3);RPS6KA3, RSK2, MRX19;300075;IC, XLD;Xp22.12
RPS7;Diamond-Blackfan anemia 8, 612563 (3);RPS7, DBA8;603658;-;2p25.3
RPSA;Asplenia, isolated congenital, 271400 (3);RPSA, LAMR1, LAMBR, ICAS;150370;AD;3p22.1
RPY;Retinitis pigmentosa, Y-linked (2);RPY;400004;YL;Chr.Y
RRAS2;Ovarian carcinoma (3);RRAS2, TC21;600098;-;11p15.2
RRDX;Radial ray deficiency (2);RRDX;300378;-;Xq24-q25
RRM2B;Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy), 612075 (3),Mitochondrial DNA depletion syndrome 8B (MNGIE type), 612075 (3),Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5, 613077 (3);RRM2B, P53R2, PEOA5, MTDPS8A, MTDPS8B;604712;AR, AD;8q22.3
RS1;Retinoschisis, 312700 (3);RS1, XLRS1;300839;XLD;Xp22.13
RSCIS;Radiation sensitivity/chromosome instability syndrome, autosomal dominant (1);RSCIS;605463;-;14q11.2
RSPH1;Ciliary dyskinesia, primary, 24, 615481 (3);RSPH1, TSGA2, TSA2, CILD24;609314;AR;21q22.3
RSPH3;Ciliary dyskinesia, primary, 32, 616481 (3);RSPH3, RSHL2, RSP3, CILD32;615876;AR;6q25.3
RSPH4A;Ciliary dyskinesia, primary, 11, 612649 (3);RSPH4A, CILD11;612647;-;6q22.1
RSPH9;Ciliary dyskinesia, primary, 12, 612650 (3);RSPH9, CILD12;612648;-;6p21.1
RSPO1;Palmoplantar hyperkeratosis and true hermaphroditism, 610644 (3),Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 (3);RSPO1, FLJ40906;609595;-;1p34.3
RSPO4;Anonychia congenita, 206800 (3);RSPO4, CRISTIN4;610573;AR;20p13
RSPRY1;Spondylopeimetaphyseal dsyplasia, Faden-Alkuraya type, 616723 (3);RSPRY1, KIAA1972, SEMDFA;616585;AR;16q13
RTEL1;Dyskeratosis congenita, autosomal dominant 4, 615190 (3),Dyskeratosis congenita, autosomal recessive 5, 615190 (3),Pulmonary fibrosis and/or bone marrow failure, telomere-related, 3, 616373 (3);RTEL1, C20orf41, NHL, KIAA1088, DKCB5, DKCA4, PFBMFT3;608833;AD, AR;20q13.33
RTN2;Spastic paraplegia 12, autosomal dominant, 604805 (3);RTN2, NSPL1, SPG12;603183;AD;19q13.32
RTN4IP1;Optic atrophy 10 with or without ataxia, mental retardation, and seizures, 616732 (3);RTN4IP1, NIMP, OPA10;610502;AR;6q21
RTTN;Microcephaly, short stature, and polymicrogyria with seizures, 614833 (3);RTTN, MSSP;610436;AR;18q22.2
RUBCN;?Spinocerebellar ataxia, autosomal recessive 15, 615705 (3);RUBCN, RUBICON, KIAA0226, SCAR15;613516;AR;3q29
RUNX1;Leukemia, acute myeloid, 601626 (3),Platelet disorder, familial, with associated myeloid malignancy, 601399 (3);RUNX1, CBFA2, AML1;151385;AD;21q22.12
RUNX2;Cleidocranial dysplasia, 119600 (3),Cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 (3),Cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 (3),Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 (3);RUNX2, CBFA1, PEBP2A1, AML3, CCD, CLCD;600211;AD;6p21.1
RWS;?Ragweed sensitivity (2);RWS;179450;AD;6p21.3
RYR1;Central core disease, 117000 (3),King-Denborough syndrome, 145600 (3),Minicore myopathy with external ophthalmoplegia, 255320 (3),Neuromuscular disease, congenital, with uniform type 1 fiber, 117000 (3);RYR1, MHS, CCO;180901;AR, AD;19q13.2
RYR2;Arrhythmogenic right ventricular dysplasia 2, 600996 (3),Ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 (3);RYR2, VTSIP, ARVD2, ARVC2;180902;AD;1q43
S1PR2;Deafness, autosomal recessive 68, 610419 (3);S1PR2, EDG5, DFNB68;605111;AR;19p13.2
SACS;Spastic ataxia, Charlevoix-Saguenay type, 270550 (3);SACS, ARSACS;604490;AR;13q12.12
SAG;Oguchi disease-1, 258100 (3),Retinitis pigmentosa 47, 613758 (3);SAG, RP47;181031;AR;2q37.1
SALL1;Townes-Brocks branchiootorenal-like syndrome, 107480 (3),Townes-Brocks syndrome, 107480 (3);SALL1, HSAL1, TBS;602218;AD;16q12.1
SALL2;?Coloboma, ocular, autosomal recessive, 216820 (3);SALL2, HSAL2, COLB;602219;AR;14q11.2
SALL4;Duane-radial ray syndrome, 607323 (3),IVIC syndrome, 147750 (3);SALL4, HSAL4;607343;AD;20q13.2
SAMD9;Tumoral calcinosis, familial, normophosphatemic, 610455 (3);SAMD9, NFTC;610456;AD, AR;7q21.2
SAMHD1;?Chilblain lupus 2, 614415 (3),Aicardi-Goutieres syndrome 5, 612952 (3);SAMHD1, AGS5, DCIP, CHBL2;606754;AD,-;20q11.23
SANS;Usher syndrome, type 1G, 606943 (3);SANS, USH1G;607696;AR;17q25.1
SAR1B;Chylomicron retention disease, 246700 (3);SAR1B, CMRD, SARA2, ANDD;607690;AR;5q31.1
SARS2;Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3);SARS2;612804;AR;19q13.2
SASS6;?Microcephaly 14, primary, autosomal recessive, 616402 (3);SASS6, SAS6, MCPH14;609321;AR;1p21.2
SATB2;Glass syndrome, 612313 (3);SATB2, KIAA1034, GLSS;608148;AD;2q33.1
SBDS;Shwachman-Diamond syndrome, 260400 (3);SBDS, SDS;607444;AR, -;7q11.21
SBF1;Charcot-Marie-Tooth disease, type 4B3, 615284 (3);SBF1, MTMR5, CMT4B3;603560;AR;22q13.33
SBF2;Charcot-Marie-Tooth disease, type 4B2, 604563 (3);SBF2, MTMR13, CMT4B2;607697;AR;11p15.4
SC5DL;Lathosterolosis, 607330 (3);SC5DL, ERG3;602286;AR;11q23.3-q24.1
SCA18;Spinocerebellar ataxia 18 (2);SCA18, SMNA;607458;AD;7q22-q32
SCA20;Spinocerebellar ataxia 20 (4);SCA20, DUP11q12, C11DUPq12;608687;AD;11q12
SCA25;Spinocerebellar ataxia 25 (2);SCA25;608703;AD;2p21-p13
SCA30;?Spinocerebellar ataxia 30 (2);SCA30;613371;AD;4q34.3-q35.1
SCA32;Spinocerebellar ataxia 32 (2);SCA32;613909;AD;7q32-q33
SCA37;Spinocerebellar ataxia 37 (2);SCA37;615945;AD;1p32
SCA4;Spinocerebellar ataxia 4 (2);SCA4;600223;AD;16q22.1
SCAR3;Spinocerebellar ataxia, autosomal recessive 3 (2);SCAR3, SCABD;271250;AR;6p23-p21
SCAR4;Spinocerebellar ataxia, autosomal recessive 4 (2);SCAR4, SCASI;607317;AR;1p36
SCAR6;Spinocerebellar ataxia, autosomal recessive 6 (2);SCAR6, CLA3;608029;AR;20q11-q13
SCARB2;Epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3);SCARB2, CD36L2, LIMPII, AMRF, EPM4;602257;AR;4q21.1
SCARF2;Van den Ende-Gupta syndrome, 600920 (3);SCARF2, SREC2, VDEGS;613619;AR;22q11.21
SCAX5;Spinocerebellar ataxia, X-linked 5 (2);SCAX5;300703;XLR;Xq25-q27.1
SCLC1;Small-cell cancer of lung (2);SCLC1;182280;AD;3p23-p21
SCLL;Chromosome 8p11 myeloproliferative syndrome (4);SCLL;613523;-;8p11
SCN10A;Episodic pain syndrome, familial, 2, 615551 (3);SCN10A, FEPS2;604427;AD;3p22.2
SCN11A;Episodic pain syndrome, familial, 3, 615552 (3),Neuropathy, hereditary sensory and autonomic, type VII, 615548 (3);SCN11A, HSAN7, FEPS3;604385;AD;3p22.2
SCN1A;Dravet syndrome, 607208 (3),Epilepsy, generalized, with febrile seizures plus, type 2, 604403 (3),Febrile seizures, familial, 3A, 604403 (3),Migraine, familial hemiplegic, 3, 609634 (3);SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3;182389;AD;2q24.3
SCN1B;Atrial fibrillation, familial, 13, 615377 (3),Brugada syndrome 5, 612838 (3),Cardiac conduction defect, nonspecific, 612838 (3),Epilepsy, generalized, with febrile seizures plus, type 1, 604233 (3);SCN1B, GEFSP1, BRGDA5, ATFB13;600235;AD, -;19q13.11
SCN2A;Epileptic encephalopathy, early infantile, 11, 613721 (3),Seizures, benign familial infantile, 3, 607745 (3);SCN2A, SCN2A1, BFIC3, EIEE11, BFIS3, BFNIS;182390;AD;2q24.3
SCN2B;Atrial fibrillation, familial, 14, 615378 (3);SCN2B, ATFB14;601327;AD;11q23.3
SCN3B;Atrial fibrillation, familial, 16, 613120 (3),Brugada syndrome 7, 613120 (3);SCN3B, SCNB3, BRGDA7, ATFB16;608214;AD;11q24.1
SCN4A;Hyperkalemic periodic paralysis, type 2, 170500 (3),Hypokalemic periodic paralysis, type 2, 613345 (3),Myasthenic syndrome, congenital, 16, 614198 (3),Myotonia congenita, atypical, acetazolamide-responsive, 608390 (3),Paramyotonia congenita, 168300 (3);SCN4A, HYPP, NAC1A, HOKPP2, CMS16;603967;AD;17q23.3
SCN4B;Atrial fibrillation, familial, 17, 611819 (3),Long QT syndrome-10, 611819 (3);SCN4B, LQT10, ATFB17;608256;AD;11q23.3
SCN5A;Atrial fibrillation, familial, 10, 614022 (3),Brugada syndrome 1, 601144 (3),Cardiomyopathy, dilated, 1E, 601154 (3),Heart block, nonprogressive, 113900 (3),Heart block, progressive, type IA, 113900 (3),Long QT syndrome-3, 603830 (3),Sick sinus syndrome 1, 608567 (3),Ventricular fibrillation, familial, 1, 603829 (3);SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2;600163;AD, AR;3p22.2
SCN8A;?Cognitive impairment with or without cerebellar ataxia, 614306 (3),Epileptic encephalopathy, early infantile, 13, 614558 (3);SCN8A, CIAT, EIEE13;600702;AD;12q13.13
SCN9A;Epilepsy, generalized, with febrile seizures plus, type 7, 613863 (3),Erythermalgia, primary, 133020 (3),Febrile seizures, familial, 3B, 613863 (3),HSAN2D, autosomal recessive, 243000 (3),Insensitivity to pain, congenital, 243000 (3),Paroxysmal extreme pain disorder, 167400, (3),Small fiber neuropathy, 133020 (3);SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP, HSAN2D;603415;AD, AR;2q24.3
SCNN1A;Bronchiectasis with or without elevated sweat chloride 2, 613021 (3),Pseudohypoaldosteronism, type I, 264350 (3);SCNN1A, BESC2;600228;AD, AR;12p13.31
SCNN1B;Bronchiectasis with or without elevated sweat chloride 1, 211400 (3),Liddle syndrome, 177200 (3),Pseudohypoaldosteronism, type I, 264350 (3);SCNN1B, BESC1;600760;AD, AR;16p12.2
SCNN1G;Bronchiectasis with or without elevated sweat chloride 3, 613071 (3),Liddle syndrome, 177200 (3),Pseudohypoaldosteronism, type I, 264350 (3);SCNN1G, PHA1, BESC3;600761;AD, AR;16p12.2
SCO1;Mitochondrial complex IV deficiency, 220110 (3);SCO1, SCOD1;603644;Mi, AR;17p13.1
SCO2;Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1, 604377 (3),Myopia 6, 608908 (3);SCO2, CEMCOX1, MYP6;604272;AR, AD;22q13.33
SCP2;Leukoencephalopathy with dystonia and motor neuropathy, 613724 (3);SCP2;184755;AR;1p32.3
SCYL1;Spinocerebellar ataxia, autosomal recessive 21, 616719 (3);SCYL1, NTKL, SCAR21;607982;AR;11q13.1
SCZD16;Schizophrenia 16 (4);SCZD16, C16DUPq36.3, DUP7q36.3;613959;-;7q36.3
SDCCAG8;Bardet-Biedl syndrome 16, 615993 (3),Senior-Loken syndrome 7, 613615 (3);SDCCAG8, CCCAP, SLSN7, BBS16;613524;AR, -;1q43-q44
SDHA;Cardiomyopathy, dilated, 1GG, 613642 (3),Leigh syndrome, 256000 (3),Mitochondrial respiratory chain complex II deficiency, 252011 (3),Paragangliomas 5, 614165 (3);SDHA, SDH1, SDHF, CMD1GG, PGL5;600857;-, Mi, AR, AD;5p15.33
SDHAF1;Mitochondrial complex II deficiency, 252011 (3);SDHAF1;612848;AR;19q13.12
SDHAF2;Paragangliomas 2, 601650 (3);SDHAF2, SDH5, PGL2;613019;AD;11q12.2
SDHB;Cowden syndrome 2, 612359 (3),Gastrointestinal stromal tumor, 606764 (3),Paraganglioma and gastric stromal sarcoma, 606864 (3),Paragangliomas 4, 115310 (3),Pheochromocytoma, 171300 (3);SDHB, SDH2, SDHIP, PGL4, CWS2;185470;AD, ICM ;1p36.13
SDHC;Gastrointestinal stromal tumor, 606764 (3),Paraganglioma and gastric stromal sarcoma, 606864 (3),Paragangliomas 3, 605373 (3);SDHC, PGL3;602413;IC, AD ;1q23.3
SDHD;Carcinoid tumors, intestinal, 114900 (3),Cowden syndrome 3, 615106 (3),Merkel cell carcinoma, somatic (3),Mitochondrial complex II deficiency, 252011 (3),Paraganglioma and gastric stromal sarcoma, 606864 (3),Paragangliomas 1, with or without deafness, 168000 (3),Pheochromocytoma, 171300 (3);SDHD, PGL1, CWS3;602690;AD, AR, -;11q23.1
SEC23A;Craniolenticulosutural dysplasia, 607812 (3);SEC23A, CLSD;610511;AR;14q21.1
SEC23B;Cowden syndrome 7, 616858 (3),Dyserythropoietic anemia, congenital, type II, 224100 (3);SEC23B, CDAN2, HEMPAS, CWS7;610512;AD, AR;20p11.23
SEC24D;Cole-Carpenter syndrome 2, 616294 (3);SEC24D, KIAA0755, CLCRP2;607186;AR;4q26
SEC63;Polycystic liver disease, 174050 (3);SEC63;608648;AD;6q21
SECISBP2;Thyroid hormone metabolism, abnormal, 609698 (3);SECISBP2, SBP2;607693;-;9q22.2
SEMA3E;?CHARGE syndrome, 214800 (3);SEMA3E, SEMAH, KIAA0331;608166;AD;7q21.11
SEMA4A;Cone-rod dystrophy 10, 610283 (3),Retinitis pigmentosa 35, 610282 (3);SEMA4A, SEMB, RP35, CORD10;607292;AR, AD;1q22
SEPN1;Muscular dystrophy, rigid spine, 1, 602771 (3),Myopathy, congenital, with fiber-type disproportion, 255310 (3);SEPN1, SELN, RSMD1, CFTD;606210;AR, AD;1p36.11
SEPSECS;Pontocerebellar hypoplasia type 2D, 613811 (3);SEPSECS, SLA, LP, PCH2D;613009;AR;4p15.2
SEPT12;Spermatogenic failure 10, 614822 (3);SEPT12, SPGF10;611562;AD;16p13.3
SEPT9;Amyotrophy, hereditary neuralgic, 162100 (3),Leukemia, acute myeloid, therapy-related (1),Ovarian carcinoma (1);SEPT9, MSF, MSF1, NAPB;604061;AD, -;17q25.3
SERAC1;3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 614739 (3);SERAC1, MEGDEL;614725;AR;6q25.3
SERPINA1;Emphysema due to AAT deficiency, 613490 (3),Emphysema-cirrhosis, due to AAT deficiency, 613490 (3),Hemorrhagic diathesis due to \'antithrombin\' Pittsburgh, 613490 (3);SERPINA1, PI, AAT;107400;AR, -;14q32.13
SERPINA3;Alpha-1-antichymotrypsin deficiency (3),Cerebrovascular disease, occlusive (3);SERPINA3, AACT, ACT;107280;-;14q32.13
SERPINB6;?Deafness, autosomal recessive 91, 613453 (3);SERPINB6, PI6, PTI, SPI3, DFNB91;173321;-;6p25.2
SERPINB7;Palmoplantar keratoderma, Nagashima type, 615598 (3);SERPINB7, MEGSIN, PPKN;603357;AR;18q21.33
SERPINC1;Thrombophilia due to antithrombin III deficiency, 613118 (3);SERPINC1, AT3, AT3D, THPH7;107300;AD, AR;1q25.1
SERPINF1;Osteogenesis imperfecta, type VI, 613982 (3);SERPINF1, PEDF, OI6;172860;-;17p13.3
SERPINH1;?Osteogenesis imperfecta, type X, 613848 (3);SERPINH1, SERPINH2, PPROM, CBP2, CBP1, OI10;600943;AR;11q13.5
SERPINI1;Encephalopathy, familial, with neuroserpin inclusion bodies, 604218 (3);SERPINI1, PI12;602445;AD;3q26.1
SETBP1;Mental retardation, autosomal dominant 29, 616078 (3),Schinzel-Giedion midface retraction syndrome, 269150 (3);SETBP1, KIAA0437, SEB, MRD29;611060;AD;18q12.3
SETD2;Luscan-Lumish syndrome, 616831 (3);SETD2, SET2, HYPB, HBP231, KIAA1732, LLS;612778;AD;3p21.31
SETD5;Mental retardation, autosomal dominant 23, 615761 (3);SETD5, KIAA1757;615743;AD;3p25.3
SETX;Amyotrophic lateral sclerosis 4, juvenile, 602433 (3),Spinocerebellar ataxia, autosomal recessive 1, 606002 (3);SETX, SCAR1, AOA2, ALS4;608465;AD, AR;9q34.13
SF3B1;Myelodysplastic syndrome, somatic, 614286 (3);SF3B1, SF3B155, SAP155, MDS;605590;-;2q33.1
SF3B4;Acrofacial dysostosis 1, Nager type, 154400 (3);SF3B4, SF3B49, SAP49, AFD1;605593;AD;1q21.2
SFRP4;Pyle disease, 265900 (3);SFRP4, FRPHE, PYL;606570;AR;7p14.1
SFTPA2;Pulmonary fibrosis, idiopathic, 178500 (3);SFTPA2, SPA2, COLEC5;178642;AD;10q22.3
SFTPB;Surfactant metabolism dysfunction, pulmonary, 1, 265120 (3);SFTPB, SFTB3, SMDP1;178640;AR;2p11.2
SFTPC;Surfactant metabolism dysfunction, pulmonary, 2, 610913 (3);SFTPC, SFTP2, SMDP2;178620;AD;8p21.3
SFXN4;Combined oxidative phosphorylation deficiency 18, 615578 (3);SFXN4, COXPD18;615564;AR;10q26.11
SGCA;Muscular dystrophy, limb-girdle, type 2D, 608099 (3);SGCA, ADL, DAG2, LGMD2D, DMDA2;600119;AR;17q21.33
SGCB;Muscular dystrophy, limb-girdle, type 2E, 604286 (3);SGCB, LGMD2E;600900;AR;4q12
SGCD;Cardiomyopathy, dilated, 1L, 606685 (3),Muscular dystrophy, limb-girdle, type 2F, 601287 (3);SGCD, SGD, LGMD2F, CMD1L;601411;-, AR;5q33.2-q33.3
SGCE;Dystonia-11, myoclonic, 159900 (3);SGCE, DYT11;604149;AD;7q21.3
SGCG;Muscular dystrophy, limb-girdle, type 2C, 253700 (3);SGCG, LGMD2C, DMDA1, SCG3;608896;AR;13q12.12
SGOL1;Chronic atrial and intestinal dysrhythmia, 616201 (3);SGOL1, SGO, SGO1, CAID;609168;AR;3p24.3
SGSH;Mucopolysaccharidosis type IIIA (Sanfilippo A), 252900 (3);SGSH, MPS3A, SFMD;605270;AR;17q25.3
SH2B3;Erythrocytosis, somatic, 133100 (3),Myelofibrosis, somatic, 254450 (3),Thrombocythemia, somatic, 187950 (3);SH2B3, LNK;605093;-;12q24.12
SH2D1A;Lymphoproliferative syndrome, X-linked, 1, 308240 (3);SH2D1A, LYP, IMD5, XLP, XLPD1;300490;XLR;Xq25
SH3BP2;Cherubism, 118400 (3);SH3BP2, CRPM;602104;AD;4p16.3
SH3GL1;Leukemia, acute myeloid, 601626 (1);SH3GL1, EEN;601768;AD;19p13.3
SH3PXD2B;Frank-ter Haar syndrome, 249420 (3);SH3PXD2B, TKS4, KIAA1295, FTHS;613293;AR;5q35.1
SH3TC2;Charcot-Marie-Tooth disease, type 4C, 601596 (3),Mononeuropathy of the median nerve, mild, 613353 (3);SH3TC2, KIAA1985, MNMN;608206;AR, AD;5q32
SHANK3;Phelan-McDermid syndrome, 606232 (3);SHANK3, PSAP2, PROSAP2, KIAA1650, DEL22q13.3, SCZD15;606230;IC, -;22q13.33
SHFL1;Split-hand/foot malformation with long bone deficiency 1 (2);SHFL1, SHFLD;119100;AD;1q42.2-q43
SHFLD2;Split-hand/foot malformation with long bone deficiency 2 (2);SHFLD2;610685;-;6q14.1
SHFLD3;Split-hand/foot malformation with long bone deficiency 3 (4);SHFLD3, DUP17p13.3, C17DUPp13.3;612576;AD;17p13.3-p13.1
SHFM1;Split hand/foot malformation 1 (4);SHFM1, SHFD1, SHSF1;183600;AD;7q21.2-q21.3
SHFM2;Split hand/foot malformation 2 (2);SHFM2, SHFD2;313350;XL;Xq26
SHFM3;Split-hand/foot malformation 3, gene duplication syndrome (4);SHFM3, SHSF3, DUP10q24, C10DUPq24;246560;AD;10q24
SHFM5;Split-hand/foot malformation 5 (2);SHFM5;606708;-;2q31
SHH;Holoprosencephaly 3, 142945 (3),Microphthalmia with coloboma 5, 611638 (3),Schizencephaly, 269160 (3),Single median maxillary central incisor, 147250 (3);SHH, HPE3, HLP3, SMMCI, MCOPCB5;600725;AD, -;7q36.3
SHOC2;Noonan-like syndrome with loose anagen hair, 607721 (3);SHOC2, SIAA0862, SOC2, SUR8;602775;AD;10q25.2
SHOX;Langer mesomelic dysplasia, 249700 (3),Leri-Weill dyschondrosteosis, 127300 (3),Short stature, idiopathic familial, 300582 (3);SHOX, GCFX, SS, PHOG;312865;AR, AD, -;Xp22.33
SHOXY;Langer mesomelic dysplasia, 249700 (3),Leri-Weill dyschondrosteosis, 127300 (3),Short stature, idiopathic familial, 300582 (3);SHOXY;400020;AR, AD, -;Yp11.2
SHROOM4;?Stocco dos Santos X-linked mental retardation syndrome, 300434 (3);SHROOM4, KIAA1202, SDSX;300579;-;Xp11.22
SI;Sucrase-isomaltase deficiency, congenital, 222900 (3);SI;609845;AR;3q26.1
SIAT9;Amish infantile epilepsy syndrome, 609056 (3);SIAT9, ST3GALV;604402;AR;2p11.2
SIGMAR1;?Amyotrophic lateral sclerosis 16, juvenile, 614373 (3),?Spinal muscular atrophy, distal, autosomal recessive, 2, 605726 (3);SIGMAR1, SRBP, ALS16, DSMA2;601978;AR,AR;9p13.3
SIK1;Epileptic encephalopathy, early infantile, 30, 616341 (3);SIK1, SNF1LK, MSK, EIEE30;605705;AD;21q22.3
SIL1;Marinesco-Sjogren syndrome, 248800 (3);SIL1, BAP, MSS;608005;AR;5q31.2
SIM1;Obesity, severe, 601665 (3);SIM1;603128;Mu, AD, AR;6q16.3
SIPA1L3;?Cataract 45, 616851 (3);SIPA1L3, SPAL3, SPAR3, KIAA0545, CTRCT45;616655;AR;19q13.1-q13.2
SIX1;Branchiootic syndrome 3, 608389 (3),Deafness, autosomal dominant 23, 605192 (3);SIX1, BOS3, DFNA23;601205;AD;14q23.1
SIX3;Holoprosencephaly 2, 157170 (3),Schizencephaly, 269160 (3);SIX3, HPE2;603714;IC, AD, -;2p21
SIX5;Branchiootorenal syndrome 2, 610896 (3);SIX5, DMAHP, BOR2;600963;-;19q13.32
SIX6;Optic disc anomalies with retinal and/or macular dystrophy, 212550 (3);SIX6, ODRMD;606326;AR;14q23.1
SKI;Shprintzen-Goldberg syndrome, 182212 (3);SKI, SGS;164780;AD;1p36.33-p36.32
SKIV2L;Trichohepatoenteric syndrome 2, 614602 (3);SKIV2L, SKI2, SKI2W, THES2;600478;AR;6p21.33
SLC10A2;Bile acid malabsorption, primary, 613291 (3);SLC10A2, NTCP2, PBAM;601295;AR;13q33.1
SLC11A2;Anemia, hypochromic microcytic, with iron overload 1, 206100 (3);SLC11A2, NRAMP2, DCT1, DMT1, AHMIO1;600523;AR;12q13.12
SLC12A1;Bartter syndrome, type 1, 601678 (3);SLC12A1, NKCC2;600839;AR;15q21.1
SLC12A3;Gitelman syndrome, 263800 (3);SLC12A3, NCCT, TSC;600968;AR;16q13
SLC12A5;Epileptic encephalopathy, early infantile, 34, 616645 (3);SLC12A5, KCC2, KIAA1176, EIEE34, EIG14;606726;AR, AD;20q13.12
SLC12A6;Agenesis of the corpus callosum with peripheral neuropathy, 218000 (3);SLC12A6, KCC3A, KCC3B, KCC3, ACCPN;604878;AR;15q14
SLC13A5;Epileptic encephalopathy, early infantile, 25, 615905 (3);SLC13A5, NACT, EIEE25;608305;AR;17p13.1
SLC16A1;Erythrocyte lactate transporter defect, 245340 (3),Hyperinsulinemic hypoglycemia, familial, 7, 610021 (3),Monocarboxylate transporter 1 deficiency, 616095 (3);SLC16A1, MCT1, HHF7, MCT1D;600682;AD, AR;1p13.2
SLC16A12;Cataract, juvenile, with microcornea and glucosuria, 612018 (3);SLC16A12, MCT12, CJMG;611910;AD;10q23.31
SLC16A2;Allan-Herndon-Dudley syndrome, 300523 (3);SLC16A2, DXS128, XPCT;300095;XLD;Xq13.2
SLC17A5;Salla disease, 604369 (3),Sialic acid storage disorder, infantile, 269920 (3);SLC17A5, SIASD, SLD;604322;AR;6q13
SLC17A8;Deafness, autosomal dominant 25, 605583 (3);SLC17A8, VGLUT3, DFNA25;607557;AD;12q23.1
SLC17A9;Porokeratosis 8, disseminated superficial actinic type, 616063 (3);SLC17A9, C20orf59, POROK8;612107;AD;20q13.33
SLC19A2;Thiamine-responsive megaloblastic anemia syndrome, 249270 (3);SLC19A2, THTR1, TRMA, THMD1;603941;AR;1q24.2
SLC19A3;Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 (3);SLC19A3, THMD2, BBGD;606152;AR;2q36.3
SLC1A1;Dicarboxylic aminoaciduria, 222730 (3);SLC1A1, EAAC1, SCZD18, DCBXA;133550;AR, -;9p24.2
SLC1A3;Episodic ataxia, type 6, 612656 (3);SLC1A3, EAAT1, EA6;600111;-;5p13.2
SLC1A4;Spastic tetraplegia, thin corpus callosum, and progressive microcephaly, 616657 (3);SLC1A4, SATT, ASCT1, SPATCCM;600229;AR;2p14
SLC20A2;Basal ganglia calcification, idiopathic, 1, 213600 (3);SLC20A2, MLVAR, GLVR2, IBGC1;158378;AD;8p11.21
SLC22A12;Hypouricemia, renal, 220150 (3);SLC22A12, OAT4L, URAT1;607096;AR;11q13.1
SLC22A1L;Breast cancer, somatic, 114480 (3),Lung cancer, somatic, 211980 (3),Rhabdomyosarcoma, somatic, 268210 (3);SLC22A1L, BWSCR1A, IMPT1;602631;-;11p15.4
SLC22A5;Carnitine deficiency, systemic primary, 212140 (3);SLC22A5, OCTN2, CDSP, SCD;603377;AR;5q31.1
SLC24A1;Night blindness, congenital stationary (complete), 1D, autosomal recessive, 613830 (3);SLC24A1, NCKX1, CSNB1D;603617;AR;15q22.31
SLC24A4;Amelogenesis imperfecta, type IIA5, 615887 (3);SLC24A4, NCKX4, SHEP6, AI2A5;609840;AR;14q32.12
SLC24A5;Albinism, oculocutaneous, type VI, 113750 (3);SLC24A5, NCKX5, SHEP4, OCA6;609802;AR;15q21.1
SLC25A1;?Nephrolithiasis, calcium oxalate, 167030 (3),Combined D-2- and L-2-hydroxyglutaric aciduria, 615182 (3);SLC25A1, SLC20A3, CTP, D2L2AD;190315;AR;22q11.21
SLC25A12;Hypomyelination, global cerebral, 612949 (3);SLC25A12, ARALAR;603667;AR;2q31.1
SLC25A13;Citrullinemia, adult-onset type II, 603471 (3),Citrullinemia, type II, neonatal-onset, 605814 (3);SLC25A13, CTLN2;603859;AR;7q21.3
SLC25A15;Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3);SLC25A15, ORNT1, HHH;603861;AR;13q14.11
SLC25A19;Microcephaly, Amish type, 607196 (3),Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 (3);SLC25A19, DNC, MUP1, MCPHA, THMD3, THMD4;606521;AR;17q25.1
SLC25A20;Carnitine-acylcarnitine translocase deficiency, 212138 (3);SLC25A20, CACT, CAC;613698;AR;3p21.31
SLC25A22;Epileptic encephalopathy, early infantile, 3, 609304 (3);SLC25A22, GC1, EIEE3;609302;AR;11p15.5
SLC25A26;Combined oxidative phosphorylation deficiency 28, 616794 (3);SLC25A26, SAMC, COXPD28;611037;AR;3p14.1
SLC25A3;Mitochondrial phosphate carrier deficiency, 610773 (3);SLC25A3, PHC;600370;-;12q23.1
SLC25A32;?Exercise intolerance, riboflavin-responsive, 616839 (3);SLC25A32, MFT, RREI;610815;AR;8q22.3
SLC25A38;Anemia, sideroblastic, 2, pyridoxine-refractory, 205950 (3);SLC25A38, SIDBA2;610819;AR;3p22.1
SLC25A4;Mitochondrial DNA depletion syndrome 12 (cardiomyopathic type), 615418 (3),Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 2, 609283 (3);SLC25A4, ANT1, T1, PEO3, PEO2, MTDPS12, PEOA2;103220;AR, AD;4q35.1
SLC25A46;Neuropathy, hereditary motor and sensory, type VIB, 616505 (3);SLC25A46, HMSN6B;610826;AR;5q22.1
SLC26A2;Achondrogenesis Ib, 600972 (3),Atelosteogenesis II, 256050 (3),De la Chapelle dysplasia, 256050 (3),Diastrophic dysplasia, 222600 (3),Diastrophic dysplasia, broad bone-platyspondylic variant, 222600 (3),Epiphyseal dysplasia, multiple, 4, 226900 (3);SLC26A2, DTD, DTDST, D5S1708, EDM4;606718;AR;5q32
SLC26A3;Diarrhea 1, secretory chloride, congenital, 214700 (3);SLC26A3, DRA, CLD;126650;AR;7q22.3-q31.1
SLC26A4;Deafness, autosomal recessive 4, with enlarged vestibular aqueduct, 600791 (3),Pendred syndrome, 274600 (3);SLC26A4, PDS, DFNB4, EVA, TDH2B;605646;AR;7q22.3
SLC26A5;?Deafness, autosomal recessive 61, 613865 (3);SLC26A5, PRES, DFNB61;604943;AR;7q22.1
SLC26A8;Spermatogenic failure 3, 606766 (3);SLC26A8, TAT1, SPGF3;608480;AD;6p21.31
SLC27A4;Ichthyosis prematurity syndrome, 608649 (3);SLC27A4, FATP4, IPS;604194;-;9q34.11
SLC29A3;Histiocytosis-lymphadenopathy plus syndrome, 602782 (3);SLC29A3, ENT3, PHID, HCLAP;612373;AR;10q22.1
SLC2A1;Dystonia 9, 601042 (3),GLUT1 deficiency syndrome 1, infantile onset, severe, 606777 (3),GLUT1 deficiency syndrome 2, childhood onset, 612126 (3),Stomatin-deficient cryohydrocytosis with neurologic defects, 608885 (3);SLC2A1, GLUT1, DYT18, PED, GLUT1DS, EIG12, DYT9, SDCHCN;138140;AD, AR;1p34.2
SLC2A10;Arterial tortuosity syndrome, 208050 (3);SLC2A10, GLUT10, ATS;606145;AR;20q13.12
SLC2A2;Fanconi-Bickel syndrome, 227810 (3);SLC2A2, GLUT2;138160;AD, AR;3q26.2
SLC2A9;Hypouricemia, renal, 2, 612076 (3);SLC2A9, GLUT9, UAQTL2;606142;AD, AR;4p16.1
SLC30A10;Hypermanganesemia with dystonia 1, 613280 (3);SLC30A10, ZNT10, HMNDYT1;611146;AR;1q41
SLC30A2;Zinc deficiency, transient neonatal, 608118 (3);SLC30A2, ZNT2, TNZD;609617;AD;1p36.11
SLC33A1;Congenital cataracts, hearing loss, and neurodegeneration, 614482 (3),Spastic paraplegia 42, autosomal dominant, 612539 (3);SLC33A1, ACATN, AT1, SPG42, CCHLND;603690;AR, AD;3q25.31
SLC34A1;Fanconi renotubular syndrome 2, 613388 (3),Hypercalcemia, infantile, 2, 616963 (3),Nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3);SLC34A1, SLC17A2, NPT2, NPHLOP1, FRTS2, HCINF2;182309;AR, AD;5q35.3
SLC34A2;Pulmonary alveolar microlithiasis, 265100 (3);SLC34A2;604217;AR;4p15.2
SLC34A3;Hypophosphatemic rickets with hypercalciuria, 241530 (3);SLC34A3, NPTIIC, HHRH;609826;AR;9q34.3
SLC35A1;Congenital disorder of glycosylation, type IIf, 603585 (3);SLC35A1, CST, CDG2F;605634;AR;6q15
SLC35A2;Congenital disorder of glycosylation, type IIm, 300896 (3);SLC35A2, UGALT, UGTL, UGT2, CDGX, CDG2M;314375;SMo, XLD;Xp11.23
SLC35A3;?Arthrogryposis, mental retardation, and seizures, 615553 (3);SLC35A3, AMRS;605632;AR;1p21.2
SLC35C1;Congenital disorder of glycosylation, type IIc, 266265 (3);SLC35C1, FUCT1, CDG2C;605881;AR;11p11.2
SLC35D1;Schneckenbecken dysplasia, 269250 (3);SLC35D1, UGTREL7, KIAA0260;610804;AR;1p31.3
SLC36A2;Hyperglycinuria, 138500 (3),Iminoglycinuria, digenic, 242600 (3);SLC36A2, PAT2;608331;AD, AR;5q33.1
SLC37A4;Glycogen storage disease Ib, 232220 (3),Glycogen storage disease Ic, 232240 (3);SLC37A4, G6PT1;602671;AR;11q23.3
SLC38A8;Foveal hypoplasia 2, with or without optic nerve misrouting and/or anterior segment dysgenesis, 609218 (3);SLC38A8, FVH2;615585;AR;16q23.3
SLC39A13;Spondylocheirodysplasia, Ehlers-Danlos syndrome-like, 612350 (3);SLC39A13;608735;AR;11p11.2
SLC39A14;Hypermanganesemia with dystonia 2, 617013 (3);SLC39A14, ZIP14, KIAA0062, HMNDYT2;608736;AR;8p21.3
SLC39A4;Acrodermatitis enteropathica, 201100 (3);SLC39A4, ZIP4;607059;AR;8q24.3
SLC39A5;Myopia 24, autosomal dominant, 615946 (3);SLC39A5, MYP24;608730;AD;12q13.3
SLC39A8;Congenital disorder of glycosylation, type IIn, 616721 (3);SLC39A8, BIGM103, CDG2N;608732;AR;4q24
SLC3A1;Cystinuria, 220100 (3);SLC3A1, ATR1, D2H, NBAT;104614;AD, AR;2p21
SLC40A1;Hemochromatosis, type 4, 606069 (3);SLC40A1, SLC11A3, FPN1, IREG1, HFE4;604653;-;2q32.2
SLC45A2;Albinism, oculocutaneous, type IV, 606574 (3);SLC45A2, MATP, AIM1, SHEP5, OCA4;606202;-;5p13.2
SLC46A1;Folate malabsorption, hereditary, 229050 (3);SLC46A1, HCP1, PCFT;611672;AR;17q11.2
SLC4A1;Cryohydrocytosis, 185020 (3),Ovalocytosis, SA type, 166900 (3),Renal tubular acidosis, distal, AD, 179800 (3),Renal tubular acidosis, distal, AR, 611590 (3),Spherocytosis, type 4, 612653 (3);SLC4A1, AE1, EPB3, SPH4, SAO, CHC;109270;AD, AR, -;17q21.31
SLC4A11;Corneal dystrophy, Fuchs endothelial, 4, 613268 (3),Corneal endothelial dystrophy and perceptive deafness, 217400 (3),Corneal endothelial dystrophy, autosomal recessive, 217700 (3);SLC4A11, BTR1, NABC1, CHED, CDPD, FECD4;610206;-, AR;20p13
SLC4A4;Renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3);SLC4A4, NBC1, KNBC;603345;AR;4q13.3
SLC52A1;Riboflavin deficiency, 615026 (3);SLC52A1, GPR172B, GPCR42, PAR2, FLJ10060, RBFVD;607883;AD;17p13.2
SLC52A2;Brown-Vialetto-Van Laere syndrome 2, 614707 (3);SLC52A2, GPR172A, GPCR41, PAR1, FLJ11856, BVVLS2;607882;AR;8q24.3
SLC52A3;Brown-Vialetto-Van Laere syndrome 1, 211530 (3),Fazio-Londe disease, 211500 (3);SLC52A3, C20orf54, RFT2, BVVLS1;613350;AR;20p13
SLC5A1;Glucose/galactose malabsorption, 606824 (3);SLC5A1, SGLT1;182380;AR;22q12.3
SLC5A2;Renal glucosuria, 233100 (3);SLC5A2, SGLT2;182381;AD, AR;16p11.2
SLC5A5;Thyroid dyshormonogenesis 1, 274400 (3);SLC5A5, NIS, TDH1;601843;AR;19p13.11
SLC5A7;Neuronopathy, distal hereditary motor, type VIIA, 158580 (3);SLC5A7, CHT1, HMN7A;608761;AD;2q12.3
SLC6A1;Myoclonic-atonic epilepsy, 616421 (3);SLC6A1, GABATR, MAE;137165;AD;3p25.3
SLC6A17;Mental retardation, autosomal recessive 48, 616269 (3);SLC6A17, NTT4, MRT48;610299;AR;1p13.3
SLC6A19;Hartnup disorder, 234500 (3),Hyperglycinuria, 138500 (3),Iminoglycinuria, digenic, 242600 (3);SLC6A19, HND;608893;AR, AD;5p15.33
SLC6A2;Orthostatic intolerance, 604715 (3);SLC6A2, NAT1, NET1;163970;-;16q12.2
SLC6A20;Hyperglycinuria, 138500 (3),Iminoglycinuria, digenic, 242600 (3);SLC6A20, XT3;605616;AR, AD;3p21.31
SLC6A3;Parkinsonism-dystonia, infantile, 613135 (3);SLC6A3, DAT1, PKDYS;126455;AR, -;5p15.33
SLC6A5;Hyperekplexia 3, 614618 (3);SLC6A5, GLYT2, HKPX3;604159;AR, AD;11p15.1
SLC6A8;Cerebral creatine deficiency syndrome 1, 300352 (3);SLC6A8, CRTR, CCDS1;300036;XLR;Xq28
SLC7A14;Retinitis pigmentosa 68, 615725 (3);SLC7A14, KIAA1613, RP68;615720;AR;3q26.2
SLC7A7;Lysinuric protein intolerance, 222700 (3);SLC7A7, LPI;603593;AR;14q11.2
SLC7A9;Cystinuria, 220100 (3);SLC7A9, CSNU3;604144;AD, AR;19q13.11
SLC9A1;?Lichtenstein-Knorr syndrome, 616291 (3);SLC9A1, NHE1, APNH, LIKNS;107310;AR;1p36.11
SLC9A3;Diarrhea 8, secretory sodium, congenital, 616868 (3);SLC9A3, NHE3, DIAR8;182307;AR;5p15.33
SLC9A3R1;Nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 (3);SLC9A3R1, EBP50, NHERF1, NPHLOP2;604990;AD;17q25.1
SLC9A6;Mental retardation, X-linked syndromic, Christianson type, 300243 (3);SLC9A6, NHE6;300231;XLD;Xq26.3
SLC9A9;?{Autism susceptibility 16}, 613410 (3);SLC9A9, AUTS16;608396;-;3q24
SLCO1B1;Hyperbilirubinemia, Rotor type, digenic, 237450 (3);SLCO1B1, LST1, OATP2, OATPC, OATP1B1, HBLRR;604843;DR ;12p12.1
SLCO1B3;Hyperbilirubinemia, Rotor type, digenic, 237450 (3);SLCO1B3, OATP8, OATP1B3, SLC21A8, HBLRR;605495;DR ;12p12.2
SLCO2A1;Hypertrophic osteoarthropathy, primary, autosomal recessive 2, 614441 (3);SLCO2A1, OATP2A1, PGT, SLC21A2, PHOAR2;601460;AR;3q22.1-q22.2
SLFN14;Bleeding disorder, platelet-type, 20, 616913 (3);SLFN14, BDPLT20;614958;AD;17q12
SLI1;Specific language impairment QTL, 1 (2);SLI1;606711;Mu ;16q
SLI2;Specific language impairment QTL, 2 (2);SLI2;606712;Mu ;19q
SLI3;Specific language impairment QTL, 3 (2);SLI3;607134;-;13q21
SLITRK1;?Trichotillomania, 613229 (3),Tourette syndrome, 137580 (3);SLITRK1, KIAA1910, TTM;609678;Mu, AD ;13q31.1
SLITRK6;Deafness and myopia, 221200 (3);SLITRK6, DFNMYP;609681;AR;13q31.1
SLSN3;Senior-Loken syndrome 3 (2);SLSN3;606995;AR;3q22
SLURP1;Meleda disease, 248300 (3);SLURP1, MDM;606119;AR;8q24.3
SLX4;Fanconi anemia, complementation group P, 613951 (3);SLX4, BTBD12, MUS312, KIAA1784, KIAA1987, FANCP;613278;AR;16p13.3
SMAC;Deafness, autosomal dominant 64, 614152 (3);SMAC, DIABLO, DFNA64;605219;AD;12q24.31
SMAD3;Loeys-Dietz syndrome 3, 613795 (3);SMAD3, MADH3, LDS3;603109;AD;15q22.33
SMAD6;Aortic valve disease 2, 614823 (3);SMAD6, MADH6, AOVD2;602931;AD;15q22.31
SMAR;Spinal muscular atrophy, chronic distal, autosomal recessive (2);SMAR;607088;AR;11q13
SMARCA2;Nicolaides-Baraitser syndrome, 601358 (3);SMARCA2, SNF2L2, NCBRS;600014;AD;9p24.3
SMARCA4;Coffin-Siris syndrome 4, 614609 (3);SMARCA4, BRG1, RTPS2, MRD16, CSS4;603254;AD;19p13.2
SMARCAD1;Adermatoglyphia, 136000 (3);SMARCAD1, KIAA1122, ETL1, HEL1, ADERM;612761;AD;4q22.3
SMARCAL1;Schimke immunoosseous dysplasia, 242900 (3);SMARCAL1, HARP, SIOD;606622;AR;2q35
SMARCB1;Coffin-Siris syndrome 3, 614608 (3),Rhabdoid tumors, somatic, 609322 (3);SMARCB1, SNF5, INI1, RDT, RTPS1, MRD15, SWNTS1, CSS3;601607;AD;22q11.23
SMARCE1;Coffin-Siris syndrome 5, 616938 (3);SMARCE1, BAF57, CSS5;603111;AD;17q21.2
SMC3;Cornelia de Lange syndrome 3, 610759 (3);SMC3, CSPG6, HCAP, BAM, CDLS3;606062;AD;10q25.2
SMCHD1;Fascioscapulohumeral muscular dystrophy 2, digenic, 158901 (3);SMCHD1, KIAA0650;614982;-;18p11.32
SMN1;Spinal muscular atrophy-1, 253300 (3),Spinal muscular atrophy-2, 253550 (3),Spinal muscular atrophy-3, 253400 (3),Spinal muscular atrophy-4, 271150 (3);SMN1, SMA1, SMA2, SMA3, SMA4;600354;AR;5q13.2
SMOC1;Microphthalmia with limb anomalies, 206920 (3);SMOC1, OAS;608488;AR;14q24.2
SMOC2;Dentin dysplasia, type I, with microdontia and misshapen teeth, 125400 (3);SMOC2, SMAP2, DTDP1;607223;AR;6q27
SMOH;Basal cell carcinoma, somatic (3);SMOH, SMO;601500;-;7q32.1
SMPD1;Niemann-Pick disease, type A, 257200 (3),Niemann-Pick disease, type B, 607616 (3);SMPD1, NPD;607608;AR;11p15.4
SMPX;Deafness, X-linked 4, 300066 (3);SMPX, DFNX4;300226;XLD;Xp22.12
SMS;Mental retardation, X-linked, Snyder-Robinson type, 309583 (3);SMS, SRS, MRSR;300105;XLR;Xp22.11
SNAI2;Piebaldism, 172800 (3),Waardenburg syndrome, type 2D, 608890 (3);SNAI2, SLUG, WS2D;602150;AD, AR;8q11.21
SNAP25;?Myasthenic syndrome, congenital, 18, 616330 (3);SNAP25, CMS18;600322;AD;20p12.2
SNAP29;Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528 (3);SNAP29, CEDNIK;604202;AR;22q11.21
SNCA;Dementia, Lewy body, 127750 (3),Parkinson disease 1, 168601 (3),Parkinson disease 4, 605543 (3);SNCA, NACP, PARK1, PARK4;163890;AD;4q22.1
SNCB;Dementia, Lewy body, 127750 (3);SNCB;602569;AD;5q35.2
SNIP1;Psychomotor retardation, epilepsy, and craniofacial dysmorphism, 614501 (3);SNIP1, PMRED;608241;AR;1p34.3
SNORA2C;Small nucleolar RNA, H/ACA box, 2C, 615487 (3);SNORA2C, SNORA34, ACA34, MIR1291;615487;-;12q13.11
SNRNP200;Retinitis pigmentosa 33, 610359 (3);SNRNP200, ASCC3L1, KIAA0788, RP33;601664;AD;2q11.2
SNRPB;Cerebrocostomandibular syndrome, 117650 (3);SNRPB, CCMS;182282;AD, AR;20p13
SNRPE;Hypotrichosis 11, 615059 (3);SNRPE, HYPT11;128260;AD;1q32.1
SNRPN;Prader-Willi syndrome, 176270 (3);SNRPN;182279;IC;15q11.2
SNTA1;Long QT syndrome 12, 612955 (3);SNTA1, SNT1, TACIP1, LQT12;601017;AD;20q11.21
SNX10;Osteopetrosis, autosomal recessive 8, 615085 (3);SNX10, OPTB8;614780;AR;7p15.2
SNX14;Spinocerebellar ataxia, autosomal recessive 20, 616354 (3);SNX14, SCAR20;616105;AR;6q14.3
SOBP;Mental retardation, anterior maxillary protrusion, and strabismus, 613671 (3);SOBP, JXC1, MRAMS;613667;AR;6q21
SOD1;Amyotrophic lateral sclerosis 1, 105400 (3);SOD1, ALS1;147450;AR, AD;21q22.11
SORD;?Cataract, congenital (2);SORD, SORD1;182500;-;15q21.1
SOS1;?Fibromatosis, gingival, 1, 135300 (3),Noonan syndrome 4, 610733 (3);SOS1, GINGF, GF1, HGF, NS4;182530;AD;2p22.1
SOS2;Noonan syndrome 9, 616559 (3);SOS2, NS9;601247;AD;14q21.3
SOST;Craniodiaphyseal dysplasia, autosomal dominant, 122860 (3),Sclerosteosis 1, 269500 (3),Van Buchem disease, 239100 (3);SOST, VBCH, CDD, SOST1;605740;AD, AR;17q21.31
SOX10;PCWH syndrome, 609136 (3),Waardenburg syndrome, type 2E, with or without neurologic involvement, 611584 (3),Waardenburg syndrome, type 4C, 613266 (3);SOX10, WS4, WS4C, PCWH;602229;AD;22q13.1
SOX11;Mental retardation, autosomal dominant, 27, 615866 (3);SOX11, MRD27;600898;AD;2p25.2
SOX17;Vesicoureteral reflux 3, 613674 (3);SOX17, VUR3;610928;AD;8q11.23
SOX18;Hypotrichosis-lymphedema-telangiectasia syndrome, 607823 (3),Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome, 137940 (3);SOX18, HLTS, HLTRS;601618;AR, AD;20q13.33
SOX2;Microphthalmia, syndromic 3, 206900 (3),Optic nerve hypoplasia and abnormalities of the central nervous system, 206900 (3);SOX2, MCOPS3;184429;AD;3q26.33
SOX3;Mental retardation, X-linked, with isolated growth hormone deficiency, 300123 (3),Panhypopituitarism, X-linked, 312000 (3);SOX3, MRGH;313430;-, XL;Xq27.1
SOX5;Lamb-Shaffer syndrome, 616803 (3);SOX5, LAMSHF;604975;AD;12p12.1
SOX9;Acampomelic campomelic dysplasia, 114290 (3),Campomelic dysplasia with autosomal sex reversal, 114290 (3),Campomelic dysplasia, 114290 (3);SOX9, CMD1, SRA1;608160;AD;17q24.3
SP110;Hepatic venoocclusive disease with immunodeficiency, 235550 (3);SP110, IFI41, IFI75, VODI;604457;AR, -;2q37.1
SP7;?Osteogenesis imperfecta, type XII, 613849 (3);SP7, OSX, OI12;606633;AR;12q13.13
SPAG1;Ciliary dyskinesia, primary, 28, 615505 (3);SPAG1, CILD28;603395;AR;8q22.2
SPARC;Osteogenesis imperfecta, type XVII, 616507 (3);SPARC, ON, OI17;182120;AR;5q33.1
SPAST;Spastic paraplegia 4, autosomal dominant, 182601 (3);SPAST, SPG4;604277;AD;2p22.3
SPATA16;?Spermatogenic failure 6, 102530 (3);SPATA16, SPGF6;609856;AR;3q26.31
SPATA5;Epilepsy, hearing loss, and mental retardation syndrome, 616577 (3);SPATA5, SPAF, EHLMRS;613940;AR;4q28.1
SPATA7;Leber congenital amaurosis 3, 604232 (3),Retinitis pigmentosa, juvenile, autosomal recessive, 604232 (3);SPATA7, HSD3, LCA3;609868;-;14q31.3
SPD3;Synpolydactyly 3 (2);SPD3;610234;-;14q11.2-q12
SPDT;Spondyloepiphyseal dysplasia tarda, autosomal dominant (2);SPDT;184100;AD;12q13
SPECC1L;?Facial clefting, oblique, 1, 600251 (3),Opitz GBBB syndrome, type II, 145410 (3);SPECC1L, KIAA0376, OBLFC1, GBBB2;614140;IC, AD;22q11.23
SPEG;Centronuclear myopathy 5, 615959 (3);SPEG, APEG1, CNM5;615950;AR;2q35
SPG11;Amyotrophic lateral sclerosis 5, juvenile, 602099 (3),Charcot-Marie-Tooth disease, axonal, type 2X, 616668 (3),Spastic paraplegia 11, autosomal recessive, 604360 (3);SPG11, KIAA1840, FLJ21439, ALS5, CMT2X;610844;AR;15q21.1
SPG14;Spastic paraplegia 14, autosomal recessive (2);SPG14;605229;AR;3q27-q28
SPG16;Spastic paraplegia 16, X-linked, complicated (2);SPG16;300266;XLR;Xq11.2
SPG19;Spastic paraplegia 19, autosomal dominant (2);SPG19;607152;AD;9q
SPG20;Troyer syndrome, 275900 (3);SPG20;607111;AR;13q13.3
SPG23;Spastic paraplegia 23 (2);SPG23;270750;AR;2q24-q32
SPG24;Spastic paraplegia 24, autosomal recessive (2);SPG24;607584;AR;13q14
SPG25;Spastic paraplegia 25, autosomal recessive (2);SPG25;608220;AR;6q23-q24.1
SPG27;Spastic paraplegia 27, autosomal recessive (2);SPG27;609041;AR;10q22.1-q24.1
SPG29;Spastic paraplegia 29, autosomal dominant (2);SPG29;609727;AD;1p31.1-p21.1
SPG32;Spastic paraplegia 32, autosomal recessive (2);SPG32;611252;AR;14q12-q21
SPG34;Spastic paraplegia 34, X-linked (2);SPG34;300750;XLR;Xq24-q25
SPG36;Spastic paraplegia 36, autosomal dominant (2);SPG36;613096;AD;12q23-q24
SPG37;Spastic paraplegia 37, autosomal dominant (2);SPG37;611945;AD;8p21.1-q13.3
SPG38;Spastic paraplegia 38, autosomal dominant (2);SPG38;612335;AD;4p16-p15
SPG41;?Spastic paraplegia 41, autosomal dominant (2);SPG41;613364;AD;11p14.1-p11.2
SPGF2;Spermatogenic failure 2 (2);SPGF2, ASG;108420;AD;Chr.1
SPINK1;Pancreatitis, hereditary, 167800 (3),Tropical calcific pancreatitis, 608189 (3);SPINK1, PSTI, PCTT, TATI, TCP;167790;AD, AR;5q32
SPINK5;Atopy, 147050 (3),Netherton syndrome, 256500 (3);SPINK5, LEKTI;605010;AD, AR;5q32
SPINT2;Diarrhea 3, secretory sodium, congenital, syndromic, 270420 (3);SPINT2, HAI2, DIAR3;605124;AR;19q13.2
SPR;Dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 (3);SPR;182125;?AD, AR;2p13.2
SPRED1;Legius syndrome, 611431 (3);SPRED1, NFLS;609291;AD;15q14
SPRTN;Ruijs-Aalfs syndrome, 616200 (3);SPRTN, DVC1, C1orf124, RJALS;616086;AR;1q42.2
SPRY4;Hypogonadotropic hypogonadism 17 with or without anosmia, 615266 (3);SPRY4, HH17;607984;AD;5q31.3
SPTA1;Elliptocytosis-2, 130600 (3),Pyropoikilocytosis, 266140 (3),Spherocytosis, type 3, 270970 (3);SPTA1, EL2, SPH3, HS3, HPP;182860;AD, AR;1q23.1
SPTAN1;Epileptic encephalopathy, early infantile, 5, 613477 (3);SPTAN1, NEAS, EIEE5;182810;AD;9q34.11
SPTB;Anemia, neonatal hemolytic, fatal and near-fatal (3),Elliptocytosis-3 (3),Spherocytosis, type 2, 616649 (3);SPTB, SPH2, EL3, HS2;182870;AD;14q23.3
SPTBN2;Spinocerebellar ataxia 5, 600224 (3),Spinocerebellar ataxia, autosomal recessive 14, 615386 (3);SPTBN2, SCA5, SCAR14;604985;AD, AR;11q13.2
SPTLC1;Neuropathy, hereditary sensory and autonomic, type IA, 162400 (3);SPTLC1, LBC1, SPT1, HSN1, HSAN;605712;AD;9q22.31
SPTLC2;Neuropathy, hereditary sensory and autonomic, type IC, 613640 (3);SPTLC2, KIAA0526, SPT2, LCB2, HSN1C, NSAN1C;605713;AD;14q24.3
SQSTM1;Frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3),Paget disease of bone 3, 167250 (3);SQSTM1, P62, PDB3, FTDALS3;601530;AD;5q35.3
SRC;?Thrombocytopenia 6, 616937 (3),Colon cancer, advanced, somatic, 114500 (3);SRC, ASV, SRC1, THC6;190090;AD, -;20q11.23
SRCAP;Floating-Harbor syndrome, 136140 (3);SRCAP, SWR1, KIAA0309, FLHS;611421;AD;16p11.2
SRD5A2;Pseudovaginal perineoscrotal hypospadias, 264600 (3);SRD5A2;607306;AR;2p23.1
SRD5A3;Congenital disorder of glycosylation, type Iq, 612379 (3),Kahrizi syndrome, 612713 (3);SRD5A3, SRD5A2L, CDG1Q, KRIZI;611715;AR;4q12
SRP72;Bone marrow failure syndrome 1, 614675 (3);SRP72, BMFS1;602122;AD;4q12
SRPX2;?Rolandic epilepsy, mental retardation, and speech dyspraxia, 300643 (3);SRPX2, SRPUL, RESDX;300642;-;Xq22.1
SRS;Silver-Russell syndrome (4);SRS, RSS;180860;IC ;7p11.2
SRTD1;Short-rib thoracic dysplasia 1 with or without polydactyly (2);SRTD1, ATD1;208500;AR;15q13
SRXX2;46XX sex reversal 2 (4);SRXX2, DUP17q24.3;278850;AD;17q24.3-q25.1
SRXX3;46XX sex reversal 3 (4);SRXX3;300833;XLD;Xq26.3
SRXY10;46XY sex reversal 10 (4);SRXY10;616425;AD;17q24
SRY;46XX sex reversal 1, 400045 (3),46XY sex reversal 1, 400044 (3);SRY, TDF, TDY, SRXX1, SRXY1;480000;-;Yp11.2
SS18;Sarcoma, synovial (1);SS18, SSXT, SYT;600192;-;18q11.2
SSR4;?Congenital disorder of glycosylation, type Iy, 300934 (3);SSR4, TRAPD, CDG1Y;300090;XLR;Xq28
SSTR5;Somatostatin analog, resistance to (3);SSTR5;182455;AD, Smu;16p13.3
SSX1;?Sarcoma, synovial, 300813 (3);SSX1, SSRC;312820;-;Xp11.23
SSX2;?Sarcoma, synovial, 300813 (3);SSX2;300192;-;Xp11.22
ST11;?Pancreatic endocrine tumors (1);ST11, PETS1;602011;-;3p25
ST12;Prostate adenocarcinoma (2);ST12, PAC1;601188;-;10pter-q11
ST14;Ichthyosis, congenital, autosomal recessive 11, 602400 (3);ST14, MTSP1, ARCI11;606797;AR;11q24.3
ST3;Cervical carcinoma (2);ST3;191181;-;11q13
ST3GAL3;Epileptic encephalopathy, early infantile, 15, 615006 (3),Mental retardation, autosomal recessive 12, 611090 (3);ST3GAL3, SIAT6, ST3GALII, MRT12, EIEE15;606494;AR;1p34.1
STAC3;Native American myopathy, 255995 (3);STAC3, NAM;615521;AR;12q13.3
STAG3;Premature ovarian failure 8, 615723 (3);STAG3, POF8;608489;AR;7q22.1
STAMBP;Microcephaly-capillary malformation syndrome, 614261 (3);STAMBP, AMSH, MICCAP;606247;AR;2p13.1
STAR;Lipoid adrenal hyperplasia, 201710 (3);STAR;600617;AR;8p11.23
STAT1;Immunodeficiency 31A, mycobacteriosis, autosomal dominant, 614892 (3),Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive, 613796 (3),Immunodeficiency 31C, autosomal dominant, 614162 (3);STAT1, CANDF7, IMD31A, IMD31B, IMD31C;600555;AD, AR;2q32.2
STAT2;Immunodeficiency 44, 616636 (3);STAT2, IMD44;600556;AR;12q13.3
STAT3;Autoimmune disease, multisystem, infantile-onset, 1, 615952 (3),Hyper-IgE recurrent infection syndrome, 147060 (3);STAT3, APRF, HIES, ADMIO1;102582;AD;17q21.2
STAT5B;Growth hormone insensitivity with immunodeficiency, 245590 (3),Leukemia, acute promyelocytic, somatic, 102578 (3);STAT5B;604260;-;17q21.2
STEAP3;?Anemia, hypochromic microcytic, with iron overload 2, 615234 (3);STEAP3, TSAP6, AHMIO2;609671;AD;2q14.2
STHAG2;Tooth agenesis, selective, 2 (2);STHAG2, HYD2;602639;-;16q12.1
STHAG5;Tooth agenesis, selective, 5 (2);STHAG5;610926;-;10q11.2-q21
STIL;Microcephaly 7, primary, autosomal recessive, 612703 (3);STIL, SIL, MCPH7;181590;AR;1p33
STIM1;Immunodeficiency 10, 612783 (3),Myopathy, tubular aggregate, 1 160565 (3),Stormorken syndrome, 185070 (3);STIM1, TAM1, IMD10, STRMK;605921;AR, AD;11p15.4
STK11;Melanoma, malignant, somatic (3),Pancreatic cancer, 260350 (3),Peutz-Jeghers syndrome, 175200 (3),Testicular tumor, somatic, 273300 (3);STK11, PJS, LKB1;602216;-, Smu, Mu, AD;19p13.3
STK4;T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 (3);STK4, MST1, KRS2, TIIAC;604965;-;20q13.12
STOX1;Preeclampsia/eclampsia 4, 609404 (3);STOX1, PEE4;609397;-;10q22.1
STRA6;Microphthalmia, isolated, with coloboma 8, 601186 (3),Microphthalmia, syndromic 9, 601186 (3);STRA6, MCOPS9, MCOPCB8;610745;AR;15q24.1
STRADA;Polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 (3);STRADA, STRAD, LYK5;608626;AR;17q23.3
STRC;Deafness, autosomal recessive 16, 603720 (3);STRC, DFNB16;606440;AR;15q15.3
STS;Ichthyosis, X-linked, 308100 (3);STS, ARSC1, ARSC, SSDD, XLI;300747;XLR;Xp22.31
STT3A;?Congenital disorder of glycosylation, type Iw, 615596 (3);STT3A, ITM1, TMC;601134;AR;11q24.2
STT3B;?Congenital disorder of glycosylation, type Ix, 615597 (3);STT3B, SIMP, CDG1X;608605;AR;3p23
STUB1;Spinocerebellar ataxia, autosomal recessive 16, 615768 (3);STUB1, CHIP, SCAR16;607207;AR;16p13.3
STUT2;Stuttering, familial persistent, 2 (2);STUT2;609261;-;12q24.1
STUT3;Stuttering, familial persistent, 3 (2);STUT3;614655;-;3q13.2-q13.33
STUT4;Stuttering, familial persistent, 4 (2);STUT4;614668;-;16q12.1-q23.1
STX11;Hemophagocytic lymphohistiocytosis, familial, 4, 603552 (3);STX11, FHL4, HPLH4, HLH4;605014;AR;6q24.2
STX16;Pseudohypoparathyroidism, type IB, 603233 (3);STX16, SYN16;603666;AD;20q13.32
STX1B;Generalized epilepsy with febrile seizures plus, type 9, 616172 (3);STX1B, GEFSP9;601485;AD;16p11.2
STXBP1;Epileptic encephalopathy, early infantile, 4, 612164 (3);STXBP1, UNC18, EIEE4;602926;AD;9q34.11
STXBP2;Hemophagocytic lymphohistiocytosis, familial, 5, 613101 (3);STXBP2, UNC18B, FHL5;601717;-;19p13.2
SUCLA2;Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria), 612073 (3);SUCLA2, MTDPS5;603921;AR;13q14.2
SUCLG1;Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400 (3);SUCLG1, SUCLA1, MTDPS9;611224;AR;2p11.2
SUFU;Basal cell nevus syndrome, 109400 (3),Medulloblastoma, desmoplastic, 155255 (3);SUFU, SUFUXL, SUFUH;607035;AD;10q24.32
SUMF1;Multiple sulfatase deficiency, 272200 (3);SUMF1, FGE;607939;AR;3p26.1
SUMO1;Orofacial cleft 10, 613705 (3);SUMO1, UBL1, SMT3, OFC10;601912;-;2q33.1
SUOX;Sulfite oxidase deficiency, 272300 (3);SUOX;606887;AR;12q13.2
SURF1;Charcot-Marie-Tooth disease, type 4K, 616684 (3),Leigh syndrome, due to COX IV deficiency, 256000 (3);SURF1, CMT4K;185620;AR, Mi, AR;9q34.2
SXI2;X inactivation, familial skewed, 2 (2);SXI2;300179;-;Xq25-q26
SYCE1;?Premature ovarian failure 12, 616947 (3),?Spermatogenic failure 15, 616950 (3);SYCE1, POF12, SPGF15;611486;AR,AR;10q26.3
SYCP3;Pregnancy loss, recurrent, 4, 270960 (3),Spermatogenic failure 4, 270960 (3);SYCP3, SCP3, COR1, SPGF4, RPRGL4;604759;AD;12q23.2
SYN1;Epilepsy, X-linked, with variable learning disabilities and behavior disorders, 300491 (3);SYN1;313440;XLR, XLD;Xp11.3-p11.2
SYNE1;Emery-Dreifuss muscular dystrophy 4, autosomal dominant, 612998 (3),Spinocerebellar ataxia, autosomal recessive 8, 610743 (3);SYNE1, KIAA0796, KIAA1756, KIAA1262, SCAR8, EDMD4;608441;AD, AR;6q25.2
SYNE2;Emery-Dreifuss muscular dystrophy 5, autosomal dominant, 612999 (3);SYNE2, NUANCE, KIAA1011, EDMD5;608442;AD;14q23.2
SYNE4;Deafness, autosomal recessive 76, 615540 (3);SYNE4, NESP4, C19orf46, DFNB76;615535;AR;19q13.12
SYNGAP1;Mental retardation, autosomal dominant 5, 612621 (3);SYNGAP1, MRD5;603384;AD;6p21.32
SYNJ1;Parkinson disease 20, early-onset, 615530 (3);SYNJ1, PARK20;604297;AR;21q22.11
SYNSTH;Synesthesia (2);SYNSTH;612759;-;2q24.1
SYP;Mental retardation, X-linked 96, 300802 (3);SYP, MRXSYP;313475;XLD;Xp11.23
SYT14;Spinocerebellar ataxia, autosomal recessive 11, 614229 (3);SYT14, SCAR11;610949;AR;1q32.2
SYT2;Myasthenic syndrome, congenital, 7, presynaptic, 616040 (3);SYT2, CMS7, MYSPC;600104;AD;1q32.1
SZT2;Epileptic encephalopathy, early infantile, 18, 615476 (3);SZT2, KIAA0467, EIEE18;615463;AR;1p34.2
T;Sacral agenesis with vertebral anomalies, 615709 (3);T, TFT, SAVA;601397;AR, AD;6q27
TAB2;Congenital heart defects, nonsyndromic, 2, 614980 (3);TAB2, MAP3K7IP2, KIAA0733, CHTD2;605101;AD;6q25.1
TAC3;Hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3);TAC3, NKNB, HH10;162330;AR;12q13.3
TACO1;Mitochondrial complex IV deficiency, 220110 (3);TACO1, CCDC44;612958;Mi, AR;17q23.3
TACR3;Hypogonadotropic hypogonadism 11 with or without anosmia, 614840 (3);TACR3, NK3R, HH11;162332;AR;4q24
TACSTD2;Corneal dystrophy, gelatinous drop-like, 204870 (3);TACSTD2, TROP2, M1S1;137290;AR;1p32.1
TAF1;Dystonia-Parkinsonism, X-linked, 314250 (3),Mental retardation, X-linked, syndromic 33, 300966 (3);TAF1, TAF2A, CCG1, BA2R, DYT3, MRXS33;313650;XLR;Xq13.1
TAF15;Chondrosarcoma, extraskeletal myxoid, 612237 (1);TAF15, TAF2N, RBP56;601574;-;17q12
TAF2;Mental retardation, autosomal recessive 40, 615599 (3);TAF2, TAF2B, TAFII150, CIF150, MRT40;604912;AR;8q24.12
TAF4B;?Spermatogenic failure 13, 615841 (3);TAF4B, TAF2C2, TAFII105, SPGF13;601689;AR;18q11.2
TAL1;Leukemia, T-cell acute lymphocytic, somatic, 613065 (3);TAL1, TCL5, SCL;187040;-;1p33
TAL2;Leukemia, T-cell acute lymphocytic, somatic, 613065 (3);TAL2;186855;-;9q31.2
TALDO1;Transaldolase deficiency, 606003 (3);TALDO1;602063;AR;11p15.5
TAM;Leukemia, transient, of Down syndrome (2);TAM, MST;159595;-;21q11.2
TANGO2;Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration, 616878 (3);TANGO2, C22orf25, MECRCN;616830;AR;22q11.21
TAP1;Bare lymphocyte syndrome, type I, 604571 (3);TAP1, ABCB2, TAP1, RING4, PSF1;170260;AR;6p21.32
TAP2;Bare lymphocyte syndrome, type I, due to TAP2 deficiency, 604571 (3),Wegener-like granulomatosis (3);TAP2, ABCB3, PSF2, RING11;170261;AR;6p21.32
TAPBP;Bare lymphocyte syndrome, type I, 604571 (3);TAPBP, TPSN;601962;AR;6p21.32
TAPT1;Osteochondrodysplasia, complex lethal, Symoens-Barnes-Gistelinck type, 616897 (3);TAPT1, CMVFR, OCLSBG;612758;AR;4p15.32
TAPVR1;Total anomalous pulmonary venous return (2);TAPVR1;106700;AD;4q12
TARDBP;Amyotrophic lateral sclerosis 10, with or without FTD, 612069 (3),Frontotemporal lobar degeneration, TARDBP-related, 612069 (3);TARDBP, TDP43, ALS10;605078;AD;1p36.22
TARS2;?Combined oxidative phosphorylation deficiency 21, 615918 (3);TARS2, COXPD21;612805;AR;1q21.2
TAT;Tyrosinemia, type II, 276600 (3);TAT;613018;AR;16q22.2
TAZ;Barth syndrome, 302060 (3);TAZ, EFE2, BTHS, CMD3A, LVNCX;300394;XLR;Xq28
TBC1D20;Warburg micro syndrome 4, 615663 (3);TBC1D20, C20orf140, WARBM4;611663;AR;20p13
TBC1D24;DOOR syndrome, 220500 (3),Deafness , autosomal recessive 86, 614617 (3),Deafness, autosomal dominant 65, 616044 (3),Epileptic encephalopathy, early infantile, 16, 615338 (3),Myoclonic epilepsy, infantile, familial, 605021 (3);TBC1D24, KIAA1171, FIME, EIEE16, DOORS, DFNB86, DFNA65;613577;AR, AD;16p13.3
TBC1D7;Macrocephaly/megalencephaly syndrome, autosomal recessive, 248000 (3);TBC1D7, PIG51, TBC7, MGCPH;612655;AR;6p24.1
TBCE;Hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3),Kenny-Caffey syndrome, type 1, 244460 (3);TBCE, KCS, KCS1, HRD;604934;AR;1q42.3
TBCK;Hypotonia, infantile, with psychomotor retardation and characteristic facies 3, 616900 (3);TBCK, IHPRF3;616899;AR;4q24
TBG;Thyroxine-binding globulin deficiency (3);TBG;314200;-;Xq22.3
TBK1;Frontotemporal dementia and/or amyotrophic lateral sclerosis 4, 616439 (3);TBK1, NAK, FTDALS4;604834;AD;12q14.2
TBL1XR1;Mental retardation, autosomal dominant 41 , 616944 (3),Pierpont syndrome, 602342 (3);TBL1XR1, TBLR1, IRA1, C21, MRD41;608628;AD;3q26.32
TBP;Spinocerebellar ataxia 17, 607136 (3);TBP, SCA17, HDL4;600075;AD, IC, Mu;6q27
TBX1;Conotruncal anomaly face syndrome, 217095 (3),DiGeorge syndrome, 188400 (3),Tetralogy of Fallot, 187500 (3),Velocardiofacial syndrome, 192430 (3);TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR;602054;AD;22q11.21
TBX15;Cousin syndrome, 260660 (3);TBX15;604127;AR;1p12
TBX18;Congenital anomalies of kidney and urinary tract 2, 143400 (3);TBX18, CAKUT2;604613;AD;6q14.3
TBX19;Adrenocorticotropic hormone deficiency, 201400 (3);TBX19;604614;AR;1q24.2
TBX20;Atrial septal defect 4, 611363 (3);TBX20, ASD4;606061;-;7p14.2
TBX21;Asthma and nasal polyps, 208550 (3);TBX21, TBET;604895;AR;17q21.32
TBX22;?Abruzzo-Erickson syndrome, 302905 (3),Cleft palate with ankyloglossia, 303400 (3);TBX22, CPX, ABERS;300307;XL;Xq21.1
TBX3;Ulnar-mammary syndrome, 181450 (3);TBX3;601621;AD;12q24.21
TBX4;Ischiocoxopodopatellar syndrome, 147891 (3);TBX4, ICPPS;601719;AD;17q23.2
TBX5;Holt-Oram syndrome, 142900 (3);TBX5;601620;AD;12q24.21
TBX6;Spondylocostal dysostosis 5, 122600 (3);TBX6, SCDO5;602427;AD;16p11.2
TBXAS1;?Thromboxane synthase deficiency, 614158 (1),Ghosal hematodiaphyseal syndrome, 231095 (3);TBXAS1, GHOSAL, CYP5, BDPLT14;274180;AD, AR;7q34
TCAP;Cardiomyopathy, hypertrophic, 25, 607487 (3),Muscular dystrophy, limb-girdle, type 2G, 601954 (3);TCAP, LGMD2G, CMH25;604488;AD, AR;17q12
TCF12;Craniosynostosis 3, 615314 (3);TCF12, HTF4, CRS3;600480;AD;15q21.3
TCF3;Agammaglobulinemia 8, autosomal dominant, 616941 (3);TCF3, E2A, AGM8;147141;AD;19p13.3
TCF4;Corneal dystrophy, Fuchs endothelial, 3, 613267 (3),Pitt-Hopkins syndrome, 610954 (3);TCF4, SEF2, ITF2, PTHS, FECD3;602272;AD;18q21.2
TCIRG1;Osteopetrosis, autosomal recessive 1, 259700 (3);TCIRG1, TIRC7, OC116, OPTB1;604592;AR;11q13.2
TCL1A;Leukemia/lymphoma, T-cell (2);TCL1A, TCL1;186960;-;14q32.13
TCL1B;Leukemia/lymphoma, T-cell (2);TCL1B, TML1;603769;-;14q32.13
TCL4;Leukemia/lymphoma, T-cell (2);TCL4;186860;-;2q34
TCN2;Transcobalamin II deficiency, 275350 (3);TCN2, TC2;613441;AR;22q12.2
TCO;Thyroid carcinoma, nonmedullary, with cell oxyphilia (2);TCO;603386;-;19p13.2
TCOF1;Treacher Collins syndrome 1, 154500 (3);TCOF1, MFD1, TCS1;606847;AD;5q32-q33
TCPT;?Thrombocytopenia, Paris-Trousseau type (4);TCPT;188025;IC;11q23
TCTN2;?Meckel syndrome 8, 613885 (3),Joubert syndrome 24, 616654 (3);TCTN2, TECT2, MKS8, JBTS24;613846;AR;12q24.31
TCTN3;Joubert syndrome 18, 614815 (3),Orofaciodigital syndrome IV, 258860 (3);TCTN3, TECT3, C10orf61, OFD4, JBTS18;613847;AR;10q24.1
TDGF1;Forebrain defects (3);TDGF1;187395;-;3p21.31
TDP1;Spinocerebellar ataxia, autosomal recessive with axonal neuropathy, 607250 (3);TDP1;607198;-;14q32.11
TDP2;Spinocerebellar ataxia, autosomal recessive 23, 616949 (3);TDP2, TTRAP;605764;AR;6p22.3
TDRD7;Cataract 36, 613887 (3);TDRD7, KIAA1529, TRAP, CATC4, CTRCT36;611258;-;9q22.33
TEAD1;Sveinsson chorioretinal atrophy, 108985 (3);TEAD1, TCF13, REF1;189967;AD;11p15.3
TEC;Transient erythroblastopenia of childhood (2);TEC;227050;AR;19q13.2
TECPR2;Spastic paraplegia 49, autosomal recessive, 615031 (3);TECPR2, KIAA0329, SPG49;615000;AR;14q32.31
TECR;Mental retardation, autosomal recessive 14, 614020 (3);TECR, GPSN2, TER, SC2, MRT14;610057;AR;19p13.12
TECT1;Joubert syndrome 13, 614173 (3);TECT1, JBTS13;609863;AR;12q24.11
TECTA;Deafness, autosomal dominant 8/12, 601543 (3),Deafness, autosomal recessive 21, 603629 (3);TECTA, DFNA8, DFNA12, DFNB21;602574;AD, AR;11q23.3
TEK;Venous malformations, multiple cutaneous and mucosal, 600195 (3);TEK, TIE2, VMCM;600221;AD;9p21.2
TELO2;You-Hoover-Fong syndrome, 616954 (3);TELO2, TEL2, CLK2, KIAA0683, HCLK2, YHFS;611140;AR;16p13.3
TEMPS;Temple syndrome (4);TEMPS;616222;IC;14q32
TENM3;?Microphthalmia, isolated, with coloboma 9, 615145 (3);TENM3, ODZ3, TNM3, KIAA1455, MCOPCB9;610083;AR;4q34.3-q35.1
TENM4;Tremor, hereditary essential, 5, 616736 (3);TENM4, ODZ4, TNM4, DOC4, KIAA1302, ETM5;610084;AD;11q14.1
TERC;Dyskeratosis congenita, autosomal dominant 1, 127550 (3);TERC, TRC3, TR, DKCA1, PFBMFT2;602322;AD;3q26.2
TET18P;Tetrasomy 18p (4);TET18P;614290;-;18p
TET2;Myelodysplastic syndrome, somatic, 614286 (3);TET2, KIAA1546, MDS;612839;-;4q24
TEX11;Spermatogenic failure, X-linked, 2, 309120 (3);TEX11, SPGFX2;300311;XLR;Xq13.1
TF;Atransferrinemia, 209300 (3);TF, TFQTL1;190000;AR;3q22.1
TFAP2A;Branchiooculofacial syndrome, 113620 (3);TFAP2A, AP2TF, BOFS;107580;AD;6p24.3
TFAP2B;Char syndrome, 169100 (3);TFAP2B, CHAR, PDA2;601601;AD;6p12.3
TFE3;Renal cell carcinoma, papillary, 1, 300854 (3);TFE3, RCCX1;314310;-;Xp11.23
TFG;?Spastic paraplegia 57, autosomal recessive, 615658 (3),Hereditary motor and sensory neuropathy, Okinawa type, 604484 (3);TFG, HMSNP, SPG57;602498;AR, AD;3q12.2
TFR2;Hemochromatosis, type 3, 604250 (3);TFR2, HFE3;604720;-;7q22.1
TFRC;Immunodeficiency 46, 616740 (3);TFRC, TFR, CD71, IMD46;190010;AR;3q29
TG;Thyroid dyshormonogenesis 3, 274700 (3);TG, AITD3, TDH3;188450;AR, -;8q24.22
TGCT1;Testicular germ cell tumor (2);TGCT1;300228;-;Xq27
TGDS;Catel-Manzke syndrome, 616145 (3);TGDS, SDR2E1, CATMANS;616146;AR;13q32.1
TGFB1;Camurati-Engelmann disease, 131300 (3);TGFB1, DPD1, CED;190180;AD;19q13.2
TGFB2;Loeys-Dietz syndrome 4, 614816 (3);TGFB2, LDS4;190220;AD;1q41
TGFB3;Arrhythmogenic right ventricular dysplasia 1, 107970 (3),Loeys-Dietz syndrome 5, 615582 (3);TGFB3, ARVD1, RNHF, LDS5;190230;AD;14q24.3
TGFBI;Corneal dystrophy, Avellino type, 607541 (3),Corneal dystrophy, Groenouw type I, 121900 (3),Corneal dystrophy, Reis-Bucklers type, 608470 (3),Corneal dystrophy, Thiel-Behnke type, 602082 (3),Corneal dystrophy, epithelial basement membrane, 121820 (3),Corneal dystrophy, lattice type I, 122200 (3),Corneal dystrophy, lattice type IIIA, 608471 (3);TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD;601692;AD, -;5q31.1
TGFBR1;Loeys-Dietz syndrome 1, 609192 (3);TGFBR1, ALK5, AAT5, LDS1, MSSE;190181;AD;9q22.33
TGFBR2;Colorectal cancer, hereditary nonpolyposis, type 6, 614331 (3),Esophageal cancer, somatic, 133239 (3),Loeys-Dietz syndrome 2, 610168 (3);TGFBR2, HNPCC6, AAT3, MFS2, LDS2;190182;-, AD;3p24.1
TGIF;Holoprosencephaly 4, 142946 (3);TGIF, HPE4;602630;AD;18p11.31
TGM1;Ichthyosis, congenital, autosomal recessive 1, 242300 (3);TGM1, ICR2, ARCI1;190195;AR;14q12
TGM5;Peeling skin syndrome 2, 609796 (3);TGM5, TGX, PSS2;603805;AR;15q15.2
TGM6;Spinocerebellar ataxia 35, 613908 (3);TGM6, TG6, TGY, SCA35;613900;AD;20p13
TH;Segawa syndrome, recessive, 605407 (3);TH, TYH;191290;AR;11p15.5
THAP1;Dystonia 6, torsion, 602629 (3);THAP1, DYT6;609520;AD;8p11.21
THAS;Thoracoabdominal syndrome (2);THAS, TAS;313850;XL;Xq25-q26.1
THBD;Thrombophilia due to thrombomodulin defect, 614486 (3);THBD, THRM, AHUS6, THPH12;188040;-, AD;20p11.21
THCYTX;Thrombocythemia, X-linked (2);THCYTX;300331;XLR;Chr.X
THM;?Tibial hemimelia (2);THM;275220;AR;8q24.1
THOC2;Mental retardation, X-linked 12/35, 300957 (3);THOC2, THO2, MRX12, MRX35;300395;XLR;Xq25
THOC6;Beaulieu-Boycott-Innes syndrome, 613680 (3);THOC6, FSAP35, BBIS;615403;AR;16p13.3
THPH9;?Thrombophilia due to decreased release of tissue plasminogen (1);THPH9;612348;-;8p12
THPO;Thrombocythemia 1, 187950 (3);THPO, MGDF, MPLLG, TPO, THCYT1;600044;AD;3q27.1
THRA;Hypothyroidism, congenital, nongoitrous, 6, 614450 (3);THRA, ERBA1, THRA1, CHNG6;190120;AD;17q21.1
THRB;Thyroid hormone resistance, 188570 (3),Thyroid hormone resistance, autosomal recessive, 274300 (3),Thyroid hormone resistance, selective pituitary, 145650 (3);THRB, ERBA2, THR1, PRTH;190160;AD, AR;3p24.2
TIA1;Welander distal myopathy, 604454 (3);TIA1, WDM;603518;AD, AR;2p13.3
TIMM8A;Mohr-Tranebjaerg syndrome, 304700 (3);TIMM8A, DFN1, DDP, MTS, DDP1;300356;XLR;Xq22.1
TIMP3;Sorsby fundus dystrophy, 136900 (3);TIMP3, SFD;188826;AD;22q12.3
TINF2;Dyskeratosis congenita, autosomal dominant 3, 613990 (3),Revesz syndrome, 268130 (3);TINF2, TIN2, DKCA3;604319;AD;14q12
TJP2;Cholestasis, progressive familial intrahepatic 4, 615878 (3),Hypercholanemia, familial, 607748 (3);TJP2, ZO2, PFIC4;607709;AR, -;9q21.11
TK2;Mitochondrial DNA depletion syndrome 2 (myopathic type), 609560 (3);TK2, MTDPS2;188250;AR;16q21
TKCR;Goeminne TKCR syndrome (2);TKCR, TKC;314300;XL;Xq28
TLE6;Preimplantation embryonic lethality, 616814 (3);TLE6, GRG6, PREMBL;612399;AR;19p13.3
TLL1;Atrial septal defect 6, 613087 (3);TLL1, TLL, ASD6;606742;AD;4q32.3
TMC1;Deafness, autosomal dominant 36, 606705 (3),Deafness, autosomal recessive 7, 600974 (3);TMC1, DFNB7, DFNB11, DFNA36;606706;AD, AR;9q21.13
TMC6;Epidermodysplasia verruciformis, 226400 (3);TMC6, EVER1, EV1;605828;AR;17q25.3
TMC8;Epidermodysplasia verruciformis, 226400 (3);TMC8, EVER2, EV2;605829;AR;17q25.3
TMCO1;Craniofacial dysmorphism, skeletal anomalies, and mental retardation syndrome, 213980 (3);TMCO1, CFSMR;614123;AR;1q24.1
TMEM126A;Optic atrophy 7, 612989 (3);TMEM126A, OPA7;612988;AR;11q14.1
TMEM138;Joubert syndrome 16, 614465 (3);TMEM138, JBTS16;614459;AR;11q12.2
TMEM15;Congenital disorder of glycosylation, type Im, 610768 (3);TMEM15, DK1, SEC59, KIAA1094, CDG1M;610746;AR;9q34.11
TMEM165;Congenital disorder of glycosylation, type IIk, 614727 (3);TMEM165, FT27, CDG2K;614726;AR;4q12
TMEM173;STING-associated vasculopathy, infantile-onset, 615934 (3);TMEM173, STING, MPYS, SAVI;612374;AD;5q31.2
TMEM199;Congenital disorder of glycosylation, type IIp, 616829 (3);TMEM199, VMA12, VPH2, C17orf32, CDG2P;616815;AR;17q11.2
TMEM216;Joubert syndrome 2, 608091 (3),Meckel syndrome 2, 603194 (3);TMEM216, JBTS2, CORS2, MKS2;613277;AR;11q12.2
TMEM231;Joubert syndrome 20, 614970 (3),Meckel syndrome 11, 615397 (3);TMEM231, JBTS20, MKS11;614949;AR;16q23.1
TMEM237;Joubert syndrome 14, 614424 (3);TMEM237, ALS2CR4, JBTS14;614423;AR;2q33.1
TMEM240;Spinocerebellar ataxia 21, 607454 (3);TMEM240, C1orf70, SCA21;616101;AD;1p36.33
TMEM38B;Osteogenesis imperfecta, type XIV, 615066 (3);TMEM38B, TRICB, OI14;611236;-;9q31.2
TMEM43;Arrhythmogenic right ventricular dysplasia 5, 604400 (3),Emery-Dreifuss muscular dystrophy 7, AD, 614302 (3);TMEM43, ARVD5, ARVC5, EDMD7;612048;AD;3p25.1
TMEM5;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, 615041 (3);TMEM5, MDDGA10;605862;AR;12q14.2
TMEM67;COACH syndrome, 216360 (3),Joubert syndrome 6, 610688 (3),Meckel syndrome 3, 607361 (3),Nephronophthisis 11, 613550 (3);TMEM67, MKS3, JBTS6, NPHP11;609884;AR;8q22.1
TMEM70;Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2, 614052 (3);TMEM70, MC5DN2;612418;AR;8q21.11
TMEM98;Nanophthalmos 4, 615972 (3);TMEM98, NNO4;615949;AD;17q11.2
TMIE;Deafness, autosomal recessive 6, 600971 (3);TMIE, DFNB6;607237;AR;3p21.31
TMPO;?Cardiomyopathy, dilated, 1T, 613740 (3);TMPO, LAP2, CMD1T;188380;-;12q23.1
TMPRSS3;Deafness, autosomal recessive 8/10, 601072 (3);TMPRSS3, ECHOS1, DFNB8, DFNB10;605511;AR;21q22.3
TMPRSS6;Iron-refractory iron deficiency anemia, 206200 (3);TMPRSS6, IRIDA;609862;AR;22q12.3
TNC;Deafness, autosomal dominant 56, 615629 (3);TNC, HXB, DFNA56;187380;AD;9q33.1
TNFAIP3;Autoinflammatory syndrome, familial, Behcet-like, 616744 (3);TNFAIP3, A20, OTUD7C, AISBL;191163;AD;6q23.3
TNFRSF10B;Squamous cell carcinoma, head and neck, 275355 (3);TNFRSF10B, DR5, TRAILR2;603612;AR;8p21.3
TNFRSF11A;Osteolysis, familial expansile, 174810 (3),Osteopetrosis, autosomal recessive 7, 612301 (3);TNFRSF11A, RANK, ODFR, FEO, OPTB7, PDB2;603499;AD, -;18q21.33
TNFRSF11B;Paget disease of bone 5, juvenile-onset, 239000 (3);TNFRSF11B, OPG, OCIF, PDB5;602643;AR;8q24.12
TNFRSF13B;Immunodeficiency, common variable, 2, 240500 (3),Immunoglobulin A deficiency 2, 609529 (3);TNFRSF13B, TACI, CVID2;604907;AD, AR, -;17p11.2
TNFRSF13C;Immunodeficiency, common variable, 4, 613494 (3);TNFRSF13C, BAFFR, CVID4;606269;AR;22q13.2
TNFRSF1A;Periodic fever, familial, 142680 (3);TNFRSF1A, TNFR1, TNFAR, FPF, MS5;191190;AD, -;12p13.31
TNFRSF4;?Immunodeficiency 16, 615593 (3);TNFRSF4, TXGP1L, OX40, ACT35, IMD16;600315;AR;1p36.33
TNFRSF7;Lymphoproliferative syndrome 2, 615122 (3);TNFRSF7, CD27, S152. LPFS2;186711;AR;12p13.31
TNFSF11;Osteopetrosis, autosomal recessive 2, 259710 (3);TNFSF11, OPGL, TRANCE, OPTB2;602642;AR;13q14.11
TNFSF5;Immunodeficiency, X-linked, with hyper-IgM, 308230 (3);TNFSF5, CD40LG, HIGM1, IGM;300386;XLR;Xq26.3
TNIK;Mental retardation, autosomal recessive 54, 617028 (3);TNIK, KIAA0551, MRT54;610005;AR;3q26.2-q26.3
TNNC1;Cardiomyopathy, dilated, 1Z, 611879 (3),Cardiomyopathy, hypertrophic, 13, 613243 (3);TNNC1, CMD1Z, CMH13;191040;-;3p21.1
TNNI2;Arthrogryposis multiplex congenita, distal, type 2B, 601680 (3);TNNI2, AMCD2B, DA2B, FSSV;191043;AD;11p15.5
TNNI3;?Cardiomyopathy, dilated, 2A, 611880 (3),Cardiomyopathy, dilated, 1FF, 613286 (3),Cardiomyopathy, familial restrictive, 1, 115210 (3),Cardiomyopathy, hypertrophic, 7, 613690 (3);TNNI3, CMH7, CMD2A, RCM1, CMD1FF;191044;AR,-,AD,AD;19q13.42
TNNI3K;?Cardiac conduction disease with or without dilated cardiomyopathy, 616117 (3);TNNI3K, CCDD;613932;AD;1p31.1
TNNT1;Nemaline myopathy 5, Amish type, 605355 (3);TNNT1, ANM, NEM5;191041;AR;19q13.42
TNNT2;Cardiomyopathy, dilated, 1D, 601494 (3),Cardiomyopathy, familial restrictive, 3, 612422 (3),Cardiomyopathy, hypertrophic, 2, 115195 (3),Left ventricular noncompaction 6, 601494 (3);TNNT2, CMH2, CMD1D, RCM3, LVNC6;191045;AD;1q32.1
TNNT3;Arthyrgryposis, distal, type 2B, 601680 (3);TNNT3, AMCD2B, DA2B, FSSV;600692;AD;11p15.5
TNPO3;Muscular dystrophy, limb-girdle, type 1F, 608423 (3);TNPO3, TRNSR, LGMD1F;610032;AD;7q32.1
TNXB;Ehlers-Danlos syndrome due to tenascin X deficiency, 606408 (3),Vesicoureteral reflux 8, 615963 (3);TNXB, TNX, TNXB1, TNXBS, TNXB2, EDS3, VUR8;600985;AR, AD;6p21.33-p21.32
TOP1;DNA topoisomerase I, camptothecin-resistant (3);TOP1;126420;-;20q12
TOP2A;DNA topoisomerase II, resistance to inhibition of, by amsacrine (3);TOP2A, TOP2;126430;-;17q21.2
TOPORS;Retinitis pigmentosa 31, 609923 (3);TOPORS, P53BP3, LUN, RP31;609507;-;9p21.1
TP53;Adrenal cortical carcinoma, 202300 (3),Breast cancer, 114480 (3),Choroid plexus papilloma, 260500 (3),Colorectal cancer, 114500 (3),Hepatocellular carcinoma, 114550 (3),Li-Fraumeni syndrome, 151623 (3),Nasopharyngeal carcinoma, 607107 (3),Osteosarcoma, 259500 (3),Pancreatic cancer, 260350 (3);TP53, P53, LFS1 , BCC7;191170;AD, AR, Smu, Mu;17p13.1
TP63;ADULT syndrome, 103285 (3),Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3),Hay-Wells syndrome, 106260 (3),Limb-mammary syndrome, 603543 (3),Orofacial cleft 8, 129400 (3),Rapp-Hodgkin syndrome, 129400 (3),Split-hand/foot malformation 4, 605289 (3);TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8;603273;AD;3q28
TP73;?Neuroblastoma (1);TP73;601990;-;1p36.32
TPI1;Hemolytic anemia due to triosephosphate isomerase deficiency, 615512 (3);TPI1, TPID;190450;AR;12p13.31
TPK1;Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 (3);TPK1, THMD5;606370;AR;7q35
TPM1;Cardiomyopathy, dilated, 1Y, 611878 (3),Cardiomyopathy, hypertrophic, 3, 115196 (3),Left ventricular noncompaction 9, 611878 (3);TPM1, CMH3, CMD1Y , LVNC9;191010;AD;15q22.2
TPM2;Arthrogryposis multiplex congenita, distal, type 1, 108120 (3),Arthrogryposis, distal, type 2B, 601680 (3),CAP myopathy 2, 609285 (3),Nemaline myopathy 4, autosomal dominant, 609285 (3);TPM2, TMSB, AMCD1, DA1, DA2B, NEM4;190990;AD;9p13.3
TPM3;CAP myopathy 1, 609284 (3),Myopathy, congenital, with fiber-type disproportion, 255310 (3),Nemaline myopathy 1, autosomal dominant or recessive, 609284 (3);TPM3, NEM1, CFTD, CAPM1;191030;AD, AR;1q21.3
TPO;Thyroid dyshormonogenesis 2A, 274500 (3);TPO, TPX, TDH2A;606765;AR;2p25.3
TPP1;Ceroid lipofuscinosis, neuronal, 2, 204500 (3),Spinocerebellar ataxia, autosomal recessive 7, 609270 (3);TPP1, CLN2, SCAR7;607998;AR;11p15.4
TPRN;Deafness, autosomal recessive 79, 613307 (3);TPRN, C9orf75, DFNB79;613354;AR;9q34.3
TRAC;Immunodeficiency 7, TCR-alpha/beta deficient, 615387 (3);TRAC, TRCA, TRA, IMD7;186880;AR;14q11.2
TRAF3IP1;Senior-Loken syndrome 9, 616629 (3);TRAF3IP1, MIPT3, SLSN9;607380;AR;2q37.3
TRAF3IP2;?Candidiasis, familial, 8, 615527 (3);TRAF3IP2, C6orf5, ACT1, CIKS, C6orf4, C6orf6, PSORS13, CANDF8;607043;AR;6q21
TRAIP;Seckel syndrome 9, 616777 (3);TRAIP, TRIP, RNF206, SCKL9;605958;AR;3p21.31
TRAPPC11;Muscular dystrophy, limb-girdle, type 2S, 615356 (3);TRAPPC11, C4orf41, LGMD2S;614138;AR;4q35.1
TRAPPC2;Spondyloepiphyseal dysplasia tarda, 313400 (3);TRAPPC2, SEDL, SEDT;300202;XLR;Xp22.2
TRAPPC9;Mental retardation, autosomal recessive 13, 613192 (3);TRAPPC9, NIBP, KIAA1882, MRT13;611966;AR;8q24.3
TRDN;Ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness, 615441 (3);TRDN, TDN, CPVT5;603283;AR;6q22.31
TREH;Trehalase deficiency, 612119 (1);TREH;275360;-;11q23.3
TREM2;Nasu-Hakola disease, 221770 (3);TREM2;605086;AR;6p21.1
TREX1;Aicardi-Goutieres syndrome 1, dominant and recessive, 225750 (3),Chilblain lupus, 610448 (3),Vasculopathy, retinal, with cerebral leukodystrophy, 192315 (3);TREX1, AGS1, CRV, HERNS;606609;AD, AR;3p21.31
TRH;Thyrotropin-releasing hormone deficiency, 275120 (1);TRH;613879;AR;3q22.1
TRHR;Thyrotropin-releasing hormone resistance, generalized (3);TRHR;188545;-;8q23.1
TRICY1;Trichilemmal cyst 1 (2);TRICY1;609649;AD;3p24-p21.2
TRIM2;Charcot-Marie-Tooth disease, type 2R, 615490 (3);TRIM2, KIAA0517, CMT2R;614141;AR;4q31.3
TRIM32;?Bardet-Biedl syndrome 11, 615988 (3),Muscular dystrophy, limb-girdle, type 2H, 254110 (3);TRIM32, HT2A, LGMD2H, BBS11;602290;AR;9q33.1
TRIM37;Mulibrey nanism, 253250 (3);TRIM37, MUL, KIAA0898;605073;AR;17q22
TRIOBP;Deafness, autosomal recessive 28, 609823 (3);TRIOBP, KIAA1662;609761;AR;22q13.1
TRIP11;Achondrogenesis, type IA, 200600 (3);TRIP11, TRIP230, CEV14, ACG1A;604505;AR;14q32.12
TRIP4;Spinal muscular atrophy with congenital bone fractures 1, 616866 (3);TRIP4, ASC1, SMABF1;604501;AR;15q22.31
TRIP4q32.1q32.2;Chromosome 4q32.1-q32.2 triplication syndrome (4);TRIP4q32.1q32.2, C4TRIPq32.1q32.2;613603;AD;4q32.1-q32.2
TRMT10A;Microcephaly, short stature, and impaired glucose metabolism 1, 616033 (3);TRMT10A, RG9MTD2, MSSGM1;616013;AR;4q23
TRMT10C;Combined oxidative phosphorylation deficiency 30, 616974 (3);TRMT10C, RG9MTD1, MRPP1, COXPD30;615423;AR;3q12.3
TRMT5;Combined oxidative phosphorylation deficiency 26, 616539 (3);TRMT5, TRM5, KIAA1393, COXPD26;611023;AR;14q23.1
TRMU;Liver failure, transient infantile, 613070 (3);TRMU, MTO2;610230;AR, -;22q13.31
TRNT1;Retinitis pigmentosa and erythrocytic microcytosis, 616959 (3),Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, 616084 (3);TRNT1, SIFD, RPEM;612907;AR;3p26.2
TRPA1;Episodic pain syndrome, familial, 615040 (3);TRPA1, ANKTM1, FEPS;604775;AD;8q21.11
TRPC3;?Spinocerebellar ataxia 41, 616410 (3);TRPC3, TRP3, SCA41;602345;AD;4q27
TRPC6;Glomerulosclerosis, focal segmental, 2, 603965 (3);TRPC6, TRP6, FSGS2;603652;-;11q22.1
TRPM1;Night blindness, congenital stationary (complete), 1C, autosomal recessive, 613216 (3);TRPM1, MLSN1, CSNB1C;603576;-;15q13.3
TRPM4;Progressive familial heart block, type IB, 604559 (3);TRPM4, PFHB1B;606936;AD;19q13.33
TRPM6;Hypomagnesemia 1, intestinal, 602014 (3);TRPM6, CHAK2, HOMG1;607009;AR;9q21.13
TRPS1;Trichorhinophalangeal syndrome, type I, 190350 (3),Trichorhinophalangeal syndrome, type III, 190351 (3);TRPS1;604386;AD;8q23.3
TRPS2;Trichorhinophalangeal syndrome, type II (4);TRPS2, LGCR, LGS;150230;AD;8q24.11-q24.13
TRPV3;?Palmoplantar keratoderma, nonepidermolytic, focal 2, 616400 (3),Olmsted syndrome, 614594 (3);TRPV3, OLMS, FNEPPK2;607066;AD;17p13.2
TRPV4;Brachyolmia type 3, 113500 (3),Digital arthropathy-brachydactyly, familial, 606835 (3),Hereditary motor and sensory neuropathy, type IIc, 606071 (3),Metatropic dysplasia, 156530 (3),Parastremmatic dwarfism, 168400 (3),SED, Maroteaux type, 184095 (3),Scapuloperoneal spinal muscular atrophy, 181405 (3),Spinal muscular atrophy, distal, congenital nonprogressive, 600175 (3),Spondylometaphyseal dysplasia, Kozlowski type, 184252 (3);TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL, BCYM3;605427;AD, -;12q24.11
TSC1;Focal cortical dysplasia, Taylor balloon cell type, 607341 (3),Lymphangioleiomyomatosis, 606690 (3),Tuberous sclerosis-1, 191100 (3);TSC1, LAM;605284;AD, -;9q34.13
TSC2;Lymphangioleiomyomatosis, somatic, 606690 (3),Tuberous sclerosis-2, 613254 (3);TSC2, LAM;191092;-, AD;16p13.3
TSEN15;Pontocerebellar hypoplasia, type 2F, 617026 (3);TSEN15, SEN15, C1orf19, PCH2F;608756;-;1q25.3
TSEN2;Pontocerebellar hypoplasia type 2B, 612389 (3);TSEN2, SEN2, PCH2B;608753;AR;3p25.2
TSEN34;Pontocerebellar hypoplasia type 2C, 612390 (3);TSEN34, PCH2C, LENG5, SEN34;608754;-;19q13.42
TSEN54;?Pontocerebellar hypoplasia type 5, 610204 (3),Pontocerebellar hypoplasia type 2A, 277470 (3),Pontocerebellar hypoplasia type 4, 225753 (3);TSEN54, SEN54, PCH2A, PCH4, PCH5;608755;AR;17q25.1
TSFM;Combined oxidative phosphorylation deficiency 3, 610505 (3);TSFM, COXPD3;604723;AR;12q14.1
TSG101;Breast cancer, somatic, 114480 (3);TSG101;601387;-;11p15.1
TSHB;Hypothryoidism, congenital, nongoitrous 4, 275100 (3);TSHB, CHNG4;188540;AR;1p13.2
TSHR;Hyperthyroidism, familial gestational, 603373 (3),Hyperthyroidism, nonautoimmune, 609152 (3),Hypothyroidism, congenital, nongoitrous, 1 275200 (3),Thyroid adenoma, hyperfunctioning, somatic (3),Thyroid carcinoma with thyrotoxicosis (3);TSHR, CHNG1;603372;-, IC, AD, AR;14q31.1
TSHZ1;Aural atresia, congenital, 607842 (3);TSHZ1, TSH1, CAA;614427;AD;18q22.3
TSPAN12;Exudative vitreoretinopathy 5, 613310 (3);TSPAN12, NET2, EVR5;613138;AD;7q31.31
TSPAN7;Mental retardation, X-linked 58, 300210 (3);TSPAN7, TM4SF2, MXS1, A15, MRX58;300096;XLR;Xp11.4
TSPEAR;Deafness, autosomal recessive 98, 614861 (3);TSPEAR, C21orf29, DFNB98;612920;AR;21q22.3
TSPYL1;Sudden infant death with dysgenesis of the testes syndrome, 608800 (3);TSPYL1, TSPYL, SIDDT;604714;AR;6q22.1
TSR2;?Diamond-Blackfan anemia 14 with mandibulofacial dysostosis, 300946 (3);TSR2, WGG1, DBA14;300945;XLR;Xp11.22
TTBK2;Spinocerebellar ataxia 11, 604432 (3);TTBK2, SCA11;611695;AD;15q15.2
TTC19;Mitochondrial complex III deficiency, nuclear type 2, 615157 (3);TTC19, MC3DN2;613814;AR;17p12
TTC21B;Nephronophthisis 12, 613820 (3),Short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3);TTC21B, THM1, NPHP12, SRTD4, ATD4;612014;AD, AR;2q24.3
TTC37;Trichohepatoenteric syndrome 1, 222470 (3);TTC37, KIAA0372;614589;AR;5q15
TTC7A;Gastrointestinal defects and immunodeficiency syndrome, 243150 (3);TTC7A, TTC7, KIAA1140, MINAT, GIDID;609332;AR;2p21
TTC8;?Retinitis pigmentosa 51, 613464 (3),Bardet-Biedl syndrome 8, 615985 (3);TTC8, BBS8, RP51;608132;AR;14q31.3
TTI2;Mental retardation, autosomal recessive 39, 615541 (3);TTI2, C8orf41, MRT39;614426;AR;8p12
TTLL5;Cone-rod dystrophy 19, 615860 (3);TTLL5, STAMP, KIAA0998, CORD19;612268;AR;14q24.3
TTN;Cardiomyopathy, dilated, 1G, 604145 (3),Cardiomyopathy, familial hypertrophic, 9, 613765 (3),Muscular dystrophy, limb-girdle, type 2J, 608807 (3),Myopathy, early-onset, with fatal cardiomyopathy, 611705 (3),Myopathy, proximal, with early respiratory muscle involvement, 603689 (3),Tibial muscular dystrophy, tardive, 600334 (3);TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC;188840;-, AR, AD;2q31.2
TTPA;Ataxia with isolated vitamin E deficiency, 277460 (3);TTPA, TTP1, AVED;600415;AR;8q12.3
TTR;Amyloidosis, hereditary, transthyretin-related, 105210 (3),Carpal tunnel syndrome, familial, 115430 (3);TTR, PALB;176300;AD;18q12.1
TUB;?Retinal dystrophy and obesity, 616188 (3);TUB, RDOB;601197;AR;11p15.4
TUBA1A;Lissencephaly 3, 611603 (3);TUBA1A, TUBA3, LIS3;602529;AD;12q13.12
TUBA4A;Amyotrophic lateral sclerosis 22 with or without frontotemoral dementia, 616208 (3);TUBA4A, TUBA1, ALS22;191110;AD;2q35
TUBA8;Polymicrogyria with optic nerve hypoplasia, 613180 (3);TUBA8, TUBAL2;605742;AR;22q11.21
TUBB;Cortical dysplasia, complex, with other brain malformations 6, 615771 (3),Symmetric circumferential skin creases, congenital, 1, 156610 (3);TUBB, TUBB5, M40, CDCBM6, CSCSC1;191130;AD;6p21.33
TUBB1;Macrothrombocytopenia, autosomal dominant, TUBB1-related, 613112 (3);TUBB1;612901;AD;20q13.32
TUBB2A;Cortical dysplasia, complex, with other brain malformations 5, 615763 (3);TUBB2A, CDCBM5;615101;AD;6p25.2
TUBB2B;Polymicrogyria, symmetric or asymmetric, 610031 (3);TUBB2B, PMGYSA;612850;AD;6p25.2
TUBB3;Cortical dysplasia, complex, with other brain malformations 1, 614039 (3),Fibrosis of extraocular muscles, congenital, 3A, 600638 (3);TUBB3, TUBB4, CFEOM3A, CDCBM1;602661;AD;16q24.3
TUBB4A;Dystonia 4, torsion, autosomal dominant, 128101 (3),Leukodystrophy, hypomyelinating, 6, 612438 (3);TUBB4A, DYT4, HLD6;602662;AD;19p13.3
TUBB8;Oocyte maturation defect 2, 616780 (3);TUBB8, OOMD2;616768;AD;10p15.3
TUBG1;Cortical dysplasia, complex, with other brain malformations 4, 615412 (3);TUBG1, CDCBM4;191135;AD;17q21.2
TUBGCP4;Microcephaly and chorioretinopathy, autosomal recessive, 3, 616335 (3);TUBGCP4, GCP4, MCCRP3;609610;AR;15q15.3
TUBGCP6;Microcephaly and chorioretinopathy, autosomal recessive, 1, 251270 (3);TUBGCP6, GCP6, KIAA1669, MCCRP1;610053;AR;22q13.33
TUFM;Combined oxidative phosphorylation deficiency 4, 610678 (3);TUFM, EFTU, COXPD4;602389;-;16p11.2
TUKLS;Tukel syndrome (2);TUKLS;609428;AR;21q22
TULP1;Leber congenital amaurosis 15, 613843 (3),Retinitis pigmentosa 14, 600132 (3);TULP1, RP14, LCA15;602280;AR;6p21.31
TUSC3;Mental retardation, autosomal recessive 7, 611093 (3);TUSC3, M33, D8S1992, MRT7, MRT22;601385;AR;8p22
TWIST1;Craniosynostosis, type 1, 123100 (3),Robinow-Sorauf syndrome, 180750 (3),Saethre-Chotzen syndrome with eyelid anomalies, 101400 (3),Saethre-Chotzen syndrome, 101400 (3);TWIST1, ACS3, SCS, CRS1;601622;AD;7p21.1
TWIST2;Ablepharon-macrostomia syndrome, 200110 (3),Barber-Say syndrome, 209885 (3),Focal facial dermal dysplasia 3, Setleis type, 227260 (3);TWIST2, DERMO1, SETLSS, FFDD3, BBRSAY, AMS;607556;AD,AR;2q37.3
TXN2;?Combined oxidative phosphorylation deficiency 29, 616811 (3);TXN2, TRX2, MTRX, COXPD29;609063;AR;22q12.3
TXNL4A;Burn-McKeown syndrome, 608572 (3);TXNL4A, DIM1, BMKS;611595;AR;18q23
TYK2;Immunodeficiency 35, 611521 (3);TYK2, IMD35;176941;AR;19p13.2
TYMP;Mitochondrial DNA depletion syndrome 1 (MNGIE type), 603041 (3);TYMP, ECGF1, MNGIE, PDECGF, MEDPS1, MTDPS1;131222;AR;22q13.33
TYR;Albinism, oculocutaneous, type IA, 203100 (3),Albinism, oculocutaneous, type IB, 606952 (3),Waardenburg syndrome/albinism, digenic, 103470 (3);TYR, SHEP3, CMM8, OCA1A, ATN;606933;AR, AD, -;11q14.3
TYROBP;Nasu-Hakola disease, 221770 (3);TYROBP, PLOSL, DAP12;604142;AR;19q13.12
TYRP1;Albinism, oculocutaneous, type III, 203290 (3);TYRP1, CAS2, GP75, SHEP11;115501;AR;9p23
TYS;Huriez syndrome (2);TYS, HRZ;181600;AD;4q23
UBA1;Spinal muscular atrophy, X-linked 2, infantile, 301830 (3);UBA1, UBE1, GXP1, A1ST, SMAX2, AMCX1;314370;XLR;Xp11.3
UBB;Cleft palate, isolated, 119540 (2);UBB;191339;AD;17p11.2
UBE2A;Mental retardation, X-linked syndromic, Nascimento-type, 300860 (3);UBE2A, RAD6A, MRXSN, MRXS30;312180;XLR;Xq24
UBE2B;?Male infertility (1);UBE2B, RAD6B;179095;-;5q31.1
UBE2T;Fanconi anemia, complementation group T, 616435 (3);UBE2T, HSPC150, FANCT;610538;AR;1q32.1
UBE3A;Angelman syndrome, 105830 (3);UBE3A, ANCR;601623;IC;15q11.2
UBE3B;Kaufman oculocerebrofacial syndrome, 244450 (3);UBE3B, BPIDS, KOS;608047;AR;12q24.11
UBIAD1;Corneal dystrophy, Schnyder type, 121800 (3);UBIAD1, TERE1, SCCD;611632;AD;1p36.22
UBQLN2;Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3);UBQLN2, PLIC2, CHAP1, ALS15;300264;XLD;Xp11.21
UBR1;Johanson-Blizzard syndrome, 243800 (3);UBR1, JBS;605981;AR;15q15.2
UCHL1;?Neurodegeneration with optic atrophy, childhood onset, 615491 (3),?{Parkinson disease 5, susceptibility to}, 613643 (3);UCHL1, PARK5, NDGOA;191342;AR,-;4p13
UFSP2;?Hip dysplasia, Beukes type, 142669 (3);UFSP2, C4orf20, BHD;611482;AD;4q35.1
UGT1A1;Crigler-Najjar syndrome, type I, 218800 (3),Crigler-Najjar syndrome, type II, 606785 (3),Hyperbilirubinemia, familial transient neonatal, 237900 (3);UGT1A1, UGT1, GNT1, BILIQTL1;191740;AR, -;2q37.1
UMOD;Glomerulocystic kidney disease with hyperuricemia and isosthenuria, 609886 (3),Hyperuricemic nephropathy, familial juvenile 1, 162000 (3),Medullary cystic kidney disease 2, 603860 (3);UMOD, HNFJ1, FJHN, MCKD2, ADMCKD2;191845;-, AD;16p12.3
UMPS;Orotic aciduria, 258900 (3);UMPS, OPRT;613891;AR;3q21.2
UNC119;?Cone-rod dystrophy (3),?Immunodeficiency 13, 615518 (3);UNC119, HRG4, IMD13;604011;-,AD;17q11.2
UNC13D;Hemophagocytic lymphohistiocytosis, familial, 3, 608898 (3);UNC13D, MUNC13-4, HPLH3, HLH3, FHL3;608897;-;17q25.1
UNC45B;?Cataract 43, 616279 (3);UNC45B, SMUNC45, CTRCT43;611220;AD;17q12
UNC80;Hypotonia, infantile, with psychomotor retardation and characteristic facies 2, 616801 (3);UNC80, C2orf21, KIAA1843;612636;AR;2q34
UNG;Immunodeficiency with hyper IgM, type 5, 608106 (3);UNG, DGU, HIGM5;191525;AR;12q24.11
UPB1;Beta-ureidopropionase deficiency, 613161 (3);UPB1, BUP1;606673;AR;22q11.23
UPF3B;Mental retardation, X-linked, syndromic 14, 300676 (3);UPF3B, RENT3B, MRXS14;300298;XLR;Xq24
UQCC2;?Mitochondrial complex III deficiency, nuclear type 7, 615824 (3);UQCC2, C6orf126, M19;614461;AR;6p21.31
UQCC3;?Mitochondrial complex III deficiency, nuclear type 9, 616111 (3);UQCC3, C11orf83, MC3DN9;616097;AR;11q12.3
UQCRB;Mitochondrial complex III deficiency, nuclear type 3, 615158 (3);UQCRB, UQBP, QPC, MC3DN3;191330;AR;8q22.1
UQCRC2;Mitochondrial complex III deficiency, nuclear type 5, 615160 (3);UQCRC2, MC3DN5;191329;AR;16p12.2
UQCRQ;Mitochondrial complex III deficiency, nuclear type 4, 615159 (3);UQCRQ, QPC, MC3DN4;612080;AR;5q31.1
UROC1;?Urocanase deficiency, 276880 (3);UROC1, UROCD;613012;AR;3q21.3
UROD;Porphyria cutanea tarda, 176100 (3),Porphyria, hepatoerythropoietic, 176100 (3);UROD;613521;AD;1p34.1
UROS;Porphyria, congenital erythropoietic, 263700 (3);UROS;606938;AR;10q26.2
USH1C;Deafness, autosomal recessive 18A, 602092 (3),Usher syndrome, type 1C, 276904 (3);USH1C, DFNB18A;605242;AR;11p15.1
USH1E;Usher syndrome, type 1E (2);USH1E;602097;AR;21q21
USH1H;Usher syndrome, type 1H (2);USH1H;612632;-;15q22-q23
USH1K;Usher syndrome, type IK (2);USH1K;614990;AR;10p11.21-q21.1
USH2A;Retinitis pigmentosa 39, 613809 (3),Usher syndrome, type 2A, 276901 (3);USH2A, RP39;608400;-, AR;1q41
USP9X;Mental retardation, X-linked 99, 300919 (3),Mental retardation, X-linked 99, syndromic, female-restricted, 300968 (3);USP9X, DFFRX, MRX99, MRXS99F;300072;XLR, XLD;Xp11.4
USP9Y;Spermatogenic failure, Y-linked, 2, 415000 (3);USP9Y, DFFRY, SPGFY2;400005;YL;Yq11.221
UVSSA;UV-sensitive syndrome 3, 614640 (3);UVSSA, KIAA1530, UVSS3;614632;AR;4p16.3
VAMP1;Spastic ataxia 1, autosomal dominant, 108600 (3);VAMP1, SYB1, SPAX1;185880;AD;12p13.31
VANGL1;Caudal regression syndrome, 600145 (3);VANGL1, STBM2;610132;AD;1p13.1
VANGL2;Neural tube defects, 182940 (3);VANGL2, LTAP;600533;AD;1q23.2
VAPB;Amyotrophic lateral sclerosis 8, 608627 (3),Spinal muscular atrophy, late-onset, Finkel type, 182980 (3);VAPB, VAPC, ALS8;605704;AD;20q13.32
VARS2;Combined oxidative phosphorylation deficiency 20, 615917 (3);VARS2, KIAA1885, COXPD20;612802;AR;6p21.33
VAX1;?Microphthalmia, syndromic 11, 614402 (3);VAX1, MCOPS11;604294;AR;10q25.3
VCAN;Wagner syndrome 1, 143200 (3);VCAN, CSPG2, WGN, WGN1, ERVR;118661;AD;5q14.2-q14.3
VCL;Cardiomyopathy, dilated, 1W, 611407 (3),Cardiomyopathy, hypertrophic, 15, 613255 (3);VCL, CMD1W, CMH15;193065;-;10q22.2
VCP;Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia, 613954 (3),Charcot-Marie-Tooth disease, type 2Y, 616687 (3),Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1, 167320 (3);VCP, IBMPFD1, ALS14, CMT2Y;601023;-, AD;9p13.3
VDR;?Osteoporosis, involutional, 166710 (1),Rickets, vitamin D-resistant, type IIA, 277440 (3);VDR;601769;AD, AR;12q13.11
VEGFC;Lymphedema, hereditary, ID, 615907 (3);VEGFC, VRP, LMPH1D;601528;AD;4q34.3
VHL;Erythrocytosis, familial, 2, 263400 (3),Hemangioblastoma, cerebellar, somatic (3),Pheochromocytoma, 171300 (3),Renal cell carcinoma, somatic, 144700 (3);VHL;608537;AR, AD;3p25.3
VIL1;Cholestasis, progressive canalicular (1);VIL1;193040;-;2q35
VIM;?Cataract 30, pulverulent, 116300 (3);VIM, CTRCT30;193060;AD;10p13
VIPAS39;Arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3);VIPAS39, VIPAR, SPE39, C14orf133;613401;AR;14q24.3
VKORC1;Vitamin K-dependent clotting factors, combined deficiency of, 2, 607473 (3),Warfarin resistance, 122700 (3);VKORC1, VKOR, VKCFD2, FLJ00289;608547;-, AD;16p11.2
VLDLR;Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1, 224050 (3);VLDLR, CAMRQ1;192977;AR;9p24.2
VMA21;Myopathy, X-linked, with excessive autophagy, 310440 (3);VMA21, XMEA;300913;XLR;Xq28
VPS11;Leukodystrophy, hypomyelinating, 12, 616683 (3);VPS11, HLD12;608549;AR;11q23.3
VPS13A;Choreoacanthocytosis, 200150 (3);VPS13A, CHAC;605978;AR;9q21.2
VPS13B;Cohen syndrome, 216550 (3);VPS13B, KIAA0532, COH1;607817;AR;8q22.2
VPS13C;Parkinson disease 23, autosomal recessive, early onset, 616840 (3);VPS13C, KIAA1421, PARK23;608879;AR;15q22.2
VPS33B;Arthrogryposis, renal dysfunction, and cholestasis 1, 208085 (3);VPS33B;608552;AR;15q26.1
VPS37A;Spastic paraplegia 53, autosomal recessive, 614898 (3);VPS37A, HCRP1, SPG53;609927;AR;8p22
VPS45A;Neutropenia, severe congenital, 5, autosomal recessive, 615285 (3);VPS45A, VPS45, SCN5;610035;AR;1q21.2
VPS53;Pontocerebellar hypoplasia, type 2E, 615851 (3);VPS53, HCCS1, PCH2E;615850;AR;17p13.3
VRK1;Pontocerebellar hypoplasia type 1A, 607596 (3);VRK1, PCH1A;602168;AR;14q32.2
VSPA;Turner syndrome-associated neurocognitive phenotype (2);VSPA;313000;?XLR;Xp22.33
VSX1;?Craniofacial anomalies and anterior segment dysgenesis syndrome, 614195 (3),Keratoconus 1, 148300 (3);VSX1, RINX, KTCN1, CAASDS;605020;-, AD;20p11.21
VUR;Vesicoureteral reflux (2);VUR;193000;AD;1p13
VUR4;Vesicoureteral reflux 4 (2);VUR4;614317;-;5q14.2
VUR5;Vesicoureteral reflux 5 (2);VUR5;614318;-;13q33.2
VUR6;Vesicoureteral reflux 6 (2);VUR6;614319;-;18q12.3
VUR7;Vesicoureteral reflux 7 (2);VUR7;615390;-;12p11-q13
VVS;Syncope, familial vasovagal (2);VVS;609289;AD;15q26
VWA3B;?Spinocerebellar ataxia, autosomal recessive 22, 616948 (3);VWA3B, SCAR22;614884;AR;2q11.2
WAC;Desanto-Shinawi syndrome, 616708 (3);WAC, KIAA1844, DESSH;615049;AD;10p12.1
WAGRO;WAGRO syndrome (4);WAGRO, DEL11p14p12;612469;-;11p13-p12
WAS;Neutropenia, severe congenital, X-linked, 300299 (3),Thrombocytopenia, X-linked, 313900 (3),Thrombocytopenia, X-linked, intermittent, 313900 (3),Wiskott-Aldrich syndrome, 301000 (3);WAS, IMD2, THC1, SCNX;300392;XLR;Xp11.23
WBS;Williams-Beuren syndrome (4);WBS, WMS, WS, DEL7q11, C7DELq11;194050;AD;7q11.23
WDPCP;?Bardet-Biedl syndrome 15, 615992 (3),?Congenital heart defects, hamartomas of tongue, and polysyndactyly, 217085 (3);WDPCP, C2orf86, BBS15, CHDTHP;613580;AR,AR;2p15
WDR11;Hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3);WDR11, DR11, KIAA1351, BRWD2, HH14;606417;AD;10q26.12
WDR19;?Cranioectodermal dysplasia 4, 614378 (3),?Short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3),Nephronophthisis 13, 614377 (3),Senior-Loken syndrome 8, 616307 (3);WDR19, SRTD5, ATD5, NPHP13, CED4;608151;AR;4p14
WDR34;Short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3);WDR34, SRTD11;613363;AR;9q34.11
WDR35;Cranioectodermal dysplasia 2, 613610 (3),Short-rib thoracic dysplasia 7 with or without polydactyly, 614091 (3);WDR35, NAOFEN, KIAA1336, CED2, SRTD7;613602;AR;2p24.1
WDR36;Glaucoma 1, open angle, G, 609887 (3);WDR36, TAWDRP, GLC1G;609669;-;5q22.1
WDR45;Neurodegeneration with brain iron accululation 5, 300894 (3);WDR45, WIPI4, NBIA5;300526;XLD;Xp11.23
WDR60;Short-rib thoracic dysplasia 8 with or without polydactyly, 615503 (3);WDR60, SRTD8, SRPS6;615462;AR;7q36.3
WDR62;Microcephaly 2, primary, autosomal recessive, with or without cortical malformations, 604317 (3);WDR62, C19orf14, MCPH2;613583;AR;19q13.12
WDR72;Amelogenesis imperfecta, type IIA3, 613211 (3);WDR72, AI2A3;613214;AR;15q21.3
WDR73;Galloway-Mowat syndrome, 251300 (3);WDR73, HSPC264, GAMOS;616144;AR;15q25.2
WDR81;Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2, 610185 (3);WDR81, CAMRQ2;614218;AR;17p13.3
WFS1;?Cataract 41, 116400 (3),Deafness, autosomal dominant 6/14/38, 600965 (3),Wolfram syndrome, 222300 (3),Wolfram-like syndrome, autosomal dominant, 614296 (3);WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38, WFSL, CTRCT41;606201;AD, AR;4p16.1
WG;Wegener granulomatosis (2);WG;608710;-;6p21.3
WHRN;Deafness, autosomal recessive 31, 607084 (3),Usher syndrome, type 2D, 611383 (3);WHRN, CIP98, KIAA1526, DFNB31, USH2D;607928;AR;9q32
WHS;Wolf-Hirschhorn syndrome (4);WHS;194190;IC;4p16.3
WHSC1L1;Leukemia, acute myeloid, 601626 (3);WHSC1L1, NSD3;607083;AD;8p11.23
WIPF1;?Wiskott-Aldrich syndrome 2, 614493 (3);WIPF1, WASPIP, WIP, WAS2;602357;-;2q31.1
WISP3;Arthropathy, progressive pseudorheumatoid, of childhood, 208230 (3),Spondyloepiphyseal dysplasia tarda with progressive arthropathy, 208230 (3);WISP3, PPAC, PPD;603400;AR;6q21
WNK1;Neuropathy, hereditary sensory and autonomic, type II, 201300 (3),Pseudohypoaldosteronism, type IIC, 614492 (3);WNK1, PRKWNK1, KDP, PHA2C, HSAN2, HSN2;605232;AR, AD;12p13.33
WNK4;Pseudohypoaldosteronism, type IIB, 614491 (3);WNK4, PRKWNK4, PHA2B;601844;AD;17q21.2
WNT1;Osteogenesis imperfecta, type XV, 615220 (3);WNT1, INT1, OI15, BMND16;164820;AR, -;12q13.12
WNT10A;Odontoonychodermal dysplasia, 257980 (3),Schopf-Schulz-Passarge syndrome, 224750 (3),Tooth agenesis, selective, 4, 150400 (3);WNT10A, SSPS, STHAG4, OODD;606268;AR, AD;2q35
WNT10B;Split-hand/foot malformation 6, 225300 (3);WNT10B, SHFM6;601906;AR, AD;12q13.12
WNT3;?Tetra-amelia syndrome, 273395 (3);WNT3, INT4, TETAMS;165330;AR;17q21.31-q21.32
WNT4;Mullerian aplasia and hyperandrogenism, 158330 (3),SERKAL syndrome, 611812 (3);WNT4, SERKAL;603490;AD, -;1p36.12
WNT5A;Robinow syndrome, autosomal dominant 1, 180700 (3);WNT5A;164975;AD;3p14.3
WNT7A;Fuhrmann syndrome, 228930 (3),Ulna and fibula, absence of, with severe limb deficiency, 276820 (3);WNT7A;601570;AR;3p25.1
WRAP53;Dyskeratosis congenita, autosomal recessive 3, 613988 (3);WRAP53, TCAB1, WDR79, DKCB3;612661;AR;17p13.1
WS2B;Waardenburg syndrome, type 2B (2);WS2B;600193;AD;1p21-p13.3
WS2C;Waardenburg syndrome, type 2C (2);WS2C;606662;-;8p23
WT1;Denys-Drash syndrome, 194080 (3),Frasier syndrome, 136680 (3),Meacham syndrome, 608978 (3),Mesothelioma, somatic, 156240 (3),Nephrotic syndrome, type 4, 256370 (3),Wilms tumor, type 1, 194070 (3);WT1, NPHS4;607102;AD, SMu, -;11p13
WT3;Wilms tumor, type 3 (2);WT3;194090;AD;16q
WT4;Wilms tumor, type 4 (2);WT4;601363;AD;17q12-q21
WWOX;Epileptic encephalopathy, early infantile, 28, 616211 (3),Esophageal squamous cell carcinoma, somatic, 133239 (3),Spinocrebellar ataxia, autosomal recessive 12, 614322 (3);WWOX, FOR, SCAR12, EIEE28;605131;AR, -;16q23.1-q23.2
XDH;Xanthinuria, type I, 278300 (3);XDH;607633;AR;2p23.1
XECD;Corneal dystrophy, endothelial, X-linked (2);XECD;300779;XLD;Xq25
XIAP;Lymphoproliferative syndrome, X-linked, 2, 300635 (3);XIAP, BIRC4, API3, XLP2;300079;-;Xq25
XIC;X-inactivation, familial skewed, 300087 (3);XIC, XCE, XIST, SXI1;314670;-;Xq13.2
XK;McLeod syndrome with or without chronic granulomatous disease, 300842 (3);XK, MCLDS;314850;XL;Xp21.1
XPA;Xeroderma pigmentosum, group A, 278700 (3);XPA, XPAC;611153;AR;9q22.33
XPC;Xeroderma pigmentosum, group C, 278720 (3);XPC, XPCC;613208;AR;3p25.1
XPNPEP3;Nephronophthisis-like nephropathy 1, 613159 (3);XPNPEP3, APP3, NPHPL1;613553;AR;22q13.2
XPR1;Basal ganglia calcification, idiopathic, 6, 616413 (3);XPR1, SYG1, IBGC6;605237;AD;1q25.3
XRCC4;Short stature, microcephaly, and endocrine dysfunction, 616541 (3);XRCC4, SSMED;194363;AR;5q14.2
XRCC9;Fanconi anemia, complementation group G, 614082 (3);XRCC9, FANCG;602956;-;9p13.3
XYLT1;Desbuquois dysplasia 2, 615777 (3);XYLT1, XT1, DBQD2;608124;AR;16p12.3
XYLT2;Spondyloocular syndrome, 605822 (3);XYLT2, XT2, SOS;608125;AR;17q21.33
YAP1;Coloboma, ocular, 120433 (3),Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or mental retardation, 120433 (3);YAP1, COB1;606608;AD;11q22.1
YARS;Charcot-Marie-Tooth disease, dominant intermediate C, 608323 (3);YARS, CMTDIC, TYRRS, YTS, YRS;603623;AD;1p35.1
YARS2;Myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 (3);YARS2, TYRRS, MLASA2;610957;AR;12p11.21
YUHAL;Yuan-Harel-Lupski syndrome (4);YUHAL;616652;AD;17p12-p11.2
ZAK;Split-foot malformation with mesoaxial polydactyly, 616890 (3);ZAK, MLTK, MRK, SFMMP;609479;AR;2q31.1
ZAP70;Autoimmune disease, multisystem, infantile-onset, 2, 617006 (3),Immunodeficiency 48, 269840 (3);ZAP70, SRK, ADMIO2, IMD48;176947;AR;2q11.2
ZBTB16;Leukemia, acute promyelocytic, PL2F/RARA type (3),Skeletal defects, genital hypoplasia, and mental retardation, 612447 (3);ZBTB16, ZNF145, PLZF;176797;-, AR;11q23.2
ZBTB18;?Mental retardation, autosomal dominant 22, 612337 (3);ZBTB18, ZNF238, RP58, MRD22;608433;AD;1q44
ZBTB20;Primrose syndrome, 259050 (3);ZBTB20, ZNF288, DPZF, PRIMS;606025;AD;3q13.31
ZBTB24;Immunodeficiency-centromeric instability-facial anomalies syndrome-2, 614069 (3);ZBTB24, PATZ2, ZNF450, KIAA0441, ICF2;614064;AR;6q21
ZBTB42;?Lethal congenital contracture syndrome 6, 616248 (3);ZBTB42, ZNF925, LCCS6;613915;AR;14q32.33
ZC4H2;Wieacker-Wolff syndrome, 314580 (3);ZC4H2, KIAA1166, WRWF;300897;XLR;Xq11.2
ZD1;Zygodactyly 1 (2);ZD1;609815;-;3p21.31
ZDHHC15;?Mental retardation, X-linked 91, 300577 (3);ZDHHC15, MRX91;300576;XLD;Xq13.3
ZDHHC9;Mental retardation, X-linked syndromic, Raymond type, 300799 (3);ZDHHC9, DHHC9, MRXSZ;300646;-;Xq26.1
ZEB1;Corneal dystrophy, Fuchs endothelial, 6, 613270 (3),Corneal dystrophy, posterior polymorphous, 3, 609141 (3);ZEB1, TCF8, NIL2A, PPCD3, FECD6;189909;-;10p11.22
ZEB2;Mowat-Wilson syndrome, 235730 (3);ZEB2, ZFHX1B, SMADIP1, SIP1;605802;AD;2q22.3
ZFHX4;?Ptosis, congenital, 178300 (2);ZFHX4, ZFH4;606940;AD;8q21.13
ZFP57;Diabetes mellitus, transient neonatal, 1, 601410 (3);ZFP57, TNDM1;612192;-;6p22.1
ZFPM2;46XY sex reversal 9, 616067 (3),Diaphragmatic hernia 3, 610187 (3),Tetralogy of Fallot, 187500 (3);ZFPM2, FOG2, DIH3, SRXY9;603693;AD, -;8q23.1
ZFYVE26;Spastic paraplegia 15, autosomal recessive, 270700 (3);ZFYVE26, KIAA0321, SPG15;612012;AR;14q24.1
ZFYVE27;Spastic paraplegia 33, autosomal dominant, 610244 (3);ZFYVE27, SPG33;610243;AD;10q24.2
ZIC1;Craniosynostosis 6, 616602 (3);ZIC1, CRS6;600470;AD;3q24
ZIC2;Holoprosencephaly 5, 609637 (3);ZIC2, HPE5;603073;AD;13q32.3
ZIC3;Congenital heart defects, nonsyndromic, 1, X-linked, 306955 (3),Heterotaxy, visceral, 1, X-linked 306955 (3),VACTERL association, X-linked, 314390 (3);ZIC3, HTX1, HTX, VACTERLX;300265;XLR;Xq26.3
ZMPSTE24;Mandibuloacral dysplasia with type B lipodystrophy, 608612 (3),Restrictive dermopathy, lethal, 275210 (3);ZMPSTE24, FACE1, STE24, MADB;606480;AR;1p34.2
ZMYND10;Ciliary dyskinesia, primary, 22, 615444 (3);ZMYND10, BLU;607070;AR;3p21.31
ZMYND11;Mental retardation, autosomal dominant 30, 616083 (3);ZMYND11, BS69, BRAM1, MRD30;608668;AD;10p15.3
ZMYND15;?Spermatogenic failure 14, 615842 (3);ZMYND15, SPGF14;614312;AR;17p13.2
ZNF141;?Polydactyly, postaxial, type A6, 615226 (3);ZNF141, D4S90, PAPA6;194648;AR;4p16.3
ZNF335;?Microcephaly 10, primary, autosomal recessive, 615095 (3);ZNF335, NIF1, NIF2, MCPH10;610827;AR;20q13.12
ZNF408;?Exudative vitreoretinopathy 6, 616468 (3),Retinitis pigmentosa 72, 616469 (3);ZNF408, EVR6, RP72;616454;AD, AR;11p11.2
ZNF423;Joubert syndrome 19, 614844 (3),Nephronophthisis 14, 614844 (3);ZNF423, ZFP423, OAZ, KIAA0760, NPHP14, JBTS19;604557;AD, AR;16q12.1
ZNF469;Brittle cornea syndrome 1, 229200 (3);ZNF469, KIAA1858, BCS1;612078;AR;16q24.2
ZNF513;Retinitis pigmentosa 58, 613617 (3);ZNF513, RP58;613598;-;2p23.3
ZNF644;Myopia 21, autosomal dominant, 614167 (3);ZNF644, MYP21;614159;AD;1p22.2
ZNF687;Paget disease of bone 6, 616833 (3);ZNF687, KIAA1441, PDB6;610568;AD;1q21.3
ZNF711;Mental retardation, X-linked 97, 300803 (3);ZNF711, ZNF6, CMPX1, MRX97;314990;XL;Xq21.1
ZNF750;Seborrhea-like dermatitis with psoriasiform elements, 610227 (3);ZNF750, FLJ13841;610226;-;17q25.3
ZNF81;Mental retardation, X-linked 45, 300498 (3);ZNF81, MRX45;314998;XL;Xp11.23
ZNF9;Myotonic dystrophy 2, 602668 (3);ZNF9, CNBP1, DM2, PROMM;116955;AD;3q21.3
ZP1;Oocyte maturation defect 1, 615774 (3);ZP1, OOMD1;195000;AR;11q12.2
ZSWIM6;Acromelic frontonasal dysostosis, 603671 (3);ZSWIM6, KIAA1577, AFND;615951;AD;5q12.1
